

SECURITIES AND EXCHANGE COMMISSION

FORM 20-F

Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d)

Filing Date: **2022-03-15** | Period of Report: **2021-12-31**
SEC Accession No. [0001178913-22-001119](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

CAMTEK LTD

CIK: **1109138** | IRS No.: **000000000** | State of Incorporation: **L3** | Fiscal Year End: **1231**
Type: **20-F** | Act: **34** | File No.: **000-30664** | Film No.: **22741157**
SIC: **3827** Optical instruments & lenses

Mailing Address

*INDUSTRIAL ZONE
PO BOX 544
MIGDAL HAEMEK L3 23105*

Business Address

*INDUSTRIAL ZONE
PO BOX 544
MIGDAL HAEMEK L3 23105
972-4-604-8100*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 20-F

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report _____

Commission file number 000-30664

Camtek Ltd.

(Exact name of Registrant as specified in its charter)

Israel

(Jurisdiction of incorporation or organization)

Ramat Gavriel Industrial Zone, P.O. BOX 544, Migdal Ha'Emek, 23150, Israel

(Address of principal executive offices)

Moshe Eisenberg, Telephone: (972) (4) 6048100, Facsimile: (972) (4) 6048300, E-mail: moshee@camtek.com

Ramat Gavriel Industrial Zone, P.O. BOX 544, Migdal Ha'Emek, 23150, Israel

(Name, Telephone, E-Mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, nominal value NIS 0.01 per share	CAMT	Nasdaq Global Market

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report:

43,847,393 (as of March 8, 2022) ordinary shares, par value NIS 0.01 per share.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP

International Financial Reporting Standards as issued by the International Accounting Standards Board

Other

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

TABLE OF CONTENTS

	<u>PAGE</u>
<u>PART I</u>	
<u>Item 1.</u> <u>Identity of Directors, Senior Management and Advisers</u>	4
<u>Item 2.</u> <u>Offer Statistics and Expected Timetable</u>	4
<u>Item 3.</u> <u>Key Information</u>	4
<u>Item 4.</u> <u>Information on the Company</u>	18
<u>Item 4A.</u> <u>Unresolved Staff Comments</u>	26
<u>Item 5.</u> <u>Operating and Financial Review and Prospects</u>	26
<u>Item 6.</u> <u>Directors, Senior Management and Key Employees</u>	34
<u>Item 7.</u> <u>Major Shareholders and Related Party Transactions</u>	56
<u>Item 8.</u> <u>Financial Information</u>	58
<u>Item 9.</u> <u>The Offer and Listing</u>	58
<u>Item 10.</u> <u>Additional Information</u>	58
<u>Item 11.</u> <u>Quantitative and Qualitative Disclosures about Market Risk</u>	72
<u>Item 12.</u> <u>Description of Securities Other than Equity Securities</u>	73
<u>PART II</u>	73
<u>Item 13.</u> <u>Defaults, Dividend Arrearages and Delinquencies</u>	73
<u>Item 14.</u> <u>Material Modifications to the Rights of Security Holders and Use of Proceeds</u>	73
<u>Item 15.</u> <u>Controls and Procedures</u>	73
<u>Item 16A.</u> <u>Audit Committee Financial Expert</u>	74
<u>Item 16B.</u> <u>Code of Ethics</u>	74
<u>Item 16C.</u> <u>Principal Accountant Fees and Services</u>	74
<u>Item 16D.</u> <u>Exemption From the Listing Standards for Audit Committees</u>	75
<u>Item 16E.</u> <u>Purchases of Equity Securities By the Issuer and Affiliated Purchasers</u>	75
<u>Item 16F.</u> <u>Change in Registrant's Certifying Accountant</u>	75
<u>Item 16G.</u> <u>Corporate Governance</u>	75
<u>Item 16H.</u> <u>Mine Safety Disclosure</u>	76
<u>PART III</u>	76
<u>Item 17.</u> <u>Financial Statements</u>	76
<u>Item 18.</u> <u>Financial Statements</u>	76
<u>Item 19.</u> <u>Exhibits</u>	77

INTRODUCTION

Definitions

In this Annual Report, unless the context otherwise requires:

- references to “Camtek,” the “Company,” “us,” “we,” “our” and the “Registrant” refer to Camtek Ltd., an Israeli company, and its consolidated subsidiaries (unless otherwise indicated);
- references to “ordinary shares,” “our shares” and similar expressions refer to the Registrant’s ordinary shares, NIS 0.01 nominal (par) value per share;
- references to “dollars,” “U.S. dollars” and “\$” are to United States Dollars;
- references to “shekels” and “NIS” are to New Israeli Shekels, the Israeli currency;
- references to the “Companies Law” are to Israel’s Companies Law, 5759-1999;
- references to the “Israeli Securities Law” are to Israel’s Securities Law, 5728-1968;
- references to the “SEC” are to the United States Securities and Exchange Commission; and
- references to the “Nasdaq Rules” are to rules of the Nasdaq Global Market.

Cautionary Language Regarding Forward-Looking Statements

This Annual Report on Form 20-F includes certain statements that are intended to be, and are hereby identified as, “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events.

Forward-looking statements can be identified by the use of forward-looking terminology words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “seeks,” “strategy,” “potential” or “continue” or the negative or other variations of these words, or other comparable words or phrases, but are not the only way these statements are identified. These statements discuss future expectations, plans and events, contain projections of results of operations or of financial condition or state other “forward-looking” information. When a forward-looking statement includes an underlying assumption, we caution that, while we believe the assumption to be reasonable and make it in good faith, assumed facts almost always vary from actual results, and the difference between a forward-looking statement and actual results can be material. Forward-looking statements may be found in Item 4. “Information on the Company” and Item 5. “Operating and Financial Review and Prospects” and in this Annual Report generally. Our actual results could differ materially from those anticipated in these statements as a result of various factors, including all the risks discussed in “Risk Factors” and other cautionary statements in this Annual Report.

All of our forward-looking statements are qualified by and should be read in conjunction with those disclosures. These statements are only predictions that represent our views only as of the date they are made and may change as time passes. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this Annual Report might not occur. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PART I

Item 1. Identity of Directors, Senior Management and Advisers.

Not applicable.

Item 2. Offer Statistics and Expected Timetable.

Not applicable.

Item 3. Key Information.

A. [Reserved.]

B. *Capitalization and Indebtedness.*

Not applicable.

C. *Reasons for the Offer and Use of Proceeds.*

Not applicable.

D. *Risk Factors.*

There is a high degree of risk associated with our Company and business. If any of the following risks occur, our business, revenues, operating results and financial condition could be materially adversely affected and the trading price of our ordinary shares could decline.

Risks Related to Our Business and Our Industry

The waves of the global COVID-19 pandemic may continue to negatively impact the global economy in a significant manner for a further extended period of time, and may also adversely affect our operating results in a material manner.

The COVID-19 worldwide pandemic, which began in December 2019, has created macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, have been taking measures designed to limit the continued spread of COVID-19, including closing workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. As our global operations require physical presence in many stages of our business activities, including travel for installation and services, shipment of materials and products, as well as teamwork, we are particularly vulnerable to the consequences of and the restrictions caused by COVID-19. While our results of operations have not been adversely affected so far in a material manner, given the continued uncertainty around the extent and timing of the future spread or mitigation of COVID-19 and around the imposition or relaxation of protective measures, we cannot reasonably estimate the impact to our future results of operations, cash flows or financial condition. If COVID-19 continues to negatively impact the global economy in a significant manner for a further extended period of time, this may adversely affect our future operations and results in a material manner.

Below are some of the risks and challenges that we may face as a result of the continuation of the COVID-19 pandemic for a further extended period of time:

- Economic downturn or slowdown of macro-economic development and significant decline of business which could harm the strength of the worldwide electronics industry in general and the semiconductor fabrication and packaging industry in particular. Such downturn or slowdown could affect demand for our customers' end products and as a result may cause manufacturers in the semiconductor industry to suspend or reduce capital investments in our products for use in their manufacturing processes, and decrease our sales of products and related services to such industry;

- An extended period of global supply chain and economic disruption as a result of the COVID-19 pandemic could have a material adverse effect on our business, results of operations, access to sources of liquidity and financial condition, though the full extent and duration is uncertain;

- Disruptions to production and installation operations. Although we have so far managed, in general, to manufacture, install and maintain our products, we may suffer as a result of additional, more extensive or continuous restrictions on our operations and those of our suppliers and contractors, including on our or their ability to manufacture, distribute, install or maintain our products or provide services relating thereto;

- Disruptions to our supply chain and outsourced production-activities that could extend lead times and significantly increase the price of one or more component or materials, as well as our supply chain and shipment costs. COVID-19 presents various challenges to our supply chain and manufacturing activities, which we outsource;

- COVID-19 has also adversely affected, and may continue to adversely affect and increase our costs in doing business, including a significant increase in components, materials and shipment costs;

- Disruptions to our marketing and sales activities or to our after-sale activities. Disruptions or restrictions may also be imposed on our marketing and sales operations, including on our ability to submit bids and purchase orders, participate in RFPs, perform site-visits and surveys, or other after sale support, maintenance and repair services;

- Disruptions or restrictions on our operations and those of our contractors and customers, including on our ability to travel or to install or provide services to our products, as well as temporary closures of our facility or the facilities of our suppliers, manufacturers or customers, and prohibitions on the export, import or release from customs of products and components;

- Lower work efficiency, productivity and service quality; while most of our employees in Israel and globally are vaccinated against COVID-19, such vaccination may become ineffective after a certain period of time or against any mutation thereof, COVID-19 could continue to harm the health of one or more of our employees. Employees may lose their ability to manage and run our operations, share their knowhow and further pursue the development of our products and business;

- Disruption, reduction or interruption in supply, disruption to our suppliers, manufacturers or customers and their other vendors, lack or delay in the supply of raw materials and goods, or in the performance of work or services by our contractors and subcontractors;

- Disruption to R&D efforts. A slowdown and delays in our research and development (“R&D”) projects, due to the effect of COVID-19 restrictions and constraints, might delay introductions of new products while exposing us to significant loss;

- Imposition of fines, penalties, damages and contract terminations (including the exercise of certain force majeure clauses), and damage to our reputation and relationship with our customers, as a result of delays in production, shipment, deliveries and services due to any of the above constraints;

- COVID-19 has had and could continue to have an adverse effect on our business as a result of the materialization of any of the above or similar risks with respect to our significant customers. Our business has been and could further be impacted negatively if there is a prolonged impact of COVID-19 in countries from which we generate a significant portion of our business. For example, this may cause, and to some extent has caused a freeze of procurement budgets, cancellation, suspension or reduction in new equipment purchases from us, failure by our customers in meeting their obligations under purchase orders already issued, postponement or cancellation of rollout projects, and postponement in the introduction of our new products and capabilities;

- Financial difficulties and insolvencies of major customers, which could lead to slowing the payment of their obligations to us or even discharging those obligations; and

- Difficulties in collection of amounts due from customers and in satisfying revenue recognition procedures.

- We are closely monitoring the developments and continually assessing the potential impact of COVID-19 on our business and the mitigation measures to minimize that impact. However, there is a global uncertainty with respect to the expected timing for the defeat of COVID-19. It is not clear for how long protective measures will continue to be imposed, how quickly the vaccination will be effective in stopping the continued spread of the virus and any mutation thereof globally, if at all, and whether there will be enough of the population vaccinated for such solution to become effective. As the scale and duration of these effects remain uncertain, further realization of any of the above-mentioned or other risks could have macro and micro negative effects on the global economy and financial markets in general, and on our business in particular, and cause a material risk to our operations, financial condition and share

price. Furthermore, to the extent that the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other factors described in this section.

Risk Factors Related to Our Business and Our Markets

A substantial majority of our sales have been to manufacturers in the Asia Pacific region, with China being our largest territory. The concentration of our sales and other resources within a particular geographical region, subjects us to additional material risks.

In 2021, our sales in the Asia Pacific region (mainly China, Taiwan and South Korea) accounted for approximately 83% of our total revenues with sales to China being the majority within this region. A number of Asian countries have experienced or could experience political and economic instability. For instance, Taiwan and China encountered a number of continuous disputes, as have North and South Korea, and Japan has experienced significant economic instability for a number of years. Additionally, the Asia-Pacific region is susceptible to the occurrence of natural disasters, such as earthquakes, cyclones, tsunamis and flooding. Changes in local legislation, changes in governmental policies, controls and regulations, trade restrictions, a downturn in economic or financial conditions, an outbreak of hostilities or other political upheaval, as well as any further extraordinary events having an adverse effect on the economy or business environment in this region, would likely harm the operations of our customers in these countries, may cause a significant decline in our future revenues and may have an adverse effect on our results of operations and cash flow. These general risks are heightened in China, which is our largest territory, where the nature of the economy, local legislation, governmental policies and regulatory environment are rapidly evolving and where foreign companies may face the negative effects of changed governmental policies, regulatory, business and cultural obstacles. Additionally, recent policies adopted by China with respect to trade, may present obstacles, such as regulatory restraints or significant increases in tariffs on goods imported into these markets.

Changes in global trade policies and other factors beyond our control may adversely impact our business, financial condition and results of operations, as we are dependent on international sales, which expose us to global political and economic risks that could impede our plans for expansion and growth.

The international environment in which we operate is affected from inter-country trade agreements and tariffs. Specifically, recent revisions made in the U.S. administrative policy with respect to China, as well as future actions of the U.S. administration and that of foreign governments with respect to tariffs or international trade agreements and policies are creating a global trade environment which remains currently unclear. The escalation of a trade war, tariffs, retaliatory tariffs or other trade restrictions on products and materials exported by us to China may significantly impede our ability to sell our products and provide services to our customers in China or other affected territories. Such developments may result in a decrease in demand for our products and technologies as well as delays in payments from our customers. Furthermore, other governmental action related to tariffs or international trade agreements, changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment in the territories and countries, where our customers are located, could adversely affect our business, financial condition, operating results and cash flows.

Our principal customers are located in the Asia Pacific region and the United States, and we manufacture our products in Israel. International operations expose us to a variety of risks that could seriously impact our financial condition and impede our growth including:

- Instability in political or economic conditions, including but not limited to inflation, recession, foreign currency exchange restrictions and devaluations, restrictive governmental controls on the movement and repatriation of earnings and capital, and actual or anticipated military or political conflicts, particularly in emerging markets;
- Rising inflation and elevated U.S. budget deficits and overall debt levels, including as a result of federal pandemic relief and stimulus legislation and/or economic or market and supply chain conditions, can put upward pressure on interest rates and could be among the factors that could lead to higher interest rates in the future.
- Higher interest rates could adversely affect our overall business or reduce our liquidity.

- Intergovernmental conflicts or actions, including but not limited to armed conflict, trade wars and acts of terrorism or war, including current war between Russia and Ukraine; and

- Interruptions to the Company's business with its largest customers, distributors and suppliers resulting from but not limited to, strikes, and financial instabilities. For instance, trade restrictions, changes in tariffs and import and export license requirements could adversely affect our ability to sell our products in the countries adopting or changing those restrictions, tariffs or requirements. This could reduce our sales by a material amount.

All of these risks could result in increased costs or decreased revenues, either of which could have a materially adverse effect on our profitability.

The global supply of electronic components, including integrated circuits, has experienced, and is likely to continue to experience, a sharp increase in demand, while production capacity remains limited. This has had, and may continue to have, an adverse effect on the lead-time for our components and increase in their prices.

The global demand for electronic components has experienced a sharp increase, with a growing number of industries dramatically increasing their demand and consumption. This, together with the effect of COVID-19 and trade restrictions, which have, for example, discouraged U.S. companies from using fabs in China, have led to a longer lead-time to receive electronic components, which in turn has led many companies to stock up and increase their inventory levels, which has added to the pressure on the supply chain and caused an increase in the prices of the electronic components. As a result of this situation, we may be unable to obtain essential components in a timely manner and at a reasonable cost that is necessary for us to remain competitive. During such times, supplier-specific or industry-wide lead times for delivery can be as long as twelve months or more. Industry-wide demand increases for such components could increase its market price as well as the market price of replacement parts and consumable materials needed to manufacture our products. If we are unable to obtain components in a timely manner to fulfill our customers' demand on technology and production capacity, or at a reasonable cost, we may be unable to meet commitments under our contracts with customers, which could expose us to substantial liquidated damages and other claims and could materially and adversely affect our results of operations, financial condition, business and prospects.

In the current highly competitive business environment, our customers require us to fill orders within a very short period of time. Our products are complex and require essential components and subsystems that are produced by a number of suppliers and subcontractors. In order to meet our customers' needs in the timeframe they require, we usually need to pre-order components and subsystems based on our forecasts of future orders, rather than on actual orders. While we believe that we have sufficient inventory to fill our customers' orders, our predictions may not correspond to our actual future needs and our suppliers and subcontractors cannot always supply such components and subsystems within a shorter than anticipated time frame; this concern is heightened due to the supply chain obstacles detailed above. Our inability to anticipate rapid market changes or the implications of the global components shortage may cause an increase of inventory which could result in material inventory write-offs, which we have incurred in the past, or may alternately limit our ability to satisfy customer orders, which could result in the loss of sales and could cause customers to seek products from our competitors. To date, we have successfully managed our supply chain, but if these factors continue or become more severe, they may have an adverse effect on our supply chain and on our ability to fulfill customer orders in a timely manner, which could in turn have an adverse effect on our position in the market and on our business and operations.

Our business could be materially disrupted by negative effects on the semiconductor industry.

The semiconductor industry, including semiconductor equipment industry, relies on a global supply chain and is considered strategically important by major trading countries. Political, economic and financial crises have in the past negatively affected the semiconductor industry and its end markets and could do so again in the future. Our business may also be materially affected by the impact of geopolitical tensions and related actions. Trade barriers have had a particular adverse impact on the semiconductor industry and related markets. Prolonged or increased use of trade barriers may result in a decrease in the growth of the global economy and semiconductor industry and could cause turmoil in global markets, which in turn often results in declines in our customers' electronic products sales and could decrease demand for our products and services. Also, any increase in the use of economic sanctions or export control restrictions to target certain countries and companies could impact our ability to continue supplying products and services to our customers globally and to our customers' demand for our products and services, and could disrupt semiconductor supply chains.

Any future systemic political, economic or financial crisis or market volatility, including interest rate fluctuations, inflation or deflation and changes in economic, trade, fiscal and monetary policies in major economies, could cause revenue or profits for us or the semiconductor industry as a whole to decline dramatically. If the economic conditions in the markets in which our customers operate or the financial condition of our customers were to deteriorate, the demand for our products and services may decrease and impairments, write-downs and other accounting charges may be required, which could reduce our operating income and net income.

Global and local price-pressures may increase our costs of operations

We have encountered during the last year, and there is a global concern that such trend will continue, an increase in the costs of raw materials, components, electric power and water, shipping and in turn the cost of the R&D, production and sales work-force. If the price pressure intensifies, this could materially and adversely affect our results of operations, financial condition and business.

Our customers' manufacturing processes are highly complex, costly and potentially vulnerable to impurities and other disruptions, and cost increases, that can significantly increase their costs and delay products' purchase by our customers.

Our customers' manufacturing processes are highly complex, require advanced and costly equipment, and are continuously being modified to improve manufacturing yields and product performance. Disruptions in manufacturing operations could be caused by numerous issues including impurities in raw materials (such as chemicals, gases and wafers), facilities issues (such as electrical power and water outages), equipment failures (such as performance issues or defects) or IT issues (such as down computer systems and viruses). For example, during 2021 Chinese provinces have implemented power rationing and diverted electricity to critical sectors due to coal shortages and in order to meet energy intensity targets. Any of these issues, and others, could lower production yields or interrupt manufacturing, which could result in the cancellation or delay of purchase of our products, as well as cause our customers to experience reduced revenues, increased costs or reduced quality delivered to their customers.

The markets we serve are highly competitive and have dominant market participants, some with greater resources than us. Such competition could adversely affect the terms on which we sell our products and may negatively affect our financial results.

The markets that we serve are highly competitive. During market slowdowns, competition is intensified due to the reduced demand for the products that we manufacture. When competitors respond to declining demand by offering discounts, free evaluation machines or more favorable credit terms, we may need to implement some or all of the same methods in order to maintain our market position. These could mean lower prices for our products and a corresponding reduction in our gross margin, as well as more favorable payment terms to our customers and a corresponding decline in our cash flow. If we have to lower prices to remain competitive and are unable to reduce our costs to offset price reductions or are unable to introduce new, higher performance products with higher prices, our operating results may be adversely affected. Some of our competitors have greater financial, personnel and other resources and offer a broader range of products and services. These competitors may be able to respond more quickly to new or emerging technologies or changes in customer requirements, develop additional or superior products, benefit from greater economies of scale, offer more aggressive pricing or devote greater resources to the promotion of their products. Other competitors are local smaller competitors, which target the low-end market and may offer products at lower prices. If we are unsuccessful in effectively responding to our competition, our financial results will be adversely affected by reduced revenues as well as lower margins, which may lead to financial losses.

Technology in the markets in which we operate is rapidly evolving, and we may not be able to adequately predict these changes or keep pace with emerging industry standards, which could lead to a loss of revenues or adversely affect our profits.

The markets for our products are characterized by changing technology, evolving industry standards, changes in end-user requirements and new product introductions. Our future success will depend on our ability to accurately predict new market needs and requirements and to enhance accordingly our existing products and develop and introduce new technologies for the markets in which we operate. These products must keep pace with technological developments and address the increasingly sophisticated needs of our customers. If we fail to anticipate correctly, or if we are unable to keep pace with, technological changes, products offered by our competitors or emerging industry standards, our ability to generate revenues may be negatively affected. Adopting new technologies may also result in material inventory write-offs which would adversely affect our results of operations.

Our operating results have varied, and will likely continue to vary significantly from quarter to quarter, and from our expectations for any specific period making it difficult to predict future results.

Our quarterly operating results have varied in the past and could continue to vary from quarter to quarter or from our expectations for any specific period in the future. This complicates our planning processes, reduces the predictability of our earnings and subjects our stock to price and volume fluctuations. Period-to-period comparisons of our results of operations may not always provide indications of our future performance.

Some of the factors that may influence our operating results include:

- global economic conditions and worldwide demand for electronic equipment;
- instability in the global markets and in the geopolitical environment in many parts of the world, including the current war between Russia and Ukraine, as well as other disruptions may continue to put pressure on global economic conditions;
- changes in demand for our systems;
- changes made by customers to orders for our systems and/or installation schedules;
- product introductions and the market penetration period of new products;
- rapid shifts in industry capacity;
- the size, timing and shipment of substantial orders;
- timing of evaluation and qualification of our products by new customers;
- lack of visibility/low levels of backlog from the preceding quarter;
- product mixes;
- pricing of our products;
- timing of new product, upgrades or enhancements;
- level of operating expenses such as R&D expenses, agent commissions;
- fluctuations in interest rates;
- an outbreak of a contagious disease, such as COVID-19, which may cause us or our suppliers and/or customers to temporarily suspend our operations in the affected city or country; and
- Because most of our revenues are generated in U.S. dollars, but a significant portion of our expenses is incurred in currencies other than U.S. dollars, and mainly New Israeli Shekels, our profitability may be seriously harmed by currency fluctuations.

In light of these factors and the cyclical nature of the markets we target, we expect to continue to experience significant fluctuations in our quarterly operating results.

We have expanded, and may further attempt to expand our activity within and/or beyond our current served markets, through M&A activity. Such activity may adversely affect our results of operations.

We have in the past expanded our activity to adjacent markets through M&A, and we may further decide to expand our activity through M&A activities. Such M&A activity could lead to post-merger integration difficulties and increased expenses; diversion of management's attention from our core business and operations; failure to estimate the acquired businesses' future performance and failure to execute on such expectations; inaccurate evaluation of the fair value of certain assets acquired, liabilities assumed and contingent liabilities; the loss of key employees of the acquired operations. We may incur significant costs in connection with seeking acquisitions or other strategic opportunities regardless of whether the transaction is completed and, to the extent applicable, in combining our operations if such a transaction is completed.

In addition, as a result of acquisition activity, our future results of operations may be influenced by the possibility of our incurring impairment charges as a result of decline in value of goodwill and other intangible assets, ongoing amortization of intangible assets acquired and financing expenses due to re-evaluation of contingent liabilities and other liabilities assumed presented at fair value (see also in Item 5.A below - "***Operating Results - Critical Accounting Policies***"). Future acquisitions could also result in potentially dilutive issuances of equity securities, a decrease in our cash resources, incurrence of debt, contingent liabilities or impairment charges related to goodwill and other intangible assets, any of which could harm our business. Furthermore, we compete for acquisition and investment opportunities with other well-established and well-capitalized entities. There can be no assurance that we will be able to locate acquisition or investment opportunities upon favorable terms.

Increased cyber-attacks, data breaches, risks and threats, along with changes in privacy and data protection laws could have an adverse effect on our business.

Threats to network and data security are constantly evolving and becoming increasingly diverse and sophisticated. Our servers and computer systems could be vulnerable to cybersecurity risks. An increasing number of organizations have disclosed breaches of their information security systems, some of which have involved sophisticated and highly targeted attacks. Given the substantial increase of cyber-attacks in recent years, we have implemented network security technological, operational and organizational measures and drafted an internal global information technology security policy. This policy, which follows industry best practices and focuses on Camtek's network and information security, was reviewed by our audit committee and board of directors. The possible cyber-attacks via unauthorized access, exploitation, manipulation, deception, corruption, disruption, damage, leak, theft or loss of our intellectual property or any other digital assets could result in liabilities to us and other material costs. Cyber-attacks aimed at our digital assets could accumulate increased costs to prevent, respond to or mitigate these incidents. It is also possible that our digital assets and business processes could be jeopardized, compromised or halted via cyber-attacks, without being noticed for some time.

Although we have not yet experienced any cyber-attacks that affected our operations, we have experienced several failed attempts to penetrate our systems and cannot fully guarantee that any potential cyber incidents will not have an adverse effect on our company in the future. Even though we have invested in implementing various cyber security solutions in our networks and systems, in order to mitigate and reduce our exposure to these cyber risks, we can provide no assurance that our current digital assets are fully protected against all sorts of cyber-attacks by malicious third parties. We have purchased a cyber-liability insurance policy to cover certain security and privacy damages. However, we cannot be certain that our coverage will be adequate for liabilities actually incurred. In addition, the potential liabilities associated with these events could exceed the insurance coverage we maintain as they could lead to financial losses, damage to our reputation, business processes, financial condition and results of operations.

The regulatory framework for data and privacy protection issues is rapidly evolving worldwide. New comprehensive data protection laws, including the General Data Protection Regulation ("GDPR"), which imposes stricter obligations and provides for greater penalties for noncompliance. We may be required to incur significant costs to comply with such data and privacy protection laws, as applicable to our company, or else face an adverse effect on our business prospects and/or financial position. As we have a presence in Europe, our European subsidiaries are subject to the GDPR in relation to their collection, control, processing, sharing, disclosure and other use of data relating to their employees or customers. These laws and regulations constantly evolve and remain subject to significant change. In addition, the application and interpretation of these laws and regulations are often uncertain. New privacy laws add additional complexity, requirements, restrictions and potential legal risk, require additional investment in resources to compliance programs, and could result in increased compliance costs and/or changes in business practices and policies.

Fluctuations in currency exchange rates may result in additional expenses being recorded or in the prices of our products becoming less competitive and thus may have negative impact on our profitability.

We are a global company that operates in a multi-currency environment. As a major portion of the costs of our Israeli operations, such as personnel, subcontractors, materials and facility-related costs, are incurred in NIS, an increase in the NIS value relative to the U.S. Dollar will increase our costs expressed in U.S. Dollars. We may, from time to time, take various measures designed to reduce our exposure to these effects, but any such steps may be inadequate to protect us from currency rate fluctuations. In addition, although our products' prices in most countries are denominated in U.S. Dollars, in certain territories (currently, Europe and Japan) our products' prices are denominated in local currencies, and much of our service income in these territories is denominated in local currencies. If there is a significant devaluation in the relevant local currencies in which we operate compared to the U.S. Dollar, we may be required to increase those prices and as a result our products and services may become less competitive.

A longer sales process for new products may increase our costs and delay time to market of our products, both of which may negatively impact our revenues, results of operations, cash flow and may result in inventory write-offs.

Our sales process to new and existing customers usually involves: demonstrations and testing against industry benchmarks in our sales centers; sales and technical presentations and presentations regarding our products' competitive advantages; and installation of the systems at the customer's site for side-by-side competitive evaluations for a period of approximately six months. More evaluation time is devoted during the initial market penetration period for new products such as new products under our Eagle product line, and for new customers in new markets, since these circumstances usually require qualification of the systems by the customers and engineering efforts to fix errors, customize tasks and add new features. Considering the above factors, the length of time until we recognize revenue can vary and affect our revenues, and results of operations. The long sales process may cause an increase in inventory levels and a risk for inventory write downs and write-offs; for more details regarding recent inventory write downs and write-offs see Item 5.A – "*Operating Results – Critical Accounting Policies – Valuation of Inventory*".

We depend on our intellectual property and litigation to enforce or defend our intellectual property rights may be costly and expose us to risks. If we are unable to protect our proprietary technologies, we may not be able to compete effectively as well as incur significant expenses.

Our intellectual property, including our patents, is material to the conduct of our business. Our success depends on our continued ability to use our intellectual property and on the adequate protection and enforcement of such intellectual property. There can be no assurance that the steps we take to protect and maintain our rights in our intellectual property will be adequate, or that third parties will not infringe, misappropriate or violate our intellectual property. If any of our efforts to protect our intellectual property is not adequate, or if any third party infringes, misappropriates or violates our intellectual property, the value of our products may be harmed. As a result, if we are unable to successfully protect, maintain, or enforce our rights in our intellectual property, there could be a material adverse effect on our business and results of operations. In addition, to the extent that we do, from time to time, institute litigation to enforce our intellectual property rights, such litigation could result in substantial costs and diversion of resources and could negatively affect profits, regardless of whether we are able to successfully enforce such rights.

Third parties, including one of our competitors in the field of semiconductor wafer inspection equipment, Rudolph Technologies Inc. ("Rudolph" which, on October 25, 2019, merged with Nanometric Inc. into a company named Onto Innovation Inc., hereinafter referred to as "Onto Innovation"), previously asserted claims, and may assert additional claims in the future, that we have infringed their patents or intellectual property rights. Following the settlement of \$13 million and dismissal of all of Rudolph's outstanding claims in 2017, we do not currently have any outstanding intellectual property claims against us (and, in accordance with the terms of the settlement agreement with Rudolph, no such claims were asserted by Rudolph within the three years following the execution thereof, i.e., until July 2020).

However, we may in the future face such intellectual property claims against us, which, even if without merit, could lead to protracted litigation, could cause delays in introducing new products, could be costly to defend and could divert management's attention from our business. As a result, any such claim could harm our business and cause a decline in our results of operations and financial condition, which in turn may materially and adversely affect our business and results of operations. Successful claims against us (such as the claim asserted by Rudolph regarding our Falcon product in which a final ruling was granted in Rudolph's favor in 2016) could impose on us monetary awards for damages, as well as for plaintiff's attorney's fees and other costs, and could limit our ability to sell products in certain jurisdictions. Additional costs and expenses may also be incurred in the event of out of court settlement of claims against us (such as the settlement of the Rudolph claims in 2017), which could result in monetary consequences and affect our profitability.

We differentiate our products and technologies from those of our competitors by using our intellectual property for the development of our products. We rely on a combination of patents, copyrights, trade secrets, trademarks, confidentiality and non-disclosure agreements to protect our intellectual property. These measures may not be adequate to protect our proprietary technologies and it may be possible for a third party, including a competitor, to copy or otherwise obtain and use our products or technologies without authorization or to develop similar technologies independently. The inability to protect our intellectual property may affect our competitive advantage and we may incur significant expenses.

We depend on a number of key personnel who would be difficult to replace.

Our continued growth and success significantly depend on the managerial and technical skills of the members of our senior management and key employees. If our operations rapidly expand, we believe that we will need to promote and hire qualified engineering, administrative, operational, financial and marketing personnel. In particular, we may find it difficult to hire key personnel with the requisite knowledge of our business, products and technologies. The process of locating, training and successfully integrating qualified personnel into our operations can be lengthy and expensive. During periods of economic growth, competition for qualified engineering and technical personnel is intense.

We may not sustain profitable operations or continue to have positive operating cash flows in the future.

Our ability to generate profits is dependent mainly on our ability to generate sufficient sales. In the future, our sales may not be sufficient to cover an increase in our expenses and we may not be able to maintain profitability, mainly during a protracted slowdown. We have from time to time in the past undertaken cost cutting initiatives in response to economic conditions, including reducing our worldwide workforce, and may again in the future have to undertake cost reduction initiatives. Our failure to maintain profitability or to continue to have positive operating cash flows may impact our ability to compete in the market for the short and long term and impair our financial condition.

Compliance with environmental, health, export controls, and other laws and potential liabilities could materially impact our business, results of operations and financial condition.

Due to our global operations, we must comply with certain international and domestic laws, export control regulations and restrictions which may expose our business to risks. In addition, our business is subject to numerous domestic laws and regulations designed to protect the environment, including with respect to discharges and management of hazardous substances, wastes and emissions and soil and ground water contamination. The failure to comply with current or future environmental requirements could expose us to criminal, civil and administrative charges and monetary liability. We believe that we have complied with these requirements and that such compliance has not had a material adverse effect on our results of operations, financial condition or cash flows. Although we are not presently aware of any liability that could be material to our business, financial condition or operating results, due to the nature of our business and environmental risks, we cannot provide assurance that any such material liability will not arise in the future.

We may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002.

The Sarbanes-Oxley Act of 2002 (the “**Sarbanes Oxley Act**”) imposes certain duties on us and our executives and directors, including the requirements of Section 404 (Assessment of Internal Control), which requires (i) management’s annual review and evaluation of our internal control over financial reporting and (ii) an attestation report issued by an independent registered public accounting firm on our internal control over financial reporting, in connection with the filing of our Annual Report on Form 20-F for each fiscal year. We have documented and tested our internal control systems and procedures in order for us to comply with the requirements of Section 404. Our efforts to comply with such requirements have resulted in increased general and administrative expenses and a diversion of management time and attention, and we expect these efforts to require the continued commitment of resources.

In addition, while our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2021, our internal control over financial reporting was effective, we cannot predict the outcome of our testing in future periods. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting. Failure to maintain effective internal control over financial reporting could result in investigation or sanctions by regulatory authorities, and could have a material adverse effect on our operating results, investor confidence in our reported financial information, and the market price of our ordinary shares.

Risks Relating to Our Ordinary Shares

Sales of our ordinary shares may depress our share price.

Offerings of ordinary shares by us and any issuances or sales of a substantial number of ordinary shares in the public market or otherwise, or the perception that such sales may occur, could cause the market price of our ordinary shares to decline or could impair our ability to raise capital through a future sale of our ordinary shares. In addition, we have issued a substantial number of ordinary shares in connection with the exercise of options to purchase our ordinary shares, and in the future we may issue additional shares in connection with the exercise of existing options, which are eligible for, or may become eligible for, unrestricted resale. Any sales of such shares in the public market or otherwise could reduce the prevailing market price of our ordinary shares, as well as make future sales of ordinary shares by us less attractive or not feasible, thus limiting our capital resources.

Our share price and trading volumes have demonstrated significant volatility in the past and may continue to fluctuate in the future. Such share price volatility could limit investors' ability to sell our shares at a profit, could limit our ability to raise funds successfully and may cause additional exposure for securities class action litigation.

The stock market in general and the market price of our ordinary shares, in particular, are subject to fluctuation. As a result, changes in our share price may be unrelated to our operating performance. The price of our ordinary shares has experienced significant volatility in the past and may continue to do so in the future. During the period from January 1, 2021 through March 9, 2022, the closing price of our ordinary shares ranged from \$21.50 to \$48.15 per share. The price volatility of our shares and periodic volatile trading volume may make it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time or to plan purchases and sales in advance. A variety of factors may affect the market price and the trading volume of our ordinary shares, including:

- global economic conditions, which generally influence stock market prices and volume fluctuations, including as a result of the effects of COVID-19 and the current war between Russia and Ukraine;
- investors' views of the attractiveness of our new products;
- changes in expectations as to our future financial performance and/or announcements of actual results that vary significantly from such expectations;
- the announcement by us or our competitors of corporate transactions, merger and acquisition activities or other similar events impacting our financial performance;
- changes in financial estimates by securities analysts;
- our earnings releases and the earnings releases of our competitors;
- market conditions relating to our customers' industries;
- announcements of technological innovations or new products by us or our competitors;
- other announcements, whether by us or others, referring to our financial condition, results of operations and changes in strategy;
- large block transactions in our ordinary shares;
- additions or departures of our key personnel;
- future offerings or sales of our ordinary shares; and
- announcements of significant claims or proceedings against us. Many of these factors are out of our control, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.

Moreover, the market prices of equity securities of companies that have a significant presence in Israel may also be affected by the changing security situation in the Middle East and particularly in Israel. As a result, these companies may experience volatility in their share prices and/or difficulties in raising additional funds required to effectively operate and grow their businesses. Thus, market and industry-wide fluctuations and political, economic and military conditions in the Middle East may adversely affect the trading price of our ordinary shares, regardless of our actual operating performance. Further, as a result of the volatility of our stock price, we could be subject, and were subject in the past, to securities litigation, which could result in substantial costs and could divert management's attention and Company resources from business. Securities class action litigations are being brought from time to time against companies following periods of volatility in the market price of their securities, and in the past, one was brought against us. Although this claim was dismissed, we cannot guarantee that similar litigation would not be brought against us in the future.

Our principal shareholders, Prioritech and Chroma, hold a controlling interest in us and could be able to exercise their control in ways that may be adverse to the interests of our other shareholders. Our relationship with Prioritech and Chroma may give rise to a conflict of interests.

Prioritech Ltd. (“Prioritech”) and Chroma ATE Inc. (“Chroma”), beneficially hold in the aggregate 38.94% of our issued and outstanding ordinary shares. As a result of the voting agreement between Prioritech and Chroma, according to which they vote together in Camtek’s shareholders meetings and therefore deemed to be joint controlling shareholders of Camtek, they have the ability to influence the outcome of certain matters submitted to a vote of Camtek’s shareholders, including the election of members of its board of directors and the approval of significant corporate transactions. This concentration of ownership may also have the effect of making it more difficult to obtain approval for a change in control of Camtek. Mr. Rafi Amit, our Chief Executive Officer and Chairman of the Board, and Mr. Yotam Stern, a member of our Board, hold, as of March 10, 2022, an aggregate of approximately 20.33% of the voting power at Prioritech’s general meeting of shareholders, through a voting agreement with David Kishon, Itzhak Krell (deceased), Haim Langmas (deceased), Zehava Wineberg (deceased) and Hanoch Feldstien (including the estates of the foregoing deceased founders, the “Founding Members”), governing inter-alia joint voting at Prioritech’s general meetings of shareholders and the right of first refusal among themselves (the “Prioritech Voting Agreement”), and as such may be deemed to control Prioritech. Messrs. Amit and Stern also hold various positions in Prioritech and its affiliated companies, which may give rise to conflicts of interest. Mr. Amit, who serves as our Chief Executive Officer on a 90% position, acts as Prioritech’s Chairman of the board of directors and provides consulting and management services to Prioritech on a 10% basis. Mr. Stern holds several other positions in the Prioritech group including the position of Chief Executive Officer at Prioritech.

In addition, in the framework of the series of definitive agreements signed in February 2019, in which Chroma acquired ordinary shares from Prioritech and additional new shares were issued to Chroma by Camtek, Leo Huang, the chairman of the board of directors and a controlling shareholder of Chroma, and I-Shih Tseng, a director and Business Unit President of Chroma, were appointed to serve as members of our board of directors, which may give rise to conflicts of interest. Despite our efforts to conduct ourselves by Israeli law procedural requirements concerning interested party transactions, including with respect to audit committee, board of directors and shareholder approvals (including the special majority requirement in appropriate cases), we cannot be certain that the possible conflicts of interest in any of these transactions and activities is fully eliminated. For more details regarding our senior management arrangements, see Item 6.B below - *“Compensation – Employment Agreements”*.

If we are classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences.

There is a risk that we may be classified as a passive foreign investment company (“PFIC”). Our treatment as a PFIC could result in a reduction in the after-tax return of U.S. holders of our ordinary shares and may generally cause a reduction in the value of our shares. For U.S. federal income tax purposes, we will generally be classified as a PFIC for any taxable year in which either: (i) 75% or more of our gross income is passive income, or (ii) at least 50% of the average value of our total assets (generally determined on a quarterly basis) for the taxable year consist of assets that produce or are held for the production of passive income. Based on an analysis of our current income, assets, activities and market capitalization and expectations about our future, income, assets, activities and market capitalization, we do not believe that we were a PFIC for the taxable year ended December 31, 2021 and do not expect to be a PFIC for the current year or in the foreseeable future. However, there can be no assurance that the U.S. Internal Revenue Service (“IRS”) will not challenge our analysis or our conclusion regarding our PFIC status. This is a factual determination that must be made annually after the close of each taxable year. The value of our assets for purposes of the PFIC determination may be determined by reference to the public price of ordinary shares, which could fluctuate significantly. Therefore, there can be no assurance that we will not be classified as a PFIC for the current taxable year or in the foreseeable future. If we were a PFIC at any time when a U.S. holder acquired or held our ordinary shares, such U.S. holder generally will be subject to the PFIC rules with respect to such ordinary shares. If we were determined to be a PFIC for U.S. federal income tax purposes, highly complex rules would apply to U.S. holders owning our ordinary shares and such U.S. holders could suffer adverse U.S. tax consequences. For more information, please see Item 10.E below - *“U.S. Federal Income Tax Considerations– Tax Consequences if We Are a Passive Foreign Investment Company”*.

Our ordinary shares are traded on more than one market and this may result in price variations.

In addition to being traded on the Nasdaq Global Market, our ordinary shares are traded on the Tel Aviv Stock Exchange (“TASE”). Trading in our ordinary shares on these markets take place in different currencies (U.S. Dollars on Nasdaq and NIS on TASE) and at different times (resulting from different time zones, trading days and public holidays in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading price of our ordinary shares on the other market.

Risks Relating to Our Operations in Israel

Conditions in the Middle East and Israel may adversely affect our operations.

Our headquarters and sole facility (including manufacturing facilities) are located in the North of the State of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly influence our operations. Specifically, we could be adversely affected by hostilities involving Israel; the interruption or curtailment of trade between Israel and its present trading partners; a downturn in the economic or financial condition of Israel; and a full or partial mobilization of the reserve forces of the Israeli army. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Middle Eastern neighbors. While Israel has entered into peace arrangements and/or understandings with Egypt, Jordan, UAE, Bahrein, Sudan and Morocco, it has no peace arrangements with any other neighboring or Arab countries. Over the years, this state of hostility, varying from time to time in intensity and degree, has led to security and economic problems for Israel.

Further, all efforts to improve Israel’s relationship with the Palestinians have failed to result in a permanent peaceful solution, and there have been numerous periods of hostility as well as civil insurrection of Palestinians in the West Bank and the Gaza Strip in recent years. Also, relations between Israel and Iran continue to be hostile, due to the fact that Iran is perceived by Israel as sponsor of Hamas (a militia group and political party controlling the Gaza Strip) and Hezbollah (a Shia Islamist political party and militant group based in Lebanon), while maintaining a military presence in Syria, and with regard to Iran’s nuclear program. The recent maritime attacks over Israeli civil targets contributed to the tension in the region and further intensified the hostility between Iran and Israel and between Israel and Hezbollah, which operates adjacent to Israel’s northern border.

Lastly, Israel has been engaged, from time to time, in armed conflicts with Hamas. These conflicts involve missile strikes against civilian targets in the southern parts of Israel and have also involved such missile strikes against central parts of Israel, most recently in May 2021. All of the above raise a concern as to the stability in the region, which may affect the political and security situation in Israel and therefore could adversely affect our business, financial condition and results of operations. Furthermore, the continued conflict with the Palestinians is already disrupting some of Israel’s trading activities. Certain countries, primarily in the Middle East, but also in Malaysia and Indonesia, as well as certain companies and organizations around the world, continue to participate in a boycott of Israeli brands, and others doing business with Israel and Israeli companies. The boycott, restrictive laws, policies or practices directed towards Israel or Israeli businesses could, individually or in the aggregate, have a material adverse effect on our business, for example by way of sales opportunities that we could not pursue or from which we will be precluded in the future. In addition, should the BDS Movement, the movement for boycotting, divesting and sanctioning Israel and Israeli institutions (including universities) and products become increasingly influential in the United States and Europe, this may also adversely affect our business and financial condition. Further deterioration of our relations with the Palestinians or countries in the Middle East could expand the disruption of international trading activities in Israel, may materially and negatively affect our business conditions, could harm our results of operations, and adversely affect the share price of our ordinary shares.

Our business may also be disturbed by the obligation of personnel to perform military service. Our employees who are Israeli citizens are generally subject to a periodical obligation to perform reserve military service, until they reach the age of 45 (or older, for reservists with certain occupations), but during military conflicts, these employees may be called to active duty for longer periods of time. In response to the increase in violence and terrorist activity in the past years, there have been periods of significant call-ups for military reservists and it is possible that there will be further military reserve duty call-ups in the future. In case of further regional instability such employees, who may include one or more of our key employees, may be absent for extended periods of time, which may materially adversely affect our business. Furthermore, our Company’s insurance does not cover any loss arising of events related to the security situation in the Middle East. While the Israeli government currently covers the reinstatement value of direct damages caused by acts of war or terror attacks, we cannot be certain that such coverage will be maintained. We can give no assurance that the political, economic and security situation in Israel will not have a material adverse impact on our business in the future.



Our ability to take advantage of Israeli government programs and tax benefits may change, which could increase our tax expenses.

We have previously participated in certain Israeli government programs and enjoyed certain tax benefits, particularly tax exemptions, resulting from our “Approved Enterprise” status, provided to us due to our manufacturing facilities in Israel. In order to continue to be eligible for these programs, or similar programs, and tax benefits, we must continue to meet certain conditions, including making specified investments in fixed assets and equipment. If we fail to meet such conditions in the future, these tax benefits could be cancelled, and we could be required to refund any tax benefits already received. Further, these programs and tax benefits may not continue in the future at their current levels or at any level. The termination or reduction of these tax benefits would likely increase our tax liability. For information regarding the above-mentioned tax benefits, see Item 10.E below – “*Taxation – Israeli Taxation - Tax Benefits under the Law for the Encouragement of Capital Investments, 1959.*”

The government grants we received for know-how research and development expenditures impose certain restrictions on utilization of the funded grants and may expose us to payment of royalties in connection with the commercialization thereof.

We have received government grants from the Israel Innovation Authority (the “IIA”) for the financing of a portion of our research and development expenditures over the years. Even following full repayment of any IIA grants, and unless otherwise agreed by the applicable authority of the IIA, we must nevertheless continue to comply with the requirements of the Encouragement of Industrial Research and Development Law, 1984 and the regulations promulgated there under (together: the “R&D Law”), with respect to technologies the development of which was financed by such grants (the “Financed Know-How”), including an obligation for repayment of such grants from sales of products based on the Financed Know-How, if and when such sales occur.

In addition to the obligation to pay royalties to the IIA, the R&D Law requires that products which incorporate Financed Know-How be manufactured in Israel, and prohibits the transfer of the Financed Know-How and any right derived therefrom to third parties, unless otherwise approved in advance by the IIA. Such prior consent may be given by the IIA subject to payment of increased royalties. Although as of the date of this Annual Report, no Financed Know-How is used or incorporated in our current or currently anticipated product lines, these restrictions and requirements for payment could in the future – if and as applicable – impair our ability to sell such Financed Know-How, or to outsource or transfer manufacturing activities with respect to any product or technology based on Financed Know-How, outside of Israel.

Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of Financed Know-How (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA. For more information regarding the above-mentioned and other restrictions imposed by the R&D Law and regarding grants received by us from the IIA (and the repayment thereof), see Item 4.B below - “*Business Overview – The Israel Innovation Authority*”.

It may be difficult to enforce a U.S. judgment against us or our officers and directors, or to assert U.S. securities law claims in Israel.

We are incorporated under the laws of the State of Israel. Service of process upon our directors and officers, all of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore, because the majority of our assets and all of our directors and officers are located outside the United States, any judgment obtained in the United States against us or any of them may not be collectible within the United States. Further, it may be difficult for an investor to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear such a claim, it is not certain whether Israeli law or U.S. law will be applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by an expert witness, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing these matters.

Being a foreign private issuer exempts us from certain SEC requirements and Nasdaq Rules, which may result in less protection than is afforded to investors under rules applicable to domestic issuers.

We are a “foreign private issuer” within the meaning of rules promulgated by the SEC. As such, we are exempt from certain provisions under the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”) applicable to U.S. public companies, including:

- the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q and current reports on Form 8-K;
- the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of securities registered under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives as well as disclosure of the compensation determination process;
- the provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information; and
- the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and establishing insider liability for profit realized from any “short-swing” trading transaction (a purchase and sale, or sale and purchase, of the issuer’s equity securities within less than six months).

In addition, we are permitted to follow certain home country corporate governance practices and law instead of those rules and practices otherwise required by Nasdaq for domestic issuers. For instance, we have relied on the foreign private issuer exemption with respect to shareholder approval requirements for equity-based compensation plans, with respect to the Nasdaq requirement to have a separate compensation committee and a formal charter for such committee, and with respect to the quorum requirement for the convening of general meetings of shareholders; See in Item 16G. “**Corporate Governance**” below. Following our home country corporate governance practices, as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq, may provide less protection to investors than is afforded under the Nasdaq Rules applicable to domestic issuers.

Provisions of Israeli law may delay, prevent or make undesirable an acquisition of all or a significant portion of our shares or assets.

Israeli corporate law regulates mergers and acquisitions and requires that a tender offer be effected when certain thresholds of percentage ownership of voting power in a company are exceeded (subject to certain conditions), which may have the effect of delaying, preventing or making more difficult a merger with, or acquisition of, us. See Item 10.B - “**Memorandum and Articles - Anti-Takeover Effects of Israeli Laws; Mergers and Acquisitions Under Israeli Law**” below. Further, Israeli tax considerations may make potential transactions undesirable to us, or to some of our shareholders whose country of residence does not have a tax treaty with Israel, granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred. See Item 10.E - “**Taxation - Israeli Taxation**” below. In addition, in accordance with the Restrictive Trade Practices Law, 1988 and under the R&D Law, approvals regarding a change in control (such as a merger or similar transaction) may be required in certain circumstances. For more information regarding such required approvals please see in Item 4.B - “**Business Overview - The Israel Innovation Authority**” below.

In addition, as a corporation incorporated under the laws of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988 and the regulations promulgated thereunder (formerly known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances to obtain the approval of the Israel Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or substantially all of our assets. These provisions of Israeli law could have the effect of delaying or preventing a change in control and may make it more difficult for a third-party to acquire us, even if doing so would be beneficial to our shareholders, and may limit the price that investors may be willing to pay in the future for our ordinary shares.

Shareholder rights and responsibilities are governed by Israeli law which differs in some respects from the rights and responsibilities of shareholders of U.S. companies.

Since we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our articles of association, as amended from time to time (our “**Articles**”) and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in United States-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to a company’s articles of association, an increase of a company’s authorized share capital, a merger of a company and approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders.

In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of an Office Holder in a company, or who otherwise has the power to direct a company’s operations, has a duty to act in fairness towards such company. Israeli law does not define the substance of this duty of fairness and there is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.

Item 4. Information on the Company.

A. History and Development of the Company

Our legal and commercial name is Camtek Ltd. We were incorporated under the laws of the State of Israel in 1987 and operate under the Companies Law. Our headquarters are located in Ramat Gavriel Industrial Zone, P.O. Box 544, Migdal Ha’Emek 23150, Israel, and our telephone number is +972-4-604-8100. Other than Israel, we currently have operations in the Asia Pacific region, North America and Europe. Our agent for service of process in the United States is Camtek USA, Inc., located at Fremont Blvd., Ste. 112, Fremont, California 48389, Tel: 510-624-9905. We have been a public company since July 2000. Our ordinary shares are listed on the Nasdaq Global Market and on the TASE.

In our first years of operation, we provided manual optical inspection equipment to address the needs of the PCB industry. In September 2001, we acquired a developer and producer of Automatic Optical Inspection (AOI) Inspection systems for the semiconductor fabrication industry. This acquisition allowed us to enter the back-end semiconductor inspection market. After a period of intense internal research and development, in the fourth quarter of 2003, we shipped our first new Falcon system for the back-end market of the semiconductor industry. The first revenue recognition of the Falcon system was in the second quarter of 2004. In the following years, applying our core technologies, we introduced three additional Inspection and Metrology product lines for the semiconductor industry - the Condor, the Gannet and the Eagle; sales of all four semiconductor Inspection and Metrology product lines have since accounted for a significant portion of our total sales. In 2017, we consolidated all of our products for the semiconductor industry (which, following the PCB Sale Transaction in 2017 (see in this Item 4.A below), constitute all of our product lines) under the Eagle product lines. See in Item 4.B - “**Business Overview**” below.

In 2017, we concluded the sale of our Printed Circuit Board (“PCB”) inspection business unit (the “PCB Sale Transaction”), to Trophy Imaging Technology Co. Ltd. Pursuant to the PCB Sale Transaction, we sold the entire assets and activity of our PCB business unit (including our subsidiaries in China and Taiwan which were engaged primarily in such activity), in consideration for a total cash payment of \$32 million at closing and an additional cash amount of \$1.257 million, the payment of which was conditioned upon the financial performance of the PCB business unit and was made in full in 2019. Since the closing of the PCB Sale Transaction, we have devoted, and will continue to devote, our resources and attention to further developing and expanding our semiconductor Inspection and Metrology field of activity.

Further, as a result of our acquisition of the assets and certain liabilities of Printar Ltd. (“Printar”) in 2009, we became involved in the field of the Functional InkJet Technology (“FIT”), which we gradually reduced over a few years, until eventually reaching the decision to fully cease such activity in 2018. In 2009 we also completed the acquisition of the entire share capital of SELA – Semiconductor Engineering Laboratories Ltd. (“Sela”) which was engaged in the development, manufacturing and marketing of automated SEM (Scanning Electron Microscope) and TEM (Transmission Electron Microscope) sample preparation equipment, primarily for the front-end semiconductor industry. In 2015, the Company concluded a definitive agreement for the transfer of the Sela division activity (assets and liabilities) to a company fully owned by Sela’s long time business manager, thereby effectively terminating any and all involvement of the Company in the Sela business.

In July 2000, we sold 5,835,000 ordinary shares in an initial public offering, in which we received net proceeds of approximately \$35 million. In August 2002, we sold 5,926,730 ordinary shares in a rights offering of ordinary shares to our then existing shareholders (of which 5,922,228 shares were sold to Priortech), in which we received net proceeds of \$6.1 million. On August 23, 2005, we raised \$5 million as a convertible loan from FIMI Opportunity Fund L.P and FIMI Israel Opportunity Fund, Limited Partnership (FIMI), which amount was repaid in full by August 2010. On April 30, 2006, we completed a private placement in which we issued 2,525,252 ordinary shares to Israeli institutional investors at a price of \$5.94 per share, raising \$14.5 million. In May 2015, we completed a public offering of our shares on Nasdaq in which we issued 4,655,982 shares at a price of \$2.85 per share, raising net proceeds of \$11.9 million. In November 2020, we issued 4,025,000 ordinary shares in a public offering, which included the full exercise of the underwriters’ option to purchase 525,000 ordinary shares, at a price of \$17.00 per share, raising \$64.3 million net of underwriting discounts and commissions and other offering expenses. In November 2021, we closed an offering of \$200 million aggregate principal amount of 0% Convertible Senior Notes due 2026 (“Convertible Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act, which included the full exercise of underwriters’ option to purchase an additional \$25 million of Convertible Notes, raising \$194.5 million net of underwriting discounts and commissions and other offering expenses.

In February 2019, the Company signed a series of definitive agreements, referred to as the “Chroma Transaction”, in the framework of which Chroma acquired a total of 6,117,440 ordinary shares from Priortech at a price of \$9.50 per share, and an additional 1,700,000 new shares were issued to Chroma by the Company, at the same price of \$9.50 per share; as of March 8, 2022, Chroma holds 17.83% of our ordinary shares, while Priortech holds 21.11% of our ordinary shares. The Chroma Transaction was closed in June, 19, 2019 (the “Chroma Closing Date”), following the occurrence of closing conditions defined therein, including the approval of the Chroma Transaction by the Company’s shareholders in the 2019 AGM (as defined below) as well as the grant of approvals by certain regulatory bodies, including the Committee on Foreign Investment in the United States (CFIUS) and the Taiwan Overseas Foreign Investment Commission (MOEAIC).

In addition, the Company entered into a Technological Cooperation Agreement with Chroma under which the Company granted Chroma a license for an application under Company’s triangulation technology platform. In addition, Priortech and Chroma entered into a voting agreement according to which they vote together in the Company’s shareholders meetings and have joint control over the Company (the “Chroma Voting Agreement”). Under the Chroma Voting Agreement, Chroma is entitled to nominate individuals for two seats on the Company’s eight-member Board and Priortech is entitled to nominate three members. The remaining seats are held by two external directors. The Company also entered into a Second Amended and Restated Registration Rights Agreement with Priortech and Chroma, according to which Chroma is entitled to the same rights Priortech has with respect to registration of our shares (see Item 7.B. – “**Related Party Transactions**”).

For a discussion of material cash requirements, including capital expenditures, see Item 5.B - “*Liquidity and Capital Resources*” below.

The SEC maintains an Internet web site at <http://www.sec.gov> that contains reports and other material that are filed through the SEC’s Electronic Data Gathering, Analysis and Retrieval, or EDGAR, system. Our website is located at www.camtek.com. The information on our website is not incorporated by reference into this Annual Report.

B. *Business Overview.*

Our Business

Camtek is a developer and manufacturer of high-end inspection and metrology equipment for the semiconductor industry. Camtek’s systems inspect IC and measure IC features on wafers throughout the production process of semiconductor devices, covering the front and mid-end and up to the beginning of assembly (Post Dicing). Camtek’s systems inspect wafers for the most demanding semiconductor market segments, including Advanced Packaging, Memory, CMOS Image Sensors, Power, RF and MEMS, serving the industry’s leading global IDMs, OSATs, and foundries.

Semiconductors wafers are scanned under the advanced optic heads (2D Inspection and metrology and 3D metrology) in our systems, advanced software and algorithms are implemented on the scanned wafers data, as a result our systems automatically sort good dies and defected dies, the defected dies will be sort out of the production lots and will not be inserted into a package or a product. Hence, the total end product yield is enhanced by ensuring that only known good dies will be shipped to end-users. The systems are easy to operate and offer high accuracy and productivity in high volume manufacturing environments. These systems incorporate proprietary advanced image processing software and algorithms, as well as advanced electro-optics and precision mechanics and are designed for easy operation and maintenance. Our global, direct customer support organization provides responsive, local pre- and post- sales support for our customers through our wholly owned subsidiaries located in 8 offices around the world.

Inspection and Metrology are implemented at various stages along the semiconductor manufacturing process. Camtek’s systems serve various manufacturing stages starting from the front-end macro inspection and Outgoing Quality Control (OQC), through Inspection and Metrology of bumps in the mid-end and the inspection of post-diced wafers in the back end (Assembly).

Our Markets

The semiconductor manufacturing industry produces integrated circuits mainly on silicon wafers but also on other materials. Each wafer contains numerous integrated dice containing microelectronic devices. The growth of the semiconductor manufacturing industry in the past few years has been driven largely by demand from electronics such as smartphones and the proliferation of applications including the Internet of Things and cloud computing. Continued growth is expected with the enhancements of existing products, the introduction of the 5G networks and the inclusion of emerging technologies such as Artificial Intelligence (AI), as well as rapid growth in automotive and industrial electronics. The effect of such market growth trends on the demand of Inspection and Metrology systems is driven by two main factors: (i) growing electronic devices manufacturing volume requires more equipment (ii) applications such as automotive and mobile phones require a higher level of reliability and hence more Inspection and Metrology.

In the fast-growing advanced packaging market segment, which includes wide variety of devices and technologies, a new inspection and measurements steps become crucial to ensure a known good package. The bumps are becoming the main interface instead of the conventional wire bonding. There is a wide variety of bump types and sizes which are used for different packaging requirements. Camtek’s systems are equipped with state-of-the-art metrology and inspection capabilities designed to address many of those inspection and metrology steps, including bump height, die stack planarity, RDL dimensions and surface defects. These are examples of typical process steps where inspection and metrology are critical to ensure high quality products.

Wafers with tens of millions of bumps in very dense architecture are becoming more common and require 100% inspection and metrology due to the packaging reliability requirements. The high cost of packages which in many cases combine multiple dice requires Known Good Dice in order to ensure that each die in the package is fully functional. Camtek's systems are designed to deliver 100% Inspection and Metrology in high volume manufacturing environment, without compromising on throughput and performance. We expect that the two fastest growing segments in advanced packaging will be the Heterogeneous Integration (HI), which is becoming the standard for high performance computing, and Fan Out Wafer Level Packaging (FOWLP). Camtek's flexible inspection and metrology systems utilize a wide variety of technologies to address the complex requirements of these growing segments.

The shift of memory devices to advanced packaging is growing to support high-end systems. A good example is High Bandwidth Memory (HBM) of DRAM dice stacked on top of each other enabling higher bandwidth at less power consumption. Camtek provides 100% inspection and metrology of all the components in the stack ensuring known-good-package.

Another fast-growing segment is the CMOS image sensors ("CIS") used for cameras. With the growing number of cameras in each mobile phone and the increase in the number of pixels per each sensor and reduction in the size of each pixel, a high-resolution inspection is mandatory. Camtek has developed unique capabilities to address these requirements and its systems are being used by the largest CIS manufacturers.

The transition toward 5G, the fifth generation of cellular networks, also creates opportunities for Camtek. 5G smartphones and provides improved efficiency and wide bandwidth, by using an increased number of RF filters (up to three times the former amount) with much smaller geometries. These challenges require more accurate and, in many cases, 100% inspection and metrology. Camtek offers dedicated inspection solutions to support the growing RF manufacturing market, enabling high-volume manufacturing at high throughput

Compound semiconductors are undergoing a major expansion addressing many new applications and using various materials such SiC, GaN, GaAs and others, to improve the performance of new devices such as Power and Face Recognition applications

The compound semiconductors manufacturing process is unique and requires dedicated solutions for Inspection and Metrology. Camtek's offering includes the inspection of Epitaxial layers, inner cracks within the Epitaxial layer, surface topography, Bow measurement, data analysis and more.

During the last couple of years, Camtek has penetrated the macro inspection in the Front End of the manufacturing process addressing the challenges of defect-free and high-yield wafer manufacturing. The variety of defects calls for detection optimization, fast screening and categorization of the high-volume manufacturing environment, while maintaining high throughput. Camtek's Eagle platform can handle these challenges and detect all defects of interest at high volume manufacturing rate.

Product Lines

Inspection and Metrology Systems

Our systems consist of:

- an electro-optical assembly unit which consists of a video camera, precision optics and illumination sources. The electro-optical unit captures the image of the inspected product;
- a precise, movable table, that holds the inspected product; and
- an electronic hardware unit, which operates the entire system and includes embedded components that process and analyze the captured image by using our proprietary algorithms.

The inspected product is placed on a designated platform and is scanned under the optical assembly unit. The optical assembly unit then captures images of the product, while the electronic hardware unit processes the image using the analysis algorithms. Detected discrepancies are logged and reported as defects per the user definitions. The image of the defect is immediately available for verification by the system operator. Our systems can also compile and communicate statistical reports of inspection findings via the customer's factory information system.

We offer a broad range of systems for automated optical Inspection and Metrology of semiconductor wafers. We invest significant resources in R&D to provide our customers with advantageous performance, low cost of ownership, high reliability and ease of operation. We believe that a significant part of our competitive advantage derives from our R&D innovative capabilities which enable us to adapt our technologies to evolving market needs and customers' requirements.

Over the years, our Inspection and Metrology products for the semiconductor industry included the Falcon, Condor, Gannet and Eagle products lines. As of today, we produce and sell only the Eagle platform and have phased out all other models.

Product	Function
Eagle-i	The Eagle-i system family is designed for high volume 2D inspection, delivering superior 2D inspection and 2D metrology capabilities. The system utilizes the most advanced algorithms enabling detection of down to sub-micron defects and measuring two micron line and space redistribution layer (“RDL”). The Eagle-i system family includes the Eagle ^T -I and Eagle ^T -I <i>Plus</i> models, which were designed for better accuracy and optical resolutions and higher throughput.
Eagle-AP	The Eagle-AP system family addresses the fast-growing advanced packaging market using state of the art technologies, both software and hardware, that deliver superior 2D and 3D inspection and metrology capabilities on the same platform. The Eagle-AP metrology capabilities support the wide spectrum of bump sizes and all bump types, including copper pillars, micro-bumps, solder and gold bumps, meeting the advanced packaging market requirements, including measurement of bumps down to 2µm (microns) and providing high throughput. The Eagle-AP system family includes the Eagle ^T -AP and Eagle ^T -AP <i>Plus</i> models, equipped with higher throughput and improved metrology capabilities.
Golden Eagle	Designed mainly for Fanout Panel-Level-Package (FO-PLP) applications, Camtek’s Golden Eagle is used for the inspection and metrology of standard panel sizes, up to 650mm x 650mm. The Golden Eagle addresses the challenges of Fanout Wafer Level Packaging (FOWLP), while providing a robust system that addresses high-volume manufacturing requirements.

In addition, we intend to offer certain software solutions we develop, such as the Automatic Defect Classification (ADC), which provides automatic defect classification of color images, utilizing deep learning techniques, and will enable our customers to reduce and even eliminate manual verification.

Customers

We target wafer manufacturers and companies involved in the testing, assembly and packaging of semiconductor devices.

Our customers are semiconductor manufacturers, among them outsourced semiconductor assembly and test (OSAT), integrated device manufacturers (IDMs) and wafer level packaging subcontractors. Our customers, many of whom have multiple facilities, are located throughout Asia, Europe and North America. In 2019, one customer accounted for 11% of our total revenues. However, in 2020 and 2021, no individual customer accounted for more than 10% of our total revenues. As of December 31, 2021, our installed base was over 1,500 systems.

The following table shows our revenues classified by geographical region for each of the last three years:

	Year Ended December 31,		
	2021	2020	2019
U.S. Dollars (In thousands)			
Asia Pacific	224,931	137,555	115,925
United States	28,641	9,847	10,388
Europe	16,087	8,457	7,706
Total	269,659	155,859	134,019

Marketing and Customer Support

We have established a global distribution and support network throughout the territories in which we sell, install and support our products, including the Asia Pacific region, North America and Europe. We believe that this is an essential factor in our customers' decision to purchase our products. We primarily utilize our own employees to provide these customer support services. We may expand our network into additional territories as market conditions warrant.

We have a distribution rights agreement with a Japanese company, under which this company sells, installs and supports our products in Japan.

As of December 31, 2021, 160 of our employees were engaged in our worldwide marketing and support efforts, including support and marketing administration staff. Due to the concentration of customers in the Asia Pacific region, we have significantly expanded our marketing and support teams in this region.

Our marketing efforts include participation in various trade shows and conventions, publications and trade press, product demonstrations performed at our facilities and regular contact with customers by marketing personnel. We generally provide a 12-month warranty to our customers. In addition, for a fee, we offer service and maintenance contracts commencing after the expiration of the warranty period. Under our service and maintenance contracts, we provide prompt local, on-site customer support. Our experienced local teams have been able to install and support our customers throughout the pandemic with virtual support, as needed, from our experts in the headquarters

We take various measures to secure customers' payment on a case by case basis by means of letters of credit. Also, we receive advanced payments before shipment from most customers.

Manufacturing

Our manufacturing activities consist primarily of the assembly and final integration of parts, components and subassemblies, which are acquired from third-party vendors and subcontractors. The manufacturing process for our products generally lasts six to twelve weeks. We utilize subcontractors for the production of subsystems, and our current main product, the Eagle system, is manufactured by two Israeli contractors who perform most of the material planning, procurement, manufacturing, testing and assembly work with respect to such systems.

We rely on single source and limited source suppliers and subcontractors for a number of essential components and subsystems of our products. We have increased our inventories and production capacity to meet our needs taking in account the global shortage. During times of rapid increase in demand in the semiconductor fabrication industry, the delivery time of suppliers in this industry is extended. However, to date, we have been able to obtain sufficient units of these components to meet our needs in a timely fashion.

Our manufacturing facility is located in Migdal Ha'Emek, Israel.

Competition

The markets in which we operate are highly competitive. Our main competitors are Onto Innovations, Skyverse, ATI Electronics Pty Ltd., Cheng Mei Instrument Technology Co., ASTI Holding Limited, Toray Industries Inc. and, for some limited applications, KLA-Tencor Corporation.

We believe that the principal elements of a sustainable competitive advantage are:

- ongoing research, development and commercial implementation of new image acquisition, processing and analysis technologies;
- product architecture based on proprietary core technologies and commercially available hardware. Such architecture supports shorter time-to-market, flexible cost structure, longer service life and higher margins;
- fast response to evolving customer needs;

- ability to maintain competitive pricing;
- product compatibility with customer automation environment; and
- strong pre- and post-sale support (applications, service and training) deployed in immediate proximity to customer sites.

We believe that we compete effectively on all of these factors.

The Israel Innovation Authority

The Government of Israel encourages research and development projects in Israel through the IIA (the Israel Innovation Authority), pursuant to and subject to the provisions of the R&D Law. We received grants from the IIA for several projects and may receive additional grants in the future.

Under the terms of certain IIA grants, a company may be required to pay royalties ranging between 3% to 6% of the revenues generated from its products or services incorporating Financed Know-How, until 100% of the dollar value of the grant is repaid (plus LIBOR interest applicable to grants received on or after January 1, 1999).

The R&D Law generally requires that a product incorporating Financed Know-how be manufactured in Israel. However, subject to receipt of an approval from the IIA, some of the manufacturing volume may be performed outside of Israel. Such approval is subject to the repayment of increased royalties, in an amount of up to 300% of the total grant amount, plus applicable interest, and an increase of 1% in the royalty rate, depending on the extent of the manufacturing that is to be conducted outside of Israel.

The R&D Law also provides that Financed Know-How and any right derived therefrom may not be transferred to third parties, unless such transfer was approved in accordance with the R&D Law. The research committee operating under the IIA may approve the transfer of Financed Know-How between Israeli entities, provided that the transferee undertakes all the obligations in connection with the R&D grant as prescribed under the R&D Law. In certain cases, the research committee may also approve a transfer of Financed Know-How outside of Israel, in both cases subject to the receipt of certain payments, calculated according to a formula set forth in the R&D Law. In the case of transfer outside of Israel, a payment of up to six times the total amount of the grants plus applicable interest, and in the case the R&D activity related to the know-how remains in Israel, a payment of three times of such total amount. These approvals are not required for the sale or export of any products resulting from such R&D activity or based on such Financed Know-How.

Further, the R&D Law imposes reporting requirements on certain companies with respect to changes in the ownership of a grant recipient. The grant recipient, its controlling shareholders, and foreign interested parties of such companies must notify the IIA of any change in control of the grant's recipient or the holdings of the "means of control" of the recipient that result in an Israeli or a non-Israeli becoming an interested party directly in the recipient. The R&D Law also requires the new interested party to undertake to comply with the R&D Law. For this purpose, "control" means the ability to direct the activities of a company (other than any ability arising solely from serving as an officer or director of the company), including the holding of 25% or more of the "means of control", if no other shareholder holds 50% or more of such "means of control." "Means of control" refers to voting rights or the right to appoint directors or the chief executive officer. An "interested party" of a company includes a holder of 5% or more of its outstanding share capital or voting rights, its chief executive officer and directors, someone who has the right to appoint its chief executive officer or at least one director, and a company with respect to which any of the foregoing interested parties owns 25% or more of the outstanding share capital or voting rights or has the right to appoint 25% or more of the directors. Accordingly, in certain cases, any non-Israeli who acquires 5% or more of our ordinary shares may be required to notify the IIA that it has become an interested party and to sign an undertaking to comply with the R&D Law. In addition, the rules of the IIA may require additional information or representations with respect to such events.

As of December 31, 2021, the total amount of grants received by us from the IIA and not yet repaid (including interest accrued by Camtek) was \$7.9 million. This amount also includes grants received by Printar, which we assumed in the framework of the acquisition of Printar's assets and certain liabilities, and which we have written off as we believe that no such payments will be made to the IIA (for more information please see the discussion relating to the cessation of the FIT activity in Item 4.B above - "**Business Overview – Our Business**"). As of the date of this Annual Report, no Financed Know-How is utilized in our current or currently anticipated activities.

At the end of 2021, the publication of the LIBOR is scheduled to cease and alternative interests will be applied on, among other things, the grants received from the IIA. While the effect that the replacement of the LIBOR interest will have on the Company remains uncertain as of the date of this annual report, and as the IIA has not yet published the alternative interest that will be applied by it, the Company assesses that such change will not have a material effect on its operations and financial condition in light of the common interests in the market.

Capital Expenditures

The following table shows our capital expenditures in fixed assets for the last three years:

	December 31,		
	2021	2020	2019
	(U.S. Dollars in thousands)		
Machinery and equipment*	3,390	2,939	1,998
Right of use (ROU) assets **	2,546	831	904
Computer equipment and software	990	631	305
Building and leasehold improvements	1,777	273	154
Vehicles	216	176	-
Office furniture and equipment	76	168	97
Total	\$ 8,995	\$ 5,018	\$ 3,458

* including transfer of inventory to fixed assets in the aggregate of \$2,204, \$1,772, and \$1,405 in 2021, 2020 and 2019, respectively.

** related to implementation of ASC 842 - Leases as of January 1, 2019.

Material Effects of Governmental Regulations

The following EU directives, which represent the European standard required in order to sell in Europe, apply to our business: Machinery Directive 2006/42/EC and EMC 2004/108/EC. The following SEMI Standards, which define uniform standards for manufacturers in the semiconductor fabrication industry and production equipment producers, apply to us: SEMI S-2 (safety requirements for sale of equipment in the semiconductor fabrication) and SEMI S-8 (ergonomic requirements for sale of equipment in the semiconductor fabrication industry). We comply with the above-mentioned governmental regulations during the systems' design process, which is conducted in accordance with the Company's quality assurance manual ISO9001:2015. In addition, all modules of systems are tested by independent laboratories that certify their compliance with these governmental regulations and have required accreditation.

C. Organizational Structure

Through its affiliated companies, one of our principal shareholders, Priortech, engages in various aspects of the electronic production, including, advance packaging designs for the semiconductor industry and advanced organic coreless substrate technology. Priortech currently holds 21.11% of our outstanding ordinary shares, and is a party to the Chroma Voting Agreement. Under the Chroma Voting Agreement, Priortech is entitled to nominate three Board members. We have no revenues from sales to affiliates and subsidiaries of Priortech.

The following table shows the Company's subsidiaries, all of which are wholly owned by us or by our subsidiaries (except for Camtek HK Ltd., in which Priortech holds no more than one percent of the voting rights), together with each subsidiary's jurisdiction of incorporation, as of the date of this Annual Report:

Name of Subsidiary	Jurisdiction of Incorporation
Camtek H.K. Ltd.	Hong Kong
Camtek USA Inc.	New Jersey, USA
Camtek (Europe) NV	Belgium
Camtek Germany GmbH	Germany
Camtek Inspection Technology (Suzhou) Ltd.	China

Camtek Japan Ltd.	Japan
Camtek Inspection Technology Limited	Taiwan
Camtek South East Asia Pte Ltd.	Singapore
Camtek Korea Ltd.	South Korea

D. *Property, Plants and Equipment*

Our main office, manufacturing and research and development facilities are located in the Ramat Gavriel Industrial Zone of Migdal Ha'Emek in northern Israel. These facilities occupy 110,000 square feet of which 16,000 square feet are devoted to the manufacturing of our products, and approximately 10,500 square feet are leased to a third-party lessee.

Our sales offices and demonstration centers, which we lease in various locations around the world, occupy an aggregate of approximately 33,900 square feet.

Item 4A. *Unresolved Staff Comments.*

None.

Item 5. *Operating and Financial Review and Prospects.*

A. *Operating Results*

General

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the notes to those statements included therein, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The following discussion does not address certain items in respect of our fiscal year ended December 31, 2019 in reliance on amendments to disclosure requirements adopted by the SEC. A discussion of our fiscal year ended December 31, 2019 may be found in “Item 5 – *Operating and Financial Review and Prospects*” of our Annual Report on Form 20-F for the fiscal year ended December 31, 2020, filed with the SEC on March 17, 2021.

Overview

We design, develop, manufacture and market automated solutions dedicated for enhancing production processes and yield for the semiconductor fabrication industry, principally based on our Inspection and Metrology core technology; see in Item 4.B *“Business Overview - Our Business”* above.

We sell our systems internationally. The majority of sales of our systems in 2021 were to manufacturers in the Asia Pacific region, including South Korea, China, Taiwan and South East Asia, due to, among other factors, the migration of the electronic manufacturers into this region following the development and growth of electronics industry centers.

In the year ended December 31, 2021, our sales in the Asia Pacific region (mostly China, Taiwan and South Korea) accounted for approximately 83% of our total revenues.

In addition to revenues derived from the sale of systems and related products, we generate revenues from providing maintenance and support services for our products. We generally provide a one-year warranty with our systems. Accordingly, service revenues are not earned during the warranty period.

In regular market conditions, the demand for our systems is characterized by short notice. To meet customers' needs for quick delivery and to realize the competitive advantage of the ability to do so, we have to pre-order components and subsystems based on our forecast of future orders, rather than on actual orders. This need is compounded by the fact that, in times of increasing demand in our markets, our suppliers and subcontractors tend to extend their delivery schedules or fail to meet their delivery deadlines. To compensate for these unscheduled delays, we build inventories further into the future, which increases the risk that our forecast may not correspond to our actual future needs. The uncertainties involved in these longer-term estimates during regular times of business expansion tend to increase the level of component and subsystem inventories (See also in Item 3.D. - "**Risk Factors - A longer sales process for new products may increase our costs and delay time to market of our products, both of which may negatively impact our revenues, results of operations, cash flow and may result in inventory write-offs**" above and under Item 5.A - "**Operating Results - Critical Accounting Policies - Valuation of Inventory**" below). Compared to our sales cycles for repeat orders from existing customers, we have longer sales cycles for new customers in our markets as well as for new customers in new markets. In addition, the selling cycle in our markets typically takes several quarters from first contact to revenue recognition, including on-site evaluation. Naturally, repeat orders take less time.

Critical Accounting Policies and Estimates

The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, accounts receivable, inventories, intangible assets, contingent liabilities, long-lived assets, income taxes, share-based payments and leases. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Results may differ from these estimates due to actual outcomes being different from those on which we based our assumptions. These estimates and judgments are regularly reviewed by management on an ongoing basis at the end of each quarter prior to the public release of our financial results.

Critical accounting policies are those that, in management's view, are most important to the portrayal of a company's financial condition and results of operations and most demanding on their calls on judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. We believe our most critical accounting policies and estimates relate to:

Revenue Recognition.

The Company's contracts with its customers include performance obligations to provide its products or to service the installed products. A product sale contract may include an extended warranty (that is, for longer than the twelve-month standard warranty) as well as installation, both of which are considered separate performance obligations.

The Company recognizes revenue from contracts for sales of products when the Company transfers control of the product to the customer. From October 2020, this generally occurs upon shipment whereas previously it was generally upon installation at the customer's premises. This policy change was made following changes to pre-shipment calibration and testing processes which have enabled the simplification and streamlining of the installation at the customer site. The change did not have a material effect on revenues. Revenues from the contract are recognized in an amount that reflects the consideration the Company expects to be entitled to receive once the product is operating in accordance with its specifications and signed documentation of the arrangement, such as a signed contract or purchase order, has been received. Payment terms with customers may vary, but are generally based on milestones within the delivery process such as shipping and installation. Payment terms do not include significant financing components.

The Company does not incur costs in obtaining a contract except for agents' commissions, which are incurred upon the recognition of revenues. Revenues are recognized over a period of less than a year and as such, there are no underlying sales commissions to be capitalized.

Service revenues consist mainly of contracts charged under time and material arrangements. Service revenues from maintenance contracts are recognized ratably over the contract period.

Contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged to customers.

The Company's multiple performance obligations consist of product sales, installation services and non-standard warranties. Since October 2020, following the change in the point in time at which product revenues are recognized, for cases in which product revenue has been recognized but installation has not occurred as of the balance sheet date, a fixed amount is deferred from revenue in respect of the installation services yet to be performed. A non-standard warranty is one that is for a period longer than 12 months. Accordingly, income from a non-standard warranty is deferred as unearned revenue and is recognized ratably as revenue commencing with and over the applicable warranty term.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations. These amounts are recorded as deferred revenue in the Consolidated Balance Sheets.

Valuation of Accounts Receivable. We review accounts receivable to determine which are doubtful of collection. In making this determination of the appropriate allowance for doubtful accounts, we consider information at hand regarding specific customers, including aging of the receivable balance, evaluation of the security received from customers, our history of write-offs, relationships with our customers and the overall credit worthiness of our customers. Changes in the credit worthiness of our customers, the general economic environment and other factors may impact the level of our future write-offs.

Valuation of Inventory. Inventories consist of completed systems, partially completed systems and components, and are recorded at the lower of cost, determined by the moving – average basis, or net realizable value. We review inventory for obsolescence and excess quantities to determine that items deemed obsolete or excess inventory are appropriately reserved. In making the determination, we consider forecasted future sales or service/maintenance of related products and the quantity of inventory at the balance sheet date, assessed against each inventory item's past usage rates and future expected usage rates. Changes in factors such as technology, customer demand, competing products and other matters could affect the level of our obsolete and excess inventory in the future.

In the years 2021 and 2020 we wrote-off inventory in the amount of approximately \$0.4 million and \$0.1 million, respectively which were related to damaged, obsolete, excess and slow-moving inventory. These amounts are included in the item line called "Cost of revenues" in the consolidated statements of operations. The write-offs create a new cost basis and are a permanent reduction of inventory cost. Inventory that is not expected to be converted or consumed in 2022 is classified as non-current. As of December 31, 2021, a \$5.2 million portion of our inventory was classified as non-current. Management periodically evaluates our inventory composition, giving consideration to factors such as the probability and timing of anticipated usage and the physical condition of the items, and then estimates a charge (reducing the inventory) to be provided for slow moving, technologically obsolete or damaged inventory. These estimates could vary significantly from actual requirements based upon future economic conditions, customer inventory levels or competitive factors that were not foreseen or did not exist when the inventory write-offs were established.

Intangible assets. Patent registration costs are capitalized at cost and amortized, beginning with the first year of utilization, over its expected life of ten years.

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the long-lived asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as computed by subtracting the fair market value of the asset from its carrying value.

Provisions for contingent liabilities. A contingency (provision) in accordance with ASC Topic 450-10-05, Contingencies, is an existing condition or situation involving uncertainty as to the range of possible loss to the entity. A provision for claims is recognized if it is probable (likely to occur) that a liability has been incurred and the amount can be estimated reasonably. Provisions in general are highly judgmental, especially in cases of legal disputes. We assess the probability of an adverse event if the probability is evaluated to be probable, we are required to fully provide for the total amount of the estimated contingent liability. We continually evaluate our pending provisions to determine if accruals are required. It is often difficult to accurately estimate the ultimate outcome of a contingent liability. Different variables can affect the timing and amount we provide for certain contingent liabilities. Our assessments are therefore subject to estimates made by us and our legal counsel. Adverse revision in our estimates of the potential liability could materially impact our financial condition, results of operations or liquidity.

Valuation of Long-Lived Assets. We apply ASC Subtopic 360-10, "Property, Plant and Equipment". This Statement requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the long-lived asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as computed by subtracting the fair market value of the asset from its carrying value. We prepare future cash flows based on our best estimates including projections and financial statements, future plans and growth estimates.

Income Taxes. We account for income taxes under ASC Subtopic 740-10 Income Taxes – Overall. Deferred tax assets or liabilities are recognized in respect of temporary differences between the tax bases of assets and liabilities and their financial reporting amounts as well as in respect of tax losses and other deductions which may be deductible for tax purposes in future years, based on tax rates applicable to the periods in which such deferred taxes will be realized. The rates applied are those enacted in law as of December 31, 2021. In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible and during which the carry-forwards are available. Valuation allowances are established when necessary to reduce deferred tax assets to the amount considered more likely than not to be realized.

Our financial statements include deferred tax assets, net, which are calculated according to the above methodology. If there is an unexpected critical deterioration in our operating results and forecasts, we would have to increase the valuation allowance with respect to those assets. We believe that it is more likely than not that those net deferred tax assets included in our financial statements will be realized in subsequent years.

Stock Option and Restricted Share Plans. We account for our employee stock-based compensation awards in accordance with ASC Topic 718, *Compensation - Stock Compensation*. ASC Topic 718 requires that all employee stock-based compensation is recognized as a cost in the financial statements and that for equity-classified awards such cost is measured at the grant date fair value of the award. We estimate grant date fair value using the Black-Scholes-Merton option-pricing model. Forfeitures are recognized when they occur.

Leases. Results and disclosure requirements are presented under Topic 842, *Leases*.

Under Topic 842, we determine if an arrangement is a lease at inception. ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, we consider only payments that are fixed and determinable at the time of commencement. As most of our leases do not provide an implicit rate, we use its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is a hypothetical rate based on its understanding of what our credit rating would be 2.43% in 2021. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. When determining the probability of exercising such options, we consider contract-based, asset-based, entity-based, and market-based factors. Lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease

costs are expensed as incurred on the consolidated statements of income. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.

Operating lease ROU assets are presented as property, plant and equipment on the consolidated balance sheet. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented within long-term liabilities on the consolidated balance sheet.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

ROU assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.

New standards not yet adopted

In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance became effective in the first quarter of 2021 on a prospective basis. The adoption of this guidance has not had a material impact on the Company's consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. ASU 2020-06 reduces the number of accounting models for convertible instruments and allows more contracts to qualify for equity classification. Adoption is either a modified retrospective method or a fully retrospective method of transition. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach.

Comparison of Period-to-Period Results of Operations

The following table presents consolidated statement of operations data for the periods indicated as a percentage of total revenues:

	Year Ended December 31,		
	2021	2020	2019
Total Revenues	100.00%	100.00%	100.00%
Total Cost of revenues	49.07%	53.01%	51.66%
Gross profit	50.93%	46.99%	48.34%
Operating expenses:			
Research and development costs	8.70%	12.56%	12.19%
Selling, general and administrative expenses	15.94%	19.91%	19.76%
Total operating expenses	24.64%	32.47%	31.94%
Operating income	26.29%	14.52%	16.39%
Financial income, net	0.38%	0.50%	0.60%
Income tax expenses	(4.32)%	(1.04)%	(1.46)%
Net income from continuing operations	22.35%	13.97%	15.54%
Net income from discontinued operations	-	-	0.87%
Net income	22.35%	13.97%	16.41%

Year Ended December 31, 2021 compared to Year Ended December 31, 2020

Revenues. Revenues increased by 73% to \$269.7 million in 2021 from \$155.9 million in 2020, due primarily to an increase in the number of product units sold.

Gross Profit. Gross profit consists of revenues less cost of revenues, which includes the cost of components, production materials, labor, depreciation, factory and service center overheads and provisions for warranties. These expenditures are only partially affected by sales volume. Our total gross profit increased to \$137.3 million in 2021 from \$73.2 million in 2020, an increase of \$64.1 million, or 88%. Our gross margin increased to 50.9% in 2021, compared to a gross margin of 47.0% in 2020, mainly as a function of increased revenues.

Research and Development Costs. Research and development expenses consist primarily of salaries, materials consumption and costs associated with subcontracting certain development efforts. Total research and development expenses for 2021 increased to \$23.5 million from \$19.6 million in 2020 due to increased research and development activity, due to higher investment in new products and technologies, as well as an increase in headcount.

Selling, General and Administrative Expenses. Selling, general and administrative expenses consist primarily of expenses associated with salaries, commissions, promotion and travel, professional services and rent costs. Our selling, general and administrative expenses increased by 38% to \$43.0 million in 2021 from \$31.0 million in 2020, mainly due to increased commissions, salary expenses and marketing expenses resulting from the increased sales, offset by decreased shipping expenses.

Financial Income, Net. We had net financial income of \$1.0 million in 2021 compared to \$0.8 in 2020. Foreign currency income, net, resulting from transactions not denominated in U.S. Dollars, amounted to \$0.05 million in 2021 compared to expenses of \$0.35 in 2020.

Provision for Income Taxes. Income tax expense was \$11.7 million in 2021, an increase of \$10.1 million from the \$1.6 million expense in 2020. This is partially due to the Company's increased income and partially due to a settlement with the Israeli Tax Authorities which resulted in a one-time tax expense of \$5.3 million in respect of its historical exempt earnings.

Net Income from continuing operations. We realized net income of \$60.3 million in 2021 compared to net income of \$21.8 million in 2020, due to increased revenues.

B. Liquidity and Capital Resources

At December 31, 2021, our cash and cash equivalent and short-term deposit balances totaled approximately \$397.9 million. At December 31, 2020, our cash and cash equivalent balances totaled approximately \$177.8 million. The year-to-year increase in cash and cash equivalents and short-term deposits mainly results from the successful issuance of the Convertible Notes, in addition to increased revenues. Our cash is invested in bank deposits spread among several banks, primarily in Israel.

From our inception through December 31, 2021 we raised approximately \$36.0 million from our initial public offering in 2000, approximately \$6.1 million in a rights offering of ordinary shares to our then existing shareholders in 2002, \$14.5 million from a private placement to Israeli institutional investors in 2006, \$11.9 million in a public offering of our shares in May 2015, \$16.2 million pursuant to the share issuance under the Chroma Transaction in June 2019, and \$64.3 million in a public offering of our shares in November 2020. Further, in November 2021, we closed an offering of \$200 million aggregate principal amount of Convertible Notes due 2026 (see Item 4.A. – “*History and Development of the Company*”).

Our working capital was approximately \$430.5 million in 2021 and \$204.5 million in 2020. The increase is mainly attributed to increased cash and cash equivalents, and short-term deposits, increased inventories and accounts receivable, offset by increased trade accounts payable.

Our capital expenditures during 2021 were approximately \$4.2 million, mainly to increase our production capacity and to support our R&D, operations and IT activities.

Cash flow from operating activities

Net cash and cash equivalents provided by operating activities for the years ended December 31, 2021 and 2020 totaled \$61.0 million and \$25.8 million, respectively.

During 2021, cash provided by operating activities was primarily attributed to net income and the increases in other current liabilities, offset by increases in inventory and trade accounts receivable.

During 2020, cash provided by operating activities was primarily attributed to net income and the increase in trade account payable and other current liabilities, offset by increases in inventory and trade accounts receivable.

Cash flow from investing activities

Cash flow used in investing activities in 2021 was \$120.2 million, due to investment in short-term and long-term deposits and fixed and intangible assets. Cash flow used in investing activities in 2020 was \$23.1 million, due to investment in short-term deposits and fixed and intangible assets.

Our capital expenditures in 2021 and 2020 were used primarily for operating activities. In 2022, we expect our capital expenditures to increase to over \$7 million as we invest in our facilities.

Cash flow from financing activities

Cash flow provided by financing activities in 2021 was \$194.8 million, mainly due to the issuance of the Convertible Notes.

Cash flow provided by financing activities in 2020 was \$64.9 million, mainly due to the public offering of our shares.

Our principal liquidity requirement is expected to be for working capital and capital expenditures, as well as acquisitions. We anticipate funding these cash requirements and capital expenditures through a combination of cash flow from operations and existing balances of cash and cash equivalents and short-term deposits. We anticipate that our existing capital resources and cash flows from operations will be adequate to satisfy our liquidity requirements for at least the next 12 months. If available liquidity is not sufficient to meet our operating obligations as they come due, our plans include pursuing alternative financing arrangements or reducing expenditures as necessary to meet our cash requirements (see also Item 3.D “Risk Factors - ***We have historically incurred significant losses and negative cash flows and may not sustain profitable operations or continue to have positive operating cash flows in the future***” above).

Effective Corporate Tax Rate

Camtek’s production facility in Israel has been granted “Approved Enterprise” status under the Investment Law (as defined in Item 10.E – “***Taxation – Israeli Taxation - Tax Benefits Under the Law for the Encouragement of Capital Investments, 1959***” below). We participate in the Alternative Benefits Program and, accordingly, income from our Approved Enterprise will be tax exempt for a period of 10 years, commencing on the first year in which the Approved Enterprise first generates taxable income, due to the fact that we operate in Zone “A” in Israel.

On April 1, 2005, an amendment to the Investment Law came into effect (the “**Amendment**”) and significantly changed the provisions of the Investment Law. The Amendment limits the scope of an enterprise which may be approved by the Investment Center by setting criteria for the approval of a facility as a “Beneficiary Enterprise”; such criteria generally require that at least 25% of the Beneficiary Enterprise’s income will be derived from export. Additionally, the Amendment enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits.

In addition, the Amendment provides that terms and benefits included in any certificate of approval issued prior to December 31, 2004 will remain subject to the provisions of the Investment Law as they were on the date of such prior approval. Therefore, our existing Approved Enterprise will generally not be subject to the provisions of the Amendment. As a result of the Amendment, tax-exempt income generated under the provisions of the new law, as part of a new Beneficiary Enterprise, will subject us to taxes upon distribution or liquidation.



Camtek has been granted the status of Approved Enterprise, under the Investment Law, for investment programs for the periods which ended in 2007 and 2010, and the status of Beneficiary Enterprise according to the Amendment, for a period which ended in 2014. In addition, Camtek has elected 2010 as the year of election for a period ending 2021 (collectively, “**Programs**”).

On December 29, 2010, the Investment Law was amended to significantly revise the tax incentive regime in Israel commencing on January 1, 2011. For more information, see Item 10.E – “*Taxation – Israeli Taxation - Tax Benefits Under the Law for the Encouragement of Capital Investments, 1959*” below.

During the years 1998-2006 the company was subject to tax in accordance with the Approved and Beneficiary Enterprise under the Law for the Encouragement of Capital Investments. As such, the Company has income that was exempt from tax. Distribution of dividend from the exempt income requires the Company to pay income tax on the amount of the dividend distributed at the tax rate that would have been applicable to it in the year the income was produced if it had not been exempt from tax. In February 2022, the Company, in a settlement with the Israeli Tax Authorities, elected to take advantage of the temporary rule of 2022 in Israel and pay a reduced tax rate on its historical exempt earnings to allow the Company to distribute dividends from these earnings in the future with no additional corporate tax liability. The Company’s Statement of Income for the year ended December 31, 2021 included a one-time tax expense of \$5,315, as a result of this settlement.

Foreign Currency Fluctuation

See Item 3.D – “*Risk Factors – Risk Factors Related to Our Business and Our Markets – Fluctuations in currency exchange rates may result in additional expenses being recorded or in the prices of our products becoming less competitive and thus may have negative impact on our profitability*” above.

C. Research and Development, Patents and Licenses.

We believe that intensive R&D is essential to our business. We devote substantial R&D resources to developing new products and to improving our existing products to meet our customers’ evolving needs. We have dedicated teams with expertise in image processing software and algorithms, electronic hardware, electro-optics, physics, mechanics and systems design.

Our R&D efforts are primarily focused on:

- improving our defect detection capabilities while reducing the number of false alarms, simplifying operation and reducing the level of user expertise required to realize the benefits of our systems;
- increasing the throughput of our Inspection and Metrology systems;
- providing unique technological solutions to our customers; and
- adding capabilities to expand our market segments.

In addition, we are focusing our efforts on leveraging our core technologies, expertise and experience into continually enhancing the value to the user and the return on investment from our products. We believe that our internal multi-disciplinary expertise will enable us to maintain and enhance our technological edge.

As of December 31, 2021, we had 104 employees engaged in R&D, all of whom are based in our headquarters in Israel. We also use subcontractors for the development of some of the hardware components of our systems. Our R&D expenses were \$23.5 million and \$19.6 million for the years ended December 31, 2021 and 2020, respectively, representing 8.7% and 12.6% of the total revenues for the years then ended.

We will continue to devote our R&D resources to maintaining and extending our technology leadership position.

Our R&D costs are expensed as incurred.

In general, we rely on a combination of our copyrights, trade secrets, patents, trademarks and non-disclosure agreements to protect our proprietary know-how and intellectual property. We also enter into confidentiality agreements with our employees and with all of the subcontractors who develop and manufacture components for use in our products. We also employ specialists whose main role is to maintain and protect our intellectual property from both professional and legal perspectives. We cannot be certain that actions we take to protect our proprietary rights will be adequate nor can we be certain that we will be able to deter reverse engineering or that there will not be independent third-party development of our technology.

We have 153 issued and applied-for patents worldwide, of which 99 are registered patents, and 6 U.S. provisional applications. These patents relate to our proprietary technology and know-how developed for Inspection and Metrology and Functional Inkjet Technology tools. We also have one registered trademark in Israel.

D. Trend Information

Currently, the outlook for 2022 and beyond is positive as projected by VLSI Research and SEMI Organization. However, the global outbreak of the COVID-19 may impose unpredictable implications on the global economy which may affect the semiconductor industry. See "**Item 3D. Risk Factors**" above. The semiconductor industry has been influenced by weakness or uncertainties in global economic conditions. The OECD had forecasted the world GDP to grow by 4.5% in 2022 which is a positive indication for our industry. According to several research reports, key drivers for future demand in the semiconductor industry include mobile devices, data centers infrastructure, Artificial Intelligence, augmented and virtual reality, smart sensors, Internet-of-Things and other electronic equipment.. See "Item 3D. Risk Factors" in this annual report on Form 20-F. For specific trend information regarding the markets in which we operate see Item 4.B - "**Business Overview - Our Markets**" above.

E. Critical Accounting Estimates – see Item 5.A “Operating Results – Critical Accounting Policies and Estimates”

Item 6. Directors, Senior Management and Key Employees

A. Directors and Senior Management

The following table lists the name, age and position of each of our current directors and senior management:

Name	Age	Title
Rafi Amit	73	Chief Executive Officer and Chairman of the Board of Directors*
Yotam Stern	69	Director
Leo Huang	68	Director
I-Shih Tseng	60	Director
Yael Andorn	51	Director**
Yosi Shacham-Diamand	68	Director**
Moty Ben-Arie	67	Director
Orit Stav	51	Director
Moshe Eisenberg	55	Chief Financial Officer
Ramy Langer	68	Chief Operating Officer
Orit Geva Dvash	50	Vice President - Human Resources

* Rafi Amit serves as our Chairman of the Board of Directors as of our 2019 annual general meeting of shareholders, dated June 3, 2019 (the "**2019 AGM**"). The approval of Mr. Amit's appointment as Chairman, while continuing to assume CEO's responsibilities, was last obtained in the 2019 AGM.

** Ms. Yael Andorn and Prof. Yosi Shacham-Diamand have served as our external directors (as such term is defined under the Companies Law) since October 2018.

Set forth below is a biographical summary of each of the above-named directors and senior management.

Rafi Amit has served as our Chief Executive Officer since January 2014, and as our Chairman of the Board of Directors since the 2019 AGM. Between 2010 and March 2017, Mr. Amit also served as our Active Chairman of the Board of Directors. Previously, Mr. Amit served as our Chief Executive Officer from January 1998 until August 2010 and as Chairman of the Board of Directors from 1987 until April 2009. Since 1981, Mr. Amit has also served as the President and director of Priortech and has been the Chairman of the Board of Directors of Priortech since 1988. From 1981 until 2004, Mr. Amit served as Priortech's Chief Executive Officer. Mr. Amit holds a B.Sc. in Industrial Engineering and Management from Technion - Israel Institute of Technology.

Yotam Stern has served on our Board of Directors since 1987. From May 2009 until August 2010, Mr. Stern served as the Chairman of the Board of Directors and from 2001 until 2012, Mr. Stern served as our Executive Vice President, Business & Strategy. From 1998 until 2001, Mr. Stern served as our Chief Financial Officer. Mr. Stern served in the past as the Chief Financial Officer of Priortech and has been serving as a director of Priortech since 1985 and as its Chief Executive Officer since 2004. He holds a B.A. in Economics from Hebrew University of Jerusalem.

Leo Huang has served on our Board of Directors as a representative of Chroma since June 3, 2019. Mr. Huang co-founded Chroma in 1984 and has been serving as chairman of the board of directors of Chroma since October 23, 1984. Mr. Huang was the QA Engineer of TIMEX Corp. from 1975 to 1977 and served as the Sales Manager of Philips Electronics Industries (Taiwan) Ltd. from 1978 to 1984. Mr. Huang holds a bachelor's degree in Electronics Engineering from National Chiao Tung University in 1973.

I-Shih Tseng has served on our Board of Directors as a representative of Chroma since June 3, 2019. Mr. Tseng joined Chroma in 1998, serving as a director since June 6, 2012 and as Business Unit President of Chroma since July 1, 2007. Mr. Tseng was a Research Assistant at Pennsylvania State University from 1986 to 1992 and served as the Project Manager of Institute for Information Industry from 1992 to 1998. Mr. Tseng received his PhD degree in Mechanical Engineering from Pennsylvania State University in 1992.

Yael Andorn has served on our Board of Directors since October 3, 2018 and she is currently the Chairperson of our Audit Committee. Ms. Andorn is the founder and CEO of CapitalA, and serves on the Boards of Directors of Israeli public companies such as El-Al Airlines and Castro. Ms. Andorn previously served on private and public boards, including Midroog-Moody's Rating, Oil Refineries (Bazan), Retalix, The National Lottery, Clal Health Insurance and Clal Credit Insurance, and as head of the Investment Committee of the Teacher's Saving Fund. Ms. Andorn served as director general of Israel's Ministry of Finance between 2013 and 2015 and as Partner at Viola Credit between 2012 and 2013. Between 2005 and 2011, Ms. Andorn served as CEO at Amitim and also served on its investment committee. Ms. Andorn held several positions at Israel's Ministry of Finance Budget Department, Bank of Israel and IDF 8200 Intelligence Unit. Ms. Andorn holds a Bachelor of Economics and a Master in Business Administration from the Hebrew University of Jerusalem.

Yosi Shacham-Diamand has served on our Board of Directors since October 3, 2018. Since 2001, Prof. Shacham-Diamand serves as The Bernard L. Schwartz Academic Chair for nano scale information technologies in the Department of Electrical Engineering - Physical Electronics, and in the Department of Material Science and Technology, Faculty of Engineering, Tel Aviv University. Prof. Shacham-Diamand currently serves on the advisory board of CartaSense Ltd. and SolChip Ltd., and previously served as consultant to numerous manufacturing companies such as: Zoran Inc., Intel Inc., Applied Materials Inc., Nova Instruments Inc., as well as to numerous investment and holding companies in Israel and abroad. Prof. Shacham-Diamand previously served on the board of directors of PCB Ltd. (today, Priortech Ltd.) and "RAMOT" by Tel Aviv University. He is a visiting professor at Waseda University, Tokyo, Japan (Since 2004) and a visiting professor at the Department of Electronics and Telecommunication, The Politecnico di Torino, Torino, Italy (Since 2018), and serves as a distinguished international Chair Professor in Feng Chia University, Taichung, Taiwan (since 2012). Since 2014, Prof. Shacham-Diamand serves as a member of the MAGNET committee, Ministry of Trade and Industry. Prof. Shacham-Diamand holds a D.Sc. EE, M.Sc. EE, and B.Sc. EE (Summa-cum Laude), all from the Technion- Israel Institute of Technology, Haifa, Israel, and also completed a postdoctoral research at U.C. Berkeley, CA, USA.

Moty Ben-Arie has served on our Board of Directors since March 28, 2017. From March 2017 until the 2019 AGM, Mr. Ben-Arie served as the Chairman of the Board of Directors. Mr. Ben-Arie is the co-founder and serves as the Chairman of the board of directors of Invisicare Ltd. Mr. Ben-Arie has served as a consultant to entrepreneurs and investors since 2014. Previously, Mr. Ben-Arie served as the CEO of Sital Technology from 2012 until 2014. From 2006 until 2011, Mr. Ben-Arie also served as a managing partner of Vertex Ventures, where he focused on investments in Israeli-related hi-tech companies and evaluation of companies in the field of telecommunication, IT, test equipment, medical equipment and multidisciplinary systems. During these years, Mr. Ben-Arie served as a member of the fund investment committee, managed investments in several companies and served as a board member in companies in their early stages, including Color Chip Inc., MultiPhi, Expand Networks, Comability and Ethos Networks. From 2000 until 2006, Mr. Ben-Arie also served as a partner of Walden Israel Ventures, where he focused on investments in Israeli-related hi-tech companies. During these years, Mr. Ben-Arie managed investments in several companies and served as a board member in companies from early stage, including Color Chip Inc. and Passave. From 1998 until 2000, Mr. Ben-Arie served as a director in Radcom Ltd., as a consultant in Walden Israel, and financed seed phases for new startups. From 1991 until 1998, Mr. Ben-Arie served as the co-founder and CEO of Radcom Ltd., Israel. From 1978 until 1982, Mr. Ben-Arie served as an electronic engineer and a project manager in Elisra Ltd. Mr. Ben-Arie holds a MBA from Tel Aviv University, and a B.Sc. in Electrical Engineering from the Technion - Israel Institute of Technology.

Orit Stav has served on our Board of Directors since September 24, 2020. Ms. Stav is an experienced investment manager with 20 years of experience in the field of Venture Capital & Private Equity, as well as in the technology sector. Ms. Stav is a co-founder and serves as a managing partner at Israel Innovation Partners, a business advisory firm that specializes in building business relationship between global companies and Israeli technology start-ups. Currently, Ms. Stav serves as a board member in Altshuler Shaham Properties Ltd., Hadasit Bio Technologies Holdings Ltd., Doral Group Renewable Energy Resources Ltd., Aran Research and Development Ltd, ORT Technologies Ltd, A. Luzon Real Estate & Finance Ltd and Ya'acobi Brothers Group (YSB) Ltd. From 2014 until 2015, Ms. Stav served as a managing partner of EVA Ventures venture capital. From 2010 until 2012, Ms. Stav served as a country manager in Wimdu GmbH, an international internet company. From 2006 until 2009 she served as an investment manager in Siemens Venture Capital, and from 1998 until 2005 served as an investment partner in Platinum Neurone Ventures, PNV, an Israeli venture capital fund. Ms. Stav Holds a MBA from the University of Hertfordshire, UK and a B.A. in Economics and Management from Tel Aviv University.

Moshe Eisenberg has served as our Chief Financial Officer since November 2011. From 2010 to 2011, Mr. Eisenberg served as the Chief Financial Officer of Exlibris, a global provider of library automation solution for the academic market. Prior to that, from 2005 to 2009, Mr. Eisenberg served as the Chief Financial Officer of Scopus Video Networks Ltd., a leading provider of digital compression, decoding & video processing equipment. Prior to that, Mr. Eisenberg held various professional and managerial positions at Gilat Satellite Networks Ltd. and its wholly owned US subsidiary, Spacenet Inc. Mr. Eisenberg holds an MBA from Tel Aviv University and a B.Sc. in Agricultural Economics from the Hebrew University of Jerusalem.

Ramy Langer has served as our Chief Operating Officer since November 2017, following the consummation of the PCB Sale Transaction. Prior to his appointment as Chief Operating Officer he served as Vice President - Semiconductors Division from February 2014. From 2007 until 2012, Mr. Langer served as the Chief Executive Officer (and co-founder) of Infinite Memory Ltd., a fab-less developer of products based on Saifun Semiconductors Ltd.'s technology. From 2005 until 2007, Mr. Langer served as Vice President-Business Development of Saifun, where he marketed non-volatile memory IP. From 2002 until 2005, Mr. Langer served as Managing Director of Infineon Flash, a fab-less developer of products based on Saifun's technology using Infineon DRAM process. From 1999 until 2002, Mr. Langer served as Vice President- Marketing & Sales of Tower Semiconductors Ltd., manufacturer of integrated circuits. Prior to that, Mr. Langer held various executive positions at Kulicke and Soffa Industries, Inc., a leading global semiconductor assembly equipment manufacturer. Mr. Langer holds a B.Sc. in Electronic Engineering from the Technion – Israel Institute of Technology and a M.Sc. in Electronic Engineering from Drexel University, Philadelphia.

Orit Geva Dvash has served as our VP Human Resources (“HR”) since November 2017. Previously, since 2014, Ms. Geva Dvash served as our HR Director. From 2008 to 2014, Ms. Geva Dvash served as our HR manager. From 2002 to 2008, Ms. Geva Dvash served at various HR positions at IBM research lab. Ms. Geva Dvash holds a Masters in political science from Haifa University and B.A. in political science and English literature from Haifa University.

Arrangements Involving Directors and Senior Management

In accordance with the terms of the Chroma Voting Agreement, at the 2019 AGM Mr. Leo Huang and Mr. I-Shih Tseng were appointed for service as our directors (see Item 4.A. – “*History and Development of the Company*”).

Except for the Chroma Voting Agreement, there are no arrangements or understandings of which we are aware relating to the election of our directors or the appointment of executive officers in our Company. In addition, there are no family relationships among any of the individuals listed in this Section A (Directors and Senior Management).

B. *Compensation*

Aggregate Executive Compensation

The aggregate remuneration paid by us for the year ended December 31, 2021 to all persons listed in Section A (Directors and Senior Management) above, was approximately \$3,931,228. This sum includes \$181,057 paid to provide pension, retirement or similar benefits, amounts expended by us for automobiles made available to all our executive officers, and other fringe benefits commonly reimbursed or paid by companies in Israel.

We have a performance-based bonus plan which includes our executive officers. The plan is based on our overall performance, and individual performance. Up to 50% of the performance objectives of our executive officers may be qualitative, provided that with respect to our Chief Executive Officer such portion shall not exceed three monthly base salaries. The measureable performance objectives can change year over year, and are a combination of financial parameters, such as revenues, booking, operating or net income and collection. The plan for our executive officers is reviewed and approved annually by our Audit Committee (in its capacity as our Compensation Committee) and Board of Directors, as is any bonus payment to an executive officer made under such plan (provided that with respect to the bonus plan for our CEO we also obtain shareholder approval – see in Item 6.B - “*Compensation – Employment Agreements*” below).

We compensate our independent directors for serving on our board of directors by payment of cash fees in accordance with regulations promulgated under the Companies Law concerning the remuneration of external directors (the “**Remuneration Regulations**”), reimbursement for expenses and the award of share options or restricted stock units (“**RSUs**”). Messrs. Rafi Amit and Yotam Stern, as well as Chroma’s representatives on our Board, do not receive compensation for their service as our directors. See Item 6.C “*Board Practices - Remuneration of Directors*” below.

Individual Compensation of Covered Office Holders

The table below presents the compensation granted to our five most highly compensated Office Holders (as such term is defined in the Companies Law; see Item 6.C - “*Board Practices – External Directors – Qualification*” below) during or with respect to the year ended December 31, 2021. We refer to the five individuals for whom disclosure is provided herein as our “Covered Office Holders”. All amounts specified below are in terms of cost to the Company, as recorded in our financial statements.

Name and Principal Position (1)	Salary Cost (USD) (2)	Bonus (USD) (3)	Equity-Based Compensation (USD) (4)	Other (USD) (5)	Total (USD)
Rafi Amit – Chief Executive Officer	313,134	370,837	715,832	107,778	1,507,581
Ramy Langer - Chief Operating Officer	362,059	127,732	432,604	-	922,395
Moshe Eisenberg - Chief Financial Officer	303,479	114,247	391,566	-	809,292
Orit Geva-Dvash - Vice President, Human Resources	192,094	53,357	201,795	-	447,246
Yael Andorn – Director, Chairwoman of the Audit Committee	-	-	24,125	40,897	65,02
Total	1,170,766	666,173	1,765,922	148,675	3,751,536

- (1) All Covered Office Holders are employed on a full-time (100%) basis, except for Mr. Amit who dedicates 90% of his time to his role as our Chief Executive Officer and except for Ms. Yael Andorn who serves as an external director in the Company’s Board of Directors.
- (2) Salary cost includes the Covered Office Holder’s gross salary plus payment of social benefits made by the Company on behalf of such Covered Office Holder. Such benefits may include, to the extent applicable to the Covered Office Holder, payment, contributions and/or allocations for saving funds (e.g. Managers’ Life Insurance Policy), education funds (referred to in Hebrew as “*Keren Hishtalmut*”), pension, severance, risk insurances (e.g. life, or work disability insurance), payments for social security and tax gross-up payments, vacation, car, medical insurance and benefits, phone, convalescence or recreation pay, and other benefits and perquisites consistent with the Company’s policies.
- (3) Represents annual bonuses paid in accordance with the Covered Office Holder’s performance of targets as set forth in his or her bonus plan and approved by the Company’s Audit Committee and Board of Directors and/ or any special one-time bonuses as approved by the Company’s Audit Committee and Board of Directors in accordance with the Company’s Compensation Policy.
- (4) Represents the equity-based compensation expenses recorded in the Company’s consolidated financial statements for the year ended December 31, 2021 for each Covered Office Holder, based on the options’ fair value on the grant date, calculated in accordance with accounting guidance for equity-based compensation.
- (5) Includes relocation expenses which may consist of, to the extent applicable to the Covered Office Holder: housing, schooling, car, medical insurance and travel expenses for the Covered Office Holder and family members residing with him abroad.

Employment Agreements

We maintain written employment agreements with our employees, including all of our executive officers, that contain customary provisions, including non-compete and confidentiality agreements.

Effective May 26, 2015, we entered into an amended employment agreement with Mr. Amit, Chief Executive Officer and our Chairman of the Board of Directors. Under his amended employment agreement, Mr. Amit spends 90% of his time in service as our CEO, and his compensation includes: (i) an annual base salary in the amount of \$313,133 (the “**CEO Base Salary**”); (ii) an annual performance-based bonus; and (iii) an annual grant of equity. At the 2021 AGM, our shareholders approved a three-year Cash Bonus Plan for Mr. Amit, for the years 2021-2023. According to the bonus plan, Mr. Amit’s annual on target cash bonus for each of these years shall be equal to not more than the CEO Base Salary, conditioned upon his performance in each of these years measured against criteria pre-determined by our Compensation Committee and Board of Directors, with respect to the applicable year. According to the annual

equity plan, Mr. Amit's annual grant of equity for each of these three years shall not exceed 300% of the CEO Base Salary, and at least 40% of it shall be subject to performance-based vesting or otherwise comprised of options with a fair market value exercise price.

Further, Mr. Amit's amended agreement contains confidentiality provisions for the term of Mr. Amit's services and thereafter, and non-compete provisions for the term of Mr. Amit's service and for a six-month period after the termination of his service. It provides that all intellectual property developed by Mr. Amit, or in which he took part, during or in connection with his services, is our sole property. The agreement may be terminated by the Company at any time, by written notice of termination delivered to Mr. Amit six months in advance. We may, however, immediately terminate the employment of Mr. Amit in various circumstances, including in the case of a breach of fiduciary duty.

As Mr. Amit may be deemed, together with the Priortech Founding Members and Chroma, to control the Company (see Item 3.D - ***Risk Factors- Our principal shareholders, Priortech and Chroma, hold a controlling interest in us and will be able to exercise their control in ways that may be adverse to your interests. Our relationship with Priortech and Chroma may give rise to a conflict of interests***” above), in accordance with the Companies Law, his terms of employment must be approved by the Company’s shareholders at least once every three years, and, accordingly, were last re-approved at the 2021 AGM. Mr. Amit does not receive any compensation in consideration for his service as a member of our Board of Directors.

C. **Board Practices**

Corporate Governance Practices

We are incorporated in Israel and therefore are subject to various corporate governance practices under the Companies Law, relating to matters such as external directors, audit and compensation committees, internal auditor and approvals of interested parties transactions. These matters are in addition to the Nasdaq Rules and other relevant provisions of U.S. securities laws. Under applicable Nasdaq Rules, a foreign private issuer such as us may generally follow its home country rules of corporate governance in lieu of comparable Nasdaq Rules, except for certain matters such as composition and responsibilities of the audit committee and the independence of its members. See Item 3.D – ***Risk Factors - Being a foreign private issuer exempts us from certain SEC Requirements and Nasdaq Rules, which may result in less protection that is afforded to investors under rules applicable to domestic issuers***” above. For information regarding home country rules followed by us see Item 16G – ***Corporate Governance***” below.

General Board Practices

Our Articles provide that our Board of Directors shall consist of not less than five and not more than ten directors, including the external directors. Currently, our board consists of eight members. At our 2021 AGM, each of Messrs. Rafi Amit, Yotam Stern, Moty Ben-Arie, Leo Huang, I-Shih Tseng, and Orit Stav were re-appointed for service as our directors. All directors were appointed following the recommendation by the Company’s Nomination Committee, and each of them is serving an approximately one-year term, which is due to expire at our 2022 annual general meeting of shareholders (the **“2022 AGM”**). In addition, following the recommendation of our Nomination Committee and Board of Directors, our shareholders approved, at our 2021 AGM, the re-appointment for a second term of services of Ms. Yael Andorn and Prof. Yosi Shacham-Diamand as external directors in accordance with the Companies Law, for a term of three years each.

According to the Chroma Voting Agreement (see Item 4.A. – ***History and Development of the Company***”), Chroma is entitled to nominate individuals for two seats on the Company’s eight member Board and Priortech is entitled to nominate three members. The remaining seats are held by two external directors and an additional independent director.

In accordance with the Companies Law, our Board of Directors retains all the powers in managing our Company that are not specifically granted to the shareholders. For example, the Board may make decisions to borrow money for the Company, and may set aside reserves out of our profits, for whatever purposes it sees fit.

The Board of Directors may pass a resolution when a quorum is present (in person or via telecommunication), and by a vote of at least a majority of the directors present when the resolution is put to vote. A quorum is defined as at least a majority of the directors then in office who are lawfully entitled to participate in the meeting but not less than two directors. The Chairman of the Board is elected and removed by the Board members. Minutes of the meetings of the Board of Directors are recorded and kept at our offices. In addition, the Board of Directors may pass a resolution by way of a written resolution signed by all members of our Board of Directors.

The Board of Directors may, subject to the provisions of the Companies Law, appoint a committee of the Board and delegate to such committee all or any of the powers of the Board, as it deems appropriate. Notwithstanding the foregoing and subject to the provisions of the Companies Law, the Board may, at any time, amend, restate or cancel the delegation of any of its powers to any of its committees. Our Board of Directors has appointed an Audit Committee, also serving as a Compensation Committee, and a Nomination Committee. For information regarding the duties, responsibilities and composition of each of our committees, see Item 6.C – ***Board Practices - Committees of the Board of Directors***” below.

Our Articles provide that any director may appoint as an alternate director, by written notice to us or to the Chairman of the Board, any individual who is qualified to serve as director and who is not then serving as a director or alternate director for any other director. An alternate director has all of the rights and obligations of a director, excluding the right to appoint an alternate for himself. Currently no alternate directors serve on our board.

Election, Terms and Skills of Directors

Directors, other than external directors, are elected by a resolution of the shareholders at the annual general meeting and serve until the conclusion of the next annual general meeting of the shareholders, unless earlier terminated in the event of such director's death, resignation, bankruptcy, incapacity or removal by a resolution of the shareholders.

According to the Companies Law, a person who does not possess the skills required and the ability to devote the appropriate time to the performance of the office of director in a company, taking into consideration, among other things, the special requirements and size of that company, shall neither be appointed as a director nor serve as a director in a public company. A public company shall not convene a general meeting the agenda of which includes the appointment of a director, and a director shall not be appointed, unless the candidate has submitted a declaration that he or she possesses the skills required and the ability to devote the appropriate time to the performance of the office of director in the company, that sets forth the aforementioned skills and further states that the limitations set forth in the Companies Law regarding the appointment of a director do not apply in respect of such candidate.

A director who ceases to possess any qualification required under the Companies Law for holding the office of director or who becomes subject to any ground for termination of his/her office must inform the company immediately and his/her office shall terminate upon such notice.

Independent Directors

Under the Nasdaq Rules, a majority of our directors is required to be independent. The independence criteria under the Nasdaq Rules excludes, among others, any person who is: (i) a current or former (at any time during the past three years) employee of a company or its affiliates; or (ii) an immediate family member of an executive officer (at any time during the past three years) of a company or its affiliates.

In addition, under the Companies Law, an "independent director" is either an external director or a director appointed or classified as such who meets the same non-affiliation criteria as an external director, as determined by the company's audit committee, and who has not served as a director of the company for more than nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever the consecutive nature of such director's service. However, as our shares are listed on the Nasdaq Global Select Market, we may also, in accordance with the Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside of Israel), 2000 (the "**Alleviation Regulations**"), classify directors who qualify as independent directors under the relevant non-Israeli rules, as "independent directors" under the Companies Law. In addition, the Alleviation Regulations provide that "independent directors" may be elected for additional terms that do not exceed three years each, beyond the nine consecutive years permitted under the Companies Law, provided that, if the director is being re-elected for an additional term or terms beyond the nine consecutive years, the company's audit committee, followed by the board of directors, have approved that considering the expertise and special contribution of the director to the work of the board of directors and its committees, the appointment for an additional term of service is beneficial to the company.

Six of our eight members of the Board - Mses. Yael Andorn and Orit Stav and Messrs. I -Shih Tseng, Leo Huang, Yosi Shacham-Diamand and Moty Ben Arie - qualify as independent directors under the Nasdaq Rules. Four of our eight members of the Board - Mses. Yael Andorn and Orit Stav and Messrs. Yosi Shacham-Diamand and Moty Ben Arie - qualify as independent directors under the Companies Law.

External Directors

Under the Companies Law, we are required to appoint at least two external directors. Each committee of a company's board of directors which is authorized to exercise the board of directors' authorities is required to include at least one external director, except for the audit committee and the compensation committee, which are required to include all of the external directors. The Alleviation Regulations allow companies whose shares are traded on Nasdaq and which do not have a controlling shareholder (within the meaning of the Companies Law) to exempt themselves from the requirement to have external directors on their board of directors and from related requirements imposed by the Companies Law concerning the composition of the audit and compensation committees, provided that they continue to comply with the relevant U.S. securities laws and the Nasdaq Rules applicable to U.S. domestic issuers, regarding the independence of the board of directors and the composition of the audit and compensation committees. Currently, the relief provided in the Alleviation Regulations does not apply to us.

Qualification. To qualify as an external director, an individual or his or her relative, partner, employer, any person to whom such person is directly or indirectly subject to, or any entity under his or her control may not have, as of the date of appointment, or may not have had during the previous two years, any affiliation with the company, any entity controlling the company on the date of the appointment or with any entity controlled, at the date of the appointment or during the previous two years, by the company or by its controlling shareholder (and in a company that does not have a shareholder or an affiliated group of shareholders holding 25% or more of the company's voting rights, such person may not have any affiliation with any person who, at the time of appointment, is the chairman, the chief executive officer, the chief financial officer or a 5% shareholder of the company). In general, the term "affiliation" includes: an employment relationship, a business or professional relationship maintained on a regular basis, control and service as an Office Holder; "Control" is defined in the Israeli Securities Law as the ability to direct the actions of a company but excluding a power that is solely derived from a position as a director of the company or any other position with the company; a person who is holding 50% or more of the "controlling power" in the company – voting rights or the right to appoint a director or a general manager – is automatically considered to possess control. The Companies Law defines the term "**Office Holder**" of a company to include a director, the chief executive officer, an executive vice president, a vice president, any other person fulfilling or assuming any of the foregoing positions without regard to such person's title, and any manager who is directly subordinated to the chief executive officer.

In addition, no person can serve as an external director if the person's position or other business creates, or may create conflicts of interest with the person's responsibilities as an external director or may otherwise interfere with the person's ability to serve as an external director. Until the lapse of two years from termination of office, a company or its controlling shareholder may not give any direct or indirect benefit to a former external director.

Election and Term of External Directors. External directors are elected by a majority vote at a shareholders' general meeting, provided that either:

- a majority of the shares voted at the meeting, which are not held by controlling shareholders or shareholders with personal interest in approving the appointment (excluding personal interest not resulting from contacts with the controlling shareholder), not taking into account any abstentions, vote in favor of the election; or
- a vote in which the total number of shares voting against the election of the external director, does not exceed two percent of the aggregate voting rights in the company.

In a company in which, at the date of appointment of an external director, all the directors are of the same gender, the external director to be appointed shall be of the other gender.

An external director can be removed from office only by: (i) the same majority of shareholders that is required to elect an external director; or (b) a court, and provided that either (a) the external director ceases to meet the statutory qualifications with respect to his or her appointment, or (b) the external director violates his or her duty of loyalty to the company. The court may also remove an external director from office if he or she is unable to perform his or her duties on a regular basis.

An external director who ceases to possess any qualification required under the Companies Law for holding the office of an external director must inform the company immediately and his/her office shall terminate upon such notice.

In general, external directors serve a three-year term, which may then be extended for two additional three-year periods. Thereafter, in accordance with regulations promulgated under the Companies Law, an external director may be appointed for additional terms of service of not more than three years each provided that: (a) a company's audit committee, followed by the board of directors, have approved that considering the expertise and special contribution of the external director to the work of the board of directors and its committees, the appointment for an additional term of service is beneficial to the company; (b) the appointment for an additional term of service is approved in accordance with the requirements of the Companies Law; and (c) the prior periods of service of such external director, as well as the reasoning of the audit committee and board of directors for the approval of the extension of the term of service, were presented to the shareholders prior to their approval.

Re-election of an external director may be effected through one of the following mechanisms:

1. a shareholder holding one percent or more of a company's voting rights proposed the re-election of the nominee;
2. the board of directors proposed the re-election of the nominee and the election was approved by the shareholders by the majority required to appoint external directors for their initial term; or
3. the external director who is up for renewal has proposed himself or herself for re-election.

With respect to mechanisms 1 and 3 above, the re-election is required to fulfill all of the following terms: (i) to be approved by a majority of the votes cast by the shareholders of the Company, excluding the votes of controlling shareholders and shareholders who have a personal interest in approving such nomination resulting from their relations with the controlling shareholders; (ii) to include votes cast in favor of the re-election by such non-excluded shareholders constituting more than two percent of the voting rights in the Company; and (iii) the external director is not a related or competing shareholder or a relative of such a related or competing shareholder, at the time of the appointment, and does not and did not have any affiliation with a related or competing shareholder, at the time of the appointment or within the two years preceding the appointment. A "related or competing shareholder" is a shareholder proposing the re-appointment or a shareholder holding 5% or more of the outstanding shares or voting rights of the company, provided that at the time of the re-appointment, such shareholder, a controlling shareholder thereof or a company controlled by such shareholder or by a controlling shareholder thereof, have business relationships with the Company or are competitors of the Company.

Financial and Accounting Expertise. Pursuant to the Companies Law and regulations promulgated there under, (1) each external director must have either "accounting and financial expertise" or "professional qualifications" and (2) at least one of the external directors must have "accounting and financial expertise". A director with "accounting and financial expertise" is a director whose education, experience and skills qualifies him or her to be highly proficient in understanding business and accounting matters and to thoroughly understand the company's financial statements and to stimulate discussion regarding the manner in which financial data is presented. A director with "professional qualifications" is a person who meets any of the following criteria: (i) has an academic degree in economics, business management, accounting, law, public administration; (ii) has a different academic degree or has completed higher education in an area relevant to the company's business or which is relevant to his or her position; or (iii) has at least five years' experience in any of the following, or has a total of five years' experience in at least two of the following: (A) a senior position in the business management of a corporation with substantial business activities, (B) a senior public position or a senior position in the public service, or (C) a senior position in the company's main fields of business.

Compensation. An external director is entitled to compensation as provided in the Remuneration Regulations and is otherwise prohibited from receiving any other compensation, directly or indirectly, from the Company. For more information, please see “*Remuneration of Directors*” below.

Our External Directors. Ms. Yael Andorn and Prof. Yosi Shacham-Diamand were re-appointed as our external directors at the 2021 AGM, for a three-year-term which will expire on September 19, 2024. Our Board of Directors has determined that Ms. Andorn has the “accounting and financial expertise” and that Mr. Shacham-Diamand has the “professional qualifications” required by the Companies Law.

Remuneration of Directors

Generally, directors’ remuneration should be consistent with a company’s compensation policy for Office Holders (see “*Compensation Policy*” below) and requires the approval of the compensation committee, the board of directors and the shareholders (in that order). Notwithstanding the above, in certain circumstances shareholder approval may be waived (see below) and, under different circumstances, the compensation committee and the board of directors may approve an arrangement that deviates from the compensation policy, provided that such arrangement is approved by a special majority of the company’s shareholders, including (i) at least a majority of the shareholders, present and voting (abstentions are disregarded), who are not controlling shareholders and who do not have a personal interest in the matter, or (ii) the non-controlling shareholders and shareholders who do not have a personal interest in the matter who were present and voted against the matter hold two percent or less of the voting power of the Company.

According to the Remuneration Regulations, external directors are generally entitled to an annual fee, a participation fee for each meeting of the board of directors or any committee of the board on which he or she serves as a member, and reimbursement of travel expenses for participation in a meeting which is held outside of the external director’s place of residence. The minimum, fixed and maximum amounts of the annual and participation fees are set forth in the Remuneration Regulations, as supplemented by the Alleviation Regulations, based on the classification of the company according to the amount of its capital. The candidate for service as external director must be notified by the company of his or her remuneration terms prior to his or her appointment and, subject to certain exceptions, such remuneration will not be amended throughout the three-year period during which he or she is in office. A company may also compensate an external director in shares or rights to purchase shares, other than convertible debentures which may be converted into shares, in addition to the annual and participation remuneration and the reimbursement of expenses, subject to certain limitations set forth in the Remuneration Regulations.

According to regulations promulgated under the Companies Law with respect to relief in approval of certain related party transactions (the “**Relief Regulations**”), shareholders’ approval for directors’ compensation and employment arrangements is not required if both the Compensation Committee and the board of directors resolve that either (i) the directors’ compensation and employment arrangements are solely for the benefit of the company or (ii) the remuneration to be paid to any such director does not exceed the maximum amounts set forth in the Remuneration Regulations. Further, according to the Relief Regulations, shareholders’ approval for directors’ compensation and employment arrangements is not required if (i) both the Compensation Committee and the board of directors resolve that such terms (a) are not more beneficial than the former terms, or are essentially the same in their effect; and (b) are in line with the company’s compensation policy; and (ii) such terms are brought for shareholder approval at the next general meeting of shareholders. Also, according to the Remuneration Regulations, shareholder approval may be waived if the remuneration to be paid to the external directors is between the fixed and maximum amounts set forth in such regulations.

As consideration for their service as directors and their participation in each meeting of the Board or Board’s committees, we pay each of our external and independent directors (all Board members except for Messrs. Amit, Stern, Huang and Tseng) a fixed annual fee, a fixed participation fee and reimbursement of expenses in the following amounts: NIS 130,000 (approximately \$39,397) as annual fee, NIS 3,500 (approximately \$1,076) as in-person participation fee, NIS 2,100 (approximately \$645) for conference call participation and NIS 1,750 (approximately \$538) for each written resolutions. As these amounts are in the range between the fixed amounts of the annual and participation fees, as set forth in the Remuneration Regulations, based on the amount of the Company’s capital, and the maximum amounts of such fees as set forth in the Alleviation Regulations, they are exempt from shareholder approval, in accordance with the Relief Regulations. The above-mentioned cash remuneration is in line with the Company’s Executives & Directors Compensation Policy (the “**Compensation Policy**”), according to which each of the Company’s non-executive (and non-controlling) directors is entitled to receive cash fees which include annual and participation fees. Messrs. Amit, Stern, Huang and Tseng do not receive any payment with respect to their service as our directors.

At the 2021 AGM, our shareholders approved an annual equity award mechanism for our directors, pursuant to which, each of our directors who are not classified as controlling shareholders (including our external directors but excluding Mr. Tseng, who himself is not a controlling shareholder, but serves as our director pursuant to the Voting Agreement and therefore does not receive any compensation for such service), either currently serving or as shall be appointed from time to time (“**Non-Controlling Directors**”), will be entitled to a fixed annual equity award, comprised of an equal mix between options to purchase Shares at an exercise price equal to the average closing price per Share as quoted on the NASDAQ Stock Market during the 30 consecutive calendar days preceding the date of grant, and RSUs bearing an annual value of 50,000 USD (the “**Annual Equity Award**”).

The following table sets forth the number of Ordinary Shares held by our directors, as of March 10, 2022, and the number of options exercisable and RSUs vested as of March 10, 2022, and within 60 days from such date:

Name of Director	Number of RSUs vested within 60 days as of March 10, 2022	Number of RSUs vested as of March 10, 2022 and within 60 days	Number of Ordinary Shares held as of March 10, 2022
Rafi Amit	0	0	0
Yotam Stern	0	0	12,000
Moty Ben- Arie	0	0	3,229
Yael Andorn	0	0	3,229
Yosi Shacham-Diamand	0	0	3,229
Leo Huang	0	0	0
I-Shih Tseng	0	0	0
Orit Stav	0	0	0

The options were granted pursuant to our then in effect equity plan and in accordance with the grant terms included therein. The RSUs were granted pursuant to our Share Incentive Plan (and Sub-Plan for Grantees Subject to Israeli Taxation) (the “**2018 Plan**”). For additional information regarding the main terms of the option and RSUs grants, please see item 6.E below – “**Share Ownership – Share Incentive Plans**”.

Committees of the Board of Directors

Audit Committee

SEC and Nasdaq Requirements. In accordance with the Exchange Act, rules of the SEC under the Exchange Act and Nasdaq Rules, we are required to have an audit committee consisting of at least three directors, each of whom is (i) independent; (ii) does not receive any compensation from the Company (other than directors’ fees); (iii) is not an affiliated person of the Company or any of its subsidiaries; (iv) has not participated in the preparation of the Company’s (or subsidiary’s) financial statements during the past three years; and (v) financially literate and one of whom has been determined by the board to be the audit committee financial expert. The duties and responsibilities of the audit committee under the Nasdaq Rules include: (i) recommending the appointment of the Company’s independent auditor to the board of directors, determining its compensation and overseeing the work performed by it; (ii) pre-approving all services of the independent auditor; (iii) overseeing our accounting and financial reporting processes and the audits of our financial statements; and (iv) handling complaints relating to accounting, internal controls and auditing matters.

We have adopted an audit committee charter as required by the Nasdaq Rules.

Companies Law Requirements. Under the Companies Law, the board of directors of any Israeli company whose shares are publicly traded must appoint an audit committee, comprised of at least three directors including all of the external directors. In addition, the majority of the members must meet certain independence criteria and may not include: (i) the chairman of the board; (ii) any controlling shareholder or a relative thereof; (iii) any director employed by or providing services on a regular basis to the Company, a controlling shareholder or a company owned by a controlling shareholder; or (iv) any director whose main income is provided by a controlling shareholder (the “**Non-Permitted Members**”). The chairman of such audit committee must be an external director.

The duties and responsibilities of our audit committee under the Companies Law include (1) identification of irregularities and deficiencies in the management of our business, in consultation with the internal auditor and our independent auditors, and suggesting appropriate courses of action to amend such irregularities; (2) reviewing and approval of certain transactions and actions of the Company, including the approval of related party transactions, that require approval by the audit committee under the Companies Law; defining whether certain acts and transactions that involve conflicts of interest are material or not and whether transactions that involve conflict of interests are material or not and whether transactions that involve interested parties are extraordinary or not, and to approve such transactions; (3) determining with respect to transactions with controlling shareholders, even if such are not extraordinary transactions, a duty to conduct a competitive process, under the supervision of the committee or under the supervision of whomever designated by the committee and according to standards determined by the committee, or determining other proceedings, prior to entering into such transactions, all in accordance with the type of transaction; (4) determining the method of approval of transactions which are not insignificant, including the types of transactions which shall require approval of the committee; (5) recommending the appointment of the internal auditor and its compensation to the board of directors; (6) examining the performance of our internal auditor and whether he is provided with the required resources and tools necessary for him to fulfill his role, considering, among others, the Company's size and special needs; and (7) setting procedures for handling complaints made by Company's employees in connection with management deficiencies and the protection to be provided to such employees.

Non-Permitted Members shall not attend audit committee's meetings or take part in its decisions, unless the chairman of the audit committee has determined that such person is required for the presentation of a certain matter. Nevertheless, an employee who is not a controlling shareholder or a relative thereof may be present at the discussion part only, pursuant to the Committee's request, and the Company's legal counsel and secretary, who are not controlling shareholders or relatives thereof, may be present during both discussion and decision making parts - pursuant to the Committee's request.

The quorum for discussions and decisions shall be the majority of the members, provided that the majority of the members present meet the independence criteria set forth in the Companies Law and at least one of them is an external director.

Our Audit Committee. The members of our Audit Committee are Ms. Yael Andorn and Messrs. Moty Ben Aric and Yosi Shacham-Diamand, all of whom are independent directors in accordance with Nasdaq Rules and meet the independence criteria set forth in the Companies Law. Ms. Andorn is the Chairperson of our Audit Committee and qualifies as its audit committee financial expert.

Compensation Committee

Nasdaq Requirements. Under Nasdaq Rules, the compensation payable to our executive officers must be determined or recommended to the board for determination either by a majority of the independent directors on the board, in a vote in which only independent directors participate, or by a compensation committee comprised solely of independent directors, subject to certain exceptions.

Companies Law Requirements. According to the Companies Law, the board of directors of any Israeli company whose shares are publicly traded, must appoint a compensation committee, comprised of at least three directors, including all of the external directors which shall be the majority of its members and one thereof must serve as the chairman of the committee. The remaining members of the committee must satisfy the criteria for remuneration applicable to the external directors and qualified to serve as members of the audit committee pursuant to Companies Law requirements, as described above. However, an audit committee that satisfies the requirements of the Companies Law regarding the composition of a compensation committee may be authorized to carry out all duties and responsibilities of the compensation committee.

Further, under the Companies Law, a compensation committee is responsible for: (i) providing the board of directors its recommendations with respect to the approval of the compensation policy (see below - "**Compensation Policy**") and any amendments and/or extensions thereto; (ii) periodically reviewing the implementation of the compensation policy and providing the board of directors with recommendations with respect to any amendments or updates thereto; (iii) reviewing and resolving whether or not to approve arrangements with respect to the terms of office and employment of Office Holders; and (iv) determining whether or not to exempt a transaction with a candidate for chief executive officer, who is not affiliated with the Company or its controlling shareholder, from shareholder approval if subjection of such transaction to shareholder approval may prevent its conclusion, and provided that the terms approved are consistent with the compensation policy.

The attendance and participation in meetings of the compensation committee are subject to the same limitations that apply to the Audit Committee. The quorum for discussions and decisions shall be the majority of the members, provided that those members present are independent directors and at least one of them is an external director.

Our Compensation Committee. We follow the provisions of the Companies Law with respect to the composition and responsibilities of our Compensation Committee. As all of the members of our Audit Committee meet the independence requirements for compensation committee members set forth in the Nasdaq Rule 5605(d)(2), as a foreign private issuer, we have elected, pursuant to Nasdaq Rule 5615(a)(3), to follow Israeli practice, in lieu of compliance with the certain provisions of Nasdaq Rule 5605(d), which would require us to have a separate compensation committee. Pursuant to the Companies Law, allowing an audit committee that satisfies the requirements of the Companies Law regarding the composition of a compensation committee, to carry out all duties and responsibilities of the compensation committee, our Board of Directors has authorized our Audit Committee to carry out the duties and responsibilities of the compensation committee.

Nomination Committee

Nasdaq Requirements. The Nasdaq Rules require that director nominees be selected or recommended for the board's selection either by a nomination committee composed solely of independent directors or by a majority of independent directors, in a vote in which only independent directors participate, subject to certain exceptions.

Since 2018 our Nomination Committee has assumed the responsibility for recommending to the Board nominees for election (including re-election) to the Company's Board of Directors, in lieu of the recommendation by our independent directors.

Our Nomination Committee. In 2018 our Board of Directors appointed a Nomination Committee, comprised of our two external directors, Ms. Andorn and Mr. Shacham-Diamand. Consistent with the requirements of the Nasdaq Rules, our Nomination Committee is responsible for: (i) identifying potential new candidates for service on the Company's Board of Directors, taking into account, *inter alia*, the candidate's applicable experience, expertise and/or familiarity with the Company's field of business, as well as the candidate's ethical character, independent judgment and industry reputation; (ii) conducting appropriate inquiries into the backgrounds and qualifications of potential candidates for service as directors; and (iii) reviewing and resolving whether or not to approve arrangements with respect to such candidates.

Approval of Office Holders Terms of Employment

The terms of office and employment of Office Holders (other than directors and the chief executive officer) require the approval of the compensation committee and the board of directors, provided such terms are in accordance with the company's compensation policy. Shareholder approval is also required if the compensation of such officer is not in accordance with such policy. However, in special circumstances the compensation committee and then the board of directors may nonetheless approve such compensation even if such compensation was not approved by the shareholders, following a further discussion and for detailed reasoning.

The terms of office and employment of directors, the chief executive officer or controlling shareholders (or a relative thereof), regardless of whether or not such terms conform to the company's compensation policy, should be approved by the compensation committee, the board of directors and the shareholders, by a special majority, except for: (a) approval of terms of office and employment of directors, which are consistent with the company's compensation policy, and require shareholder approval by a regular majority; or (b) approval of terms of office and employment of directors pursuant to certain reliefs provided for under the Remuneration Regulations and/or the Relief Regulations, with respect to which shareholder approval is waived. Shareholder special majority should include (i) at least a majority of the shareholders who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions are disregarded), or (ii) the non-controlling shareholders and shareholders who do not have a personal interest in the matter who were present and voted against the matter hold two percent or less of the voting power of the company ("**Special Majority**"). Notwithstanding the above, in special circumstances the compensation committee and then the board of directors may nonetheless approve compensation for the chief executive officer, even if such compensation was not approved by the shareholders, following a further discussion and for detailed reasoning. In addition, under certain circumstances, a company's compensation committee may exempt the terms of office and employment of a candidate for service as the CEO from shareholders' approval, provided that the candidate is not a director and that the terms of office are compliant with the company's compensation policy.

In addition, amendment of existing terms of office and employment of Office Holders who are not directors requires the approval of the compensation committee only, if the compensation committee determines that the amendment is not material.

Compensation Policy

Under the Companies Law we are required to adopt a compensation policy, which sets forth company policy regarding the terms of office and employment of Office Holders, including compensation, equity awards, severance and other benefits, exemption from liability and indemnification. Such compensation policy should take into account, among other things, providing proper incentives to directors and officers, management of risks by the company, the officer's contribution to achieving corporate objectives and increasing profits, and the function of the officer or director.

Our Compensation Policy is designed to balance between the importance of incentivizing Office Holders to reach personal targets and the need to assure that the overall compensation meets our Company's long-term strategic performance and financial objectives. The Compensation Policy provides our Compensation Committee and our Board of Directors with adequate measures and flexibility to tailor each of our Office Holder's compensation package based, among other matters, on geography, tasks, role, seniority and capability. Moreover, the Compensation Policy is intended to motivate our Office Holders to achieve ongoing targeted results in addition to a high level business performance in the long term, without encouraging excessive risk taking.

The Compensation Policy and any amendments thereto must be approved by the board of directors, after considering the recommendations of the compensation committee, and by a Special Majority of our shareholders. The Compensation Policy must be reviewed from time to time by the board, and must be re-approved or amended by the board of directors and the shareholders no less than every three years. If the Compensation Policy is not approved by the shareholders, the compensation committee and the board of directors may nonetheless approve the policy, following further discussion of the matter and for detailed reasons.

We have adopted a new compensation policy for office holders, which was approved by our shareholders at a special general meeting of shareholders held in July 2020 and amended at the 2021 AGM (together with such amendment, the “**Compensation Policy**”). The following is a brief overview of the main terms included in the Compensation Policy, and specifically describes the amendments made in the Compensation Policy at the 2021 AGM:

Base Salaries

Executives’ Base Salaries is determined by the Compensation Committee and Board based on comparative benchmark information regarding salaries of applicable executives in peer group companies, rather than on fixed caps as provided for under the current compensation policy. Executives’ Base Salaries shall not exceed the 50th percentile of the relevant benchmark, unless the Compensation Committee and the Board deem that unique and special circumstances warrant a deviation from such cap with respect to a specific Executive.

Annual Cash Bonus

On Target Cash Plan: Under the Compensation Policy, Executives’ On Target Cash Plan shall be calculated based on each Executive’s annual Base Salary, so that the On Target Cash Plan of Executives other than the CEO shall be capped at 75% of such Executives’ annual Base Salary, and the CEO’s On Target Cash Plan shall be capped at 100% of his or her annual Base Salary.

On Target Bonus Cap: Under the Compensation Policy, the actual Cash Plan payment to all Executives (including the CEO) shall be capped at 200% of the Executive’s On Target Cash Plan.

On Target Bonus Threshold: the Compensation Policy provides for an increased threshold for payment of any amounts under an Executive’s Cash Plan, such that payment of any bonus under the Company’s Cash Plan will only be made upon the achievement of a minimum Non GAAP Net Profit of \$6,000,000.

Change of Control Bonus

The Compensation Policy provides for a “change of control” cash payment of up to six monthly Base Salaries, and further provides that in the event of a change of control that creates a significant value to the Company’s shareholders, by presenting a premium of at least 40% over the average of the closing prices per share of the Company’s ordinary shares as quoted on the Nasdaq Global Market for the 20 trading days ending one day prior to the execution of the term sheet (or similar instrument) for such change of control event, the Compensation Committee and Board may approve an increased “change in control” cash payment, of up to 12 monthly Base Salaries.

Equity Based Compensation

Under the Compensation Policy, the total yearly Equity Value granted to an Executive shall not exceed (i) with respect to the CEO - 300% of his annual Base Salary; and (ii) with respect to all other Executives, 250% of such Executive’s annual Base Salary, provided that at least 40% of the equity based components granted to each Executive (including the CEO) shall be comprised of either options at a fair market value exercise price, or shall be otherwise subject to performance-based vesting.

Directors Compensation

The Compensation Policy provides for general guidelines with respect to the Company’s non-executive and non-controlling directors’ remuneration, pursuant to which, in line with the current compensation policy, directors’ remuneration shall be comprised of cash compensation which includes annual fee and meeting participation fee as shall be determined in accordance with the provisions of the Companies Law, as well as equity based compensation, the annual value of which shall be capped at \$100,000.

Insurance Framework

The Compensation Policy provides for caps on the premium which may be paid and coverage which may be purchased under the Company’s Directors & Officers (D&O) insurance policies, pursuant to which the coverage which may be purchased shall be limited to the higher of: (i) \$30,000,000; or (ii) 10% of the Company’s market cap (based on the average closing price of the Company’s share on the Nasdaq Global Market during the preceding 30 days), and the cap on the premium which may be paid for each policy shall be increased to one million \$1,000,000. Further, the Compensation Committee shall be authorized, to the extent an additional insurance coverage is required in its opinion with respect to a specific material transaction or a series of related transactions, to purchase coverage in amounts of up to 3 times the then existing limit of coverage under the Compensation Policy, with costs of up to 3 times the then existing limit of premium amounts under the Compensation Policy, without additional shareholders’ approval, if and to the extent permitted under the Companies Law.

Additional Provisions

The Compensation Policy includes additional provisions, including with respect to: separation package; claw back policy; relocation compensation; special circumstances cash incentive; indemnification and exemption; and deviation from policy caps.

Approval of Certain Transactions with Related Parties

The Companies Law requires the approval of the audit committee or the compensation committee, thereafter the approval of the board of directors and in certain cases — the approval of the shareholders, in order to effect specified actions and extraordinary transactions, such as the following:

- transactions with Office Holders and third parties - where an Office Holder has a personal interest in the transaction;
- employment terms of Office Holders; and
- extraordinary transactions with controlling parties or with a third party where a controlling party has a personal interest in the transaction; or any transaction with the controlling shareholder or his relative regarding terms of service (provided directly or indirectly, including through a company controlled by the controlling shareholder) and terms of employment (for a controlling shareholder who is not an Office Holder). A “relative” is defined in the Companies Law as spouse, sibling, parent, grandparent, descendant, spouse’s descendant, sibling or parent and the spouse of any of the foregoing.

Such extraordinary transactions with controlling shareholders require the approval of the audit committee, or the compensation committee, the board of directors and the majority of the voting power of the shareholders present and voting at the general meeting of the company (not including abstentions), provided that either:

- the majority of the shares of shareholders who have no personal interest in the transaction and who are present and voting, vote in favor; or
- shareholders who have no personal interest in the transaction who vote against the transaction do not represent more than two percent of the aggregate voting rights in the company.

Any shareholder participating in the vote on approval of an extraordinary transaction with a controlling shareholder must inform the company prior to the voting whether or not he or she has a personal interest in the approval of the transaction, and if he or she fails to do so, his or her vote will be disregarded.

Further, such extraordinary transactions, as well as any transactions with a controlling shareholder or his relative concerning terms of service or employment, need to be re-approved no less than every three years provided however that with respect to certain such extraordinary transactions the audit committee may determine that a longer duration is reasonable given the circumstances related thereto and such extended period has been approved by the shareholders.

In accordance with regulations promulgated under the Companies Law, certain defined types of extraordinary transactions between a public company and its controlling shareholder(s) are exempt from the shareholder approval requirements.

In addition, the approval of the audit committee, followed by the approval of the board of directors and the shareholders, is required to effect a private placement of securities, in which either: (i) 20% or more of the company’s outstanding share capital prior to the placement is offered, and the payment for which (in whole or in part) is not in cash, in tradable securities registered in a stock exchange or not under market terms, and which will result in an increase of the holdings of a shareholder that holds 5% or more of the company’s outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5% of the company’s outstanding share capital or voting rights; or (ii) a person will become a controlling shareholder of the company.

A “controlling shareholder” is defined in the Israeli Securities Law and in the provisions governing related party transactions under the Companies Law as a person with the ability to direct the actions of a company but excluding a person whose power derives solely from his or her position as a director of the company or any other position with the company, and with respect to approval of transactions with related parties also as a person who holds 25% or more of the voting power in a public company, if no other shareholder owns more than 50% of the voting power in the company, and provided that two or more persons holding voting rights in the company, who each have a personal interest in the approval of the same transaction, shall be deemed to be one holder for the evaluation of their holdings with respect to approval of transactions with related parties.

Compensation committee approval is required and thereafter, in most cases, the approval of the board of directors and in certain cases – the additional approval of the shareholders, in order to approve the grant of an exemption from the responsibility for a breach of the duty of care towards the company, for the provision of insurance and for an undertaking to indemnify any Office Holder of the company; see below under “*Insurance, Indemnification and Exemption*”.

Duties of Office Holders and Shareholders

Duties of Office Holders

Fiduciary Duties

The Companies Law imposes a duty of care and a duty of loyalty on all Office Holders of a company, including directors and officers. The duty of care requires an Office Holder to act with the level of care with which a reasonable Office Holder in the same position would have acted under the same circumstances. The duty of loyalty includes avoiding any conflict of interest between the Office Holder’s position in the company and his personal affairs, any competition with the company, or exploiting any business opportunity of the company in order to receive personal advantage for himself or others. It also requires an Office Holder to reveal to the company any information or documents relating to the company’s affairs which the Office Holder has received due to his position as an Office Holder.

The company may approve an action by an Office Holder from which the Office Holder would otherwise have to refrain due to its violation of the Office Holder’s duty of loyalty if: (i) the Office Holder acts in good faith and the act or its approval does not cause harm to the company, and (ii) the Office Holder discloses the nature of his or her interest in the transaction to the company a reasonable time before the company’s approval.

Each person listed in the table under “Directors and Senior Management” above is considered an Office Holder under the Companies Law (for definition of “Office Holder” under the Companies Law see above under “*External directors*” – “*Qualification*”).

Disclosure of Personal Interests of an Office Holder

The Companies Law requires that an Office Holder of a company promptly disclose any personal interest that he or she may possess and all related material information and documents known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction, the Office Holder must also disclose any personal interest held by the Office Holder’s spouse, siblings, parents, grandparents, descendants, spouse’s siblings, parents and descendants and the spouses of any of these people, or any corporation in which the Office Holder: (i) holds at least 5% of the company’s outstanding share capital or voting rights; (ii) is a director or general manager; or (iii) has the right to appoint at least one director or the general manager. An extraordinary transaction is defined as a transaction that is either (i) not in the ordinary course of business; (ii) not on market terms; or (iii) likely to have a material impact on the company’s profitability, assets or liabilities.

In the case of a transaction which is not an extraordinary transaction, after the Office Holder complies with the above disclosure requirements, only board approval is required unless the articles of association of the company provide otherwise. The transaction must be for the benefit of the company. If a transaction is an extraordinary transaction, or with respect to terms of office and employment, then in addition to any approval stipulated by the articles of association, it also must be approved by the company's audit committee (or with respect to terms of office and employment, the compensation committee) and then by the board of directors, and, under certain circumstances, by the shareholders of the company. A director who has a personal interest in a transaction, may be present if a majority of the members of the board of directors or the audit committee (or with respect to terms of office and employment, the compensation committee), as the case may be, has a personal interest. If a majority of the board of directors has a personal interest, then shareholders' approval is also required.

Duties of Shareholders

Under the Companies Law, a shareholder has a duty to act in good faith toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, by voting in a general meeting of shareholders with respect to the following matters: (a) any amendment to the articles of association; (b) an increase of the company's authorized share capital; (c) a merger; or (d) approval of interested party transactions which require shareholders' approval.

In addition, any controlling shareholder, any shareholder who knows that he or she possess power to determine the outcome of a shareholder vote and any shareholder who, pursuant to the provisions of a company's articles of association, has the power to appoint or prevent the appointment of an Office Holder in the company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty but states that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty of fairness, taking into account such shareholder's position.

Insurance, Indemnification and Exemption

Pursuant to the Companies Law and the Israeli Securities Law, the Israeli Securities Authority is authorized to impose administrative sanctions, including monetary fines, against companies like ours and their officers and directors, for certain violations of the Israeli Securities Law (see in "***Administrative Enforcement***" below) or the Companies Law. The Companies Law further provides that companies like ours may indemnify their officers and directors and purchase an insurance policy to cover certain liabilities, if provisions for that purpose are included in their articles of association.

Our Articles allow us to indemnify and insure our Office Holders to the fullest extent permitted by law.

Office Holders' Exemption

Under the Companies Law, and provided that the company's articles of association allow it to do so, an Israeli company may exempt in advance an Office Holder from his or her liability to the company, in whole or in part, for a breach of his or her duty of care (except in connection with distributions). Exemption from liability for a breach of duty of loyalty is not allowed. Our Articles allow us to exempt our Office Holders to the fullest extent permitted by law.

Office Holders' Insurance

Our Articles provide that, subject to the provisions of the Companies Law, we may enter into a contract for the insurance of all or part of the liability imposed on our Office Holders in respect of an act performed by him or her in his or her capacity as an Office Holder, concerning the following:

- a breach of his or her duty of care to us or to another person;
- a breach of his or her duty of loyalty to us, provided that the Office Holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice our interests; and
- a financial liability imposed upon him or her in favor of another person.

Without derogating from the aforementioned, subject to the provisions of the Companies Law and the Israeli Securities Law, we may also enter into a contract to insure an Office Holder for expenses, including reasonable litigation expenses and legal fees, incurred by him or her in relation to an administrative proceeding instituted against such Office Holder or payment required to be made to an injured party pursuant to certain provisions of the Israeli Securities Law.

Office Holder's Indemnification

Our Articles provide that, subject to the provisions of the Companies Law and the Israeli Securities Law, we may indemnify any of our Office Holders in respect of an obligation or expense specified below, imposed on or incurred by the Office Holder in respect of an act performed in his capacity as an Office Holder, as follows:

- a financial liability imposed on him or her in favor of another person by any judgment, including a settlement or an arbitration award approved by a court;
- reasonable litigation expenses, including attorney's fees, incurred by the Office Holder as a result of an investigation or proceeding instituted against him by a competent authority which concluded without the filing of an indictment against him and without the imposition of any financial liability in lieu of criminal proceedings, or which concluded without the filing of an indictment against him but with the imposition of a financial liability in lieu of criminal proceedings concerning a criminal offense that does not require proof of criminal intent or in connection with a financial sanction (the phrases "proceeding concluded without the filing of an indictment" and "financial liability in lieu of criminal proceeding" shall have the meaning ascribed to such phrases in section 260(a)(1a) of the Companies Law);
- reasonable litigation expenses, including attorneys' fees, expended by an Office Holder or charged to the Office Holder by a court, in a proceeding instituted against the Office Holder by the Company or on its behalf or by another person, or in a criminal charge from which the Office Holder was acquitted, or in a criminal proceeding in which the Office Holder was convicted of an offense that does not require proof of criminal intent; and
- expenses, including reasonable litigation expenses and legal fees, incurred by an Office Holder in relation to an administrative proceeding instituted against such Office Holder, or payment required to be made to an injured party, pursuant to certain provisions of the Israeli Securities Law.

The Company may undertake to indemnify an Office Holder as aforesaid, (a) prospectively, provided that, in respect of the first act (financial liability) the undertaking is limited to events which in the opinion of the board of directors are foreseeable in light of the Company's actual operations when the undertaking to indemnify is given, and to an amount or criteria set by the board of directors as reasonable under the circumstances, and further provided that such events and amount or criteria are set forth in the undertaking to indemnify, and (b) retroactively; provided, however, that the total aggregate indemnification amount that the Company shall be obligated to pay to all of its Office Holders, for all matters and circumstances described above, shall not exceed an amount equal to twenty five percent (25%) of the shareholders' equity at the time of the indemnification.

Limitations on Insurance and Indemnification

The Companies Law provides that a company may not insure, exempt or indemnify an Office Holder for any breach of his or her liability arising from any of the following:

- a breach by the Office Holder of his or her duty of loyalty, except that the company may enter into an insurance contract or indemnify an Office Holder if the Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;
- a breach by the Office Holder of his or her duty of care if such breach was intentional or reckless, but unless such breach was solely negligent;
- any act or omission done with the intent to derive an illegal personal benefit; or

- any fine, civil fine, financial sanction or monetary settlement in lieu of criminal proceedings imposed on such Office Holder.

Under the Companies Law, exemption and indemnification of, and procurement of insurance coverage for, our Office Holders, must be approved by our compensation committee and our board of directors and, with respect to the CEO and to an Office Holder who is a director also by our shareholders. However, according to the Relief Regulations, shareholders' approval for the procurement of directors' insurance is not required if the insurance policy is approved by our compensation committee and (i) the terms of such policy are within the framework for insurance coverage as approved by our shareholders and set forth in our compensation policy; (ii) the premium paid under the insurance policy is at fair market value; and (iii) the insurance policy does not and may not have a substantial effect on the Company's profitability, assets or obligations. Further, as our insurance coverage includes Office Holders who are controlling shareholders, in accordance with the Relief Regulations, shareholders' approval may be waived, if, in addition to the approval of the compensation committee as set forth above, our board of directors approves all such matters approved by the compensation committee, and both organs approve that the terms of the insurance policy are identical with respect to all Office Holders, including the controlling shareholders.

Indemnification letters, covering exemption from, indemnification and insurance of those liabilities imposed under the Companies Law and the Israeli Securities Law discussed above, were granted to each of our present Office Holders and were approved for future Office Holders. Hence, we indemnify our Office Holders to the fullest extent permitted under the Companies Law.

We currently hold directors' and officers' liability insurance policy for the benefit of our Office Holders, including our directors. This policy was approved by our Compensation Committee on December 21, 2021, and is effective until November 30, 2022.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Administrative Enforcement

The Israeli Securities Law includes an administrative enforcement procedure to be used by the Israeli Securities Authority, or ISA, to enhance the efficacy of enforcement in the securities market in Israel. This administrative enforcement procedure may be applied to any company or person (including director, officer or shareholder of a company) performing any of the actions specifically designated as breaches of law under the Securities Law. Furthermore, the Israeli Securities Law requires that the Chief Executive Officer of a company supervise and take all reasonable measures to prevent the company or any of its employees from breaching such law. The Chief Executive Officer is presumed to have fulfilled such supervisory duty if the company adopts internal enforcement procedures designed to prevent such breaches, appoints a representative to supervise the implementation of such procedures and takes measures to correct the breach and prevent its reoccurrence.

As detailed above, under the Israeli Securities Law, a company cannot obtain insurance against or indemnify a third party (including its officers and/or employees) for any administrative procedure and/or monetary fine (other than for payment of damages to an injured party). The Israeli Securities Law permits insurance and/or indemnification for expenses related to an administrative procedure, such as reasonable legal fees, provided that it is permitted under the company's articles of association.

We have adopted and implemented an internal enforcement plan to reduce our exposure to potential breaches of the Companies Law and sections in the Israeli Securities Law, which are applicable to us. Our Articles and letters of indemnification permit, among others, insurance and/or indemnification as contemplated under the Israeli Securities Law (see "***Insurance, Indemnification and Exemption***" above).

D. *Employees*

Employees

The following table sets forth the number of our employees engaged in the specified activities at the end of each of the years 2021, 2020 and 2019:

	As of December 31,		
	2021	2020	2019
Executive management	4	4	4
Research and development	104	93	77
Sales support	113	101	92
Sales and marketing	46	37	35
Administration	45	47	47
Operations	92	74	67
Total	404	356	322

The following table sets forth the number of our employees located in the following geographic regions at the end of each of the years 2021, 2020 and 2019:

	As of December 31,		
	2021	2020	2019
Israel	255	222	200
Abroad	149	134	122
Total	404	356	322

With respect to our Israeli employees, no collective bargaining agreements apply to our employees. However, by virtue of extension orders, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations, relating primarily to the length of the work day, minimum wages, pension contributions, insurance for work-related accidents, procedures for dismissing employees, determination of severance pay and other conditions of employment - are applicable to our employees.

With respect to our (or any of our subsidiaries) Chinese employees, certain provisions of Chinese Labor Contract Law and Social Insurance Law primarily govern the formation of employer-employee relations, termination of employment, severance pay, worker dispatch, part-time employment and social insurance.

We consider our relationship with our employees to be good, and we have never experienced a labor dispute, strike or work stoppage.

E. *Share Ownership.*

The following table sets forth certain information with respect to the beneficial ownership of our outstanding ordinary shares by our directors and executive officers.

Beneficial ownership is determined in accordance with the rules of the SEC and generally means sole or shared power to vote or direct the voting or to dispose or direct the disposition of any ordinary shares. Except as indicated by footnote, the persons named in the table below have sole voting and investment power with respect to all ordinary shares shown as beneficially owned by them. The percentage of beneficial ownership is based upon 43,847,393 ordinary shares outstanding as of March 8, 2022.

Name	Number of Ordinary Shares Owned ⁽¹⁾	Percentage of Total Outstanding Ordinary Shares
Prioritech Ltd.	9,256,687	21.11%
Chroma ATE Inc.	7,817,440	17.83%
Yotam Stern ⁽³⁾	12,000	0.03%
Rafi Amit ⁽²⁾	*	*
Leo Huang ⁽⁴⁾	*	*
I-Shih Tseng	*	*
Moty Ben-Arie ⁽⁵⁾	*	*
Yosi Shacham- Diamand ⁽⁵⁾	*	*
Yael Andorn ⁽⁵⁾	*	*
Orit Stav ⁽⁵⁾	*	*
Moshe Eisenberg ⁽⁵⁾	*	*
Ramy Langer ⁽⁵⁾	*	*

* Beneficially owns less than 1%

- (1) Ordinary shares relating to options and RSUs currently exercisable or exercisable within 60 days as of March 10, 2022, are deemed outstanding for computing the percentage of the persons holding such securities but are not deemed outstanding for computing the percentage of any other person. As of the date of this Annual Report, the total number of options held by the persons included in the above table that are currently exercisable or exercisable within 60 days as of March 8, 2022, was 421.
- (2) Mr. Amit does not own directly our ordinary shares. In addition, as a result of a voting agreement relating to a majority of Prioritech's voting equity, Mr. Amit may be deemed to control Prioritech. As a result, Mr. Amit may be deemed to beneficially own the shares of the Company held by Prioritech. Mr. Amit disclaims beneficial ownership of such shares.
- (3) Mr. Stern directly owns 12,000 of our ordinary shares. In addition, as a result of a voting agreement relating to a majority of Prioritech's voting equity, Mr. Stern may be deemed to control Prioritech. As a result, Mr. Stern may be deemed to beneficially own the shares of the Company held by Prioritech. Mr. Stern disclaims beneficial ownership of such shares.
- (4) Mr. Huang does not directly own any of our ordinary shares. Based on information we received from Chroma Mr. Huang is considered a controlling person with regard to Chroma, accordingly Mr. Huang may be deemed to beneficially own the shares of the Company held by Chroma. Mr. Huang disclaims beneficial ownership of such shares.
- (5) Holding less than 1% of our outstanding ordinary shares (including options and RSUs held by each such person which have vested or will vest within 60 days as of March 8, 2022) and have therefore holding percentages have not been listed separately.

Share Incentive Plans

General

We currently maintain one active share incentive plan which is the 2018 Plan.

The 2018 Plan was adopted by the Company in April 2018 and replaced the Company's previous equity plans - the 2014 Share Option Plan (the "**2014 Plan**") and the 2007 Restricted Share Unit Plan (the "**2007 Plan**").

The purpose and intent of the 2018 Plan is to advance, pursuant to the Compensation Plan, the interests of the Company by affording to selected employees, officers, directors, consultants and other services providers of the Company and its affiliates an opportunity to acquire or increase its proprietary interest in the Company by the grant in their favor of options, restricted shares and RSUs (the "**Awards**") thus providing them with an additional incentive to become, and to remain, employed and/or engaged by the Company, encouraging their sense of proprietorship and stimulating their active interest in the success of the Company.

2018 Plan

General. As of December 31, 2021, 1,322,854 Awards were outstanding under the 2018 Plan.

Administration of the 2018 Plan. Our 2018 Plan is administered by our Board. Under the 2018 Plan, Awards may be granted to our officers, directors, employees or consultants and those of our subsidiaries. The exercise price of options under the 2018 Plan is determined by our Board, and is generally set as the fair market value on the date of grant. The purchase price for each RSU and restricted share is not more than the underlying share's nominal value, unless otherwise determined by the Board. The vesting schedule of the Awards is also determined by the Board of Directors; generally the options vest over a four-year period, with 25% of the options vest on each anniversary of the vesting start date. The vesting of Awards may also be subject to performance conditions, which shall be either in addition to or instead of the aforementioned time-based vesting. Each Award granted under the 2018 Plan is usually exercisable between its vesting time and up to seven years from the date of grant, subject to certain early expiration provisions, such as in the event of termination of employment or engagement with the Company.

Future Awards to be granted by us to our employees, officers, directors and consultants, or those of our affiliates, will only be made pursuant to the 2018 Plan.

Previous Plans

As of December 31, 2021, under the 2014 Plan there were 421 options exercisable and vested for 421 ordinary shares at a weighted average exercise price of \$4.38.

Item 7. Major Shareholders and Related Party Transactions.

A. Major Shareholders.

The following table provides information regarding the beneficial ownership of our ordinary shares as of March 8, 2022, held by each person or entity who beneficially owns more than 5% of our outstanding ordinary shares. None of these shareholders has different voting rights than any of the Company’s other shareholders.

Beneficial Ownership

Beneficial ownership is determined in accordance with the rules of the SEC and generally means sole or shared power to vote or direct the voting or to dispose or direct the disposition of any ordinary shares. Except as indicated by footnote, the person named in the table below has sole voting and investment power with respect to all ordinary shares shown as beneficially owned by it. The percentage of beneficial ownership is based upon 43,847,393 ordinary shares outstanding as of March 8, 2022.

	Number of Ordinary Shares*	Percentage
Prioritech Ltd. (1)	9,256,687	21.11%
Chroma ATE Inc. (2)	7,817,440	17.83%
Migdal Insurance & Financial Holdings Ltd (3)	3,420,170	7.80%

- (1) 29.04% of the voting equity in Prioritech Ltd. is subject to a voting agreement. As a result of this agreement, and due to the fact that there are no other shareholders holding more than 50% of the voting equity in Prioritech Ltd., Messrs. Rafi Amit, Yotam Stern, David Kishon, and Hanoch Feldstien and the estates of Itzhak Krell (deceased), Zehava Wineberg (deceased) and Haim Langmas (deceased), may be deemed to control Prioritech Ltd. The voting agreement does not provide for different voting rights for Prioritech than the voting rights of other holders of our ordinary shares. Prioritech’s principal executive offices are located at South Industrial Zone, Migdal Ha’Emek 23150, Israel.
- (2) Based on the Schedule 13G filed by Chroma ATE Inc. on August 5, 2019, which presented ownership as of June 19, 2019. The 7,817,440 Ordinary Shares reported under such Schedule 13G by Chroma are beneficially owned by Chroma. Chroma’s principal address is No. 66, Hwa Ya 1 Rd., Guishan District, Taoyuan City 333, Taiwan.
- (3) Based on the Schedule 13G filed by Migdal Insurance & Financial Holdings Ltd. (“Migdal”) on February 2, 2022, which presented ownership as of December 31, 2021. Of the 3,420,170 Ordinary Shares reported as beneficially owned by the Migdal (i) 3,420,170 Ordinary Shares are held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Migdal, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii) 562,365 Ordinary Shares are held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and investment decisions, and (iii) - are beneficially held for their own account (Nostro account). Migdal’s principal business address is 4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel.

B. Related Party Transactions.

Agreements with Priortech and Chroma

For a description of definitive agreements signed between the Company, Priortech and Chroma, see Item 4.A. – “*History and Development of the Company*”.

Registration Rights Agreement with Priortech and Chroma

On March 1, 2004, we entered into a registration rights agreement providing for us to register with the SEC certain of our ordinary shares held by Priortech. This registration rights agreement may be used in connection with future offerings of our ordinary shares, and includes, among others, the following terms: (a) Priortech is entitled to make up to three demands that we register our ordinary shares held by Priortech, subject to delay due to market conditions; (b) Priortech will be entitled to participate and sell our ordinary shares in any future registration statements initiated by us, subject to delay due to market conditions; (c) we will indemnify Priortech in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions other than information provided by Priortech, and Priortech will indemnify us in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions in written statements by Priortech made for the purpose of their inclusion in such registration statements; and (d) we will pay all expenses related to registrations which we have initiated, except for certain underwriting discounts or commissions or legal fees, and Priortech will pay all expenses related to a registration initiated at its demand in which we are not participating.

On December 30, 2004, the Registration Rights Agreement with Priortech was amended. The amendment concerns primarily the grant of unlimited shelf registration rights there under to Priortech with respect to its holdings in us, and the assignability of those shelf registration rights to its transferees.

In the framework of the Chroma Transaction, the Company, Chroma and Priortech entered into a Second Amended and Restated Registration Rights Agreement with the Company which, following the Chroma Closing Date, replaced the previous Registration Rights Agreement and grants Chroma registration rights with respect to our Ordinary Shares held by it, which are similar to those of Priortech. For a description of the definitive agreements signed under the Chroma Transaction, see Item 4.A. – “*History and Development of the Company*”.

Employment Agreement with Mr. Rafi Amit

For a description of the employment agreement with our Chief Executive Officer, Mr. Rafi Amit, see Item 6.B - “*Compensation – Employment Agreements*” above.

C. *Interests of Experts and Counsel.*

Not applicable.

Item 8. *Financial Information.*

A. *Consolidated Statements and Other Financial Information.*

Please see the consolidated financial statements listed in Item 18 for audited consolidated financial statements prepared in accordance with this Item.

Legal Proceedings

We are not a party to any material legal proceedings.

Dividends

See Item 10.B - “*Memorandum and Articles - Dividend and Liquidation Rights*” below for more information regarding our dividend policy).

B. *Significant Changes.*

None.

Item 9. *The Offer and Listing.*

A. *Offer and Listing Details.*

The Company’s ordinary shares are traded on the Nasdaq Global Market and on TASE under the symbol “CAMT”. We are subject to Israeli securities legislation which applies to companies that are traded in dual listing.

B. *Plan of distribution.*

Not applicable.

C. *Markets.*

See above.

D. *Selling Shareholders.*

Not applicable.

E. *Dilution.*

Not applicable.

F. *Expenses of the Issue.*

Not applicable.

Item 10. *Additional Information.*

A. *Share Capital*

Not applicable.

B. *Memorandum and Articles*

Following is a summary of material information concerning our share capital and a brief description of the material provisions contained in our Memorandum of Association and our Articles, which were last amended in the 2018 AGM.

Register

Our registration number at the Israeli registrar of companies is 51-123543-4.

Objectives and Purposes

Our Memorandum of Association and Articles provide that our purpose is to engage in any legal business and may contribute a reasonable amount for a worthy cause, even if such contribution is not within the framework of the Company's business considerations.

Share Capital

Our authorized share capital consists of one class of shares, which are our ordinary shares. Out of our authorized share capital of 100,000,000 ordinary shares, par value NIS 0.01 per ordinary share, 43,846,643 ordinary shares were outstanding and fully-paid as of December 31, 2021.

The ordinary shares do not have preemptive rights. The ownership and voting of our ordinary shares are not restricted in any way by our Articles, or by the laws of the State of Israel, except for shareholders who are citizens of countries in a state of war with Israel. Under the Companies Law, Israeli companies may purchase and hold their own shares, subject to the same conditions that apply to distribution of dividends (see Item 10.B - "*Memorandum and Articles - Dividend and Liquidation Rights*" below). These shares do not confer any rights whatsoever for as long as they are held by us. Additionally, a subsidiary may purchase or hold shares of its parent company to the same extent that the parent company is entitled to purchase its own shares, and these shares do not confer any voting rights for as long as they are held by the subsidiary.

Transfer of Shares

Ordinary shares are issued in registered form. Ordinary shares registered on the books of the transfer agent in the United States may be freely transferred on the transfer agent's books.

Dividend and Liquidation Rights

Our Board of Directors may declare a dividend to be paid to the holders of ordinary shares out of our retained earnings or our earnings derived over the two most recent years, whichever is higher, as reflected in the last audited or reviewed financial report prepared less than six months prior to distribution, provided that there is no reasonable concern that a payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. Dividends are distributed to shareholders in proportion to the nominal value of their respective holdings.

In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of ordinary shares in proportion to the nominal value of their respective holdings. This right may be affected by the grant of preferential dividend or distribution rights to the holders of any class of shares with preferential rights that may be authorized in the future. Our shareholders would need to approve any class of shares with preferential rights.

Modification of Class Rights

The Companies Law provides that the articles of a company may not be modified in such a manner that would have a detrimental effect on the rights of a particular class of shares without the vote of a majority of the affected class. Under our Articles, subject to the provisions of the Companies Law, the Company may, by a resolution adopted by its shareholders, amend the rights attached to all or any of its authorized share capital, whether issued or not, create new classes of shares and/or attach different rights to each class of shares, including special or preferential rights and/or different rights from those attached to the existing shares, including redeemable shares, deferred shares, etc.

Transfer Agent

The transfer agent and registrar for our ordinary shares is the American Stock Transfer & Trust Company, New York, New York.

Voting, Shareholders' Meetings and Resolutions

Holders of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of the shareholders. These voting rights may be affected by the grant of special voting rights to the holders of any class of shares with preferential rights that may be authorized in the future.

As part of the Chroma Voting Agreement, Priortech and Chroma vote together in the Company's shareholders' meetings (see Item 4.A. – "*History and Development of the Company*").

According to the Companies Law, an annual meeting of the shareholders must be held every year not later than 15 months following the last annual meeting. A special meeting of the shareholders may be convened by the board of directors at its decision or upon the demand of any of: (1) two of the directors or 25% of the then serving directors, whichever is fewer; (2) one shareholder or more owning at least 5% of the issued share capital and at least 1% of the voting rights in the Company; or (3) one shareholder or more owning at least 5% of the voting rights in the Company. If the Board of Directors does not convene a meeting upon a valid demand of any of the above then whoever made the demand, and in the case of several shareholders, those shareholders holding more than half of the voting rights of the shareholders making such demand, may convene a meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals making the demand, a court may order that a meeting be convened.

The quorum required for a meeting of shareholders consists of at least two shareholders present in person or by proxy within one half hour of the time scheduled for the beginning of the meeting, who hold or represent together at least 25% of the voting power in our company.

A meeting adjourned due to lack of a quorum is generally adjourned to the same day in the following week at the same time and place or any time and place as the directors designate in a notice to the shareholders. If a quorum is not present at the reconvened meeting, the meeting may be held with any number of participants. However, if the meeting was convened following a demand by the shareholders, the quorum will be that minimum number of shareholders authorized to make the demand.

In any shareholders' meeting, a shareholder can vote either in person or by proxy provided such proxy is received by the Company up to twenty-four hours prior to the time set for the meeting. Alternatively, shareholders who hold shares through members of TASE may vote electronically via the electronic voting system of the Israel Securities Authority, up to six hours prior to the time set for the meeting. General meetings of shareholders will be held in Israel, unless decided otherwise by our Board of Directors.

Most resolutions at a shareholders' meeting may be passed by a majority of the voting power of the company represented at the shareholders' meeting and voting on the matter. Resolutions requiring special voting procedures include the appointment and removal of external directors, approval of transactions with controlling shareholders, the terms of office and employment of directors (except for terms which are consistent with the company's compensation policy, and require approval by a regular majority), the chief executive officer or controlling shareholders, approval of the Company's compensation policy and any amendments thereto, and approval of a merger or a tender offer. See in Item 6.C - "*Board Practices - Committees of the Board of Directors*" and "*Approval of Certain Transactions with Related Parties*" above and in "*Anti-Takeover Effects of Israeli Laws; Mergers and Acquisitions under Israeli Law*" below.

Anti-Takeover Effects of Israeli Laws; Mergers and Acquisitions under Israeli Law

In general, a merger of a company that was incorporated before the enactment of the Companies Law requires the approval of the holders of a majority of 75% of the voting power represented at the annual or special general meeting in person or by proxy or by a written ballot, as shall be permitted, and voting thereon in accordance with the provisions of the Companies Law. Upon the request of a creditor of either party of the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger. In addition, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposal for the merger has been filed by each party with the Israeli Registrar of Companies and (ii) 30 days have passed since the merger was approved by the shareholders of each party.

The Companies Law also provides that an acquisition of shares in a public company must be made by means of a tender offer: (a) if there is no existing shareholder in the company holding shares conferring 25% or more of the voting rights at the general meeting (a “control block”) and as a result of the acquisition the purchaser would become a holder of a control block; or (b) if there is no existing shareholder in the company holding shares conferring 45% or more of the voting rights at the general meeting and as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights at the general meeting. Notwithstanding, the above requirements do not apply if the acquisition: (1) was made in a private placement that received shareholders’ approval (which includes an explicit approval of the purchaser becoming a holder of a “control block”, or 45% or more, of the voting power in the company, unless there is already a holder of a “control block” or 45% or more, respectively, of the voting power in the company); (2) was from a holder of a “control block” in the company and resulted in the acquirer becoming a holder of a “control block”; or (3) was from a holder of 45% or more of the voting power in the company and resulted in the acquirer becoming a holder of 45% or more of the voting power in the company. The tender offer must be extended to all shareholders, but the offeror is not required to purchase more than 5% of the company’s outstanding shares, regardless of how many shares are tendered by shareholders. The tender offer may be consummated only if: (i) at least 5% of the company’s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.

If as a result of an acquisition of shares, the acquirer will hold more than 90% of a company’s outstanding shares, the acquisition must be made by means of a tender offer for all of the outstanding shares. If as a result of such full tender offer the acquirer would own more than 95% of the outstanding shares, then all the shares that the acquirer offered to purchase will be transferred to it. The law provides for appraisal rights if any shareholder files a request in court within six months following the consummation of a full tender offer, but the acquirer will be entitled to stipulate that tendering shareholders forfeit their appraisal rights. If as a result of a full tender offer the acquirer would own 95% or less of the outstanding shares, then the acquirer may not acquire shares that will cause his shareholding to exceed 90% of the outstanding shares.

Furthermore, certain provisions of other Israeli laws may have the effect of delaying, preventing or making more difficult an acquisition of or merger with us; see in Item 3.D – ***“Risk Factors - Provisions of Israeli law could delay, prevent or make undesirable an acquisition of all or a significant portion of our shares or assets.”***

C. *Material Contracts.*

None.

D. *Exchange Controls*

There are currently no Israeli currency control restrictions on payments of dividends or other distributions with respect to our ordinary shares or the proceeds from the sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.

The ownership or voting of our ordinary shares by non-residents of Israel, except with respect to citizens of countries which are in a state of war with Israel, is not restricted in any way by our memorandum of association or articles of association or by the laws of the State of Israel.

E. *Taxation*

U.S. Federal Income Tax Considerations¹

Subject to the limitations described herein, this discussion summarizes certain U.S. federal income tax consequences of the purchase, ownership and disposition of our ordinary shares to a U.S. holder. A U.S. holder is a holder of our ordinary shares who is:

- an individual citizen or resident of the United States for U.S. federal income tax purposes;
- a corporation (or another entity taxable as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any political subdivision thereof, or the District of Columbia;
- an estate, the income of which may be included in gross income for U.S. federal income tax purposes regardless of its source; or
- a trust (i) if, in general, a U.S. court is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or (ii) that has in effect a valid election under applicable U.S. Treasury Regulations to be treated as a U.S. person.

Unless otherwise specifically indicated, this discussion does not consider the U.S. tax consequences to a person that is not a U.S. holder (a “**non-U.S. holder**”) or is a partnership and considers only U.S. holders that will own ordinary shares as capital assets (generally, for investment).

This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the “**Code**”), current and proposed Treasury Regulations promulgated under the Code and administrative and judicial interpretations of the Code, all as currently in effect and all of which are subject to change, possibly with retroactive effect. This discussion does not address all aspects of U.S. federal income taxation that may be relevant to any particular U.S. holder based on the U.S. holder’s particular circumstances. In particular, this discussion does not address the U.S. federal income tax consequences to U.S. holders who are broker-dealers, banks, insurance companies, tax-exempt organizations, or governmental organizations, tax-qualified retirement plans, individual retirement accounts and other tax-deferred accounts, financial institutions, grantor trusts, S corporations, partnerships or entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein), real estate investment trusts, regulated investment companies, certain former citizens, U.S. expatriates or former long-term residents of the United States, or U.S. holders who own, directly, indirectly or constructively, 10% or more of our shares (by vote or value), U.S. holders who have elected mark-to-market accounting, U.S. holders holding the ordinary shares as part of a hedging, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated transaction. U.S. holders that received ordinary shares as a result of exercising employee stock options or otherwise as compensation, U.S. holders whose functional currency is not the U.S. dollar, persons deemed to sell our common stock under the constructive sale provisions of the Code, persons holding our common shares in connection with a trade or business conducted outside of the United States and U.S. holders who are subject to the alternative minimum tax. This discussion does not address the U.S. federal income tax consequences of holding or converting the Convertible Notes.

If a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of the partnership and a partner in such partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Such a partner or partnership should consult its tax advisor as to its tax consequences.

You are advised to consult your tax advisor with respect to the specific U.S. federal, state, local and foreign income tax consequences of purchasing, holding or disposing of our ordinary shares.

Taxation of Distributions on the Ordinary Shares

The discussion below is subject to the discussion entitled “*Tax Consequences if We Are a Passive Foreign Investment Company*”.

The amount of a distribution with respect to the ordinary shares will equal the amount of cash and the fair market value of any property distributed and will also include the amount of any taxes withheld from such distribution. A distribution paid by us with respect to the ordinary shares to a U.S. holder will generally be treated as dividend income to the extent that the distribution does not exceed our

current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. Dividends that are received by U.S. holders that are individuals, estates or trusts will be taxed at the rate applicable to long-term capital gains, provided that such dividends meet the requirements of “qualified dividend income.” For this purpose, qualified dividend income generally includes dividends paid by a non-U.S. corporation if certain holding period and other requirements are met and either (a) the stock of the non-U.S. corporation with respect to which the dividends are paid is “readily tradable” on an established securities market in the U.S. (e.g., the Nasdaq Global Market) or (b) the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the U.S. which includes an information exchange program and is determined to be satisfactory by the U.S. Secretary of the Treasury. The IRS has determined that the U.S.-Israel income tax treaty is satisfactory for this purpose. Dividends that fail to meet such requirements are taxed at the applicable ordinary income rates. No dividend received by a U.S. holder will be a qualified dividend (1) if the U.S. holder held the ordinary share with respect to which the dividend was paid for less than 61 days during the 121-day period beginning on the date that is 60 days before the ex-dividend date with respect to such dividend, excluding for this purpose, under the rules of Code Section 246(c), any period during which the U.S. holder has an option to sell, is under a contractual obligation to sell, has made and not closed a short sale of, is the grantor of a deep-in-the-money or otherwise nonqualified option to buy, or has otherwise diminished its risk of loss by holding other positions with respect to, such ordinary share (or substantially identical securities); or (2) to the extent that the U.S. holder is under an obligation (pursuant to a short sale or otherwise) to make related payments with respect to positions in property substantially similar or related to the ordinary share with respect to which the dividend is paid. If we were to be a “passive foreign investment company” or PFIC (as such term is defined in the Code) for any taxable year, dividends paid on our ordinary shares in such year or in the following taxable year would not be qualified dividends. See discussion below regarding our PFIC status at ***“Tax Consequences if We Are a Passive Foreign Investment Company”***. In addition, a non-corporate U.S. holder will be able to take a qualified dividend into account in determining its deductible investment interest (which is generally limited to its net investment income) only if it elects to do so; in such case the dividend will be taxed at the applicable ordinary income rates.

1 KL Tax reviewing.

The amount of any distribution which exceeds the amount treated as a dividend will be treated first as a non-taxable return of capital, reducing the U.S. holder's tax basis in its ordinary shares to the extent thereof, and then, to the extent such excess amount exceeds such holder's tax basis in such ordinary shares, as capital gain from the deemed disposition of the ordinary shares. Corporate holders will not be allowed a deduction for dividends received in respect of the ordinary shares.

Distributions paid by us in NIS generally will be included in the income of U.S. holders at the dollar amount of the distribution (including any taxes withheld therefrom), based upon the exchange rate in effect on the date the distribution is included in income, regardless of whether the payment is, in fact, converted into U.S. dollars. U.S. holders will have a tax basis in the NIS for U.S. federal income tax purposes equal to that dollar value. Any subsequent gain or loss in respect of the NIS arising from exchange rate fluctuations will generally be taxable as U.S. source ordinary income or loss.

Subject to the limitations set forth in the Code and the Treasury Regulations thereunder, U.S. holders may elect to claim a foreign tax credit against their U.S. federal income tax liability for non-U.S. income taxes withheld from dividends received in respect of the ordinary shares. The conditions and limitations on claiming a foreign tax credit include, among others, computation rules under which foreign tax credits allowable with respect to specific classes of income cannot exceed the U.S. federal income taxes otherwise payable with respect to each such class of income. In this regard, dividends paid by us generally will be foreign source "passive income" for U.S. foreign tax credit purposes. U.S. holders that do not elect to claim a foreign tax credit may instead claim a deduction for the non-U.S. income taxes withheld. The rules relating to foreign tax credits are complex, and you should consult your tax advisor to determine whether and to what extent you would be entitled to this credit or deduction. A U.S. holder will be denied a foreign tax credit for non-U.S. income taxes withheld from a dividend received on the ordinary shares (i) if the U.S. holder has not held the ordinary shares for at least 16 days of the 31-day period beginning on the date which is 15 days before the ex-dividend date with respect to such dividend or (ii) to the extent the U.S. holder is under an obligation to make related payments with respect to positions in substantially similar or related property. Any days during which a U.S. holder has substantially diminished its risk of loss on the ordinary shares are not counted toward meeting the required 16-day holding period.

Taxation of the Disposition of Ordinary Shares

Subject to the discussion below under "*Tax Consequences if We Are a Passive Foreign Investment Company*" upon the sale, exchange or other disposition of our ordinary shares (other than in certain non-recognition transactions), a U.S. holder will recognize capital gain or loss in an amount equal to the difference between the amount realized on the disposition and the U.S. holder's tax basis in such ordinary shares. The gain or loss recognized on the disposition of such ordinary shares will be long-term capital gain or loss if the U.S. holder held the ordinary shares for more than one year at the time of the disposition. Gain or loss recognized by a U.S. holder on a sale, exchange or other disposition of ordinary shares generally will be treated as U.S. source income or loss for U.S. foreign tax credit purposes.

A U.S. holder that uses the cash method of accounting calculates the dollar value of the proceeds received on the sale as of the date that the sale settles. However, a U.S. holder that uses the accrual method of accounting is required to calculate the value of the proceeds of the sale as of the trade date and may therefore realize foreign currency gain or loss. A U.S. holder may avoid realizing foreign currency gain or loss by electing to use the settlement date to determine the proceeds of sale for purposes of calculating the foreign currency gain or loss. In addition, a U.S. holder that receives foreign currency upon disposition of ordinary shares and converts the foreign currency into U.S. dollars after the settlement date or trade date (whichever date the U.S. holder is required to use to calculate the value of the proceeds of sale) may have foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the dollar, which will generally be U.S. source ordinary income or loss.

Net Investment Income Tax

Non-corporate U.S. holders may be subject to an additional 3.8% surtax on all or a portion of their “net investment income”, which may include dividends on, or capital gains recognized from the disposition of, our ordinary shares. U.S. holders are urged to consult their own tax advisors regarding the implications of the additional Net Investment Income tax on their investment in our ordinary shares.

Tax Consequences if We Are a Passive Foreign Investment Company

For U.S. federal income tax purposes, we will be a passive foreign investment company, or PFIC, if, after applying certain look through rules, either (1) 75% or more of our gross income in a taxable year is passive income, or (2) 50% or more of the value (generally determined on the basis of a quarterly average) of our assets in a taxable year consist of assets that produce or are held for the production of passive income. If we own (directly or indirectly) at least 25% by value of the stock of another corporation, we will be treated for purposes of the foregoing tests as owning our proportionate share of that other corporation’s assets and as directly earning our proportionate share of that other corporation’s income. Based on an analysis of our current assets, activities, market capitalization and income and expectations about our future assets, activities, market capitalization and income, we believe that we were not a PFIC for our taxable year ended December 31, 2021. We currently expect that we will not be a PFIC in 2021 or in the foreseeable future. However, PFIC status is determined as of the end of the taxable year and is dependent on a number of factors, including the relative value of our passive assets and our non-passive assets, our market capitalization and the amount and type of our gross income. There can be no assurance that we will not become a PFIC for the current taxable year ending December 31, 2022 or in a future taxable year. No assurance can be given that the IRS or a court of law will accept our position that we are not a PFIC, and there is a risk that the IRS or a court of law could determine that we are a PFIC. If we are a PFIC, a U.S. holder may be subject to one of the following three alternative taxing regimes, assuming the applicable requirements are satisfied:

The “QEF” regime applies if the U.S. holder elects to treat us as a “qualified electing fund” (“QEF”) for the first taxable year in which the U.S. holder owns our ordinary shares or in which we are a PFIC, whichever is later, and if we comply with certain reporting requirements. Under attribution rules, if we were a PFIC for any taxable year and had any subsidiaries or other entities in which we held a direct or indirect equity interest that were also PFICs (“Lower-tier PFICs”), U.S. Holders would be deemed to own their proportionate share of any such Lower-tier PFIC and would be subject to U.S. federal income tax according to the rules described in the following paragraph on (i) certain distributions by a Lower-tier PFIC and (ii) a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holders held such shares or equity interests directly, even if the U.S. Holders would not receive the proceeds of those distributions or dispositions. A U.S. Holder must make the QEF election by attaching a properly completed IRS Form 8621 (for us and any Lower-tier PFIC) to the U.S. Holder’s timely filed U.S. federal income tax return.

(a) If the QEF regime applies, then, for each taxable year that we are a PFIC, such U.S. holder will include in its gross income a proportionate share of our ordinary earnings (which is taxed as ordinary income) and net capital gain (which is taxed as long-term capital gain), subject to a separate election to defer payment of taxes, which deferral is subject to an interest charge. These amounts would be included in income by an electing U.S. holder, whether or not such amounts are actually distributed to the U.S. holder. A U.S. holder's basis in our ordinary shares for which a QEF election has been made would be increased to reflect the amount of any taxed but undistributed income. Generally, a QEF election allows an electing U.S. holder to treat any gain realized on the disposition of its ordinary shares as capital gain. Once made, the QEF election applies to all subsequent taxable years of the U.S. holder in which it holds our ordinary shares and for which we are a PFIC and can be revoked only with the consent of the IRS.

Special rules apply if a QEF election is made after the first taxable year in which a U.S. holder holds our ordinary shares and we are a PFIC. In such an event, the U.S. holder would be treated as if it had sold our ordinary shares for their fair market value on the last day of the taxable year immediately preceding the taxable year for which the QEF election is made and will recognize gain (but not loss) on such deemed sale in accordance with the excess distribution regime described below. Under certain circumstances, a U.S. holder may be eligible to make a retroactive QEF election with respect to a taxable year in the U.S. holder's holding period if such U.S. holder (1)(a) reasonably believed that we were not a PFIC as of the QEF election due date for the prior taxable year, and (b) filed a protective statement in which the U.S. holder described the basis for its reasonable belief and extended the statute of limitation on the assessment of PFIC related taxes for all taxable years to which the protective statement applies; (2) obtains IRS consent; or (3) is a "qualified shareholder" within the meaning of the Treasury Regulations.

(b) A second regime, the "mark-to-market" regime, may be elected as an alternative to making a QEF election so long as our ordinary shares are "marketable stock" (e.g., "regularly traded" on a "qualified exchange" such as the Nasdaq Global Market). Pursuant to this regime, in any taxable year that we are a PFIC, an electing U.S. holder's ordinary shares are marked-to-market each taxable year and the U.S. holder recognizes as ordinary income or loss an amount equal to the difference as of the close of the taxable year between the fair market value of our ordinary shares and the U.S. holder's adjusted tax basis in our ordinary shares. Losses are allowed only to the extent of net mark-to-market gain previously included by the U.S. holder under the election for prior taxable years. An electing U.S. holder's adjusted basis in our ordinary shares is increased by income recognized under the mark-to-market election and decreased by the deductions allowed under the election. Under the mark-to-market election, in a taxable year that we are a PFIC, gain on the sale of our ordinary shares is treated as ordinary income, and loss on the sale of our ordinary shares, to the extent the amount of loss does not exceed the net mark-to-market gain previously included, is treated as ordinary loss and any remaining loss from an actual disposition of ordinary shares generally would be capital loss. The mark-to-market election applies to the taxable year for which the election is made and all later taxable years, unless the ordinary shares cease to be marketable stock or the IRS consents to the revocation of the election. There can be no assurances that there will be sufficient trading volume with respect to the ordinary shares in order for the ordinary shares to be considered "regularly traded" or that our ordinary shares will continue to trade on the Nasdaq Global Select Market. Accordingly, there are no assurances that the ordinary shares will be marketable stock for these purposes. A mark-to-market election generally is unlikely to be available with respect to any Lower-tier PFIC.

If the mark-to-market election is made after the first taxable year in which a U.S. holder holds our ordinary shares and we are a PFIC, then special rules would apply.

(c) A U.S. holder making neither the QEF election nor the mark-to-market election is subject to the "excess distribution" regime. Under this regime, "excess distributions" are subject to special tax rules. An excess distribution includes (1) a distribution with respect to our ordinary shares that is greater than 125% of the average distributions received by the U.S. holder from us over the shorter of either the preceding three taxable years or such U.S. holder's holding period for our ordinary shares prior to the distribution year and (2) gain from the disposition of our ordinary shares.

Excess distributions must be allocated ratably to each day that a U.S. holder has held our ordinary shares. A U.S. holder must include amounts allocated to the current taxable year and any taxable year prior to the first taxable year in which we were a PFIC, in its gross income as ordinary income for that year. All amounts allocated to other taxable years of the U.S. holder would be taxed at the highest tax rate for each such year applicable to ordinary income and the U.S. holder also would be liable for interest on the deferred tax liability for each such year calculated as if such liability had been due with respect to each such year. The portions of gains and distributions that are not characterized as "excess distributions" are subject to tax in the current taxable year as ordinary income under the normal tax rules of the Code. Similar treatment would apply to shares of any Lower-tier PFICs that are generally treated for this purpose as if held by the U.S. holder.

In addition, special reporting requirements may apply to U.S. holders with respect to our ordinary shares, if we were to be treated as a PFIC, and a failure to comply with such requirements may subject a U.S. holder to substantial penalties or other adverse tax consequences. We will notify U.S. holders in the event we conclude that we will be treated as a PFIC for any taxable year to enable U.S. holders to consider whether or not to elect to treat us as a QEF for U.S. federal income tax purposes, to “mark-to-market” the ordinary shares, or to become subject to the “excess distribution” regime, and we expect that in such event we will provide U.S. holders with the information needed to make a QEF election with respect to us or any Lower-tier PFIC.

U.S. holders are urged to consult their tax advisors regarding the application of the PFIC rules, including eligibility for and the manner and advisability of making, the QEF election or the mark-to-market election.

Non-U.S. Holders of Ordinary Shares

Except as described below, a non-U.S. holder of ordinary shares will not be subject to U.S. federal income or withholding tax on the receipt of dividends on, and the proceeds from the disposition of, an ordinary share, unless, in the case of U.S. federal income taxes, that item is effectively connected with the conduct by the non-U.S. holder of a trade or business in the United States and, in the case of a resident of a country which has an income tax treaty with the United States, that item is attributable to a permanent establishment in the United States or, in the case of an individual, a fixed place of business in the United States. In addition, gain recognized by an individual non-U.S. holder on the disposition of ordinary shares will be subject to income tax in the United States if the non-U.S. holder is present in the United States for 183 days or more in the taxable year of the sale and certain other conditions are met.

Information Reporting and Backup Withholding

A U.S. holder (except for certain exempt recipients, such as corporations) generally is subject to information reporting and may be subject to backup withholding with respect to dividends paid on, and the receipt of the proceeds from the disposition of, our ordinary shares. A U.S. holder of our ordinary shares who does not provide a correct taxpayer identification number may be subject to penalties imposed by the IRS. Backup withholding will generally not apply if a U.S. holder provides a correct taxpayer identification number, certifies that such holder is not subject to backup withholding or otherwise establishes an exemption from backup withholding applies.

Non-U.S. holders generally will not be subject to information reporting or backup withholding with respect to the payment of dividends on, or proceeds from the disposition of, our ordinary shares provided the non-U.S. holder provides its taxpayer identification number, certifies to its foreign status or otherwise establishes an exemption from backup withholding applies.

Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a holder, or alternatively, the holder may be eligible for a refund of any excess amounts withheld under the backup withholding rules, in either case, provided that the required information is timely furnished to the IRS.

Certain U.S. holders who hold interests in “specified foreign financial assets” (as defined in Section 6038D of the Code) are generally required to file an IRS Form 8938 as part of their U.S. federal income tax returns to report their ownership of such specified foreign financial assets, which may include our ordinary shares, if the total value of those assets exceed certain thresholds. Substantial penalties may apply to any failure to timely file IRS Form 8938. In addition, in the event a holder that is required to file IRS Form 8938 does not file such form, the statute of limitations on the assessment and collection of U.S. federal income taxes of such holder for the related tax year may not close until three years after the date that the required information is filed. Holders should consult their own tax advisors regarding their tax reporting obligations.

ISRAELI TAXATION

The following summary describes the current tax structure applicable to companies in Israel, with special reference to its effect on us. It also discusses Israeli tax consequences material to persons purchasing our ordinary shares. We recommend that you consult your tax advisor as to the particular tax consequences of an investment in our ordinary shares.

General Corporate Tax Structure

The regular corporate tax rate applicable in 2021 and 2022 is 23%.

However, the effective tax rate payable by a company that derives income from a preferred enterprise, discussed further below, may be considerably less. See below in Item 10.E - *“Taxation - Tax Benefits under the Law for the Encouragement of Capital Investments, 1959”*.

Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”)

The Company’s production facility has been granted “Approved Enterprise” status under the Investment Law. The Company participates in the Alternative Benefits Program and, accordingly, income from its approved enterprises will be tax exempt for a period of 10 years (or up to 14 years commencing in the year in which the company was granted “Approved Enterprise” status), commencing in the first year in which the Approved Enterprise first generates taxable income; this is due to the fact that the Company operates in Zone “A” in Israel.

On April 1, 2005, an amendment to the Investment Law came into effect (the “**Amendment**”) and has significantly changed the provisions of the Investment Law. The Amendment limits the scope of enterprises which may be approved by the Investment Center by setting criteria for the approval of a facility as a “Beneficiary Enterprise”, such as provisions generally requiring that at least 25% of the Beneficiary Enterprise’s income will be derived from export. Additionally, the Amendment enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits.

In addition, the Amendment provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the law as they were on the date of such approval. Therefore, the Company’s existing Approved Enterprise will generally not be subject to the provisions of the Amendment. As a result of the Amendment, tax-exempt income generated under the provisions of the Amendment, as part of a new Beneficiary Enterprise, will subject the Company to taxes upon distribution or liquidation.

The Company has been granted the status of Approved Enterprises, under the Investment Law, for investment programs for the periods which ended in 2007 and 2010, and the status of Beneficiary Enterprise according to the Amendment, for a period ending in 2014. In addition Camtek has elected 2010 as the year of election for a period ending 2021 (collectively, “**Programs**”).

The Investment Law and the criteria for receiving an “Approved Enterprise” or “Beneficiary Enterprise” status may be amended from time to time and there is no assurance that we will be able to obtain additional benefits under the Investment Law.

On December 29, 2010, the Investment Law was amended to significantly revise the tax incentive regime in Israel commencing on January 1, 2011 (the “**December 2010 Amendment**”). The December 2010 Amendment introduced a new status of “Preferred Enterprise,” replacing the existing status of “Beneficiary Enterprise.” Similarly to “Beneficiary Enterprise,” a Preferred Enterprise is an industrial company meeting certain conditions, including deriving a minimum of 25% of its income from export activities. However, under the December 2010 Amendment, the requirement for a minimum investment in production assets in order to be eligible for the benefits granted under the Investments Law was cancelled. A Preferred Enterprise is entitled to a reduced flat tax rate with respect to preferred enterprise income at the following rates:

Tax Year	Development “Zone A”	Other Areas within Israel	Regular Corporate Tax Rate
2011-2012	10%	15%	24%-25%
2013	7%	12.5%	25%
2014-2015	9%	16%	26.5%
2016	9%	16%	25%
2017	7.5%	16%	24%
2018	7.5%	16%	23%
2019	7.5%	16%	23%
2020	7.5%	16%	23%
2021	7.5%	16%	23%

Dividends distributed from income which is attributed to “Preferred Enterprise” will be subject to withholding tax at source at the following rates: (i) Israeli resident corporation at 0%; (ii) Israeli resident individual at 20%; and (iii) non-Israeli resident at 20%, such withholding tax rate can be reduced subject to a reduced tax rate under the provisions of an applicable double tax treaty.

The December 2010 Amendment was also revised to allow financial assistance to companies located in development Zone A to be granted not only as a cash grant but also as a loan. The rates for grants and loans could be up to 20% of the amount of the approved investment.

In December, 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Investment Law (the “December 2016 Amendment”) was published. The investment law was amended to introduce a new tax incentive regime for intellectual property (IP) based companies. Effective January 1, 2017, the December 2016 Amendment enhanced tax incentives for certain industrial companies by reducing the corporate tax rate and tax withholding obligation.

According to the December 2016 Amendment, a Preferred Enterprise located in development Zone A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2017 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%). The December 2016 Amendment also prescribes special tax tracks for Technological Enterprises, which are subject to regulation issued by the Minister of Finance on May 28, 2017.

In 2019 the Company filed a notice to the Israeli Tax Authorities regarding the implementation of the Preferred Enterprise for its 2019 preferred income (instead of a Beneficiary Enterprise). As the Company is located in Development Area A, the applied corporate tax rate is 7.5%.

The new tax tracks under the December 2016 Amendment are as follows:

Preferred Technological Enterprise - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion. A Preferred Technological Enterprise, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development zone A - a tax rate of 7.5%).

Special Preferred Technological Enterprise - an enterprise for which total consolidated revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise will be subject to tax at a rate of 6% on profits deriving from intellectual property, regardless of the enterprise’s geographical location.

In summary, as of 2019, the applicable tax rates are as follows:

Enterprise type	Development "Zone A"	Other Areas within Israel	Regular Corporate Tax Rate
Preferred Enterprise	7.5%	16%	23%
Special Preferred Enterprise	5%	8%	23%
Preferred Technological Enterprise	7.5%	12%	23%
Special Preferred Technological Enterprise	6%	6%	23%

In addition, any dividend distributed from a Preferred Technological Enterprise to foreign companies holding at least 90% of the share capital will be subject to a reduced tax rate of 4%.

Neither the provisions of the December 2010 Amendment nor the December 2016 Amendment apply to companies currently having an “Approved Enterprise” or “Beneficiary Enterprise” status, which will continue to be entitled to the tax benefits according to the provisions of the Investment Law prior to the aforementioned amendments, unless the company having the benefits of such status has elected by filing with the Israeli Tax Authority not later than the date prescribed for the filing of the company’s annual tax return for the respective year, to adopt the provisions of the December 2010 Amendment. Such election cannot be later rescinded. A company having the status of “Beneficiary Enterprise” or “Approved Enterprise” making such election by June 30, 2015 will be entitled to distribute income generated by the Beneficiary Enterprise” or “Approved Enterprise,” subject to withholding tax at source at the following rates: (i) Israeli resident corporations at 0%; (ii) Israeli resident individuals at 20%; and (iii) non-Israeli residents at 20%, such withholding tax rate can be reduced subject to a reduced tax rate under the provisions of an applicable double tax treaty.

During the years 1998-2006 Camtek was subject to tax in accordance with the Approved and Beneficiary Enterprise provisions under the Law for the Encouragement of Capital Investments. As such, Camtek has income that was exempt from tax. Distribution of dividends from the exempt income requires to pay income tax on the amount of the dividend distributed at the tax rate that would have been applicable to it in the year the income was produced if it had not been exempt from tax. In February 2022, the Company, in a settlement with the Israeli Tax Authorities, elected to take advantage of the temporary rule of 2022 in Israel and pay a reduced tax rate on its historical exempt earnings to allow the Company to distribute dividends from these earnings in the future with no additional corporate tax liability (See Note 18B(b) to the Consolidated Financial Statements). The Company’s Statement of Income for the year ended December 31, 2021 included a one-time tax expense of \$5,315, with in respect of this settlement.

Law for the Encouragement of Industrial Research and Development, 1984

For information regarding the R&D Law, see above in Item 4.B - “*Business Overview - The Israel Innovation Authority, formerly – the Israeli Office of Chief Scientist*”.

Net Operating Loss Carry forwards

As of December 31, 2021, the Company did not have a net operating loss, or NOL carry forward for Israeli tax purposes.

Law for the Encouragement of Industry (Taxes), 1969

We believe that we currently qualify as an “Industrial Company” within the meaning of the Law for the Encouragement of Industry (Taxes), 1969 (the “**Industry Encouragement Law**”). According to the Industry Encouragement Law, an “Industrial Company” is a company incorporated in, and resident of Israel, at least 90% of the income of which, in a given tax year, exclusive of income from specified government loans, capital gains, interest and dividends which are not classified for such company as business income, is derived from an industrial enterprise owned by it. In general, an “Industrial enterprise” is defined as an enterprise whose major activity in a given tax year is industrial production.

The following corporate tax benefits are available to Industrial Companies:

- amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes, from the tax year it began to use them;
- amortization of expenses incurred in some cases in connection with a public issuance of publicly traded securities over a three-year period; and

- accelerated depreciation rates on equipment and buildings.

Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. No assurance can be given that we qualify or will continue to qualify as an “Industrial Company” or that the benefits described above will be available in the future.

Taxation of Capital Gains Applicable to Non-Israeli Shareholders

Israeli law generally imposes a capital gains tax on the sale of capital assets including securities of an Israeli company (whether or not traded). The Income Tax Ordinance [New Version], 1961 (the “Ordinance”) distinguishes between “Real Capital Gain” and the “Inflationary Surplus.” The Real Capital Gain is the excess of the total capital gain over Inflationary Surplus. The Inflationary Surplus is computed generally on the basis of the cost multiplied by the difference between the Israeli consumer monthly price index as known at the date of sale and the date of purchase and, with respect to an individual, when the shares are nominated or linked to a foreign currency the Inflationary Surplus would be calculated according to the difference in changes in the foreign currency. The Inflationary Surplus accumulated after January 1, 1994 is exempt from capital gains tax.

Pursuant to the Ordinance, the Real Capital Gains tax rate applicable to individuals upon the sale of such securities is such individual’s marginal tax rate but not more than 25%, or 30% with respect to an individual who meets the definition of a ‘Substantial Shareholder’ on the date of the sale of the securities or at any time during the 12 months preceding such date. A ‘Substantial Shareholder’ is defined as a person who, either alone or together with any other person, holds, directly or indirectly, at least 10% of any of the means of control of a company (including, among other things, the right to receive profits of the Company, voting rights, the right to receive the Company’s liquidation proceeds and the right to appoint a director). Notwithstanding the foregoing, dealers in securities (Individual and corporate shareholders) in Israel are taxed at regular tax rates applicable to business income a corporate tax rate for a corporation and a marginal tax rate of up to 47% for an individual in 2021 onward.

With respect to corporate investors, capital gain tax equal to the ordinary corporate tax rate (23% in 2021 and thereafter) will be imposed on the sale of our traded shares.

However, Under Israeli law, the capital gain from the sale of shares by non-Israeli residents is tax exempt in Israel as long as our shares are listed on the Nasdaq Global Market or any other stock exchange recognized by the Israeli Ministry of Finance, and provided certain other conditions are met, the most relevant of which are: (A) the capital gain is not attributed to the foreign resident’s permanent establishment in Israel, (B) the shares were acquired by the foreign resident after the company’s shares had been listed for trading, and (C) if the seller is a non-Israeli corporation, less than 25% of its means of control are held by Israeli residents.

As our ordinary shares are traded on the NASDAQ Global Market, which qualifies as a Recognized Exchange, Real Capital Gains on the sale of our ordinary shares held by non-Israeli tax resident investors (individuals and corporations) will generally be exempt from Israeli capital gains tax so long as certain conditions are met, including that the shares were not held through a permanent establishment that the non-Israeli tax resident investor maintains in Israel.

In any event, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli resident (a) has a controlling interest of more than 25% in such non-Israeli corporation, or (b) is the beneficiary of or is entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.

Furthermore, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty, as discussed below, subject to the receipt in advance of a valid certificate from the Israel Tax Authority (the “ITA”) allowing for such exemption.

Withholding Taxes

Persons paying consideration for shares, including purchasers of shares, Israeli securities dealers effecting a transaction, or a financial institution through which securities being sold are held, are required, subject to any applicable exemptions and the demonstration by the selling shareholder of its non-Israeli residency and other requirements, to withhold tax upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% in 2021 and thereafter) for corporations.

Income Taxes on Dividend Distributions to Non-Israeli Shareholders

Non-Israeli residents (whether individuals or corporations) are generally subject to Israeli withholding tax on the receipt of dividends paid by Israeli publicly traded companies at the rate of 25%, if the shares are registered with a nominee company (as such term is used in the Israeli Securities Law, 5728-1968). If the shares are not registered with a nominee company, the rate of 25% will apply to non-Israeli residents shareholders who are not considered Substantial Shareholders, as defined above, and who were not Substantial Shareholders at any time during the 12 months preceding the date of the distribution, and the rate of 30% will apply to dividends paid to Substantial Shareholders and to persons who were Substantial Shareholders at any time during the 12 months preceding the date of the distribution. Notwithstanding the above, a lower tax rate may be provided under an applicable tax treaty between Israel and the shareholder's country of residence (subject to the receipt in advance of a valid tax certificate from the ITA allowing for a reduced tax rate). The distribution of dividends to non-Israeli residents (either individuals or corporations) from income derived from a company's Approved Enterprises or Benefited Enterprises or a Preferred Enterprise, in each case during the applicable benefits period is subject to withholding tax at a rate of 20%, unless a lower tax rate is provided under an applicable tax treaty.

A non-Israeli resident who has received dividend income derived from or accrued in Israel, from which the full amount of tax was duly withheld, is generally exempt from the duty to file tax returns in Israel in respect of such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed; and (iii) the taxpayer is not liable for excess tax.

U.S. Israel Tax Treaty

The sale of shares may also be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the Convention Between the Government of the United States and the Government of the State of Israel With Respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty. The U.S.-Israel Tax Treaty exempts U.S. residents for the purposes of the treaty from Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident company's voting power at any time within the 12-month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days during the taxable year; (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel and (iv) the capital gains is not arising from such sale, exchange or disposition which is attributed to real estate located in Israel. Otherwise, the sale, exchange or disposition of shares would be subject to Israeli tax, to the extent applicable

However, under the U.S.-Israel Tax Treaty, U.S. residents for the purposes of the treaty may be permitted to claim a credit for such taxes against U.S. federal income tax imposed on the sale, under the circumstances and subject to the limitations specified in the U.S.-Israel Tax Treaty and U.S. tax legislation, as discussed below under "Certain Material U.S. Federal Income Tax Considerations – Distributions.

Under the U.S.-Israel Tax Treaty, the maximum Israeli withholding tax on dividends paid to a holder of our ordinary shares who is a U.S. resident for the purposes of the U.S.-Israel Tax Treaty, is generally 25%. The U.S.-Israel Tax Treaty provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to dividends paid to a U.S. corporation owning 10% or more of an Israeli company's voting shares during, in general, the current tax year in which the dividend is distributed and preceding tax year of the Israeli company. The 15% rate applies to dividends distributed from income derived from an Approved Enterprise, or a Benefited Enterprise, or a Preferred Enterprise, in each case within the applicable period, and the lower 12.5% rate applies to dividends distributed from income derived from other sources. However, these provisions do not apply if the company has certain amounts of passive income. The aforementioned rates under the U.S.-Israel Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.

Excess Tax

Furthermore, an additional tax liability at the rate of 3% is applicable on the annual taxable income, including, but not limited to, income derived from dividends, interest and capital gains, of individuals who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) exceeding a certain threshold (NIS 647,640 in 2021), which amount is linked to the Israeli consumer price index.

F. *Dividends and Paying Agents.*

Not applicable.

G. *Statement by Experts.*

Not applicable.

H. *Documents on Display.*

We file annual reports and other information with the SEC. The SEC maintains an Internet web site at <http://www.sec.gov> that contains reports and other material that are filed through the SEC's Electronic Data Gathering, Analysis and Retrieval, or EDGAR, system. Information about us is also available on our site at <http://www.camtek.com>. Such information on our site is not part of this Annual Report.

I. *Subsidiary Information.*

Not applicable.

Item 11. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

Our exposure to market risk for changes in interest rates is not significant as we have no outstanding loans; see Item 5.B – *“Liquidity and Capital Resources”* above.

Foreign Currency Rate Fluctuations

We are a global company that operates in a multi-currency environment. In recent months, foreign currency exchange rates have been subject to considerable fluctuations. As a major portion of the costs of our Israeli operations, such as personnel, subcontractors, materials and facility-related costs, are incurred in NIS, an increase in the NIS value relative to the U.S. Dollar will increase our costs expressed in U.S. Dollars, and a decrease in the NIS value relative to the U.S. Dollar will decrease our costs expressed in U.S. Dollars. During 2021, the value of the U.S. Dollar weakened against the NIS by 3%. We may, from time to time, take various measures designed to reduce our exposure to these effects, but any such steps may be inadequate to protect us from currency rate fluctuations. We had no open hedging transactions as of December 31, 2021.

In our consolidated financial statements, transactions and balances originally denominated in U.S. Dollars are presented at their original amounts. Gains and losses arising from non-dollar transactions and balances are included in net income as part of financial expenses, net.

Our balance sheet exposures to fluctuations in the exchange rate between the U.S. Dollar and other currencies are primarily from NIS denominated balances. As of December 31, 2021, we had net liabilities of approximately \$12.1 million, denominated in NIS. Any fluctuation in the exchange rate between the NIS and the U.S. dollar of 1% will cause us expenses or income of \$21 thousand, in case of increase or decrease in rates, respectively.

In addition, although our products' prices in most countries are denominated in U.S. Dollars, in certain territories (currently, Europe and Japan) our products' prices are denominated in local currencies, and much of our service income in additional territories is denominated in local currencies. If there is a significant devaluation in the relevant local currencies in which we operate compared to the U.S. Dollar, those prices of our products or services that are denominated in local currency in the relevant territories will increase relative to that local currency and may be less competitive.

Item 12. Description of Securities Other than Equity Securities.

Not applicable.

PART II

Item 13. Defaults, Dividend Arrearages and Delinquencies.

Not applicable.

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.

Not applicable.

Item 15. Controls and Procedures.

(a) Disclosure Controls and Procedures.

Our management, including our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of December 31, 2021, and have concluded that, as of such date, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified by the SEC's rules and forms.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of the Company's disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, the Company's disclosure controls and procedures were effective.

(b) Management's Annual Report on Internal Control Over Financial Reporting.

Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurances with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may decline.

Our management evaluated the effectiveness of our internal control over financial reporting based on the framework established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on this evaluation, management has assessed the effectiveness of our internal control over financial reporting, as at December 31, 2021, and concluded that such internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) is effective.

(c) Attestation Report of the Registered Public Accounting Firm.

The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by our principal accountant Somekh Chaikin, a member firm of KPMG International, an independent registered public accounting firm. The related report to our shareholders and the Board of Directors appears on page F-2 of this Annual Report.



(d) Changes in Internal Control over Financial Reporting.

There were no changes to our internal control over financial reporting that occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 16A. Audit Committee Financial Expert.

Our Board of Directors has determined that Ms. Andorn qualifies as an “audit committee financial expert” for purposes of the Nasdaq Rules, and that each of Mr. Shacham-Diamand and Ms. Andorn are independent directors in accordance with Nasdaq Rules and meet the independence criteria set forth in the Companies Law.

Item 16B. Code of Ethics.

We adopted a Code of Ethics, which is applicable to all of our directors, officers and employees, including our principal executive, financial and accounting officers and persons performing similar functions. A copy of the Code of Ethics, in its current version, is available on our website, www.camtek.com. We will also provide a copy of the Code of Ethics to any person, without charge, upon written request addressed to our CFO at our corporate headquarters in Israel: Camtek Ltd., Ramat Gabriel Industrial Zone, P.O. BOX 544, Migdal Ha’Emek, Israel.

Item 16C. Principal Accountant Fees and Services.

Our Audit Committee maintains a policy of approving and recommending only those services to be performed by our independent auditors which are permitted under the Sarbanes-Oxley Act of 2002 and the applicable rules of the SEC relating to auditor’s independence, and our independent auditors are remunerated at levels that accord with such basic principles of auditor independence.

The following table presents the aggregate amount of fees for professional services rendered to the Company by our principal accountant Somekh Chaikin, Tel Aviv, Israel (PCAOB ID 1057), a member firm of KPMG International and their KPMG affiliate firms, in US\$, for the years ended December 31, 2021 and 2020:

<u>Fee Category</u>	<u>For 2021 Services Rendered</u>	<u>For 2020 Services Rendered</u>
Audit Fees (1)	334,850	302,700
Tax Fees (2)	36,500	7,700

* The comparative year has been reclassified to conform to current year presentation.

(1) *Audit Fees*: the audit fees for the year ended December 31, 2021 and 2020 were for professional services rendered for the integrated audit of Camtek’s annual consolidated financial statements and its internal controls over financial reporting and services that are normally provided by independent registered public accounting firm in connection with statutory and regulatory filings or engagements, including consultancy and consents with respect to an underwritten public offering and related prospectus supplements filed with the SEC.

(2) *Tax Fees* rendered during 2021 and 2020 by our auditor were for tax compliance, tax planning and tax advice.

Pre-Approval Policies and Procedures

Our Audit Committee has adopted a policy for pre-approval of audit and permitted non-audit services. Under the policy, the Audit Committee will pre-approve all auditing services and permitted non-audit services (including fees and other terms) to be performed for the Company by its independent auditor. All of the fees listed in the table above were approved by the Audit Committee. In addition, the Audit Committee may adopt policies and procedures to permit delegation of authority to subcommittees consisting of one or more members when appropriate, including the authority to grant pre-approvals of audit and permitted non-audit services. Decisions of the subcommittee to grant pre-approvals will be presented to the full Audit Committee at its next scheduled meeting.

Item 16D. Exemptions from the Listing Standards for Audit Committees.

Not applicable.

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

Not applicable.

Item 16F. Change in Registrant's Certifying Accountant.

Not applicable.

Item 16G. Corporate Governance.

Pursuant to Rules 5255(a) and 5615(a)(3) of the Nasdaq Rules, we are relying on our home country practice with respect to the following matters: the eligibility of our securities for a direct registration program; the composition and responsibilities of our Compensation Committee; the approval of stock option plans; certain annual meeting requirements – all as set forth below:

- We have opted out of the requirement that all securities listed on Nasdaq be eligible for a direct registration program operated by a registered clearing agency as set forth in Rule 5255(a). Our procedures regarding the issuance of stock certificates comply with Israeli law and practice. According to the Companies Law, a share certificate is defined as a certificate which states the name of the owner registered in the company's shareholders register, as well as the number of shares he or she owns. In the event that what is registered in the company's shareholders register conflicts with a share certificate, then the evidentiary value of the shareholder register outweighs the evidentiary value of the share certificate. A shareholder registered in the company's shareholders register is entitled to receive from the company a certificate evidencing his ownership of the share.
- As all members of our Audit Committee meet the independence requirements for compensation committee members set forth in Nasdaq Rule 5605(d)(2), as a foreign private issuer, we have elected, pursuant to Nasdaq Rule 5615(a)(3), to follow Israeli practice, in lieu of compliance with the certain provisions of Nasdaq Rule 5605(d), requiring us to have a separate compensation committee. Accordingly, and consistent with Israeli law allowing an audit committee that satisfies the requirements of the Companies Law regarding the composition of a compensation committee, to carry out all duties and responsibilities of the compensation committee, our Audit Committee has been authorized to assume the functions and responsibilities of a compensation committee. In this respect, we have also opted out of the requirement to adopt and file a compensation committee charter as set forth in Rule 5605(d)(1). We have opted out of the requirement for shareholder approval of stock option plans and other equity based compensation arrangements as set forth in Nasdaq Rule 5635 and Nasdaq Rule 5605(d), respectively. Nevertheless, as required under the Companies Law, special shareholder voting procedures are followed for the approval of equity based compensation of certain Office Holders or employees who are controlling shareholders or any relative thereof, as well as of our Chief Executive Officer and members of our Board of Directors. Equity based compensation arrangements with Office Holders (chief executive officer and directors excluded) or employees who are not controlling shareholders or any relative thereof, are approved by our Compensation Committee and our Board of Directors, provided they are consistent with our Compensation Policy, and in special circumstances in deviation therefrom, taking into account certain considerations as set forth in the Companies Law.

- We have opted out the requirement for conducting annual meetings as set forth in Nasdaq Rule 5620(a), which requires Camtek to hold its annual meetings of shareholders within twelve months of the end of a company's fiscal year end. Instead, Camtek is following home country practice and law in this respect. The Companies Law requires that an annual meeting of shareholders be held every year, and not later than 15 months following the last annual meeting (see in Item 10.B – *“Memorandum and Articles - Voting, Shareholders’ Meetings and Resolutions”* above). Our 2021 AGM was held on August 18, 2021, therefore our 2022 AGM must be held by November 18, 2022. Further, we have opted out the requirement set under Rule 5620(c) of the Nasdaq Rules which requires the presence of two or more shareholders holding at least 33 1/3%, and in lieu follow our home country practice and Israeli law, according to which the quorum for any shareholders meeting will be the presence of two or more shareholders holding at least 25% of the voting rights in the aggregate - within half an hour from the time set for opening the meeting.
- We have chosen to follow our home country practice in lieu of the requirements of Nasdaq Rule 5250(d)(1), relating to an issuer's furnishing of its annual report to shareholders. Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an independent accounting firm, electronically with the SEC and post a copy on our website.

Item 16H. Mine Safety Disclosure.

Not applicable.

PART III

Item 17. Consolidated Financial Statements.

The Company has furnished financial statements and related information specified in Item 18.

Item 18. Consolidated Financial Statements.

Our consolidated financial statements and report of independent registered public accounting firm in connection therewith, as appear below, are hereby incorporated into this Annual Report.

**Camtek Ltd.
and its subsidiaries**

**Consolidated Financial Statements
As of December 31, 2021**

Financial Statements as at December 31, 2021

Contents

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID No.1057)	F-2 to F-3
Consolidated Balance Sheets	F-4
Consolidated Statements of Income	F-5 to F-6
Consolidated Statements of Shareholders' Equity	F-7
Consolidated Statements of Cash Flows	F-8 to F-9
Notes to Consolidated Financial Statements	F-10 to F-44

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors

Camtek Ltd.

Opinions on the Consolidated Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Camtek Ltd. and its subsidiaries (the “Company”) as of December 31, 2021 and 2020, and the related consolidated statements of income, shareholders’ equity and cash flows, for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of the Treadway Commission.

Basis for Opinions

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s consolidated financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

Inventory Provision Estimate

As discussed in Notes 2H and 4 to the consolidated financial statements, inventory and the associated inventory provision as of December 31, 2021 were \$63,909 thousand and \$424 thousand, respectively. The Company estimates the inventory provision at the end of each period for damaged, obsolete, excess and slow-moving items in order for inventory to be presented at the lower of cost or net realizable value. In making this estimate, the Company periodically evaluates its inventory composition, giving consideration to factors such as changing product demands due to uncertain industry related market conditions and technological changes, the probability and timing of anticipated usage and the physical condition of the items. Presentation at net realizable value creates a new cost basis that is not subsequently marked up.

We identified the evaluation of the inventory provision estimate as a critical audit matter. Challenging auditor judgment was required to evaluate the Company's assumptions about changing product demands and probability of anticipated usage of inventory items.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the inventory provision process, including controls related to the assumptions noted above. We assessed the changing product demands and probability of anticipated usage assumptions by performing an independent analysis of available market information that took into consideration industry-related market conditions and possible technological changes. We considered the effect of technological changes on the inventory provision estimate through inquiry of finance and operational personnel. We also compared historical inventory provisions to actual quantity sold in subsequent periods to evaluate management's ability to accurately estimate the reserve.

/s/ Somekh Chaikin
Somekh Chaikin
Member Firm of KPMG International

We have served as the Company's auditor since 2006.

Tel Aviv, Israel

March 15, 2022

Consolidated Balance Sheets

	Note	December 31,	
		2021	2020
		U.S. Dollars (In thousands)	
Assets			
Current assets			
Cash and cash equivalents	3	241,943	105,815
Short-term deposits	3	156,000	72,000
Trade accounts receivable, net	13	57,825	41,001
Inventories	4	58,759	39,736
Other current assets	5	5,653	3,366
Total current assets		520,180	261,918
Long-term deposits	6	32,000	-
Long-term inventory	4	5,150	4,416
Deferred tax asset, net	18	227	482
Other assets		190	85
Property, plant and equipment, net	7, 2V	25,400	20,398
Intangible assets, net	8	610	609
Total non-current assets		63,577	25,990
Total assets		583,757	287,908
Liabilities and shareholder's equity			
Current liabilities			
Trade accounts payable		33,550	27,180
Other current liabilities	9	56,137	30,204
Total current liabilities		89,687	57,384
Long-term liabilities			
Other long-term liabilities	10,12	5,800	3,260
Convertible notes	11	194,643	-
		200,443	3,260
Total liabilities		290,130	60,644
Commitments and contingencies	12		
Shareholders' equity	14		
Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at December 31, 2021 and 2020; 45,939,019 and 45,365,354 issued shares at December 31, 2021 and 2020, respectively; 43,846,643 and 43,272,978 shares outstanding at December 31, 2021 and 2020, respectively		172	171
Additional paid-in capital		176,582	170,497

Retained earnings	<u>118,771</u>	<u>58,494</u>
	<u>295,525</u>	<u>229,162</u>
Treasury stock, at cost (2,092,376 shares as of December 31, 2021 and 2020)	<u>(1,898)</u>	<u>(1,898)</u>
Total shareholders' equity	<u>293,627</u>	<u>227,264</u>
Total liabilities and shareholders' equity	<u>583,757</u>	<u>287,908</u>

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Income

	Note	Year Ended December 31,		
		2021	2020	2019
		U.S. Dollars (In thousands, except per share data)		
Revenues	17A	269,659	155,859	134,019
Cost of revenues		132,315	82,628	69,235
Gross profit		137,344	73,231	64,784
Operating expenses:				
Research and development		23,473	19,575	16,331
Selling, general and administrative	17B	42,973	31,032	26,481
Total operating expenses		66,446	50,607	42,812
Operating profit		70,898	22,624	21,972
Financial income, net	17C	1,030	775	801
Income from continuing operations before incomes taxes		71,928	23,399	22,773
Income tax expense	18	(11,651)	(1,621)	(1,950)
Net income from continuing operations		<u>60,277</u>	<u>21,778</u>	<u>20,823</u>
Income from discontinued operations				
Income before income tax expense		-	-	1,257
Income tax expense		-	-	(94)
Net income from discontinued operations		-	-	1,163
Net income		<u>60,277</u>	<u>21,778</u>	<u>21,986</u>

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Income

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars		
Earnings per share information (see Note 15):			
Basic earnings from continuing operations	1.38	0.55	0.55
Basic earnings from discontinued operations	-	-	0.03
Basic net earnings per share	1.38	0.55	0.58
Diluted earnings from continuing operations	1.34	0.54	0.54
Diluted earnings from discontinued operations	-	-	0.03
Diluted net earnings per share	1.34	0.54	0.57
Weighted average number of ordinary shares outstanding:			
Basic	43,644	39,383	37,626
Diluted	45,035	40,372	38,432

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Shareholders' Equity

	Ordinary Shares NIS 0.01 par value		Treasury Stock NIS 0.01 par value		Additional paid-in capital	Retained earnings	Total shareholders' equity
	Number of Shares	U.S. Dollars (In thousands)	Number of Shares	U.S. Dollars (In thousands)			
	U.S. Dollars (In thousands)						
Balances at							
December 31, 2018	38,535,445	151	(2,092,376)	(1,898)	81,873	21,281	101,407
Issuance of shares, net	1,700,000	5	-	-	16,021	-	16,026
Exercise of share options and RSUs	506,910	1	-	-	541	-	542
Share-based compensation expense	-	-	-	-	2,892	-	2,892
Dividend	-	-	-	-	-	(6,551)	(6,551)
Net income	-	-	-	-	-	21,986	21,986
Balances at							
December 31, 2019	<u>40,742,355</u>	<u>157</u>	<u>(2,092,376)</u>	<u>(1,898)</u>	<u>101,327</u>	<u>36,716</u>	<u>136,302</u>
Issuance of shares, net	4,025,000	12	-	-	64,308	-	64,320
Exercise of share options and RSUs	597,999	2	-	-	627	-	629
Share-based compensation expense	-	-	-	-	4,235	-	4,235
Net income	-	-	-	-	-	21,778	21,778
Balances at							
December 31, 2020	<u>45,365,354</u>	<u>171</u>	<u>(2,092,376)</u>	<u>(1,898)</u>	<u>170,497</u>	<u>58,494</u>	<u>227,264</u>
Exercise of share options and RSUs	573,665	1	-	-	270	-	271
Share-based compensation expense	-	-	-	-	5,815	-	5,815
Net income	-	-	-	-	-	60,277	60,277
Balances at							
December 31, 2021	<u>45,939,019</u>	<u>172</u>	<u>(2,092,376)</u>	<u>(1,898)</u>	<u>176,582</u>	<u>118,771</u>	<u>293,627</u>

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Cash Flows

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (In thousands)		
Cash flows from operating activities:			
Net income	60,277	21,778	21,986
Discontinued operations, net of tax	-	-	(1,163)
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	2,811	2,234	2,134
Deferred tax expense	255	476	1,526
Amortization of debt issuance costs	113	-	-
Share based compensation expense	5,815	4,235	2,892
Change in provision for doubtful debts	(32)	(87)	(29)
Loss on disposal of fixed assets	4	-	64
Changes in operating assets and liabilities:			
Trade accounts receivable, gross	(17,338)	(9,696)	156
Inventories	(21,702)	(19,330)	4,798
Due from related parties	(12)	72	58
Other assets	(2,380)	(501)	(236)
Trade accounts payable	6,190	15,661	(4,100)
Other current liabilities	26,956	10,910	(3,460)
Net cash provided by operating activities from continuing operations	60,957	25,752	24,626
Net cash provided by operating activities	60,957	25,752	24,626
Cash flows from investing activities:			
Investment in short-term deposits	(84,000)	(20,500)	(51,500)
Investment in long-term deposits	(32,000)	-	-
Purchase of fixed assets	(4,065)	(2,410)	(1,256)
Purchase of intangible assets	(111)	(216)	(106)
Net cash used in investing activities from continuing operations	(120,176)	(23,126)	(52,862)
Net cash provided by investing activities from discontinued operations	-	-	1,257
Net cash used in investing activities	(120,176)	(23,126)	(51,605)

Consolidated Statements of Cash Flows (continued)

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (In thousands)		
Cash flows from financing activities:			
Share issuance, net	-	64,288	16,026
Proceeds from exercise of share options	271	629	542
Issuance of convertible notes, net	194,530	-	-
Dividend payment	-	-	(6,551)
Net cash provided by financing activities	194,801	64,917	10,017
Effect of exchange rate changes on cash	546	225	74
Net increase (decrease) in cash and cash equivalents	136,128	67,768	(16,888)
Cash and cash equivalents at beginning of the year	105,815	38,047	54,935
Cash and cash equivalents at end of the year	241,943	105,815	38,047

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (In thousands)		
Supplementary cash flows information:			
A. Cash paid and received during the year for:			
Income taxes	558	546	666
Interest received	1,057	1,420	1,112
Lease payments	1,060	1,025	1,077
B. Non-cash transactions:			
Fixed assets purchased with supplier credit	339	159	154

The accompanying notes are an integral part of the consolidated financial statements.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 1 - Nature of Operations

- A.** Camtek Ltd. (“Camtek” or “Company”), an Israeli corporation, is jointly controlled by (20.93%) Priortech Ltd. (“Priortech”), an Israeli corporation listed on the Tel-Aviv Stock Exchange and (17.83%) Chroma Ate Inc. (“Chroma”) (See Note 1(C) below). Camtek provides automated and technologically advanced solutions dedicated to enhancing production processes, increasing products yield and reliability, enabling and supporting customers’ latest technologies in the semiconductor fabrication industry.
- B.** In November 2021, the Company closed an offering of \$200,000 aggregate principal amount of 0% Convertible Senior Notes due 2026 (“Convertible Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, which included the full exercise of underwriters’ option to purchase an additional \$25,000 of Convertible Notes, raising \$194,530 net of underwriting discounts and commissions and other offering expenses. See Note 11.
- C.** In November 2020, the Company completed a successful public offering of 4,025,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase 525,000 additional ordinary shares, at a price to the public of \$17.00 per share. The net proceeds to the Company, after the deduction of underwriting discounts and commissions and other offering expenses, totaled \$64,320.
- D.** In February 2019, Chroma Ate Inc, a Taiwanese company, acquired approximately 20.5% of Camtek’s shares in a cash transaction. 6,117,440 Camtek shares were purchased from Priortech for \$58,100 whilst a further 1,700,000 new shares were issued by Camtek, for \$16,200 (before issuance costs). The cash consideration was calculated based on a share-price of \$9.50 per Camtek share, which reflected a 29% premium on Camtek’s closing price as of February 8, 2019.

A voting agreement was signed between Priortech and Chroma according to which the parties will vote together in Camtek’s shareholders’ meetings. According to the voting agreement, after the closing of the transaction, Chroma is entitled to two seats on Camtek’s Board of Directors and Priortech is entitled to three seats.

In addition to the investment, Chroma and Camtek entered into an agreement in which Camtek will license its triangulation technology, a metrology solution, in a fee-bearing license for non-semiconductor applications to be used by Chroma. In addition, Chroma and Camtek agreed to cooperate in potential projects for the semiconductor market based on synergies between their inspection and metrology technologies.

The transaction was completed in June 2019.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies**A. Basis of preparation of the financial statements**

The consolidated financial statements of Camtek and its subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in United States of America (“US GAAP”). All amounts in the notes to the financial statements are in thousands unless otherwise stated.

B. Principles of consolidation

The accompanying consolidated financial statements include the accounts of Camtek and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

C. Use of estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. As applicable to these financial statements, the most significant estimates and assumptions relate to revenue recognition, valuation of accounts receivable and inventories. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

Since January 2020, the Covid-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. At present, business activity is continuing at all of the Company’s locations, with new routines implemented as required by local Covid-19 regulations.

From the beginning of the outbreak, the Company has been carefully managing the risks and its global operations. The Israeli facility has been able to maintain its required production levels. Worldwide, the Company has benefitted from its strategy of having in place local professional teams in each of its territories that can independently install and support systems. As such, the Company has been able to deliver most of its orders on time and the impact of the Covid-19 pandemic on the its business activity has not been significant.

D. Foreign currency transactions

The functional currency of the Company and its subsidiaries is the U.S. Dollar. Revenue generated by the Company and its subsidiaries is primarily generated outside of Israel and a majority thereof is received in U.S. Dollars. A significant portion of materials and components purchased and operating expenses incurred are either paid for in U.S. Dollars or in New Israeli Shekels (“NIS”).

Transactions not denominated in U.S. Dollars are recorded upon their initial recognition according to the exchange rate in effect on the date of the transaction. Exchange rate differences arising upon the settlement of monetary items or upon reporting the Company’s monetary items at exchange rates different from that by which they were initially recorded during the period, or reported in previous financial statements, are charged to financial income (expenses), net.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**E. Cash and cash equivalents**

All highly liquid investments purchased with original maturities of three months or less are considered to be cash equivalents.

F. Short-term deposits

Short-term bank deposits are deposits with an original maturity of more than three months and less than a year from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their term deposits.

G. Trade accounts receivable and allowance for doubtful accounts

Accounts receivable are recorded at the outstanding recognized amount and do not bear interest. The allowance for doubtful accounts represents Management's best estimate of the probable loss inherent in existing accounts receivable balances as a result of possible non-collection. In determining the appropriate allowance, Management bases its estimate on information available about specific debtors, including aging of the balance, assessment of the underlying security received, the history of write-offs, relationships with the customers and the overall creditworthiness of the customers.

H. Inventories

Inventories consist of completed systems, partially completed systems and components and other raw materials, and are recorded at the lower of cost or net realizable value. Cost is determined by the moving – average cost method basis.

Inventory write-downs are recorded at the end of each fiscal period for damaged, obsolete, excess and slow-moving inventory. These write-downs, to the lower of cost or net realizable value, create a new cost basis that is not subsequently marked up based on changes in underlying facts and circumstances.

Management periodically evaluates its inventory composition, giving consideration to factors such as changing product demands due to uncertain industry related market conditions and technological changes, the probability and timing of anticipated usage and the physical condition of the items, and then estimates a charge (reducing the inventory) to be provided for slow moving, technological obsolete or damaged inventory. These estimates could vary significantly from actual use based upon future economic conditions, customer inventory levels or competitive factors that were not foreseen or did not exist when the inventory write-downs were established.

Spare parts included in inventory that are not expected to be converted or consumed within the next year are classified as non-current, based on Management's estimates taking into account market conditions.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**I. Property, plant and equipment**

These assets are stated at cost less accumulated depreciation, and are depreciated over their estimated useful lives on a straight-line basis.

Annual rates of depreciation are as follows:

Land	1%
Building	2%
Machinery and equipment	10% - 33%
Computer equipment and software	20% - 33%
Office furniture and equipment	6% - 20%
Automobiles	15%

Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful economic life of such improvements.

Certain of the Company's finished goods are systems used as demonstration systems, training systems, and for product development in the Company's laboratories ("internal use"). These systems are identical to the systems that Camtek sells in its ordinary course of business. In circumstances where the Company intends to utilize such systems for its internal use, the Company transfers them from inventory to fixed assets. The rationale for the transfer is that the Company does not have the intention to sell these systems in the ordinary course of business but rather expects to use them for its internal use over their expected useful lives. These systems are recorded as fixed assets at cost and depreciated over their useful lives.

J. Intangible assets

Patent registration costs are recorded at cost and amortized on a straight-line basis, beginning with the first year of utilization, over its expected useful life of ten years.

K. Impairment of long-lived assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the long-lived asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized to the extent that the asset's carrying amount exceeds its fair value. In 2021 and 2020, no impairment was noted.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**L. Fair values of financial instruments**

The carrying amounts of the Company's financial instruments, including cash and cash equivalents, short-term deposits, trade accounts receivable, trade accounts payable and amounts from related parties approximate fair value because of their short-term nature.

The fair values of long-term deposits are estimated based on quoted market prices for those or similar investments.

M. Revenue recognition

The Company's contracts with its customers include performance obligations to provide its products or to service the installed products. A product sale contract may include an extended warranty (that is, for longer than the twelve-month standard warranty) as well as installation, both of which are considered separate performance obligations.

The Company recognizes revenue from contracts for sales of products at the point of time when the Company transfers control of the product to the customer. Effective October 2020, the transfer in control event is generally determined upon shipping terms whereas previously it was generally upon installation at the customer's premises. This policy change was made following operational changes to pre-shipment calibration and testing processes which have enabled the simplification and streamlining of the installation at the customer site.

Revenues from the contract are recognized in an amount that reflects the consideration the Company expects to be entitled to receive once the control of the product had been transferred to the customer and signed documentation of the arrangement, such as a signed contract or purchase order, has been received. Payment terms with customers may vary, but are generally based on milestones within the delivery process such as shipping and installation. Payment terms do not include significant financing components.

The Company does not incur costs in obtaining a contract except for agents' commissions, which are incurred upon the recognition of revenues. Revenues are recognized over a period of less than a year and as such, there are no underlying sales commissions to be capitalized.

Service revenues consist mainly of contracts charged under time and material arrangements. Service revenues from maintenance contracts are recognized ratably over the contract period.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 2 - Significant Accounting Policies (cont'd)****M. Revenue recognition (cont'd)**

Contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged to customers.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations. These amounts are recorded as deferred revenue in the Consolidated Balance Sheets.

	Year Ended December	
	31,	
	2021	2020
	U.S. Dollars (in	
	thousands)	
Beginning of year	2,534	2,606
Deferral of revenue	6,245	1,864
Recognition of deferred revenue	<u>(1,912)</u>	<u>(1,936)</u>
Balance at end of year	<u><u>6,867</u></u>	<u><u>2,534</u></u>

N. Warranty

The Company records a liability for standard product warranty obligations at the time of sale based upon historical warranty experience. The term of the warranty is generally twelve months.

O. Income taxes

The Company accounts for income taxes in accordance with the asset and liability method whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company includes the foreign currency transaction gains or losses that result from re-measuring deferred taxes in income tax expense. The Company reduces deferred tax assets with a valuation allowance to the amount that is more likely than not to be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition or measurement are reflected in the period in which the change occurs.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**P. Research and development**

Research and development costs, which consists primarily of salaries, materials consumption and costs associated with subcontracting certain development efforts, are expensed as incurred.

Q. Earnings per ordinary share

Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.

The Company's convertible notes are included in the calculation of diluted Earnings Per Share ("EPS") if the assumed conversion into common shares is dilutive, using the "if-converted" method. This involves adding back the periodic non-cash interest expense net of tax associated with the Notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the denominator for the purposes of calculating diluted EPS, unless the Notes are antidilutive (See also Note 2W).

R. Share-based compensation

The Company accounts for its employee share-based compensation as an expense in the financial statements. All awards are equity classified and therefore such cost is measured at the grant date fair value of the award. The Company estimates share option grant date fair value using the Black-Scholes-Merton option-pricing model. Forfeitures are recognized when they occur. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date (For details see Note 14B).

S. Fair value measurements

The Company implements the provisions of ASC Topic 820 "*Fair Value Measurements and Disclosures*" ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy provides the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which an asset or liability is classified is based on the lowest level input that is significant to the fair value measurement in its entirety.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**T. Contingent liabilities**

A contingency (provision) is an existing condition or situation involving uncertainty as to the range of possible loss to the entity.

A provision for claims is recognized if it is probable (likely to occur) that a liability has been incurred and the amount can be estimated reasonably.

U. Government-sponsored research and development

The Company records grants received from the Israel Innovation Authority (the "IIA", formerly known as the Office of the Chief Scientist of the Israeli Ministry of Industry and Trade) as a liability, if it is probable that the Company will have to repay the grants received. If it is not probable that the grants will be repaid, the Company records the grants as a reduction to research and development expenses. Royalties paid to the IIA are recognized as a reduction of the above-mentioned liability.

V. Leases

On January 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). See also Note 11A.

Under *Topic 842*, the Company determines if an arrangement is a lease at inception. Rights of use ("ROU") assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be (2.43% in 2021). The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all of the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 2 - Significant Accounting Policies (cont'd)**V. Leases (cont'd)**

Operating lease ROU assets consist mainly of vehicles and real estate and are presented as property, plant and equipment on the consolidated balance sheet. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented within long-term liabilities on the consolidated balance sheet.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(J).

W. Convertible Notes

The Company accounts for its convertible notes in accordance with ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (Topic 470-20). The Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

The transaction costs are amortized on a straight-line basis along the lifetime of the Notes.

X. Recent Accounting Pronouncements

In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance became effective in the first quarter of 2021 on a prospective basis. The adoption of this guidance has not had a material impact on the Company's consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. ASU 2020-06 reduces the number of accounting models for convertible instruments and allows more contracts to qualify for equity classification. Adoption is either a modified retrospective method or a fully retrospective method of transition. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 3 - Cash and Cash Equivalents**

The Company's cash and cash equivalents balance at December 31, 2021 and 2020, is denominated in the following currencies:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
US Dollars	225,283	102,669
New Israeli Shekels	13,566	1,542
Other currencies	3,094	1,604
	241,943	105,815

Short-term deposits are bank deposits in US Dollars with terms at the investment date of 3-12 months with average annual interest rates of 0.81% (2020 – 0.88%).

Note 4 - Inventories

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Components	33,212	19,630
Work in process	12,688	10,123
Finished products *	18,009	14,399
	63,909	44,152

* includes systems at customer locations not yet sold, as of December 31, 2021 and 2020, in the amount of \$4,259 and \$10,613 respectively.

Inventories are presented in:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Current assets	58,759	39,736
Non-current assets (A)	5,150	4,416
	63,909	44,152

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 4 – Inventories (cont'd)****(A) Long-term Inventory:**

At December 31, 2021, \$5,150 of the Company's inventory is classified among long-term assets according to Management's estimate based on the recent level of sales (at December 31, 2020 - \$4,416). These amounts are comprised of spare parts. The Company's policy is to keep components to provide support and service to systems sold by it to its customers over the past years (usually the support is over a period of seven to ten years) until the Company announces it will not continue to support certain systems. Therefore, this inventory is usually consumed over longer periods than inventory classified as current, and as such the respective amount that is not expected to be consumed in the next year is classified as non-current. Management believes that this inventory will be utilized according to its forecasted sales and that no loss will be incurred.

(B) Inventory provision

In 2021, based on Management's estimates regarding future sales, a provision of \$424 was made against damaged, obsolete, excess and slow-moving inventory (in 2020 - \$142).

The provisions were recorded in the costs of revenues line item in the consolidated statement of income. The provisions result in a new cost basis that is not subsequently marked up based on changes in underlying facts and circumstances.

Note 5 - Other Current Assets

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Due from Government institutions and income tax receivables	2,623	2,269
Prepaid expenses	2,025	455
Interest receivable	463	207
Other	542	435
	<u>5,653</u>	<u>3,366</u>

Note 6 – Long-term Deposits

Long-term deposits are bank deposits in US Dollars with terms at the investment date of 24 months with average annual interest rates of 1.14%.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 7 - Property, Plant and Equipment, Net**

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Cost:		
Land	863	863
Building	15,208	14,438
Machinery and equipment	13,911	11,260
Office furniture and equipment	881	785
Computer equipment and software	5,383	4,760
Automobiles	479	263
Leasehold improvements	1,642	630
Right of use assets	4,969	3,014
	<u>43,336</u>	<u>36,013</u>
Less accumulated depreciation	<u>17,936</u>	<u>15,615</u>
	<u><u>25,400</u></u>	<u><u>20,398</u></u>

Depreciation expenses for the years ended December 31, 2021, 2020 and 2019 amounted to \$3,682, \$3,117, and \$3,101, respectively.

Note 8 - Intangible Assets, Net

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Patent registration costs	<u>2,038</u>	<u>1,927</u>
Accumulated amortization	<u>1,428</u>	<u>1,318</u>
Total intangible assets, net	<u><u>610</u></u>	<u><u>609</u></u>

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 8 - Intangible Assets, net (cont'd)**

Patent registration costs are amortized over their estimated useful life of 10 years.

Amortization expense for the years ended December 31, 2021, 2020 and 2019 amounted to \$110, \$98 and \$91, respectively.

As of December 31, 2021, the estimated amortization expenses of intangible assets for the years 2022 to 2026 is as follows:

Year ended December 31,	U.S. Dollars (in thousands)
2022	99
2023	97
2024	89
2025	82
2026	68

Note 9 - Other Current Liabilities

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Commissions	15,967	7,965
Government institutions and income tax payable	11,566	752
Accrued employee compensation and other related benefits	10,923	9,698
Advances from customers and deferred revenues	10,837	6,155
Accrued warranty costs (1)	3,265	2,328
Accrued expenses	2,561	2,570
Operating lease obligations (See Note 2(U))	1,018	736
	56,137	30,204

(1) Changes in the accrued warranty costs are as follows:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Beginning of year	2,328	1,723	1,714
Accruals	6,333	3,667	3,170
Usage	(5,396)	(3,062)	(3,161)
Balance at end of year	3,265	2,328	1,723

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 10 – Other Long-Term Liabilities**

Other long-term liabilities consist of the following:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Liability for severance pay (A)	1,266	1,239
Deferred revenues related to non-standard warranty (B)	2,620	1,342
Lease liabilities in respect of ROU assets	1,914	679
	<u>5,800</u>	<u>3,260</u>

A. Liability for Employee Severance Benefits

Under Israeli law and labor agreements the Company is required to pay severance payments to each employee who was employed by the Company for over one year and has been terminated by the Company or resigned under certain specified circumstances. The liability related to these severance payments is calculated on the basis of the latest salary of the employee multiplied by the number of years of employment as of the balance sheet date. The Company also has defined contribution plans for which it makes contributions to severance pay funds and appropriate insurance policies. Withdrawal of the reserve monies is contingent upon the fulfillment of detailed provision in the Severance Law.

Under local law in various territories in which the Company operates, employees with one year or more of service are entitled to receive a lump-sum payment upon termination of their employment based on their length of service and rate of pay at the time of termination.

1. The liability in respect of most of its employees in Israel is discharged by participating in a defined contribution pension plan and making regular deposits with a pension fund or by individual insurance policies. The liability deposited with the pension fund is based on salary components as prescribed in the existing labor agreement. The custody and management of the amounts so deposited are independent of the companies and accordingly such amounts funded (included in expenses on an accrual basis) and related liabilities are not reflected in the balance sheet.
2. The liability for severance pay which is not covered by the contribution plan amounted to \$1,266 and \$1,239 as of December 31, 2021 and 2020, respectively.
3. Severance pay expenses were \$1,636, \$1,362, and \$1,167 in 2021, 2020 and 2019, respectively.

B. Deferred Revenues

As of December 31, 2021, deferred revenues related to non-standard warranty of \$2,620 are expected to be recognized from 2023 onwards.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 11 – Convertible Notes

On November 17, 2021, the Company sold \$200,000 aggregate principal amount of its 0.00% convertible senior notes due 2026 (the “Notes”). The Notes will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on December 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

The Notes will be convertible based on an initial conversion rate of 17.1092 ordinary shares per \$1,000 principal amount of notes, equivalent to an initial conversion price of approximately \$58.45 per ordinary share, which represents a conversion premium of approximately 30% to the last reported sale price of the Company’s ordinary shares on The Nasdaq Global Market on November 18, 2021. The closing price of the Company’s shares on December 31, 2021 was \$46.04. The conversion rate is subject to adjustment if certain events occur. Prior to the close of business on the business day immediately preceding August 1, 2026, the Notes will be convertible at the option of the holders of Notes only upon the occurrence of certain events, the satisfaction of certain conditions and during certain periods. On or after August 1, 2026 and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes at any time irrespective of the foregoing conditions. The Notes will be convertible into cash, ordinary shares of the Company or a combination thereof, with the form of consideration determined at the Company’s election.

The Company may not redeem the Notes prior to December 6, 2024, except in the event of certain tax law changes. On or after December 6, 2024, the Company may at any time and from time to time redeem for cash all or part of the Notes (subject to a certain partial redemption limitation), at the Company’s option, if the last reported sale price of the Company’s ordinary shares has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest (if any) to, but excluding, the redemption date. Holders of the Notes will have the right to require the Company to repurchase all or a portion of their Notes upon the occurrence of a fundamental change (as defined in the indenture governing the Notes) at a cash repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus any accrued and unpaid special interest (if any) to, but excluding the fundamental change repurchase date.

The Notes are the Company’s general unsecured obligations that rank senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the Notes; will rank equal in right of payment with all of the Company’s unsecured indebtedness that is not so subordinated; will effectively rank junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and to the Company’s liabilities in priority under the applicable bankruptcy laws of Israel; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 11 – Convertible Notes (cont'd)

The Convertible Senior Notes consisted of the following as of December 31, 2021:

	December 31, 2021
	U.S. Dollars (in thousands)
Liability:	
Principle:	200,000
Unamortized issuance costs	5,357
Net carrying amount	194,643

As of December 31, 2021, the debt issuance costs of the Notes will be amortized over the remaining term of approximately 5 years.

The annual effective interest rate of the Notes is 0.56%. In the year ended December 31, 2021, \$113 was recorded as amortization of debt issuance costs.

As of December 31, 2021, the estimated fair value of the Notes, which the Company has classified as Level 2 financial instruments, is \$211,875. The estimated fair value was determined based on the quoted bid price of the Notes in an over-the-counter market on the last trading day of the reporting period.

As of December 31, 2021, the if-converted value of the Notes exceeded the principal amount by \$11,875.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 12 - Commitments and Contingencies****A. Operating leases**

The Company's subsidiaries have entered into various non-cancelable operating lease agreements for office space and operating leases for vehicles.

Amounts reported in the consolidated balance sheets are as follows:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Cost:		
ROU assets – opening balance	3,014	2,471
ROU assets – additions	2,546	831
ROU assets – disposals	(591)	(288)
	<u>4,969</u>	<u>3,014</u>
Less accumulated depreciation	<u>2,037</u>	<u>1,599</u>
	<u><u>2,932</u></u>	<u><u>1,415</u></u>
Other current liabilities	1,018	736
Other long-term liabilities	1,914	679
Total lease liabilities	<u><u>2,932</u></u>	<u><u>1,415</u></u>

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 12 - Commitments and Contingencies (contd.)****A. Operating leases (cont.)**

In the year ended December 31, 2021, the Company recognized lease costs in the amount of \$1,060 (2020 - \$1,025, 2019 - \$1,077).

Minimum future payments under non-cancellable leases as of December 31, 2021 are as follows:

<u>Year ended December 31,</u>	<u>U.S. Dollars (in thousands)</u>
2022	1,091
2023	802
2024	557
2025	429
2026	165
	<u>3,044</u>
Less imputed interest	<u>112</u>
Total lease liabilities	<u><u>2,932</u></u>

The weighted average term of the operating leases as of December 31, 2021 is 41 months.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 12 - Commitments and Contingencies (cont'd)**B. Israel Innovation Authority**

Through its acquisition of Printar in 2009, the Company participates in programs sponsored by the Israeli government for the support of research and development activities. The Company is committed to pay amounts to the IIA at rates of 3.5% of the sales of products resulting from this research and development, up to an amount equal to 100% of the grants received by the Company, bearing interest at the rate of LIBOR. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales, no payment is required.

As of December 31, 2021, the amount of non-repaid grants received including interest accrued amounted to \$7,913 (December 31, 2020 - \$7,597). The liabilities to the IIA were initially recorded at fair value as part of the purchase price allocation related to the acquisition of Printar. Since August 2016, pursuant to the Company's decision to cease supporting the Gryphon system, the Company does not expect that any payments will be made in respect of the foregoing Printar related grants and accordingly all the liabilities to the IIA were written off.

C. Outstanding Purchase Orders

As of December 31, 2021, the Company has purchase orders of \$56,375 (2020 - \$39,433) which mainly represent outstanding purchase commitments for inventory components ordered by the Company in the normal course of business.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 13 - Concentration of Risk and Financial Instruments**

Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash equivalents, short-term bank deposits and trade receivables. The carrying amounts of financial instruments approximate fair value.

Cash and cash equivalents, short-term deposits and long-term deposits

The Company's cash equivalents, short-term deposits and long-term deposits are maintained with multiple high-quality institutions and the composition and maturities of investments are regularly monitored by management.

Trade receivables

The trade receivables of the Company are derived from sales to a large number of customers, primarily large industrial corporations located mainly in Asia, the United States and Europe. The Company generally does not require collateral; however, in certain circumstances, the Company may require a letter of credit, other collateral or additional guarantees. An allowance for doubtful accounts is determined with respect to those amounts that the Company has determined to be doubtful of collection. The Company performs ongoing credit evaluations of its customers.

Allowance for doubtful debts

The following is a summary of the allowance for doubtful accounts related to accounts receivable for the years ended December 31:

	Balance at		Reversal	Write-off	Balance at
	beginning	Provision	of	of	end of
	of year		provision	provision	year
	U.S. Dollars (in thousands)				
2019	410	87	(116)	(252)	129
2020	129	-	(87)	(3)	39
2021	39	-	-	(32)	7

Trade payables

The Company relies on limited source of suppliers and in some cases a sole supplier and/or subcontractors for a number of essential components and subsystems of its products. The Company does not have agreements with all of these suppliers and subcontractors for the continued supply of the components or subsystems they provide. An interruption in supply from these sources would disrupt production and adversely affect the Company's ability to deliver products to its customers, which could have an adverse effect on the Company's business, revenues and results of operations.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 14 - Shareholders' Equity****A. General**

The Company shares are traded on the NASDAQ Global Market under the symbol of CAMT, and also listed and traded on the Tel-Aviv stock exchange.

In November 2020, the Company completed a successful public offering of 4,025,000 ordinary shares, which includes the full exercise of the underwriters' option to purchase 525,000 additional ordinary shares, at a price to the public of \$17.00 per share. The net proceeds to the Company, after the deduction of underwriting discounts and commissions and other offering expenses, totaled \$64,320.

B. Stock Option Plan

As of December 31, 2021, the Company has one effective Share Incentive Plan (and Sub-Plan for Grantees Subject to Israeli Taxation) for the issuance of options, restricted share units and/ or restricted shares to employees, officers, directors, consultants and other services providers of the Company or any affiliated companies thereof (the "2018 Plan"). The 2018 Plan was adopted by the Company in April 2018 and thereby replaced the Company's previous equity plans (the "2014 Share Option Plan" and the "2007 Restricted Share Unit Plan"). The total number of equity awards that may be granted under the 2018 Plan during each calendar year is equal to three and a half percent (3.5%) of the Company's total issued and outstanding Share capital as of December 31 of the preceding calendar year.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that used the weighted average assumptions in the following table and recognized over the vesting period of four years. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

	2021 Grant
<u>Valuation assumptions:</u>	
Dividend yield	0
Expected volatility	48%
Risk-free interest rate	1.19%
Expected life (years)	4.0
Vesting period (years)	1.0

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 14 - Shareholders' Equity (cont'd)****B. Stock Option Plan (cont'd)**

The total intrinsic value of outstanding options as of December 31, 2021, 2020, and 2019 is \$738, \$1,628 and \$2,343, respectively.

The total intrinsic value of vested options as of December 31, 2021, 2020, and 2019 is \$683, \$1,161 and \$1,746 respectively.

The total stock option compensation expense related to continued operations amounted to \$110, \$120, and \$269 in 2021, 2020 and 2019, respectively.

As of December 31, 2021, there was \$63 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of less than one year.

Share option activity during the past three years is as follows:

	Year Ended December 31,					
	2021		2020		2019	
	Number of options	Weighted average exercise price US\$	Number of options	Weighted average exercise price US\$	Number of options	Weighted average exercise price US\$
Outstanding at January 1	89,925	3.80	309,792	3.29	519,785	3.16
Granted	5,704	36.45	-	-	-	-
Forfeited and cancelled	(106)	4.38	(12,876)	3.74	(10,750)	2.41
Exercised	(73,421)	3.67	(206,991)	3.04	(199,243)	2.69
Outstanding at year end	22,102	12.66	89,925	3.80	309,792	3.29
Exercisable at year end	16,398	4.38	63,253	3.55	225,110	3.08

Notes to the Financial Statements as at December 31, 2021

(Amounts in thousands, except per share data)

Note 14 - Shareholders' Equity (cont'd)**B. Stock Option Plan (cont'd)**

	Number of options outstanding	Weighted average exercise price US\$	Weighted Average Remaining Contractual term (years)	Aggregate intrinsic Value (in US\$ thousands)
Outstanding as of December 31, 2021	<u>22,102</u>	<u>12.66</u>	<u>3.743</u>	<u>738</u>
Exercisable at December 31, 2021	<u>16,398</u>	<u>4.38</u>	<u>2.73</u>	<u>683</u>

The following table summarizes information about share options at December 31, 2021:

Exercise price US\$	Number of outstanding options	Number exercisable	average remaining Contractual term (years) of outstanding options
4.38	16,398	16,398	2.73
36.45	5,704	-	6.74
	<u>22,102</u>	<u>16,398</u>	

The following table summarizes information about non-vested options at December 31, 2021:

	Options	Weighted average grant- date fair value
Balance at January 1, 2021	26,672	2.93
Granted	5,704	17.52
Vested	(26,672)	2.93
Forfeited	-	-
Balance at December 31, 2021	<u>5,704</u>	17.52

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 14 - Shareholders' Equity (cont'd)****C. Restricted Share Unit Plan**

In April 2018, the Company adopted a Restricted Share Unit ("RSU") Plan (the "Plan") to replace the 2007 Restricted Share Unit Plan, pursuant to which the Company's Board of Directors may grant shares to officers and key employees. The total number of shares, which may be granted to directors, officers, employees and consultants under this Plan, is limited to 3.5% out of the outstanding shares (1,534,632 as of December 31, 2021). Forfeited units are returned to the pool.

The exercise price for each grantee shall be as determined by the Board and specified in the applicable RSU notice of grant; provided, however, that unless otherwise determined by the Board (which determination shall not require shareholder approval unless so required in order to comply with Mandatory Law), the exercise price shall be no more than the underlying share's nominal value. For the removal of any doubt, the Board is authorized (without the need for shareholder approval unless so required in order to comply with Mandatory Law) to determine that the exercise price of an RSU is to be \$0.00.

Unless otherwise determined by the Board with respect to any specific grantee or to any specific grant, (which determination shall not require shareholder approval unless so required in order to comply with Mandatory Law) and provided accordingly in the applicable RSU notice of grant, the RSUs shall vest (become automatically exercised) according to the vesting schedules as determined by the Board.

	<u>RSUs</u>	<u>Weighted average grant date value</u>
Balance at January 1, 2021	1,337,684	\$ 9.52
Granted	248,342	\$ 34.33
Vested	(500,244)	\$ 9.01
Forfeited	(26,601)	\$ 10.88
Balance at December 31, 2021	<u>1,059,181</u>	<u>\$ 15.55</u>

The total intrinsic value of outstanding RSUs as of December 31, 2021, 2020 and 2019 is \$46.04, \$21.91 and \$10.83, respectively.

The weighted average grant date fair value of RSUs granted during 2021, 2020, and 2019 is \$34.33, \$11.83 and \$8.61, respectively.

The total compensation cost from RSUs recognized in the year ending December 31, 2021, amounted to \$5,705. The unrecognized compensation expense in the amount of \$12,777 will be recognized in the years 2022 to 2025.

D. Dividend

On September 4, 2019, the Company paid a dividend of \$0.17 per share, totaling \$6,551.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 15 - Earnings Per Share**

The following table summarizes information related to the computation of basic and diluted earnings per Share for the years indicated:

	Year Ended December 31,		
	2021	2020	2019
Basic EPS:			
Net income attributable to Shares (US\$ in thousands)	60,277	21,778	21,986
Weighted average number of Shares outstanding used in basic earnings per Share calculation	43,644	39,383	37,626
Diluted EPS:			
Net income attributable to Shares (US\$ in thousands)	60,277	21,778	21,986
Add amortization of notes issuance costs	105	-	-
Net income used in diluted earnings per Share calculation	60,382	21,778	21,986
Weighted average number of Shares outstanding used in basic earnings per Share calculation	43,644	39,383	37,626
Add assumed exercise of outstanding dilutive			
Effect of stock-based awards	988	989	806
Effect of conversion of Notes	403	-	-
Weighted average number of Shares Outstanding used in diluted earnings per Share calculation	45,035	40,372	38,432
Basic income from continuing operations per Share (\$)	1.38	0.55	0.55
Basic income from discontinued operations per Share (\$)	-	-	0.03
Basic net income per Share (\$)	1.38	0.55	0.58
Diluted income from continuing operations per Share (\$)	1.34	0.54	0.54
Diluted income from discontinued operations per Share (\$)	-	-	0.03
Diluted net income per Share (\$)	1.34	0.54	0.57
Number of options excluded from the diluted earnings per share calculation due to their anti-dilutive effect	-	-	-

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 16 – Entity-Wide Information**

Substantially all fixed assets are located in Israel and substantially all revenues are derived from sales to other countries. Revenues are attributable to geographic areas/countries based upon the destination of shipment of products and related services as follows:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Asia Pacific	224,931	137,555	115,925
United States	28,641	9,847	10,388
Europe	16,087	8,457	7,706
	<u>269,659</u>	<u>155,859</u>	<u>134,019</u>

Notes to the Financial Statements as at December 31, 2021

(Amounts in thousands, except per share data)

Note 17 - Selected Income Statement Data**A. Revenues**

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Sales of products	259,332	148,257	127,396
Service fees	10,327	7,602	6,623
	<u>269,659</u>	<u>155,859</u>	<u>134,019</u>

In 2021 and 2020, no customer accounted for more than 10% of revenues.

In 2019, one customer accounted for 11% of the Company's revenues.

B. Selling, general and administrative expenses

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Selling (*)	33,614	22,969	19,294
General and administrative	9,359	8,063	7,187
	<u>42,973</u>	<u>31,032</u>	<u>26,481</u>
(*) Including shipping and handling costs	<u>1,867</u>	<u>2,356</u>	<u>1,063</u>

C. Financial income, net

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Interest income	1,408	1,281	1,412
Other, net (*)	(378)	(506)	(611)
	<u>1,030</u>	<u>775</u>	<u>801</u>

(*) Other, net includes foreign currency income (expense) resulting from transactions not denominated in U.S. Dollars amounting to \$58, \$(351), and \$(352) in 2021, 2020 and 2019, respectively.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 18 - Income Taxes**A. Tax under various laws**

The Company and its subsidiaries are assessed for income tax purposes on a separate basis. Each of the subsidiaries is subject to the tax rules prevailing in the country of incorporation.

B. Details regarding the tax environment of the Israeli companies**(1) Corporate tax rate**

The tax rates relevant to the Company in Israel for the years 2019-2021 is 23%.

Current taxes for the reported periods are calculated according to the enacted tax rates presented above, subject to the reduced tax rate under the Law for the Encouragement of Capital Investment discussed below.

(2) Benefits under the Law for the Encouragement of Capital Investments (hereinafter - "the Encouragement Law")**(a) Amendment to the Law for the Encouragement of Capital Investments – 1959**

On December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, preferred enterprise in development area A will be subject to tax rate of 7.5%.

In 2019 the Company filed a notice to the Israeli Tax Authorities regarding the implementation of the preferred enterprise its preferred income, beginning 2019 (instead of Beneficiary). As the Company is located in Development Area A, the applied corporate tax rate is 7.5%.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 18 - Income Taxes (cont'd)**B. Details regarding the tax environment of the Israeli companies (cont'd)**

- (b) In November 2021, an amendment to the Law of Encouragement of Capital Investment was enacted (the "2021 Amendment"). According to the 2021 Amendment, any future dividend distributed by an entity with tax exempt retained earnings will be deemed to be distributed proportionately from such tax exempt retained earnings. As part of the 2021 Amendment, the Israeli Tax Authorities enacted a temporary rule which reduces the tax rate applicable to the distribution of such tax exempt retained earnings.

During the fourth quarter of 2021, the Company entered into a tax assessment with the Israeli Tax Authorities for the years 2017-2020. During the tax assessment, the Company reevaluated certain tax positions, due to the 2021 Amendment and the interactions with the tax authorities. As of December 31, 2021, the Company measured the possible negotiation settlement outcomes regarding its tax positions and concluded that it is more-likely-than-not that it will incur tax expenses. The Company recognized a provision for these tax expenses at the expected rate which corresponds with the reduced tax rate of the temporary rule mentioned above.

The Company's Statement of Income for the year ended December 31, 2021 included income tax on earnings of previous years of \$5,315. The settlement of the tax assessment finalized in February 2022 will allow the Company to distribute dividends from these earnings in the future with no additional corporate tax liability.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 18 - Income Taxes (cont'd)****C. Details regarding the tax environment of the Non-Israeli companies**

Non-Israeli subsidiaries are taxed according to the tax laws in their countries of residence under local tax laws and regulations.

D. Composition of income from continuing operations before income taxes and income tax expense

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Income from continuing operations before income taxes:			
Israel	67,643	20,430	20,783
Non-Israeli	4,285	2,969	1,990
	71,928	23,399	22,773
Income tax expense from continuing operations:			
Current:			
Israel	(*) 9,930	-	-
Non-Israeli	1,603	670	424
	11,533	670	424
Deferred benefit:			
Israel	714	943	1,351
Non-Israeli	(596)	8	175
	118	951	1,526
	11,651	1,621	1,950

(*) see Note 18B(b)

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 18 - Income Taxes (cont'd)****E. Reconciliation of income tax expense at the statutory rate to actual income tax expense**

The following is a reconciliation of the theoretical income tax expense, assuming all income is taxed at the statutory tax rate applicable to Israeli companies, and the actual income tax expense:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Income from continuing operations before income taxes	71,928	23,399	22,773
Statutory tax rate	23%	23%	23%
Theoretical income tax expense	16,543	5,382	5,238
Increase (decrease) in income tax expense resulting from:			
Income tax on earning of previous years- see Note 18B(b)	5,306	-	-
Non-deductible expenses (*)	285	239	337
Differences between Israeli shekel and dollar-adjusted financial statements, net (**)	-	(739)	(479)
Tax rate differential	(10,715)	(3,251)	(3,340)
Other	232	(10)	194
Actual income tax expense (benefit)	11,651	1,621	1,950

(*) Including non-deductible share-based compensation.

(**) The Company has elected, as from the 2021 tax year, to measure its results for tax purposes on the basis of the changes in the exchange rate of the Dollar. The Company must continue to be taxed on this basis for at least three years.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 18 - Income Taxes (cont'd)****F. Deferred tax assets and liabilities**

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Deferred tax assets:		
Allowance for doubtful accounts	1	3
Deferred revenue	838	340
Accrued expenses	535	469
Net operating loss and tax credit carryforwards	211	644
Lease liability	278	170
Other temporary differences	217	344
Deferred tax asset	2,080	1,970
Deferred tax liabilities:		
Property, plant and equipment	(700)	(618)
Right of use assets	(278)	(170)
Undistributed earnings	(875)	(700)
Total deferred tax liabilities	(1,853)	(1,488)
Net deferred tax assets	227	482

Deferred tax assets are recognized for the anticipated tax benefits associated with operating loss carryforwards, tax credit carryforwards and deductible temporary differences. If it is more likely than not that some or all of the deferred tax assets will not be realized, the deferred tax credits are reduced by a valuation allowance.

In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

At December 31, 2021 and 2020 the Company had no valuation allowance.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 18 - Income Taxes (cont'd)****F. Deferred taxes (cont'd)**

As of December 31, 2021, a foreign subsidiary has net operating loss carryforwards aggregating approximately \$620. Included within the deferred tax expenses for the year ended December 31, 2021 is a benefit of \$211 for the recognition of a deferred tax asset for operating loss carryforwards.

G. Accounting for uncertainty in income taxes

For the years ended December 31, 2021, 2020 and 2019, the Company did not have any significant unrecognized tax benefits. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

The Company accounts for interest and penalties related to an underpayment of income taxes as a component of income tax expense. For the years ended December 31, 2021, 2020 and 2019, no interest and penalties related to income taxes have been accrued.

H. Tax assessments

The Company in Israel files its income tax returns in Israel while its principle foreign subsidiaries file their income tax returns in Belgium, Germany, Hong Kong, and United States of America. The Israeli tax return of Camtek is open to examination by the Israeli Tax Authorities for the tax year 2021, while the tax returns of its principal foreign subsidiaries remain subject to examination for the tax years beginning 1999 in Belgium, 2017 in Germany, 2014 in Hong Kong and 2017 in the United States of America.

See also Note 20.

Note 19 - Balances and Transactions with Related Parties**A. Balances with related parties:**

	December 31, 2021	December 31, 2020
	U.S. Dollars (in thousands)	
Due from related parties	15	3

B. Transactions with related parties:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Purchases from related parties	-	-	-
Reimbursement of expenses	-	-	100
Interest income (expense) from Priortech	-	-	-

Unpaid balances between the Company and Priortech or its other subsidiaries in Israel bear interest of 5.5%.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)**

Note 19 - Balances and Transactions with Related Parties (cont'd)**Registration Rights Agreement with Prioritech**

On March 1, 2004, the Company entered into a registration rights agreement providing for the Company to register with the SEC certain of its ordinary shares held by Prioritech. This registration rights agreement may be used in connection with future offerings of ordinary shares, and includes, among others, the following terms: (a) Prioritech is entitled to make up to three demands that the Company registers its ordinary shares held by Prioritech, subject to delay due to market conditions; (b) Prioritech will be entitled to participate and sell the Company's ordinary shares in any future registration statements initiated by the Company, subject to delay due to market conditions; (c) the Company will indemnify Prioritech in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions other than information provided by Prioritech, and Prioritech will indemnify the Company in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions in written statements by Prioritech made for the purpose of their inclusion in such registration statements; and (d) the Company will pay all expenses related to registrations which the Company has initiated, except for certain underwriting discounts or commissions or legal fees, and Prioritech will pay all expenses related to a registration initiated at its demand in which the Company is not participating.

On December 30, 2004, the Registration Rights Agreement with Prioritech was amended. The amendment concerns primarily the grant of unlimited shelf registration rights thereunder to Prioritech with respect to its holdings in the Company, and the assignability of those shelf registration rights to its transferees.

On May 13, 2015, following the approval of the Company's Audit Committee and Board of Directors the Registration Rights Agreement with Prioritech was renewed for an additional 5 year period effective as of December 31, 2014.

Following the Chroma transaction (See Note 1(D)), the Company entered into a Second Amended and Restated Registration Rights Agreement with Prioritech and Chroma, according to which Chroma is entitled to the same rights Prioritech has with respect to registration of the Company's shares.

Technological Cooperation Agreement with Chroma

In 2019, the Company entered into a Technological Cooperation Agreement with Chroma under which the Company granted Chroma a license for an application under Company's triangulation technology platform.

Employment Agreements with the Chief Executive Officer

Pursuant to the employment agreement with the Chief Executive Officer ("CEO"), the CEO dedicates 10% of his time in providing consulting and management services for Prioritech through Amitec – Advanced Multilayer Interconnect Technologies Ltd. – a wholly owned subsidiary of Prioritech ("Amitec"). The CEO receives from the Company 90% of a full-time salary and is compensated directly by Amitec for the remaining 10% of his time.

The CEO serves as the Chairman of Prioritech.

Notes to the Financial Statements as at December 31, 2021**(Amounts in thousands, except per share data)****Note 20 – Subsequent Events**

See Note 18B(b) regarding tax settlement.

F - 44

Item 19. Exhibits.**Exhibit No. Exhibit**

- 1.1 [Memorandum of Association of Registrant \(incorporated herein by reference to Exhibit 3.1 to Amendment No. 1 to the Registrant's Registration Statement on Form F-1, File No. 333-12292, filed with the Securities and Exchange Commission on July 21, 2000\);](#)
- 1.2 [Articles of Registrant, as amended October 24, 2011 \(incorporated herein by reference to Exhibit A to the Registrant's Registration Statement on Form 6-K, File No. 000-30664, filed with the Securities and Exchange Commission on September 27, 2011\) and November 3, 2016 \(incorporated herein by reference to Exhibit B to the Registrant's Registration Statement on Form 6-K, File No. 000-30664, filed with the Securities and Exchange Commission on September 29, 2016\) and October 3, 2018 \(incorporated herein by reference to Exhibit A to the Registrant's Registration Statement on Form 6-K, File No. 000-30664, filed with the Securities and Exchange Commission on August 16, 2018\).](#)
- 2.1 [Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934*](#)
- 4.1 [2018 Share Incentive Plan \(incorporated herein by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-8, File No. 333-227931, filed with the Securities and Exchange Commission on October 22, 2018\).](#)
- 4.2 [Form of Indemnification Agreement \(incorporated herein by reference to Exhibit A to the Registrant's Registration Statement on Form 6-K, File No. 000-30664, filed with the Securities and Exchange Commission on June 04, 2018\).](#)
- 4.4 [Share Purchase Agreement by and between Chroma ATE Inc. and the Registrant dated February 11, 2019 \(incorporated herein by reference to Exhibit 4.4 to the Registrant's Annual Report on Form 20-F, File No. 000-30664, filed with the Securities and Exchange Commission on March 30, 2020\).](#)
- 8.1 [Subsidiaries of the Registrant \(incorporated herein by reference to Exhibit 8.1 to the Registrant's Registration Statement on Form 20-F File No.000-30664 filed with the Securities and Exchange Commission on June 7, 2010\).](#)
- 12.1 [Certification of Chief Executive Officer required by Rules 13a-14\(a\) and Rule 15d-14\(a\) under the Securities Exchange Act of 1934, as amended.*](#)
- 12.2 [Certification of Chief Financial Officer required by Rules 13a-14\(a\) and Rule 15d-14\(a\) under the Securities Exchange Act of 1934, as amended.*](#)
- 13.1 [Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*](#)
- 15.1 [Consent of Somekh Chaikin, Independent Registered Public Accounting Firm, a member firm of KPMG International.*](#)
- 101 Inline XBRL Instance Document
- 101.SCH Inline XBRL Taxonomy Extension Schema Document

101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

‡ English translations from Hebrew original.

* Filed herewith.

SIGNATURES

The Company hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

CAMTEK LTD.

By: /s/ Rafi Amit

Name: Rafi Amit

Title: Chief Executive Officer

Date: March 15, 2022

DESCRIPTION OF CAMTEK LTD.

SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

Camtek Ltd., an Israeli corporation (the “Company,” “we,” or “our”), currently has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, the Company’s ordinary shares, par value NIS 0.01 per share. The following is a summary of some of the terms of our ordinary shares based on our articles of association, as may be amended and restated from time to time, and Israeli law.

The following summary is not complete and is subject to, and is qualified in its entirety by reference to, the provisions of our articles of association and Israeli law.

Name of exchange on which registered: Our ordinary shares were registered for trading began trading on the NASDAQ in July 2000, and later that year began trading on the Tel Aviv Stock Exchange Ltd.

Restrictions on Securities: The ownership or voting of ordinary shares by non-residents of Israel is not restricted in any way by our articles of association or the laws of the State of Israel, except for anti-terror legislation and except that citizens of countries which are in a state of war with Israel may not be recognized as owners of ordinary shares.

Registration.

The Company was incepted and registered with the Israeli Registrar of Companies in 1987, under registration number 511235434.

Purpose of the Company. The purposes of the Company, as provided by Article 3 of our Articles, is to engage in any legal activity, both in Israel and abroad.

Share Capital.

Our authorized share capital consists of 100,000,000 ordinary shares, par value 0.01 per share. All of our issued and outstanding shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.

The Company currently has one class of ordinary shares, 0.01 NIS par value per share. The Articles provide that the board of directors may decide on a distribution, subject to the provisions set forth under the Israeli Companies Law, 5759-1999 (the “Companies Law”) and the Articles. Under the Companies Law, dividends may be paid out of net earnings, as calculated under that law, for the two years preceding the distribution of the dividend and retained earnings, provided that there is no reasonable concern that the dividend will prevent the company from satisfying its existing and foreseeable obligations as they become due. For more information, see the Company’s balance sheet and the statement of shareholders’ equity in the financial statements.

Each ordinary share entitles its holder to the following rights:

- the equal right to participate in and vote at general meetings of the shareholders, and each share entitles its holder thereof, who is present and participating in the vote, whether in person or by proxy, to one vote;
- the equal right to participate in any distribution; and
- the equal right to participate in the distribution of assets available for distribution in the event of liquidation of the company.

Transferring Shares

According to the Articles, our shares may be freely transferred, unless the transfer is restricted or prohibited by another agreement, undertaking or any applicable law.

Changes of Rights of Holders of the Shares.

According to the Articles, any change in the rights and privileges of the holders of any class of shares requires the approval of a class meeting of such class of shares by a simple majority (unless otherwise provided by the Companies Law or the regulations thereto or by the terms of issue of the shares of that class).

Amendments to the Articles of Association.

Our Articles may be amended by a simple majority vote of our shareholders.

Shareholders Meetings.

An annual meeting should be convened at least once every calendar year, and no later than 15 months after the preceding annual meeting, to review the Company's financial statements and to transact any other business required pursuant to the Articles or to the Companies Law, and any other matter which the board of directors places on the agenda of the annual meeting, at a time and place that the board of directors will determine. A special meeting may be called by the board of directors and at the demand of any of the following: two directors or one-quarter of the directors then serving; one or more shareholders who hold at least five percent of the issued and outstanding capital stock and at least one percent of the voting rights in the Company; or one or more shareholders who hold at least five percent of the voting rights in the Company.

According to the Articles, the quorum required for an ordinary meeting of shareholders is at least two shareholders present in person or by proxy who together hold or represent in the aggregate 25 % or more of the voting power. A meeting adjourned for lack of a quorum is reconvened week to the same day, the same hour and the same place, or to a later date if so specified in the notice of the General Meeting. At the reconvened meeting, if a quorum is not present within one half hour from the time set for commencing the adjourned meeting, the required quorum will consist of any number of members present in person or by proxy, regardless of the number of shares represented. The Companies Law and regulations determine that prior notice of no less than 21 days should be given to the company's shareholders, prior to convening a meeting. In the event that the issue to be resolved is an issue subject to the Israeli proxy rules, a notice of no less than 35 days should be given to the company's shareholders. In some cases, a prior notice of not less than 14 days may be given to the company's shareholders.

Changes in Capital.

Our share capital may be increased or decreased by a vote of our shareholders in accordance with the Companies Law, either by creating new shares of an existing class or of a new class. Furthermore, and subject to applicable law, our shareholders may resolve to make the following changes to our share capital:

- alter or add classes of shares, including shares with preference rights, deferred rights, conversion rights or any other special rights or limitations;
- consolidate and/or split all or any of its share capital into shares of larger or smaller par value than the existing shares;
- cancel any registered shares not yet allocated, provided we have made no commitment to allocate such shares; and
- reduce our share capital and any reserved fund for redemption of capital.

Modification of Rights

According to our Articles, if our share capital is divided into different classes of shares, any change to the rights and privileges of the holders of such class will require the approval of a meeting of such class of shares by a simple majority vote.

Borrowing Powers

Pursuant to the Companies Law and our articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our articles of association to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.

Acquisition of a Controlling Stake.

According to the Companies Law, an acquisition pursuant to which a purchaser will hold a “controlling stake”, that is defined as 25% or more of the voting rights if no other shareholder holds a controlling stake, or an acquisition pursuant to which such purchaser will hold more than 45% of the voting rights of the company if no other shareholder owns more than 45% of the voting rights, may not be performed by way of market accumulation, but only by way of a special tender offer (as defined in the Companies Law) made to all of the company’s shareholders on a pro rata basis. A special tender offer may not be consummated unless a majority of the shareholders who announced their stand on such offer have accepted it (in counting the total votes of such shareholders, shares held by the controlling shareholders, shareholders who have personal interest in the offer, shareholders who own 25% or more of the voting rights in the company, relatives or representatives of any of the above or the bidder and corporations under their control, shall not be taken into account). A shareholder may be free to object to such an offer without such objection being deemed as a waiver of his right to sell its respective shares if the transaction is approved by a majority of the company’s shareholders despite his objection. Shares purchased not in accordance with those provisions will become “dormant shares” and will not grant the purchaser any rights so long as they are held by the purchaser.

Acquisition.

A person wishing to acquire shares or a class of shares of an Israeli public company and who would, as a result, own more than 90% of the target company’s issued and outstanding share capital or of certain class of its shares, is required by the Companies Law to make a full tender offer (as defined in the Companies Law) to all of the company’s shareholders for the purchase of all of the issued and outstanding shares of the company or class of shares. If either (i) the shareholders who do not accept the offer hold, in the aggregate, less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, or (ii) the shareholder who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class, then all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a shareholder that had its shares so transferred, whether or not it accepted the tender offer (unless otherwise provided in the offering memorandum), may, within six (6) months from the date of acceptance of the tender offer, petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. If the shareholders who did not accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class of shares, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company’s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.

The Companies Law provides that corporate mergers require the approval of both companies’ boards of directors and shareholders. In the event, however, that shares of the target company are held by the acquiring company or by a person holding 25% or more of any type of controlling means of the acquiring company, the merger will not be approved if a majority of the shareholders of the target company attending and voting at the meeting at which the merger is considered (without taking into account, for that purpose, the shares held by the acquiring company or by a person holding 25% or more of any type of controlling means of the acquiring company) object to and do not vote in favor of the merger. If a person holds 25% or more of any type of controlling means of more than one merging company, the same provisions shall apply with regard to the shareholders’ vote with respect to each such company. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if the court concludes that there exists a reasonable concern that as a result of the merger the surviving company will be unable to satisfy the target company’s obligations. Furthermore, a merger may not close unless at least 30 days have passed from the time that the general meeting of each of the merging companies was held and at least 50 days have passed from the date on which the merger proposal was sent to the Israeli Registrar of Companies.



Chief Executive Officer Certification

Required by Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended

I, Rafi Amit, certify that:

1. I have reviewed this Annual Report on Form 20-F of Camtek Ltd.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4. The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the company and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
5. The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal controls over financial reporting.

Date: March 15 2022

By: /s/ Rafi Amit
Name: Rafi Amit
Title: Chief Executive Officer

Chief Financial Officer Certification

Required by Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended

I, Moshe Eisenberg, certify that:

1. I have reviewed this Annual Report on Form 20-F of Camtek Ltd.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4. The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f) for the company and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
5. The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal controls over financial reporting.

Date: March 15, 2022

By: /s/ Moshe Eisenberg
Name: Moshe Eisenberg
Title: Chief Financial Officer

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

We, Rafi Amit, Chief Executive Officer of Camtek Ltd., and Moshe Eisenberg, Chief Financial Officer of Camtek Ltd., each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report for Camtek Ltd. on Form 20-F for the year ended December 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that information contained in the Annual Report on Form 20-F fairly presents, in all material respects, the financial condition and results of operations of Camtek Ltd.

Date: March 15, 2022

By: /s/ Rafi Amit
Name: Rafi Amit
Title: Chief Executive Officer

By: /s/ Moshe Eisenberg
Name: Moshe Eisenberg
Title: Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Camtek Ltd. and will be retained by Camtek Ltd. and furnished to the United States Securities And Exchange Commission or its staff upon request.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors

Camtek Ltd:

We consent to the incorporation by reference in the registration statements (No. 333-237680) on Form F-3 and (Nos. 333-238705, 333-227931, 333-201286, 333-174165, 333-156287 and 333-113139) on Form S-8 of our report dated March 15, 2022, with respect to the consolidated financial statements of Camtek Ltd. and the effectiveness of internal control over financial reporting.

Somekh Chaikin

A member firm of KPMG International

Tel Aviv, Israel

March 15, 2022

**Document and Entity
Information - shares****12 Months Ended****Dec. 31, 2021****Mar. 10,
2022**

Entity Central Index Key	0001109138	
Current Fiscal Year End Date	--12-31	
Document Fiscal Year Focus	2021	
Document Fiscal Period Focus	FY	
Document Type	20-F	
Amendment Flag	false	
Document Registration Statement	false	
Document Annual Report	true	
Document Transition Report	false	
Document Shell Company Report	false	
Document Period End Date	Dec. 31, 2021	
Entity File Number	000-30664	
Entity Registrant Name	Camtek Ltd.	
Entity Incorporation, State or Country Code	L3	
Entity Address, Address Line One	Ramat Gavriel Industrial Zone	
Entity Address, Address Line Two	P.O. BOX 544	
Entity Address, City or Town	Migdal Ha'Emek	
Entity Address Country	IL	
Entity Address, Postal Zip Code	23150	
Title of 12(b) Security	Ordinary Shares, nominal value NIS 0.01 per share	
Trading Symbol	CAMT	
Name of Exchange on which Security is Registered	NASDAQ	
Entity Common Stock, Shares Outstanding		43,847,393
Entity Well-known Seasoned Issuer	No	
Entity Voluntary Filers	No	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Large Accelerated Filer	
Entity Emerging Growth Company	false	
Document Accounting Standard	U.S. GAAP	
Entity Shell Company	false	
Auditor Attestation Flag	true	
Auditor Firm ID	1057	
Auditor Location	Tel Aviv, Israel	
Auditor Name	Somekh Chaikin	
Business Contact [Member]		
Contact Personnel Name	Moshe Eisenberg	
Entity Address, Address Line One	Ramat Gavriel Industrial Zone	
Entity Address, Address Line Two	P.O. BOX 544	

<u>Entity Address, City or Town</u>	Migdal Ha'Emek
<u>Entity Address Country</u>	IL
<u>Entity Address, Postal Zip Code</u>	23150
<u>City Area Code</u>	972
<u>Local Phone Number</u>	(4) 6048100
<u>Contact Personnel Fax Number</u>	(4) 6048300
<u>Contact Personnel Email Address</u>	moshee@camtek.com

Consolidated Balance Sheets
- USD (\$)
\$ in Thousands

	Dec.	Dec.
	31,	31,
	2021	2020
<u>Current assets</u>		
<u>Cash and cash equivalents</u>	\$	\$
	241,943	105,815
<u>Short-term deposits</u>	156,000	72,000
<u>Trade accounts receivable, net</u>	57,825	41,001
<u>Inventories</u>	58,759	39,736
<u>Other current assets</u>	5,653	3,366
<u>Total current assets</u>	520,180	261,918
<u>Long-term deposits</u>	32,000	0
<u>Long-term inventory</u>	5,150	4,416
<u>Deferred tax asset</u>	227	482
<u>Other assets</u>	190	85
<u>Property, plant and equipment, net</u>	25,400	20,398
<u>Intangible assets, net</u>	610	609
<u>Total non-current assets</u>	63,577	25,990
<u>Total assets</u>	583,757	287,908
<u>Current liabilities</u>		
<u>Trade accounts payable</u>	33,550	27,180
<u>Other current liabilities</u>	56,137	30,204
<u>Total current liabilities</u>	89,687	57,384
<u>Long-term liabilities</u>		
<u>Other Liabilities, Noncurrent</u>	5,800	3,260
<u>Convertible notes</u>	194,643	0
<u>Total noncurrent liabilities</u>	200,443	3,260
<u>Total liabilities</u>	290,130	60,644
<u>Shareholders' equity</u>		
<u>Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at December 31, 2020 and 2019; 45,365,354 and 40,742,355 issued shares at December 31, 2020 and 2019, respectively; 43,272,978 and 38,649,979 shares outstanding at December 31, 2020 and 2019, respectively</u>	172	171
<u>Additional paid-in capital</u>	176,582	170,497
<u>Retained earnings</u>	118,771	58,494
<u>Total shareholders' equity before treasury stock</u>	295,525	229,162
<u>Treasury stock, at cost (2,092,376 shares as of December 31, 2020 and 2019)</u>	(1,898)	(1,898)
<u>Total shareholders' equity</u>	293,627	227,264
<u>Total liabilities and shareholders' equity</u>	\$	\$
	583,757	287,908

**Consolidated Balance Sheets
(Parenthetical) - ₪ / shares**

Dec. 31, 2021 Dec. 31, 2020

Statement of Financial Position [Abstract]

<u>Common Stock, par value per share</u>	₪ 0.01	₪ 0.01
<u>Common Stock, shares authorized</u>	100,000,000	100,000,000
<u>Common Stock, shares issued</u>	45,939,019	45,365,354
<u>Common Stock, shares outstanding</u>	43,846,643	43,272,978
<u>Treasury Stock, shares</u>	2,092,376	2,092,376

**Consolidated Statements of
Income - USD (\$)
\$ in Thousands**

**12 Months Ended
Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019**

Income Statement [Abstract]

<u>Revenues</u>	\$ 269,659	\$ 155,859	\$ 134,019
<u>Cost of revenues</u>	132,315	82,628	69,235
<u>Gross profit</u>	137,344	73,231	64,784
<u>Operating expenses:</u>			
<u>Research and development</u>	23,473	19,575	16,331
<u>Selling, general and administrative</u>	42,973	31,032	26,481
<u>Total operating expenses</u>	66,446	50,607	42,812
<u>Operating income</u>	70,898	22,624	21,972
<u>Financial income, net</u>	1,030	775	801
<u>Income from continuing operations before incomes taxes</u>	71,928	23,399	22,773
<u>Income tax expense</u>	(11,651)	(1,621)	(1,950)
<u>Net income from continuing operations</u>	60,277	21,778	20,823
<u>Income from discontinued operations</u>			
<u>Income before income tax expense</u>	0	0	1,257
<u>Income tax expense</u>	0	0	(94)
<u>Net income from discontinued operations</u>	0	0	1,163
<u>Net income</u>	\$ 60,277	\$ 21,778	\$ 21,986
<u>Earning per share information:</u>			
<u>Basic earnings from continuing operations</u>	\$ 1.38	\$ 0.55	\$ 0.55
<u>Basic earnings from discontinued operations</u>	0	0	0.03
<u>Basic net income per Share</u>	1.38	0.55	0.58
<u>Diluted earnings from continuing operations</u>	1.34	0.54	0.54
<u>Diluted earnings from discontinued operations</u>	0	0	0.03
<u>Diluted net earnings per share</u>	\$ 1.34	\$ 0.54	\$ 0.57
<u>Weighted average number of ordinary shares outstanding:</u>			
<u>Basic</u>	43,644	39,383	37,626
<u>Weighted Average Number of Shares Outstanding, Diluted</u>	45,035	40,372	38,432

Consolidated Statements of Shareholders' Equity - USD (\$) \$ in Thousands	Ordinary Shares NIS 0.01 par value [Member]	Treasury Stock NIS 0.01 par value [Member]	Additional paid-in capital [Member]	Retained earnings [Member]	Total
Balance, value at Dec. 31, 2018	\$ 151	\$ (1,898)	\$ 81,873	\$ 21,281	\$ 101,407
Balance, shares at Dec. 31, 2018	38,535,445	(2,092,376)			
Issuance of shares net	\$ 5		16,021		16,026
Issuance of shares, net, shares	1,700,000				
Exercise of share options and RSUs	\$ 1		541		542
Exercise of share options and RSUs, shares	506,910				
Share-based compensation expense			2,892		2,892
Dividend				(6,551)	(6,551)
Net Income (Loss) Attributable to Parent				21,986	21,986
Balance, value at Dec. 31, 2019	\$ 157	\$ (1,898)	101,327	36,716	136,302
Balance, shares at Dec. 31, 2019	40,742,355	(2,092,376)			
Issuance of shares net	\$ 12		64,308		64,320
Issuance of shares, net, shares	4,025,000				
Exercise of share options and RSUs	\$ 2		627		629
Exercise of share options and RSUs, shares	597,999				
Share-based compensation expense			4,235		4,235
Net Income (Loss) Attributable to Parent				21,778	21,778
Balance, value at Dec. 31, 2020	\$ 171	\$ (1,898)	170,497	58,494	\$ 227,264
Balance, shares at Dec. 31, 2020	45,365,354	(2,092,376)			43,272,978
Exercise of share options and RSUs	\$ 1		270		\$ 271
Exercise of share options and RSUs, shares	573,665				
Share-based compensation expense			5,815		5,815
Net Income (Loss) Attributable to Parent				60,277	60,277

<u>Balance, value at Dec. 31, 2021</u>	\$ 172	\$ (1,898)	\$ 176,582	\$ 118,771	\$ 293,627
<u>Balance, shares at Dec. 31, 2021</u>	45,939,019	(2,092,376)			43,846,643

**Consolidated Statements of
Cash Flows - USD (\$)
\$ in Thousands**

	12 Months Ended		
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Cash flows from operating activities:</u>			
<u>Net income</u>	\$ 60,277	\$ 21,778	\$ 21,986
<u>Discontinued operations, net of tax</u>	0	0	(1,163)
<u>Adjustments to reconcile net income to net cash provided by operating activities:</u>			
<u>Depreciation and amortization</u>	2,811	2,234	2,134
<u>Deferred tax expense</u>	255	476	1,526
<u>Amortization of debt issuance costs</u>	113	0	0
<u>Share based compensation expense</u>	5,815	4,235	2,892
<u>Change in provision for doubtful debts</u>	(32)	(87)	(29)
<u>Loss on disposal of fixed assets</u>	4	0	64
<u>Changes in operating assets and liabilities:</u>			
<u>Trade accounts receivable, gross</u>	(17,338)	(9,696)	156
<u>Inventories</u>	(21,702)	(19,330)	4,798
<u>Due from related parties</u>	(12)	72	58
<u>Other assets</u>	(2,380)	(501)	(236)
<u>Trade accounts payable</u>	6,190	15,661	(4,100)
<u>Other current liabilities</u>	26,956	10,910	(3,460)
<u>Net cash provided by operating activities from continuing operations</u>	60,957	25,752	24,626
<u>Net cash provided by operating activities</u>	60,957	25,752	24,626
<u>Cash flows from investing activities:</u>			
<u>Investment in short-term deposits</u>	(84,000)	(20,500)	(51,500)
<u>Investment in long-term deposits</u>	(32,000)	0	0
<u>Purchase of fixed assets</u>	(4,065)	(2,410)	(1,256)
<u>Purchase of intangible assets</u>	(111)	(216)	(106)
<u>Net cash used in investing activities from continuing operations</u>	(120,176)	(23,126)	(52,862)
<u>Net cash provided by investing activities from discontinued operations</u>	0	0	1,257
<u>Net cash used in investing activities</u>	(120,176)	(23,126)	(51,605)
<u>Cash flows from financing activities:</u>			
<u>Share issuance, net</u>	0	64,288	16,026
<u>Proceeds from exercise of share options</u>	271	629	542
<u>Issuance of convertible notes, net</u>	194,530	0	0
<u>Dividend payment</u>	0	0	(6,551)
<u>Net cash provided by financing activities</u>	194,801	64,917	10,017
<u>Effect of exchange rate changes on cash</u>	546	225	74
<u>Net increase (decrease) in cash and cash equivalents</u>	136,128	67,768	(16,888)
<u>Cash and cash equivalents at beginning of the year</u>	105,815	38,047	54,935
<u>Cash and cash equivalents at end of the year</u>	241,943	105,815	38,047
<u>A. Cash paid and received during the year for:</u>			
<u>Income taxes</u>	558	546	666

<u>Interest received</u>	1,057	1,420	1,112
<u>Lease payments</u>	1,060	1,025	1,077
<u>B. Non-cash transactions:</u>			
<u>Fixed assets purchased with supplier credit</u>	\$ 339	\$ 159	\$ 154

Nature of Operations

**12 Months Ended
Dec. 31, 2021**

[Nature of Operations](#)

[\[Abstract\]](#)

[Nature of Operations](#)

Note 1 - Nature of Operations

- A.** Camtek Ltd. (“Camtek” or “Company”), an Israeli corporation, is jointly controlled by (20.93%) Priortech Ltd. (“Priortech”), an Israeli corporation listed on the Tel-Aviv Stock Exchange and (17.83%) Chroma Ate Inc. (“Chroma”) (See Note 1(C) below). Camtek provides automated and technologically advanced solutions dedicated to enhancing production processes, increasing products yield and reliability, enabling and supporting customers’ latest technologies in the semiconductor fabrication industry.
- B.** In November 2021, the Company closed an offering of \$200,000 aggregate principal amount of 0% Convertible Senior Notes due 2026 (“Convertible Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, which included the full exercise of underwriters’ option to purchase an additional \$25,000 of Convertible Notes, raising \$194,530 net of underwriting discounts and commissions and other offering expenses. See Note 11.
- C.** In November 2020, the Company completed a successful public offering of 4,025,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase 525,000 additional ordinary shares, at a price to the public of \$17.00 per share. The net proceeds to the Company, after the deduction of underwriting discounts and commissions and other offering expenses, totaled \$64,320.
- D.** In February 2019, Chroma Ate Inc, a Taiwanese company, acquired approximately 20.5% of Camtek’s shares in a cash transaction. 6,117,440 Camtek shares were purchased from Priortech for \$58,100 whilst a further 1,700,000 new shares were issued by Camtek, for \$16,200 (before issuance costs). The cash consideration was calculated based on a share-price of \$9.50 per Camtek share, which reflected a 29% premium on Camtek’s closing price as of February 8, 2019.

A voting agreement was signed between Priortech and Chroma according to which the parties will vote together in Camtek’s shareholders’ meetings. According to the voting agreement, after the closing of the transaction, Chroma is entitled to two seats on Camtek’s Board of Directors and Priortech is entitled to three seats.

In addition to the investment, Chroma and Camtek entered into an agreement in which Camtek will license its triangulation technology, a metrology solution, in a fee-bearing license for non-semiconductor applications to be used by Chroma. In addition, Chroma and Camtek agreed to cooperate in potential projects for the semiconductor market based on synergies between their inspection and metrology technologies.

The transaction was completed in June 2019.

Significant Accounting Policies

12 Months Ended
Dec. 31, 2021

[Significant Accounting Policies \[Abstract\]](#)

[Significant Accounting Policies](#)

Note 2 - Significant Accounting Policies

A. Basis of preparation of the financial statements

The consolidated financial statements of Camtek and its subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in United States of America (“US GAAP”). All amounts in the notes to the financial statements are in thousands unless otherwise stated.

B. Principles of consolidation

The accompanying consolidated financial statements include the accounts of Camtek and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

C. Use of estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. As applicable to these financial statements, the most significant estimates and assumptions relate to revenue recognition, valuation of accounts receivable and inventories. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

Since January 2020, the Covid-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. At present, business activity is continuing at all of the Company’s locations, with new routines implemented as required by local Covid-19 regulations.

From the beginning of the outbreak, the Company has been carefully managing the risks and its global operations. The Israeli facility has been able to maintain its required production levels. Worldwide, the Company has benefitted from its strategy of having in place local professional teams in each of its territories that can independently install and support systems. As such, the Company has been able to deliver most of its orders on time and the impact of the Covid-19 pandemic on the its business activity has not been significant.

D. Foreign currency transactions

The functional currency of the Company and its subsidiaries is the U.S. Dollar. Revenue generated by the Company and its subsidiaries is primarily generated outside of Israel and a majority thereof is received in U.S. Dollars. A significant portion of materials and components purchased and operating expenses incurred are either paid for in U.S. Dollars or in New Israeli Shekels (“NIS”).

Transactions not denominated in U.S. Dollars are recorded upon their initial recognition according to the exchange rate in effect on the date of the transaction. Exchange rate differences arising upon the settlement of monetary items or upon reporting the Company’s monetary items at exchange rates different from that by which they were initially recorded during the period, or reported in previous financial statements, are charged to financial income (expenses), net.

E. Cash and cash equivalents

All highly liquid investments purchased with original maturities of three months or less are considered to be cash equivalents.

F. Short-term deposits

Short-term bank deposits are deposits with an original maturity of more than three months and less than a year from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their term deposits.

G. Trade accounts receivable and allowance for doubtful accounts

Accounts receivable are recorded at the outstanding recognized amount and do not bear interest. The allowance for doubtful accounts represents Management’s best estimate of the probable loss inherent in existing accounts receivable balances as a result of possible non-collection. In determining the appropriate allowance, Management bases its estimate on information available about specific debtors, including aging of the balance, assessment of the underlying security received, the history of write-offs, relationships with the customers and the overall creditworthiness of the customers.

H. Inventories

Inventories consist of completed systems, partially completed systems and components and other raw materials, and are recorded at the lower of cost or net realizable value. Cost is determined by the moving – average cost method basis.

Inventory write-downs are recorded at the end of each fiscal period for damaged, obsolete, excess and slow-moving inventory. These write-downs, to the lower of cost or net realizable value, create a new cost basis that is not subsequently marked up based on changes in underlying facts and circumstances.

Management periodically evaluates its inventory composition, giving consideration to factors such as changing product demands due to uncertain industry related market conditions and technological changes, the probability and timing of anticipated usage and the physical condition of the items, and then estimates a charge (reducing the inventory) to be provided for slow moving, technological obsolete or damaged inventory. These estimates could vary significantly from actual use based upon future economic conditions, customer inventory levels or competitive factors that were not foreseen or did not exist when the inventory write-downs were established.

Spare parts included in inventory that are not expected to be converted or consumed within the next year are classified as non-current, based on Management's estimates taking into account market conditions.

I. Property, plant and equipment

These assets are stated at cost less accumulated depreciation, and are depreciated over their estimated useful lives on a straight-line basis.

Annual rates of depreciation are as follows:

Land	1%
Building	2%
Machinery equipment	and 10% - 33%
Computer equipment and software	20% - 33%
Office furniture equipment	and 6% - 20%
Automobiles	15%

Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful economic life of such improvements.

Certain of the Company's finished goods are systems used as demonstration systems, training systems, and for product development in the Company's laboratories ("internal use"). These systems are identical to the systems that Camtek sells in its ordinary course of business. In circumstances where the Company intends to utilize such systems for its internal use, the Company transfers them from inventory to fixed assets. The rationale for the transfer is that the Company does not have the intention to sell these systems in the ordinary course of business but rather expects to use them for its internal use over their expected useful lives. These systems are recorded as fixed assets at cost and depreciated over their useful lives.

J. Intangible assets

Patent registration costs are recorded at cost and amortized on a straight-line basis, beginning with the first year of utilization, over its expected useful life of ten years.

K. Impairment of long-lived assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the long-lived asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized to the extent that the asset's carrying amount exceeds its fair value. In 2021 and 2020, no impairment was noted.

L. Fair values of financial instruments

The carrying amounts of the Company's financial instruments, including cash and cash equivalents, short-term deposits, trade accounts receivable, trade accounts payable and amounts from related parties approximate fair value because of their short-term nature.

The fair values of long-term deposits are estimated based on quoted market prices for those or similar investments.

M. Revenue recognition

The Company's contracts with its customers include performance obligations to provide its products or to service the installed products. A product sale contract may include an extended warranty (that is, for longer than the twelve-month standard warranty) as well as installation, both of which are considered separate performance obligations.

The Company recognizes revenue from contracts for sales of products at the point of time when the Company transfers control of the product to the customer. Effective October 2020, the transfer in control event is generally determined upon shipping terms whereas previously it was generally upon installation at the customer's premises. This policy change was made following operational changes to pre-shipment calibration and testing processes which have enabled the simplification and streamlining of the installation at the customer site.

Revenues from the contract are recognized in an amount that reflects the consideration the Company expects to be entitled to receive once the control of the product had been transferred to the customer and signed documentation of the arrangement, such as a signed contract or purchase order, has been received. Payment terms with customers may vary, but are generally based on milestones within the delivery process such as shipping and installation. Payment terms do not include significant financing components.

The Company does not incur costs in obtaining a contract except for agents' commissions, which are incurred upon the recognition of revenues. Revenues are recognized over a period of less than a year and as such, there are no underlying sales commissions to be capitalized.

Service revenues consist mainly of contracts charged under time and material arrangements. Service revenues from maintenance contracts are recognized ratably over the contract period.

Contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged to customers.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations. These amounts are recorded as deferred revenue in the Consolidated Balance Sheets.

	Year Ended	
	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Beginning of year	2,534	2,606
Deferral of revenue	6,245	1,864
Recognition of deferred revenue	(1,912)	(1,936)
Balance at end of year	<u>6,867</u>	<u>2,534</u>

N. Warranty

The Company records a liability for standard product warranty obligations at the time of sale based upon historical warranty experience. The term of the warranty is generally twelve months.

O. Income taxes

The Company accounts for income taxes in accordance with the asset and liability method whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company includes the foreign currency transaction gains or losses that result from re-measuring deferred taxes in income tax expense. The Company reduces deferred tax assets with a valuation allowance to the amount that is more likely than not to be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition or measurement are reflected in the period in which the change occurs.

P. Research and development

Research and development costs, which consists primarily of salaries, materials consumption and costs associated with subcontracting certain development efforts, are expensed as incurred.

Q. Earnings per ordinary share

Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.

The Company's convertible notes are included in the calculation of diluted Earnings Per Share ("EPS") if the assumed conversion into common shares is dilutive, using the "if-converted" method. This involves adding back the periodic non-cash interest expense net of tax associated with the Notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the denominator for the purposes of calculating diluted EPS, unless the Notes are antidilutive (See also Note 2W).

R. Share-based compensation

The Company accounts for its employee share-based compensation as an expense in the financial statements. All awards are equity classified and therefore such cost is measured at the grant date fair value of the award. The Company estimates share option grant date fair value using the Black-Scholes-Merton option-pricing model. Forfeitures are recognized when they occur. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date (For details see Note 14B).

S. Fair value measurements

The Company implements the provisions of ASC Topic 820 "*Fair Value Measurements and Disclosures*" ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy provides the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which an asset or liability is classified is based on the lowest level input that is significant to the fair value measurement in its entirety.

T. Contingent liabilities

A contingency (provision) is an existing condition or situation involving uncertainty as to the range of possible loss to the entity.

A provision for claims is recognized if it is probable (likely to occur) that a liability has been incurred and the amount can be estimated reasonably.

U. Government-sponsored research and development

The Company records grants received from the Israel Innovation Authority (the "IIA", formerly known as the Office of the Chief Scientist of the Israeli Ministry of Industry and Trade) as a liability, if it is probable that the Company will have to repay the grants received. If it is not probable that the grants will be repaid, the Company records the grants as a reduction to research and development expenses. Royalties paid to the IIA are recognized as a reduction of the above-mentioned liability.

V. Leases

On January 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). See also Note 11A.

Under *Topic 842*, the Company determines if an arrangement is a lease at inception. Rights of use ("ROU") assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be (2.43% in 2021). The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all of the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.

Operating lease ROU assets consist mainly of vehicles and real estate and are presented as property, plant and equipment on the consolidated balance sheet. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented within long-term liabilities on the consolidated balance sheet.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(J).

W. Convertible Notes

The Company accounts for its convertible notes in accordance with ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (Topic 470-20). The Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

The transaction costs are amortized on a straight-line basis along the lifetime of the Notes.

X. Recent Accounting Pronouncements

In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance became effective in the first quarter of 2021 on a prospective basis. The adoption of this guidance has not had a material impact on the Company's consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. ASU 2020-06 reduces the number of accounting models for convertible instruments and allows more contracts to qualify for equity classification. Adoption is either a modified retrospective method or a fully retrospective method of transition. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach.

Cash and Cash Equivalents

12 Months Ended
Dec. 31, 2021

[Cash and Cash Equivalents](#)

[\[Abstract\]](#)

[Cash and Cash Equivalents](#)

Note 3 - Cash and Cash Equivalents

The Company's cash and cash equivalents balance at December 31, 2021 and 2020, is denominated in the following currencies:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
US Dollars	225,283	102,669
New Israeli Shekels	13,566	1,542
Other currencies	3,094	1,604
	<u>241,943</u>	<u>105,815</u>

Short-term deposits are bank deposits in US Dollars with terms at the investment date of 3-12 months with average annual interest rates of 0.81% (2020 – 0.88%).

Inventories

12 Months Ended
Dec. 31, 2021

[Inventory Disclosure](#)
[\[Abstract\]](#)
[Inventories](#)

Note 4 - Inventories

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Components	33,212	19,630
Work in process	12,688	10,123
Finished products *	18,009	14,399
	<u>63,909</u>	<u>44,152</u>

* includes systems at customer locations not yet sold, as of December 31, 2021 and 2020, in the amount of \$4,259 and \$10,613 respectively.

Inventories are presented in:

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Current assets	58,759	39,736
Non-current assets (A)	5,150	4,416
	<u>63,909</u>	<u>44,152</u>

(A) Long-term Inventory:

At December 31, 2021, \$5,150 of the Company's inventory is classified among long-term assets according to Management's estimate based on the recent level of sales (at December 31, 2020 - \$4,416). These amounts are comprised of spare parts. The Company's policy is to keep components to provide support and service to systems sold by it to its customers over the past years (usually the support is over a period of seven to ten years) until the Company announces it will not continue to support certain systems. Therefore, this inventory is usually consumed over longer periods than inventory classified as current, and as such the respective amount that is not expected to be consumed in the next year is classified as non-current. Management believes that this inventory will be utilized according to its forecasted sales and that no loss will be incurred.

(B) Inventory provision

In 2021, based on Management's estimates regarding future sales, a provision of \$424 was made against damaged, obsolete, excess and slow-moving inventory (in 2020 - \$142).

The provisions were recorded in the costs of revenues line item in the consolidated statement of income. The provisions result in a new cost basis that is not subsequently marked up based on changes in underlying facts and circumstances.

Other Current Assets

12 Months Ended
Dec. 31, 2021

[Current assets](#)

[Other Current Assets](#)

Note 5 - Other Current Assets

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Due from Government institutions and income tax receivables	2,623	2,269
Prepaid expenses	2,025	455
Interest receivable	463	207
Other	542	435
	<u>5,653</u>	<u>3,366</u>

Long-term Deposits

**12 Months Ended
Dec. 31, 2021**

[Long-term Investments](#)

[\[Abstract\]](#)

[Long-term Deposits](#)

Note 6 – Long-term Deposits

Long-term deposits are bank deposits in US Dollars with terms at the investment date of 24 months with average annual interest rates of 1.14%.

**Property, Plant and
Equipment, Net**

**12 Months Ended
Dec. 31, 2021**

[Property, Plant and
Equipment \[Abstract\]](#)

[Property, Plant and
Equipment, Net](#)

Note 7 - Property, Plant and Equipment, Net

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Cost:		
Land	863	863
Building	15,208	14,438
Machinery and equipment	13,911	11,260
Office furniture and equipment	881	785
Computer equipment and software	5,383	4,760
Automobiles	479	263
Leasehold improvements	1,642	630
Right of use assets	4,969	3,014
	43,336	36,013
Less accumulated depreciation	17,936	15,615
	25,400	20,398

Depreciation expenses for the years ended December 31, 2021, 2020 and 2019 amounted to \$3,682, \$3,117, and \$3,101, respectively.

Intangible Assets, Net

12 Months Ended
Dec. 31, 2021

[Goodwill and Intangible Assets
Disclosure \[Abstract\]](#)
[Intangible Assets, Net](#)

Note 8 - Intangible Assets, Net

	December 31,	
	2021	2020
	U.S. Dollars	
	(in thousands)	
Patent registration costs	<u>2,038</u>	<u>1,927</u>
Accumulated amortization	<u>1,428</u>	<u>1,318</u>
Total intangible assets, net	<u>610</u>	<u>609</u>

Patent registration costs are amortized over their estimated useful life of 10 years.

Amortization expense for the years ended December 31, 2021, 2020 and 2019 amounted to \$110, \$98 and \$91, respectively.

As of December 31, 2021, the estimated amortization expenses of intangible assets for the years 2022 to 2026 is as follows:

	U.S.
Year ended	Dollars (in
December 31,	thousands)
2022	99
2023	97
2024	89
2025	82
2026	68

Other Current Liabilities

12 Months Ended
Dec. 31, 2021

[Other Current Liabilities](#)

[\[Abstract\]](#)

[Other Current Liabilities](#)

Note 9 - Other Current Liabilities

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Commissions	15,967	7,965
Government institutions and income tax payable	11,566	752
Accrued employee compensation and other related benefits	10,923	9,698
Advances from customers and deferred revenues	10,837	6,155
Accrued warranty costs (1)	3,265	2,328
Accrued expenses	2,561	2,570
Operating lease obligations (See Note 2(U))	1,018	736
	<u>56,137</u>	<u>30,204</u>

(1) Changes in the accrued warranty costs are as follows:

	<u>Year Ended December</u>		
	<u>31,</u>		
	<u>2021</u>	<u>2020</u>	<u>2019</u>
	<u>U.S. Dollars (in thousands)</u>		
Beginning of year	2,328	1,723	1,714
Accruals	6,333	3,667	3,170
Usage	<u>(5,396)</u>	<u>(3,062)</u>	<u>(3,161)</u>
Balance at end of year	<u>3,265</u>	<u>2,328</u>	<u>1,723</u>

Other Long Term Liabilities

12 Months Ended
Dec. 31, 2021

[Other Liabilities,
Noncurrent \[Abstract\]
Other Long Term Liabilities](#)

Note 10 – Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Liability for severance pay (A)	1,266	1,239
Deferred revenues related to non-standard warranty (B)	2,620	1,342
Lease liabilities in respect of ROU assets	1,914	679
	<u>5,800</u>	<u>3,260</u>

A. Liability for Employee Severance Benefits

Under Israeli law and labor agreements the Company is required to pay severance payments to each employee who was employed by the Company for over one year and has been terminated by the Company or resigned under certain specified circumstances. The liability related to these severance payments is calculated on the basis of the latest salary of the employee multiplied by the number of years of employment as of the balance sheet date. The Company also has defined contribution plans for which it makes contributions to severance pay funds and appropriate insurance policies. Withdrawal of the reserve monies is contingent upon the fulfillment of detailed provision in the Severance Law.

Under local law in various territories in which the Company operates, employees with one year or more of service are entitled to receive a lump-sum payment upon termination of their employment based on their length of service and rate of pay at the time of termination.

1. The liability in respect of most of its employees in Israel is discharged by participating in a defined contribution pension plan and making regular deposits with a pension fund or by individual insurance policies. The liability deposited with the pension fund is based on salary components as prescribed in the existing labor agreement. The custody and management of the amounts so deposited are independent of the companies and accordingly such amounts funded (included in expenses on an accrual basis) and related liabilities are not reflected in the balance sheet.
2. The liability for severance pay which is not covered by the contribution plan amounted to \$1,266 and \$1,239 as of December 31, 2021 and 2020, respectively.

3. Severance pay expenses were \$1,636, \$1,362, and \$1,167 in 2021, 2020 and 2019, respectively.

B. Deferred Revenues

As of December 31, 2021, deferred revenues related to non-standard warranty of \$2,620 are expected to be recognized from 2023 onwards.

Convertible Notes

**12 Months Ended
Dec. 31, 2021**

[Debt Disclosure \[Abstract\]](#)
[Convertible Notes](#)

Note 11 – Convertible Notes

On November 17, 2021, the Company sold \$200,000 aggregate principal amount of its 0.00% convertible senior notes due 2026 (the “Notes”). The Notes will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on December 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

The Notes will be convertible based on an initial conversion rate of 17.1092 ordinary shares per \$1,000 principal amount of notes, equivalent to an initial conversion price of approximately \$58.45 per ordinary share, which represents a conversion premium of approximately 30% to the last reported sale price of the Company’s ordinary shares on The Nasdaq Global Market on November 18, 2021. The closing price of the Company’s shares on December 31, 2021 was \$46.04. The conversion rate is subject to adjustment if certain events occur. Prior to the close of business on the business day immediately preceding August 1, 2026, the Notes will be convertible at the option of the holders of Notes only upon the occurrence of certain events, the satisfaction of certain conditions and during certain periods. On or after August 1, 2026 and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes at any time irrespective of the foregoing conditions. The Notes will be convertible into cash, ordinary shares of the Company or a combination thereof, with the form of consideration determined at the Company’s election.

The Company may not redeem the Notes prior to December 6, 2024, except in the event of certain tax law changes. On or after December 6, 2024, the Company may at any time and from time to time redeem for cash all or part of the Notes (subject to a certain partial redemption limitation), at the Company’s option, if the last reported sale price of the Company’s ordinary shares has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest (if any) to, but excluding, the redemption date. Holders of the Notes will have the right to require the Company to repurchase all or a portion of their Notes upon the occurrence of a fundamental change (as defined in the indenture governing the Notes) at a cash repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus any accrued and unpaid special interest (if any) to, but excluding the fundamental change repurchase date.

The Notes are the Company’s general unsecured obligations that rank senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the Notes; will rank equal in right of payment with all of the Company’s

unsecured indebtedness that is not so subordinated; will effectively rank junior in right of payment to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness, and to the Company's liabilities in priority under the applicable bankruptcy laws of Israel; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company's subsidiaries.

The Convertible Senior Notes consisted of the following as of December 31, 2021:

	December 31, 2021
	U.S. Dollars (in thousands)
Liability:	
Principle:	200,000
Unamortized issuance costs	5,357
Net carrying amount	194,643

As of December 31, 2021, the debt issuance costs of the Notes will be amortized over the remaining term of approximately 5 years.

The annual effective interest rate of the Notes is 0.56%. In the year ended December 31, 2021, \$113 was recorded as amortization of debt issuance costs.

As of December 31, 2021, the estimated fair value of the Notes, which the Company has classified as Level 2 financial instruments, is \$211,875. The estimated fair value was determined based on the quoted bid price of the Notes in an over-the-counter market on the last trading day of the reporting period.

As of December 31, 2021, the if-converted value of the Notes exceeded the principal amount by \$11,875.

2024	557
2025	429
2026	165
	<u>3,044</u>
Less imputed interest	<u>112</u>
Total lease liabilities	<u><u>2,932</u></u>

The weighted average term of the operating leases as of December 31, 2021 is 41 months.

B. Israel Innovation Authority

Through its acquisition of Printar in 2009, the Company participates in programs sponsored by the Israeli government for the support of research and development activities. The Company is committed to pay amounts to the IIA at rates of 3.5% of the sales of products resulting from this research and development, up to an amount equal to 100% of the grants received by the Company, bearing interest at the rate of LIBOR. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales, no payment is required.

As of December 31, 2021, the amount of non-repaid grants received including interest accrued amounted to \$7,913 (December 31, 2020 - \$7,597). The liabilities to the IIA were initially recorded at fair value as part of the purchase price allocation related to the acquisition of Printar. Since August 2016, pursuant to the Company's decision to cease supporting the Gryphon system, the Company does not expect that any payments will be made in respect of the foregoing Printar related grants and accordingly all the liabilities to the IIA were written off.

C. Outstanding Purchase Orders

As of December 31, 2021, the Company has purchase orders of \$56,375 (2020 - \$39,433) which mainly represent outstanding purchase commitments for inventory components ordered by the Company in the normal course of business.

**Concentration of Risk and
Financial Instruments**

**12 Months Ended
Dec. 31, 2021**

Risks and Uncertainties
[Abstract]

Concentration of Risk and
Financial Instruments

Note 13 - Concentration of Risk and Financial Instruments

Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash equivalents, short-term bank deposits and trade receivables. The carrying amounts of financial instruments approximate fair value.

Cash and cash equivalents, short-term deposits and long-term deposits

The Company's cash equivalents, short-term deposits and long-term deposits are maintained with multiple high-quality institutions and the composition and maturities of investments are regularly monitored by management.

Trade receivables

The trade receivables of the Company are derived from sales to a large number of customers, primarily large industrial corporations located mainly in Asia, the United States and Europe. The Company generally does not require collateral; however, in certain circumstances, the Company may require a letter of credit, other collateral or additional guarantees. An allowance for doubtful accounts is determined with respect to those amounts that the Company has determined to be doubtful of collection. The Company performs ongoing credit evaluations of its customers.

Allowance for doubtful debts

The following is a summary of the allowance for doubtful accounts related to accounts receivable for the years ended December 31:

	Balance at beginning of year	Reversal of Provision	Write-off of provision	Balance at end of year	
	U.S. Dollars (in thousands)				
2019	410	87	(116)	(252)	129
2020	129	-	(87)	(3)	39
2021	39	-	-	(32)	7

Trade payables

The Company relies on limited source of suppliers and in some cases a sole supplier and/or subcontractors for a number of essential components and subsystems of its products. The Company does not have agreements with all of these suppliers and subcontractors for the continued supply of the components or subsystems they provide. An interruption in supply from these sources would disrupt production and adversely affect the Company's ability to deliver products to its customers, which could have an adverse effect on the Company's business, revenues and results of operations.

Shareholders' Equity

12 Months Ended
Dec. 31, 2021

[Shareholders' Equity](#)

[\[Abstract\]](#)

[Shareholders' Equity](#)

Note 14 - Shareholders' Equity

A. General

The Company shares are traded on the NASDAQ Global Market under the symbol of CAMT, and also listed and traded on the Tel-Aviv stock exchange.

In November 2020, the Company completed a successful public offering of 4,025,000 ordinary shares, which includes the full exercise of the underwriters' option to purchase 525,000 additional ordinary shares, at a price to the public of \$17.00 per share. The net proceeds to the Company, after the deduction of underwriting discounts and commissions and other offering expenses, totaled \$64,320.

B. Stock Option Plan

As of December 31, 2021, the Company has one effective Share Incentive Plan (and Sub-Plan for Grantees Subject to Israeli Taxation) for the issuance of options, restricted share units and/ or restricted shares to employees, officers, directors, consultants and other services providers of the Company or any affiliated companies thereof (the "2018 Plan"). The 2018 Plan was adopted by the Company in April 2018 and thereby replaced the Company's previous equity plans (the "2014 Share Option Plan" and the "2007 Restricted Share Unit Plan"). The total number of equity awards that may be granted under the 2018 Plan during each calendar year is equal to three and a half percent (3.5%) of the Company's total issued and outstanding Share capital as of December 31 of the preceding calendar year.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that used the weighted average assumptions in the following table and recognized over the vesting period of four years. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

	2021 Grant
<u>Valuation assumptions:</u>	
Dividend yield	0
Expected volatility	48%
Risk-free interest rate	1.19%
Expected life (years)	4.0
Vesting period (years)	1.0

The total intrinsic value of outstanding options as of December 31, 2021, 2020, and 2019 is \$738, \$1,628 and \$2,343, respectively.

Exercise price US\$	outstanding options	Number exercisable	Contractual term (years) of outstanding options
4.38	16,398	16,398	2.73
36.45	5,704	-	6.74
	<u>22,102</u>	<u>16,398</u>	

The following table summarizes information about non-vested options at December 31, 2021:

	Options	Weighted average grant- date fair value
Balance at January 1, 2021	26,672	2.93
Granted	5,704	17.52
Vested	(26,672)	2.93
Forfeited	-	-
Balance at December 31, 2021	<u>5,704</u>	<u>17.52</u>

C. Restricted Share Unit Plan

In April 2018, the Company adopted a Restricted Share Unit (“RSU”) Plan (the “Plan”) to replace the 2007 Restricted Share Unit Plan, pursuant to which the Company’s Board of Directors may grant shares to officers and key employees. The total number of shares, which may be granted to directors, officers, employees and consultants under this Plan, is limited to 3.5% out of the outstanding shares (1,534,632 as of December 31, 2021). Forfeited units are returned to the pool.

The exercise price for each grantee shall be as determined by the Board and specified in the applicable RSU notice of grant; provided, however, that unless otherwise determined by the Board (which determination shall not require shareholder approval unless so required in order to comply with Mandatory Law), the exercise price shall be no more than the underlying share’s nominal value. For the removal of any doubt, the Board is authorized (without the need for shareholder approval unless so required in order to comply with Mandatory Law) to determine that the exercise price of an RSU is to be \$0.00.

Unless otherwise determined by the Board with respect to any specific grantee or to any specific grant, (which determination shall not require shareholder approval unless so required in order to comply with Mandatory Law) and provided accordingly in the applicable RSU notice of grant, the RSUs shall vest (become automatically exercised) according to the vesting schedules as determined by the Board.

	<u>RSUs</u>	<u>Weighted average grant date value</u>
Balance at January 1, 2021	1,337,684	\$ 9.52
Granted	248,342	\$ 34.33
Vested	(500,244)	\$ 9.01
Forfeited	(26,601)	\$ 10.88
	<u>1,059,181</u>	<u>\$ 15.55</u>
Balance at December 31, 2021	<u>1,059,181</u>	<u>\$ 15.55</u>

The total intrinsic value of outstanding RSUs as of December 31, 2021, 2020 and 2019 is \$46.04, \$21.91 and \$10.83, respectively.

The weighted average grant date fair value of RSUs granted during 2021, 2020, and 2019 is \$34.33, \$11.83 and \$8.61, respectively.

The total compensation cost from RSUs recognized in the year ending December 31, 2021, amounted to \$5,705. The unrecognized compensation expense in the amount of \$12,777 will be recognized in the years 2022 to 2025.

D. Dividend

On September 4, 2019, the Company paid a dividend of \$0.17 per share, totaling \$6,551.

Earnings Per Share

12 Months Ended
Dec. 31, 2021

Earning per share information:

Earnings Per Share

Note 15 - Earnings Per Share

The following table summarizes information related to the computation of basic and diluted earnings per Share for the years indicated:

	Year Ended December 31,		
	2021	2020	2019
<u>Basic EPS:</u>			
Net income attributable to Shares (US\$ in thousands)	60,277	21,778	21,986
Weighted average number of Shares outstanding used in basic earnings per Share calculation	43,644	39,383	37,626
<u>Diluted EPS:</u>			
Net income attributable to Shares (US\$ in thousands)	60,277	21,778	21,986
Add amortization of notes issuance costs	105	-	-
Net income used in diluted earnings per Share calculation	60,382	21,778	21,986
Weighted average number of Shares outstanding used in basic earnings per Share calculation	43,644	39,383	37,626
Add assumed exercise of outstanding dilutive			
Effect of stock-based awards	988	989	806
Effect of conversion of Notes	403	-	-
Weighted average number of Shares Outstanding used in diluted earnings per Share calculation	45,035	40,372	38,432
Basic income from continuing operations per Share (\$)	1.38	0.55	0.55
Basic income from discontinued operations per Share (\$)	-	-	0.03
Basic net income per Share (\$)	1.38	0.55	0.58
Diluted income from continuing operations per Share (\$)	1.34	0.54	0.54
Diluted income from discontinued operations per Share (\$)	-	-	0.03
Diluted net income per Share (\$)	1.34	0.54	0.57
Number of options excluded from the diluted earnings per share calculation due to their anti-dilutive effect	-	-	-

Entity-Wide Information

12 Months Ended
Dec. 31, 2021

[Entity Wide Information](#)

[\[Abstract\]](#)

[Entity-Wide Information](#)

Note 16 – Entity-Wide Information

Substantially all fixed assets are located in Israel and substantially all revenues are derived from sales to other countries. Revenues are attributable to geographic areas/countries based upon the destination of shipment of products and related services as follows:

	<u>Year Ended December 31,</u>		
	<u>2021</u>	<u>2020</u>	<u>2019</u>
	<u>U.S. Dollars (in thousands)</u>		
Asia Pacific	224,931	137,555	115,925
United States	28,641	9,847	10,388
Europe	16,087	8,457	7,706
	<u>269,659</u>	<u>155,859</u>	<u>134,019</u>

**Selected Income Statement
Data**

**12 Months Ended
Dec. 31, 2021**

[Selected Income Statement
Data \[Abstract\]](#)

[Selected Income Statement
Data](#)

Note 17 - Selected Income Statement Data

A. Revenues

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Sales of products	259,332	148,257	127,396
Service fees	10,327	7,602	6,623
	<u>269,659</u>	<u>155,859</u>	<u>134,019</u>

In 2021 and 2020, no customer accounted for more than 10% of revenues.

In 2019, one customer accounted for 11% of the Company's revenues.

B. Selling, general and administrative expenses

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Selling (*)	33,614	22,969	19,294
General and administrative	9,359	8,063	7,187
	<u>42,973</u>	<u>31,032</u>	<u>26,481</u>
(*) Including shipping and handling costs	<u>1,867</u>	<u>2,356</u>	<u>1,063</u>

C. Financial income, net

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Interest income	1,408	1,281	1,412
Other, net (*)	(378)	(506)	(611)
	<u>1,030</u>	<u>775</u>	<u>801</u>

(*) Other, net includes foreign currency income (expense) resulting from transactions not denominated in U.S. Dollars amounting to \$58, \$(351), and \$(352) in 2021, 2020 and 2019, respectively.

Note 18 - Income Taxes

A. Tax under various laws

The Company and its subsidiaries are assessed for income tax purposes on a separate basis. Each of the subsidiaries is subject to the tax rules prevailing in the country of incorporation.

B. Details regarding the tax environment of the Israeli companies

(1) Corporate tax rate

The tax rates relevant to the Company in Israel for the years 2019-2021 is 23%.

Current taxes for the reported periods are calculated according to the enacted tax rates presented above, subject to the reduced tax rate under the Law for the Encouragement of Capital Investment discussed below.

(2) Benefits under the Law for the Encouragement of Capital Investments (hereinafter - "the Encouragement Law")

(a) Amendment to the Law for the Encouragement of Capital Investments – 1959

On December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, preferred enterprise in development area A will be subject to tax rate of 7.5%.

In 2019 the Company filed a notice to the Israeli Tax Authorities regarding the implementation of the preferred enterprise its preferred income, beginning 2019 (instead of Beneficiary). As the Company is located in Development Area A, the applied corporate tax rate is 7.5%.

(b) In November 2021, an amendment to the Law of Encouragement of Capital Investment was enacted (the "2021 Amendment"). According to the 2021 Amendment, any future dividend distributed by an entity with tax exempt retained earnings will be deemed to be distributed proportionately from such tax exempt retained earnings. As part of the 2021 Amendment, the Israeli Tax Authorities enacted a temporary rule which reduces the tax rate applicable to the distribution of such tax exempt retained earnings.

During the fourth quarter of 2021, the Company entered into a tax assessment with the Israeli Tax Authorities for the years 2017-2020.

During the tax assessment, the Company reevaluated certain tax positions, due to the 2021 Amendment and the interactions with the tax authorities. As of December 31, 2021, the Company measured the possible negotiation settlement outcomes regarding its tax positions and concluded that it is more-likely-than-not that it will incur tax expenses. The Company recognized a provision for these tax expenses at the expected rate which corresponds with the reduced tax rate of the temporary rule mentioned above.

The Company's Statement of Income for the year ended December 31, 2021 included income tax on earnings of previous years of \$5,315. The settlement of the tax assessment finalized in February 2022 will allow the Company to distribute dividends from these earnings in the future with no additional corporate tax liability.

C. Details regarding the tax environment of the Non-Israeli companies

Non-Israeli subsidiaries are taxed according to the tax laws in their countries of residence under local tax laws and regulations.

D. Composition of income from continuing operations before income taxes and income tax expense

	Year Ended December 31,		
	2021	2020	2019
U.S. Dollars (in thousands)			
Income from continuing operations before income taxes:			
Israel	67,643	20,430	20,783
Non-Israeli	4,285	2,969	1,990
	<u>71,928</u>	<u>23,399</u>	<u>22,773</u>
Income tax expense from continuing operations:			
Current:			
Israel	(*) 9,930	-	-
Non-Israeli	1,603	670	424
	<u>11,533</u>	<u>670</u>	<u>424</u>
Deferred benefit:			
Israel	714	943	1,351
Non-Israeli	(596)	8	175
	<u>118</u>	<u>951</u>	<u>1,526</u>
	<u>11,651</u>	<u>1,621</u>	<u>1,950</u>

(*) see Note 18B(b)

E. Reconciliation of income tax expense at the statutory rate to actual income tax expense

The following is a reconciliation of the theoretical income tax expense, assuming all income is taxed at the statutory tax rate applicable to Israeli companies, and the actual income tax expense:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Income from continuing operations before income taxes	<u>71,928</u>	<u>23,399</u>	<u>22,773</u>
Statutory tax rate	<u>23%</u>	<u>23%</u>	<u>23%</u>
Theoretical income tax expense	16,543	5,382	5,238
Increase (decrease) in income tax expense resulting from:			
Income tax on earning of previous years- see Note 18B(b)	5,306	-	-
Non-deductible expenses (*)	285	239	337
Differences between Israeli shekel and dollar-adjusted financial statements, net (**)	-	(739)	(479)
Tax rate differential	(10,715)	(3,251)	(3,340)
Other	<u>232</u>	<u>(10)</u>	<u>194</u>
Actual income tax expense (benefit)	<u>11,651</u>	<u>1,621</u>	<u>1,950</u>

(*) Including non-deductible share-based compensation.

(**) The Company has elected, as from the 2021 tax year, to measure its results for tax purposes on the basis of the changes in the exchange rate of the Dollar. The Company must continue to be taxed on this basis for at least three years.

F. Deferred tax assets and liabilities

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Deferred tax assets:		
Allowance for doubtful accounts	1	3
Deferred revenue	838	340
Accrued expenses	535	469
Net operating loss and tax credit carryforwards	211	644
Lease liability	278	170
Other temporary differences	<u>217</u>	<u>344</u>
Deferred tax asset	<u>2,080</u>	<u>1,970</u>

Deferred tax liabilities:		
Property, plant and equipment	(700)	(618)
Right of use assets	(278)	(170)
Undistributed earnings	(875)	(700)
Total deferred tax liabilities	<u>(1,853)</u>	<u>(1,488)</u>
Net deferred tax assets	<u>227</u>	<u>482</u>

Deferred tax assets are recognized for the anticipated tax benefits associated with operating loss carryforwards, tax credit carryforwards and deductible temporary differences. If it is more likely than not that some or all of the deferred tax assets will not be realized, the deferred tax credits are reduced by a valuation allowance.

In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

At December 31, 2021 and 2020 the Company had no valuation allowance.

As of December 31, 2021, a foreign subsidiary has net operating loss carryforwards aggregating approximately \$620. Included within the deferred tax expenses for the year ended December 31, 2021 is a benefit of \$211 for the recognition of a deferred tax asset for operating loss carryforwards.

G. Accounting for uncertainty in income taxes

For the years ended December 31, 2021, 2020 and 2019, the Company did not have any significant unrecognized tax benefits. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

The Company accounts for interest and penalties related to an underpayment of income taxes as a component of income tax expense. For the years ended December 31, 2021, 2020 and 2019, no interest and penalties related to income taxes have been accrued.

H. Tax assessments

The Company in Israel files its income tax returns in Israel while its principle foreign subsidiaries file their income tax returns in Belgium, Germany, Hong Kong, and United States of America. The Israeli tax return of Camtek is open to examination by the Israeli Tax Authorities for the tax year 2021, while the tax returns of its principal foreign subsidiaries remain subject to examination for the tax years beginning 1999 in Belgium, 2017 in Germany, 2014 in Hong Kong and 2017 in the United States of America. See also Note 20.

**Balances and Transactions
with Related Parties**

**12 Months Ended
Dec. 31, 2021**

Related Party Transactions
[Abstract]

Balances and Transactions
with Related Parties

Note 19 - Balances and Transactions with Related Parties

A. Balances with related parties:

	December 31, 2021	December 31, 2020
	U.S. Dollars (in thousands)	
Due from related parties	15	3

B. Transactions with related parties:

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Purchases from related parties	-	-	-
Reimbursement of expenses	-	-	100
Interest income (expense) from Priortech	-	-	-

Unpaid balances between the Company and Priortech or its other subsidiaries in Israel bear interest of 5.5%.

Registration Rights Agreement with Priortech

On March 1, 2004, the Company entered into a registration rights agreement providing for the Company to register with the SEC certain of its ordinary shares held by Priortech. This registration rights agreement may be used in connection with future offerings of ordinary shares, and includes, among others, the following terms: (a) Priortech is entitled to make up to three demands that the Company registers its ordinary shares held by Priortech, subject to delay due to market conditions; (b) Priortech will be entitled to participate and sell the Company's ordinary shares in any future registration statements initiated by the Company, subject to delay due to market conditions; (c) the Company will indemnify Priortech in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions other than information provided by Priortech, and Priortech will indemnify the Company in connection with any liabilities incurred in connection with such registration statements due to any misstatements or omissions in written statements by Priortech made for the purpose of their inclusion in such registration statements; and (d) the Company will pay all expenses related to registrations which the Company has initiated, except for certain underwriting discounts or commissions or legal fees, and Priortech will pay all expenses related to a registration initiated at its demand in which the Company is not participating.

On December 30, 2004, the Registration Rights Agreement with Priortech was amended. The amendment concerns primarily the grant of unlimited shelf registration rights thereunder to Priortech with respect to its holdings in the Company, and the assignability of those shelf registration rights to its transferees.

On May 13, 2015, following the approval of the Company's Audit Committee and Board of Directors the Registration Rights Agreement with Priortech was renewed for an additional 5 year period effective as of December 31, 2014.

Following the Chroma transaction (See Note 1(D)), the Company entered into a Second Amended and Restated Registration Rights Agreement with Priortech and Chroma, according to which Chroma is entitled to the same rights Priortech has with respect to registration of the Company's shares.

Technological Cooperation Agreement with Chroma

In 2019, the Company entered into a Technological Cooperation Agreement with Chroma under which the Company granted Chroma a license for an application under Company's triangulation technology platform.

Employment Agreements with the Chief Executive Officer

Pursuant to the employment agreement with the Chief Executive Officer ("CEO"), the CEO dedicates 10% of his time in providing consulting and management services for Priortech through Amitec – Advanced Multilayer Interconnect Technologies Ltd. – a wholly owned subsidiary of Priortech ("Amitec"). The CEO receives from the Company 90% of a full-time salary and is compensated directly by Amitec for the remaining 10% of his time.

The CEO serves as the Chairman of Priortech.

Subsequent Events

**12 Months Ended
Dec. 31, 2021**

[Subsequent Events \[Abstract\]](#)

[Subsequent Events](#)

Note 20 – Subsequent Events

See Note 18B(b) regarding tax settlement.

Significant Accounting Policies (Policies)

12 Months Ended
Dec. 31, 2021

[Significant Accounting Policies \[Abstract\]](#)

[Basis of preparation of the financial statements](#)

A. Basis of preparation of the financial statements

The consolidated financial statements of Camtek and its subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in United States of America (“US GAAP”). All amounts in the notes to the financial statements are in thousands unless otherwise stated.

[Principles of consolidation](#)

B. Principles of consolidation

The accompanying consolidated financial statements include the accounts of Camtek and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

[Use of estimates](#)

C. Use of estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. As applicable to these financial statements, the most significant estimates and assumptions relate to revenue recognition, valuation of accounts receivable and inventories. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

Since January 2020, the Covid-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. At present, business activity is continuing at all of the Company’s locations, with new routines implemented as required by local Covid-19 regulations.

From the beginning of the outbreak, the Company has been carefully managing the risks and its global operations. The Israeli facility has been able to maintain its required production levels. Worldwide, the Company has benefitted from its strategy of having in place local professional teams in each of its territories that can independently install and support systems. As such, the Company has been able to deliver most of its orders on time and the impact of the Covid-19 pandemic on the its business activity has not been significant.

[Foreign currency transactions](#)

D. Foreign currency transactions

The functional currency of the Company and its subsidiaries is the U.S. Dollar. Revenue generated by the Company and its subsidiaries is primarily generated outside of Israel and a majority thereof is received in U.S. Dollars. A significant portion of materials and

components purchased and operating expenses incurred are either paid for in U.S. Dollars or in New Israeli Shekels (“NIS”).

Transactions not denominated in U.S. Dollars are recorded upon their initial recognition according to the exchange rate in effect on the date of the transaction. Exchange rate differences arising upon the settlement of monetary items or upon reporting the Company’s monetary items at exchange rates different from that by which they were initially recorded during the period, or reported in previous financial statements, are charged to financial income (expenses), net.

Cash and cash equivalents

E. Cash and cash equivalents

All highly liquid investments purchased with original maturities of three months or less are considered to be cash equivalents.

Short-term deposits

F. Short-term deposits

Short-term bank deposits are deposits with an original maturity of more than three months and less than a year from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their term deposits.

Trade accounts receivable and allowance for doubtful accounts

G. Trade accounts receivable and allowance for doubtful accounts

Accounts receivable are recorded at the outstanding recognized amount and do not bear interest. The allowance for doubtful accounts represents Management’s best estimate of the probable loss inherent in existing accounts receivable balances as a result of possible non-collection. In determining the appropriate allowance, Management bases its estimate on information available about specific debtors, including aging of the balance, assessment of the underlying security received, the history of write-offs, relationships with the customers and the overall creditworthiness of the customers.

Inventories

H. Inventories

Inventories consist of completed systems, partially completed systems and components and other raw materials, and are recorded at the lower of cost or net realizable value. Cost is determined by the moving – average cost method basis.

Inventory write-downs are recorded at the end of each fiscal period for damaged, obsolete, excess and slow-moving inventory. These write-downs, to the lower of cost or net realizable value, create a new cost basis that is not subsequently marked up based on changes in underlying facts and circumstances.

Management periodically evaluates its inventory composition, giving consideration to factors such as changing product demands due to uncertain industry related market conditions and technological changes, the probability and timing of anticipated usage and the physical condition of the items, and then estimates a charge (reducing the inventory) to be provided for slow moving, technological obsolete or damaged inventory. These estimates could vary significantly from actual use based upon future economic conditions, customer inventory levels or competitive factors that were not foreseen or did not exist when the inventory write-downs were established.

Spare parts included in inventory that are not expected to be converted or consumed within the next year are classified as non-current, based on Management's estimates taking into account market conditions.

[Property, plant and equipment](#)

I. Property, plant and equipment

These assets are stated at cost less accumulated depreciation, and are depreciated over their estimated useful lives on a straight-line basis.

Annual rates of depreciation are as follows:

Land	1%
Building	2%
Machinery and equipment	10% - 33%
Computer equipment and software	20% - 33%
Office furniture and equipment	6% - 20%
Automobiles	15%

Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful economic life of such improvements.

Certain of the Company's finished goods are systems used as demonstration systems, training systems, and for product development in the Company's laboratories ("internal use"). These systems are identical to the systems that Camtek sells in its ordinary course of business. In circumstances where the Company intends to utilize such systems for its internal use, the Company transfers them from inventory to fixed assets. The rationale for the transfer is that the Company does not have the intention to sell these systems in the ordinary course of business but rather expects to use them for its internal use over their expected useful lives. These systems are recorded as fixed assets at cost and depreciated over their useful lives.

[Intangible assets](#)

J. Intangible assets

Patent registration costs are recorded at cost and amortized on a straight-line basis, beginning with the first year of utilization, over its expected useful life of ten years.

[Impairment of long-lived assets](#)

K. Impairment of long-lived assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the long-lived asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized to the extent that the asset's carrying amount exceeds its fair value. In 2021 and 2020, no impairment was noted.

[Fair values of financial instruments](#)

L. Fair values of financial instruments

The carrying amounts of the Company's financial instruments, including cash and cash equivalents, short-term deposits, trade accounts receivable, trade accounts payable and amounts from related parties approximate fair value because of their short-term nature.

The fair values of long-term deposits are estimated based on quoted market prices for those or similar investments.

Revenue recognition

M. Revenue recognition

The Company's contracts with its customers include performance obligations to provide its products or to service the installed products. A product sale contract may include an extended warranty (that is, for longer than the twelve-month standard warranty) as well as installation, both of which are considered separate performance obligations.

The Company recognizes revenue from contracts for sales of products at the point of time when the Company transfers control of the product to the customer. Effective October 2020, the transfer in control event is generally determined upon shipping terms whereas previously it was generally upon installation at the customer's premises. This policy change was made following operational changes to pre-shipment calibration and testing processes which have enabled the simplification and streamlining of the installation at the customer site.

Revenues from the contract are recognized in an amount that reflects the consideration the Company expects to be entitled to receive once the control of the product had been transferred to the customer and signed documentation of the arrangement, such as a signed contract or purchase order, has been received. Payment terms with customers may vary, but are generally based on milestones within the delivery process such as shipping and installation. Payment terms do not include significant financing components.

The Company does not incur costs in obtaining a contract except for agents' commissions, which are incurred upon the recognition of revenues. Revenues are recognized over a period of less than a year and as such, there are no underlying sales commissions to be capitalized.

Service revenues consist mainly of contracts charged under time and material arrangements. Service revenues from maintenance contracts are recognized ratably over the contract period.

Contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged to customers.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations. These amounts are recorded as deferred revenue in the Consolidated Balance Sheets.

**Year Ended
December 31,**

	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Beginning of year	2,534	2,606
Deferral of revenue	6,245	1,864
Recognition of deferred revenue	<u>(1,912)</u>	<u>(1,936)</u>
Balance at end of year	<u>6,867</u>	<u>2,534</u>

[Warranty](#)

N. Warranty

The Company records a liability for standard product warranty obligations at the time of sale based upon historical warranty experience. The term of the warranty is generally twelve months.

[Income taxes](#)

O. Income taxes

The Company accounts for income taxes in accordance with the asset and liability method whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company includes the foreign currency transaction gains or losses that result from re-measuring deferred taxes in income tax expense. The Company reduces deferred tax assets with a valuation allowance to the amount that is more likely than not to be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition or measurement are reflected in the period in which the change occurs.

[Research and development](#)

P. Research and development

Research and development costs, which consists primarily of salaries, materials consumption and costs associated with subcontracting certain development efforts, are expensed as incurred.

[Earnings / loss per ordinary share](#)

Q. Earnings per ordinary share

Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.

The Company's convertible notes are included in the calculation of diluted Earnings Per Share ("EPS") if the assumed conversion into common shares is dilutive, using the "if-converted" method. This involves adding back the periodic non-cash interest expense net of tax associated with the Notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out

of the money) to the denominator for the purposes of calculating diluted EPS, unless the Notes are antidilutive (See also Note 2W).

[Share-based compensation](#)

R. Share-based compensation

The Company accounts for its employee share-based compensation as an expense in the financial statements. All awards are equity classified and therefore such cost is measured at the grant date fair value of the award. The Company estimates share option grant date fair value using the Black-Scholes-Merton option-pricing model. Forfeitures are recognized when they occur. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date (For details see Note 14B).

[Fair value measurements](#)

S. Fair value measurements

The Company implements the provisions of ASC Topic 820 "*Fair Value Measurements and Disclosures*" ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy provides the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which an asset or liability is classified is based on the lowest level input that is significant to the fair value measurement in its entirety.

[Contingent liabilities](#)

T. Contingent liabilities

A contingency (provision) is an existing condition or situation involving uncertainty as to the range of possible loss to the entity.

A provision for claims is recognized if it is probable (likely to occur) that a liability has been incurred and the amount can be estimated reasonably.

[Government-sponsored research and development](#)

U. Government-sponsored research and development

The Company records grants received from the Israel Innovation Authority (the "IIA", formerly known as the Office of the Chief Scientist of the Israeli Ministry of Industry and Trade) as a liability, if it is probable that the Company will have to repay the grants received. If it is not probable that the grants will be repaid, the Company records the

grants as a reduction to research and development expenses. Royalties paid to the IIA are recognized as a reduction of the above-mentioned liability.

Leases

V. Leases

On January 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). See also Note 11A.

Under *Topic 842*, the Company determines if an arrangement is a lease at inception. Rights of use (“**ROU**”) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be (2.43% in 2021). The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all of the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.

Operating lease ROU assets consist mainly of vehicles and real estate and are presented as property, plant and equipment on the consolidated balance sheet. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented within long-term liabilities on the consolidated balance sheet.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(J).

Convertible Notes

W. Convertible Notes

The Company accounts for its convertible notes in accordance with ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (Topic 470-20). The Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

The transaction costs are amortized on a straight-line basis along the lifetime of the Notes.

[Recent Accounting Pronouncements](#)

X. Recent Accounting Pronouncements

In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance became effective in the first quarter of 2021 on a prospective basis. The adoption of this guidance has not had a material impact on the Company's consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. ASU 2020-06 reduces the number of accounting models for convertible instruments and allows more contracts to qualify for equity classification. Adoption is either a modified retrospective method or a fully retrospective method of transition. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach.

**Significant Accounting
Policies (Tables)**

**12 Months Ended
Dec. 31, 2021**

[Significant Accounting Policies \[Abstract\]](#)

[Schedule of annual rates of depreciation](#)

Land	1%
Building	2%
Machinery and equipment	10% - 33%
Computer equipment and software	20% - 33%
Office furniture and equipment	6% - 20%
Automobiles	15%

[Schedule of Deferred Revenue in Consolidated Balance Sheets](#)

	Year Ended December 31,	
	<u>2021</u>	<u>2020</u>
	U.S. Dollars (in thousands)	
Beginning of year	2,534	2,606
Deferral of revenue	6,245	1,864
Recognition of deferred revenue	<u>(1,912)</u>	<u>(1,936)</u>
Balance at end of year	<u>6,867</u>	<u>2,534</u>

**Cash and Cash Equivalents
(Tables)**

**12 Months Ended
Dec. 31, 2021**

[Cash and Cash Equivalents \[Abstract\]](#)
[Schedule of cash and cash equivalents, currencies](#)

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
US Dollars	225,283	102,669
New Israeli Shekels	13,566	1,542
Other currencies	3,094	1,604
	<u>241,943</u>	<u>105,815</u>

Inventories (Tables)

12 Months Ended
Dec. 31, 2021

[Inventory Disclosure](#)

[\[Abstract\]](#)

[Schedule of Inventories](#)

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Components	33,212	19,630
Work in process	12,688	10,123
Finished products *	18,009	14,399
	<u>63,909</u>	<u>44,152</u>

* includes systems at customer locations not yet sold, as of December 31, 2021 and 2020, in the amount of \$4,259 and \$10,613 respectively.

[Schedule of Presentation of Inventories.](#)

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars (in thousands)</u>	
Current assets	58,759	39,736
Non-current assets (A)	5,150	4,416
	<u>63,909</u>	<u>44,152</u>

**Other Current Assets
(Tables)**

**12 Months Ended
Dec. 31, 2021**

Current assets

Schedule of other current assets

	December 31,	
	2021	2020
	U.S. Dollars (in thousands)	
Due from Government institutions and income tax receivables	2,623	2,269
Prepaid expenses	2,025	455
Interest receivable	463	207
Other	542	435
	<u>5,653</u>	<u>3,366</u>

**Property, Plant and
Equipment, Net (Tables)**

**12 Months Ended
Dec. 31, 2021**

**[Property, Plant and Equipment \[Abstract\]](#)
Schedule of Property, Plant and Equipment, Net**

	December 31,	
	2021	2020
	U.S. Dollars	
	(in thousands)	
Cost:		
Land	863	863
Building	15,208	14,438
Machinery and equipment	13,911	11,260
Office furniture and equipment	881	785
Computer equipment and software	5,383	4,760
Automobiles	479	263
Leasehold improvements	1,642	630
Right of use assets	4,969	3,014
	43,336	36,013
Less accumulated depreciation	17,936	15,615
	25,400	20,398

**Intangible Assets, Net
(Tables)**

**12 Months Ended
Dec. 31, 2021**

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)

[Schedule of intangible assets](#)

**December
31,
2021 2020
U.S. Dollars
(in
thousands)**

Patent registration costs	<u>2,038</u>	<u>1,927</u>
Accumulated amortization	<u>1,428</u>	<u>1,318</u>
Total intangible assets, net	<u><u>610</u></u>	<u><u>609</u></u>

[Schedule of estimated amortization expense](#)

Year ended	U.S. December Dollars (in thousands)
2022	99
2023	97
2024	89
2025	82
2026	68

**Other Current Liabilities
(Tables)**

**12 Months Ended
Dec. 31, 2021**

[Other Current Liabilities \[Abstract\]](#)
[Schedule of other current liabilities](#)

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars</u>	
	<u>(in thousands)</u>	
Commissions	15,967	7,965
Government institutions and income tax payable	11,566	752
Accrued employee compensation and other related benefits	10,923	9,698
Advances from customers and deferred revenues	10,837	6,155
Accrued warranty costs (1)	3,265	2,328
Accrued expenses	2,561	2,570
Operating lease obligations (See Note 2(U))	1,018	736
	<u>56,137</u>	<u>30,204</u>

[Schedule of changes in product warranty obligation](#)

(1) Changes in the accrued warranty costs are as follows:

	<u>Year Ended December</u>		
	<u>31,</u>		
	<u>2021</u>	<u>2020</u>	<u>2019</u>
	<u>U.S. Dollars (in</u>		
	<u>thousands)</u>		
Beginning of year	2,328	1,723	1,714
Accruals	6,333	3,667	3,170
Usage	(5,396)	(3,062)	(3,161)
Balance at end of year	<u>3,265</u>	<u>2,328</u>	<u>1,723</u>

Other Long Term Liabilities
(Tables)

12 Months Ended
Dec. 31, 2021

[Other Liabilities, Noncurrent](#)

[\[Abstract\]](#)

[Schedule of other long term liabilities](#)

	December 31,	
	2021	2020
	U.S. Dollars	
	(in thousands)	
Liability for severance pay (A)	1,266	1,239
Deferred revenues related to non-standard warranty (B)	2,620	1,342
Lease liabilities in respect of ROU assets	1,914	679
	<u>5,800</u>	<u>3,260</u>

Convertible Notes (Tables)

**12 Months Ended
Dec. 31, 2021**

[Debt Disclosure \[Abstract\]](#)

[Scheduled of convertible senior notes](#)

	December 31, 2021
	U.S. Dollars (in thousands)
Liability:	
Principle:	200,000
Unamortized issuance costs	5,357
Net carrying amount	194,643

**Commitments and
Contingencies (Tables)**

**12 Months Ended
Dec. 31, 2021**

[Commitments and Contingencies \[Abstract\]](#)

Schedule of balance sheet information related to leases

	December 31,	
	<u>2021</u>	<u>2020</u>
	U.S. Dollars (in thousands)	
Cost:		
ROU assets – opening balance	3,014	2,471
ROU assets – additions	2,546	831
ROU assets – disposals	(591)	(288)
	<u>4,969</u>	<u>3,014</u>
Less accumulated depreciation	<u>2,037</u>	<u>1,599</u>
	<u>2,932</u>	<u>1,415</u>
	December 31,	
	<u>2021</u>	<u>2020</u>
	U.S. Dollars (in thousands)	
Other current liabilities	1,018	736
Other long-term liabilities	1,914	679
Total lease liabilities	<u>2,932</u>	<u>1,415</u>

Schedule of minimum future rental payments

	U.S. Dollars (in thousands)
<u>Year ended December 31,</u>	
2022	1,091
2023	802
2024	557
2025	429
2026	165
	<u>3,044</u>
Less imputed interest	<u>112</u>
Total lease liabilities	<u>2,932</u>

**Concentration of Risk and
Financial Instruments
(Tables)**

**12 Months Ended
Dec. 31, 2021**

[Risks and Uncertainties \[Abstract\]](#)

[Schedule of allowance for doubtful accounts](#)

	Balance at		Reversal of	Write-off of	Balance at
	beginning	Provision	provision	provision	end of
	of year	of year	of year	of year	of year
	U.S. Dollars (in thousands)				
2019	410	87	(116)	(252)	129
2020	129	-	(87)	(3)	39
2021	39	-	-	(32)	7

Shareholders' Equity
(Tables)

12 Months Ended
Dec. 31, 2021

[Shareholders' Equity \[Abstract\]](#)
[Schedule of fair value assumptions](#)

	2021 Grant
Valuation assumptions:	
Dividend yield	0
Expected volatility	48%
Risk-free interest rate	1.19%
Expected life (years)	4.0
Vesting period (years)	1.0

[Schedule of stock option activity](#)

	Year Ended December 31,					
	2021		2020		2019	
	Number of options	Weighted average exercise price US\$	Number of options	Weighted average exercise price US\$	Number of options	Weighted average exercise price US\$
Outstanding at January 1	89,925	3.80	309,792	3.29	519,785	3.16
Granted	5,704	36.45	-	-	-	-
Forfeited and cancelled	(106)	4.38	(12,876)	3.74	(10,750)	2.41
Exercised	(73,421)	3.67	(206,991)	3.04	(199,243)	2.69
Outstanding at year end	<u>22,102</u>	<u>12.66</u>	<u>89,925</u>	<u>3.80</u>	<u>309,792</u>	<u>3.29</u>
Exercisable at year end	<u>16,398</u>	<u>4.38</u>	<u>63,253</u>	<u>3.55</u>	<u>225,110</u>	<u>3.08</u>

[Schedule of options outstanding](#)

	Number of options outstanding	Weighted average exercise price US\$	Weighted Average Remaining Contractual term (years)	Aggregate intrinsic Value (in US\$ thousands)
Outstanding as of December 31, 2021	<u>22,102</u>	<u>12.66</u>	<u>3.743</u>	<u>738</u>
Exercisable at December 31, 2021	<u>16,398</u>	<u>4.38</u>	<u>2.73</u>	<u>683</u>
Exercise price US\$	Number of outstanding options	Number exercisable	average remaining Contractual term (years) of outstanding options	

[Schedule of information about share options](#)

4.38	16,398	16,398	2.73
36.45	5,704	-	6.74
	<u>22,102</u>	<u>16,398</u>	

[Schedule of information about non-vested options](#)

	Options	Weighted average grant- date fair value
	<u>Options</u>	<u>value</u>
Balance at January 1, 2021	26,672	2.93
Granted	5,704	17.52
Vested	(26,672)	2.93
Forfeited	-	-
Balance at December 31, 2021	<u>5,704</u>	17.52

[Schedule of restricted share unit activity](#)

	RSUs	Weighted average grant date value
	<u>RSUs</u>	<u>value</u>
Balance at January 1, 2021	1,337,684	\$ 9.52
Granted	248,342	\$ 34.33
Vested	(500,244)	\$ 9.01
Forfeited	(26,601)	\$ 10.88
Balance at December 31, 2021	<u>1,059,181</u>	<u>\$ 15.55</u>

Earnings Per Share (Tables)

12 Months Ended
Dec. 31, 2021

Earning per share information:
Schedule of computation of basic and
diluted earnings per share

	Year Ended December		
	2021	2020	2019
<u>Basic EPS:</u>			
Net income attributable to Shares (US\$ in thousands)	<u>60,277</u>	<u>21,778</u>	<u>21,986</u>
Weighted average number of Shares outstanding used in basic earnings per Share calculation	<u>43,644</u>	<u>39,383</u>	<u>37,626</u>
<u>Diluted EPS:</u>			
Net income attributable to Shares (US\$ in thousands)	<u>60,277</u>	<u>21,778</u>	<u>21,986</u>
Add amortization of notes issuance costs	<u>105</u>	<u>-</u>	<u>-</u>
Net income used in diluted earnings per Share calculation	<u>60,382</u>	<u>21,778</u>	<u>21,986</u>
Weighted average number of Shares outstanding used in basic earnings per Share calculation	<u>43,644</u>	<u>39,383</u>	<u>37,626</u>
Add assumed exercise of outstanding dilutive			
Effect of stock-based awards	<u>988</u>	<u>989</u>	<u>806</u>
Effect of conversion of Notes	<u>403</u>	<u>-</u>	<u>-</u>
Weighted average number of Shares Outstanding used in diluted earnings per Share calculation	<u>45,035</u>	<u>40,372</u>	<u>38,432</u>
Basic income from continuing operations per Share (\$)	<u>1.38</u>	<u>0.55</u>	<u>0.55</u>
Basic income from discontinued operations per Share (\$)	<u>-</u>	<u>-</u>	<u>0.03</u>
Basic net income per Share (\$)	<u>1.38</u>	<u>0.55</u>	<u>0.58</u>
Diluted income from continuing operations per Share (\$)	<u>1.34</u>	<u>0.54</u>	<u>0.54</u>
Diluted income from discontinued operations per Share (\$)	<u>-</u>	<u>-</u>	<u>0.03</u>
Diluted net income per Share (\$)	<u>1.34</u>	<u>0.54</u>	<u>0.57</u>
Number of options excluded from the diluted earnings per share calculation due to their anti-dilutive effect	<u>-</u>	<u>-</u>	<u>-</u>

**Entity-Wide Information
(Tables)**

**12 Months Ended
Dec. 31, 2021**

[Entity Wide Information \[Abstract\]](#)
[Schedule of revenues by geographic area](#)

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Asia			
Pacific	224,931	137,555	115,925
United States	28,641	9,847	10,388
Europe	16,087	8,457	7,706
	<u>269,659</u>	<u>155,859</u>	<u>134,019</u>

**Selected Income Statement
Data (Tables)**

**12 Months Ended
Dec. 31, 2021**

[Selected Income Statement
Data \[Abstract\]](#)

[Schedule of selected revenues](#)

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Sales of products	259,332	148,257	127,396
Service fees	10,327	7,602	6,623
	269,659	155,859	134,019

[Schedule of selected selling,
general and administrative
expenses data](#)

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
Selling (*)	33,614	22,969	19,294
General and administrative	9,359	8,063	7,187
	42,973	31,032	26,481

[Schedule of selected financial
income \(expenses\) data](#)

	Year Ended December 31,		
	2021	2020	2019
	U.S. Dollars (in thousands)		
(*) Including shipping and handling costs	1,867	2,356	1,063
Interest income	1,408	1,281	1,412
Other, net (*)	(378)	(506)	(611)
	1,030	775	801

(*) Other, net includes foreign currency income (expense) resulting from transactions not denominated in U.S. Dollars amounting to \$58, \$(351), and \$(352) in 2021, 2020 and 2019, respectively.

Income Taxes (Tables)

12 Months Ended
Dec. 31, 2021

[Income Taxes \[Abstract\]](#)

[Schedule of composition of income \(loss\) from continuing operations before income taxes and income tax expense \(benefit\)](#)

	Year Ended December 31,		
	2021	2020	2019
U.S. Dollars (in thousands)			
Income from continuing operations before income taxes:			
Israel	67,643	20,430	20,783
Non-Israeli	4,285	2,969	1,990
	<u>71,928</u>	<u>23,399</u>	<u>22,773</u>
Income tax expense from continuing operations:			
Current:			
Israel	(*)	-	-
	9,930	-	-
Non-Israeli	1,603	670	424
	<u>11,533</u>	<u>670</u>	<u>424</u>
Deferred benefit:			
Israel	714	943	1,351
Non-Israeli	(596)	8	175
	<u>118</u>	<u>951</u>	<u>1,526</u>
	<u>11,651</u>	<u>1,621</u>	<u>1,950</u>

(*) see Note 18B(b)

[Schedule of reconciliation of the theoretical income tax expense](#)

	Year Ended December 31,		
	2021	2020	2019
U.S. Dollars (in thousands)			
Income from continuing operations before income taxes	<u>71,928</u>	<u>23,399</u>	<u>22,773</u>
Statutory tax rate	<u>23%</u>	<u>23%</u>	<u>23%</u>
Theoretical income tax expense	16,543	5,382	5,238
Increase (decrease) in income tax expense resulting from:			
Income tax on earning of previous years-see Note 18B(b)	5,306	-	-
Non-deductible expenses (*)	285	239	337
Differences between Israeli shekel and dollar-adjusted financial statements, net (**)	-	(739)	(479)

Tax rate differential	(10,715)	(3,251)	(3,340)
Other	232	(10)	194
Actual income tax expense (benefit)	<u>11,651</u>	<u>1,621</u>	<u>1,950</u>

(*) Including non-deductible share-based compensation.

(**) The Company has elected, as from the 2021 tax year, to measure its results for tax purposes on the basis of the changes in the exchange rate of the Dollar. The Company must continue to be taxed on this basis for at least three years.

[Schedule of deferred tax assets and liabilities](#)

	<u>December 31,</u>	
	<u>2021</u>	<u>2020</u>
	<u>U.S. Dollars</u>	
	<u>(in thousands)</u>	
<u>Deferred tax assets:</u>		
Allowance for doubtful accounts	1	3
Deferred revenue	838	340
Accrued expenses	535	469
Net operating loss and tax credit carryforwards	211	644
Lease liability	278	170
Other temporary differences	<u>217</u>	<u>344</u>
Deferred tax asset	<u>2,080</u>	<u>1,970</u>
<u>Deferred tax liabilities:</u>		
Property, plant and equipment	(700)	(618)
Right of use assets	(278)	(170)
Undistributed earnings	<u>(875)</u>	<u>(700)</u>
Total deferred tax liabilities	<u>(1,853)</u>	<u>(1,488)</u>
Net deferred tax assets	<u>227</u>	<u>482</u>

**Balances and Transactions
with Related Parties (Tables)**

**12 Months Ended
Dec. 31, 2021**

[Related Party Transactions \[Abstract\]](#)
[Schedule of related party balances and transactions](#)

December 31, 2021	December 31, 2020
<u>U.S. Dollars (in thousands)</u>	

Due from related parties	15	3
--------------------------	----	---

[Schedule of transactions with related parties](#)

Year Ended December 31,		
<u>2021</u>	<u>2020</u>	<u>2019</u>
<u>U.S. Dollars (in thousands)</u>		

Purchases from related parties	-	-	-
Reimbursement of expenses	-	-	100
Interest income (expense) from Priortech	-	-	-

Nature of Operations (Narrative) (Details) - USD (\$) \$ / shares in Units, \$ in Thousands	1 Months Ended			12 Months Ended			
	Nov. 30, 2021	Nov. 30, 2020	Feb. 28, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 08, 2019

Schedule of Equity Method Investments [Line Items]

<u>Aggregate principal amount</u>	\$						
	200,000						
<u>Percentage of convertible senior notes</u>	0.00%						
<u>Purchase of additional convertible note</u>	\$						
	25,000						
<u>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</u>				73,421	206,991	199,243	
<u>Issuance of shares</u>		4,025,000					
<u>Amount of shares</u>	\$	\$ 64,320		\$	\$		
	194,530			64,320	16,026		
<u>Percentage of premium</u>							29.00%
<u>Underwriter [Member]</u>							

Schedule of Equity Method Investments [Line Items]

<u>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</u>	525,000						
<u>Per share price</u>	\$ 17.00						
<u>Chroma Ate Inc [Member]</u>							

Schedule of Equity Method Investments [Line Items]

<u>Percentage of Camtek shares acquired</u>	20.50%	17.83%					
<u>Number of Shares issued</u>	6,117,440						
<u>Cash transaction</u>	\$ 58,100						
<u>Issuance of shares</u>	1,700,000						
<u>Amount of shares</u>	\$ 16,200						
<u>Per share price</u>	\$ 9.50						
<u>Prioritech Ltd [Member]</u>							

Schedule of Equity Method Investments [Line Items]

<u>Ownership percentage</u>				20.93%			
-----------------------------	--	--	--	--------	--	--	--

Significant Accounting Policies (Narrative) (Details) 12 Months Ended Dec. 31, 2021

Lease borrowing rate	2.43%
Patents, useful life	10 years

**Significant Accounting
Policies (Schedule of annual
rates of depreciation)
(Details)**

12 Months Ended

Dec. 31, 2021

[Land \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

1.00%

[Building \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

2.00%

[Machinery and Equipment \[Member\] | Minimum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

10.00%

[Machinery and Equipment \[Member\] | Maximum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

33.00%

[Computer equipment and software \[Member\] | Minimum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

20.00%

[Computer equipment and software \[Member\] | Maximum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

33.00%

[Office Furniture and Equipment \[Member\] | Minimum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

6.00%

[Office Furniture and Equipment \[Member\] | Maximum \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

20.00%

[Automobiles \[Member\]](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Annual rate of depreciation](#)

15.00%

**Significant Accounting
Policies (Schedule of
Deferred Revenue in
Consolidated Balance
Sheets) (Details) - USD (\$)
\$ in Thousands**

12 Months Ended
Dec. 31, 2021 Dec. 31, 2020

Significant Accounting Policies [Abstract]

<u>Beginning of year</u>	\$ 2,534	\$ 2,606
<u>Deferral of revenue</u>	6,245	1,864
<u>Recognition of deferred revenue</u>	(1,912)	(1,936)
<u>Balance at end of year</u>	\$ 6,867	\$ 2,534

**Cash and Cash Equivalents
(Narrative) (Details)**

Dec. 31, 2021 Dec. 31, 2020

Cash and Cash Equivalents [Abstract]

Average annual interest rates 0.81% 0.88%

Cash and Cash Equivalents
(Schedule of Currencies)
(Details) - USD (\$)
\$ in Thousands

Dec. 31, 2021 **Dec. 31, 2020** **Dec. 31, 2019** **Dec. 31, 2018**

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents \$ 241,943 \$ 105,815 \$ 38,047 \$ 54,935

U.S. Dollars [Member]

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents 225,283 102,669

New Israeli Shekels [Member]

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents 13,566 1,542

Other Currencies [Member]

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents \$ 3,094 \$ 1,604

Inventories (Narrative)
(Details) - USD (\$)
\$ in Thousands

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020

Long Term Inventory [Line Items]

<u>Finished products, Systems at customer locations</u>	\$ 4,259	\$ 10,613
<u>Long-term inventory</u>	\$ 5,150	4,416
<u>Customer support, term</u>	seven to ten years	
<u>Provision for damages, obsolete, excess and slow-moving inventory</u>	\$ 424	\$ 142

**Inventories (Schedule of
Inventories) (Details) - USD
(\$)
\$ in Thousands**

	Dec. 31, 2021	Dec. 31, 2020
<u>Inventory Disclosure [Abstract]</u>		
<u>Components</u>	\$ 33,212	\$ 19,630
<u>Work in process</u>	12,688	10,123
<u>Finished products</u>	[1] 18,009	14,399
<u>Total inventories</u>	\$ 63,909	\$ 44,152

[1] includes systems at customer locations not yet sold, as of December 31, 2021 and 2020, in the amount of \$4,259 and \$10,613 respectively.

**Inventories (Schedule of
Presentation of Inventories)
(Details) - USD (\$)
\$ in Thousands**

Dec. 31, 2021 Dec. 31, 2020

[Inventory Disclosure \[Abstract\]](#)

<u>Current assets</u>	\$ 58,759	\$ 39,736
<u>Long-term assets (A)</u>	5,150	4,416
<u>Total inventories</u>	\$ 63,909	\$ 44,152

Other Current Assets
(Schedule of other current
assets) (Details) - USD (\$) **Dec. 31, 2021 Dec. 31, 2020**
\$ in Thousands

Current assets

<u>Due from Government institutions</u>	\$ 2,623	\$ 2,269
<u>Prepaid expenses</u>	2,025	455
<u>Interest receivable</u>	463	207
<u>Other</u>	542	435
<u>Other current assets</u>	\$ 5,653	\$ 3,366

**Long-term Deposits
(Narrative) (Details)**

**12 Months Ended
Dec. 31, 2021**

[Long-term Investments \[Abstract\]](#)

[Percentage of average annual interest rates](#) 1.14%

**Property, Plant and
Equipment, Net (Narrative)**
(Details) - USD (\$)
\$ in Thousands

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

[Property, Plant and Equipment \[Abstract\]](#)

[Depreciation expenses](#)

\$ 3,682

\$ 3,117

\$ 3,101

**Property, Plant and
Equipment, Net (Schedule of
property, plant and
equipment, net) (Details) -**

Dec. 31, 2021 Dec. 31, 2020

USD (\$)

\$ in Thousands

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross \$ 43,336 \$ 36,013

Less accumulated depreciation 17,936 15,615

Fixed assets, net 25,400 20,398

Land [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 863 863

Building [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 15,208 14,438

Machinery and Equipment [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 13,911 11,260

Office Furniture and Equipment [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 881 785

Computer equipment and software [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 5,383 4,760

Automobiles [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 479 263

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 1,642 630

Right Use Assets [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross \$ 4,969 \$ 3,014

**Intangible Assets, Net
(Schedule of intangible
assets, net) (Details) - USD
(\$)**

Dec. 31, 2021 Dec. 31, 2020

\$ in Thousands

Goodwill and Intangible Assets Disclosure [Abstract]

<u>Patent registration costs</u>	\$ 2,038	\$ 1,927
<u>Accumulated amortization</u>	1,428	1,318
<u>Total intangible assets, net</u>	\$ 610	\$ 609

**Intangible Assets, Net
(Schedule of estimated
amortization expense)
(Details)**

**Dec. 31, 2021
USD (\$)**

\$ in Thousands

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)

<u>2022</u>	\$ 99
<u>2023</u>	97
<u>2024</u>	89
<u>2025</u>	82
<u>2026</u>	\$ 68

Intangible Assets, Net
(Narrative) (Details) - USD
(\$)
\$ in Thousands

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)

[Patents, useful life](#)

10 years

[Amortization expense related to intangible assets](#)

\$ 110

\$ 98

\$ 91

Other Current Liabilities
(Schedule of other current
liabilities) (Details) - USD (\$)
\$ in Thousands

Dec. 31, 2021 Dec. 31, 2020

Lessee, Lease, Description [Line Items]

Total other current liabilities \$ 56,137 \$ 30,204

Accrued Expenses And Other Current Liabilities [Member]

Lessee, Lease, Description [Line Items]

Commissions 15,967 7,965

Government institutions and income tax payable 11,566 752

Accrued employee compensation and other related benefits 10,923 9,698

Advances from customers and deferred revenues 10,837 6,155

Accrued warranty costs [1] 3,265 2,328

Accrued expenses 2,561 2,570

Operating Lease, Liability, Current 1,018 736

Total other current liabilities \$ 56,137 \$ 30,204

[1] Changes in the accrued warranty costs are as follows:

Other Current Liabilities
(Schedule of changes in
product warranty obligation)
(Details) - USD (\$)
\$ in Thousands

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Other Current Liabilities [Abstract]

<u>Beginning of year</u>	\$ 2,328	\$ 1,723	\$ 1,714
<u>Accruals</u>	6,333	3,667	3,170
<u>Usage</u>	(5,396)	(3,062)	(3,161)
<u>Balance at end of year</u>	\$ 3,265	\$ 2,328	\$ 1,723

Other Long Term Liabilities
(Narrative) (Details) - USD
(\$)
\$ in Thousands

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Other Liabilities, Noncurrent [Abstract]

<u>Severance liability</u>	\$ 1,266	\$ 1,239	
<u>Severance expenses</u>	1,636	\$ 1,362	\$ 1,167
<u>Deferred revenue expected to be recognized in 2023</u>	\$ 2,620		

Other Long Term Liabilities
(Schedule of other long term
liabilities) (Details) - USD (\$)
\$ in Thousands

Dec. 31, 2021 Dec. 31, 2020

Liability for severance pay	\$ 1,266	\$ 1,239
Deferred revenues related to non-standard warranty	2,620	1,342
Operating Lease, Liability, Noncurrent	1,914	679
Total Other long term liabilities	5,800	3,260
Other Non-current Liabilities [Member]		
Operating Lease, Liability, Noncurrent	\$ 1,914	\$ 679

Convertible Notes (Narrative) (Details) - USD (\$) \$ in Thousands	1 Months Ended Nov. 17, 2021	12 Months Ended		
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Debt Instrument [Line Items]</u>				
<u>Term of debt issuance costs amortization</u>			5 years	
<u>Debt interest rate</u>			0.56%	
<u>Amortization of debt issuance costs</u>		\$ 113	\$ 0	\$ 0
<u>Estimated fair value of the notes classified as Level 2 financial instruments</u>			211,875	
<u>Exceeded principal amount Convertible Notes</u>			11,875	
<u>Debt Instrument [Line Items]</u>				
<u>Principal amount</u>	\$ 200,000		\$ 200,000	
<u>Percentage of convertible senior note</u>	0.00%			
<u>Due date</u>	2026-12-01			
<u>Conversion rate description</u>	The Notes will be convertible based on an initial conversion rate of 17.1092 ordinary shares per \$1,000 principal amount of notes, equivalent to an initial conversion price of approximately \$58.45 per ordinary share, which represents a conversion premium of approximately 30% to the last reported sale price of the Company's ordinary shares on The Nasdaq Global Market on November 18, 2021. The closing price of the Company's shares on December 31, 2021 was \$46.04.			
<u>Conversion rate percentage</u>	130.00%			
<u>Percentage of repurchase price equal to principal amount of convertible notes</u>	100.00%			

**Convertible Notes (Details) -
Convertible Senior Notes -
USD (\$)
\$ in Thousands**

**Dec. 31,
2021** **Nov. 17,
2021**

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

[Abstract]

Principle

\$ 200,000 \$ 200,000

Unamortized issuance costs

5,357

Net carrying amount

\$ 194,643

Commitments and Contingencies (Narrative) (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies [Line Items]			
Operating Lease, Weighted Average Remaining Lease Term	41 months		
Deposits Assets, Noncurrent	\$ 32,000	\$ 0	
Outstanding purchase commitments for inventory components	56,375	39,433	
Right-of-Use Asset	\$ 1,060	1,025	\$ 1,077
IIA [Member]			
Commitments And Contingencies [Line Items]			
Percent of sales derived from research and development, committed amount payable	3.50%		
IIA [Member] Printar [Member]			
Commitments And Contingencies [Line Items]			
Grants received including interest accrued	\$ 7,913	\$ 7,597	

**Commitments and
Contingencies (Schedule of
Supplemental Balance Sheet
Information Related to
Leases) (Details) - USD (\$)
\$ in Thousands**

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Operating leases

<u>ROU assets - opening balance</u>	\$ 4,969	\$ 3,014	\$ 2,471
<u>ROU assets - additions</u>	2,546	831	
<u>ROU assets - disposals</u>	(591)	(288)	
<u>ROU assets - accumulated depreciation</u>	2,037	1,599	
<u>ROU assets, net</u>	2,932	1,415	
<u>Other long term liabilities</u>	(1,914)	(679)	
<u>Other Current Liabilities [Member]</u>			

Operating leases

<u>Other current liabilities</u>	1,018	736	
<u>Other Noncurrent Liabilities [Member]</u>			

Operating leases

<u>Other long term liabilities</u>	(1,914)	(679)	
<u>Other Liabilities [Member]</u>			

Operating leases

<u>Total lease liabilities</u>	\$ (2,932)	\$ (1,415)	
--------------------------------	------------	------------	--

**Commitments and
Contingencies (Schedule of
minimum future rental
payments) (Details) - USD**

Dec. 31, 2021 Dec. 31, 2020

(\$)

\$ in Thousands

2022	\$ 1,091	
2023	802	
2024	557	
2025	429	
2026	165	
Lessee, Operating Lease, Liability, to be Paid, Total	3,044	
Less imputed interest	112	
Other Liabilities [Member]		
Total lease liabilities	\$ 2,932	\$ 1,415

**Concentration of Risk and
Financial Instruments**

12 Months Ended

(Details) - USD (\$)

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

\$ in Thousands

Risks and Uncertainties [Abstract]

<u>Balance at beginning of period</u>	\$ 39	\$ 129	\$ 410
<u>Provision</u>	0	0	87
<u>Reversal of provision</u>	0	(87)	(116)
<u>Write-off of provision</u>	(32)	(3)	(252)
<u>Balance at end of period</u>	\$ 7	\$ 39	\$ 129

Shareholders' Equity (Narrative) (Details) - USD (\$)	1 Months Ended			12 Months Ended		
	Sep. 04, 2019	Nov. 30, 2021	Nov. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation						
Arrangement by Share-based Payment						
Award [Line Items]						
Issuance of shares		4,025,000				
Amount of shares	\$	\$		\$	\$	
	194,530,000	64,320,000		64,320,000	16,026,000	
Unrecognized share-based compensation expense				\$ 63,000		
Share based compensation expense				5,815,000	4,235,000	2,892,000
Aggregate intrinsic Value, Outstanding				738,000	1,628,000	2,343,000
Aggregate intrinsic Value, Outstanding, Vested and expected to vest				\$ 683,000	\$ 1,161,000	1,746,000
Dividend	\$					\$
	6,551,000					6,551,000
Dividend paid per share	\$ 0.17					
Percentage of outstanding shares grant				3.50%		
Number of ordinary shares issued upon exercise of option				73,421	206,991	199,243
Underwriter [Member]						
Share-based Compensation						
Arrangement by Share-based Payment						
Award [Line Items]						
Per share price		\$ 17.00				
Number of ordinary shares issued upon exercise of option		525,000				
Restricted Stock Units (RSUs) [Member]						
Share-based Compensation						
Arrangement by Share-based Payment						
Award [Line Items]						
Number of shares authorized for grant				1,534,632		
Unrecognized share-based compensation expense				\$		
				12,777,000		
Share based compensation expense				5,705,000		
Aggregate intrinsic Value, Outstanding				\$	\$ 21,910	\$ 10,830
				46,040.00		
Weighted average grant- date fair value, Vested				\$ 34.33	\$ 11.83	\$ 8.61
Weighted average exercise price				\$ 0.00		
Percentage of outstanding shares grant				3.50%		
Stock Compensation Plan [Member]						

Share-based Compensation
Arrangement by Share-based Payment
Award [Line Items]

Share based compensation expense

\$ 110,000 \$ 120,000 \$ 269,000

**Shareholders' Equity
(Schedule of fair value
assumptions) (Details)**

**12 Months Ended
Dec. 31, 2018**

[Shareholders' Equity \[Abstract\]](#)

<u>Dividend yield</u>	0.00%
<u>Expected volatility</u>	48.00%
<u>Risk-free interest rate</u>	1.19%
<u>Expected life (years)</u>	4 years
<u>Vesting period (years)</u>	1 year

Shareholders' Equity
(Schedule of stock option
activity) (Details) - USD (\$)
\$ / shares in Units, \$ in
Thousands

12 Months Ended

	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Shareholders' Equity [Abstract]</u>			
<u>Outstanding, beginning balance</u>	89,925	309,792	519,785
<u>Granted</u>	5,704	0	0
<u>Forfeited and cancelled</u>	(106)	(12,876)	(10,750)
<u>Exercised</u>	(73,421)	(206,991)	(199,243)
<u>Outstanding, ending balance</u>	22,102	89,925	309,792
<u>Exercisable at year end</u>	16,398	63,253	225,110
<u>Exercisable at December 31, 2021</u>	16,398		
<u>Weighted average exercise price, Outstanding, beginning balance</u>	\$ 3.80	\$ 3.29	\$ 3.16
<u>Weighted average exercise price, Granted</u>	36.45	0	0
<u>Weighted average exercise price, Forfeited and cancelled</u>	4.38	3.74	2.41
<u>Weighted average exercise price, Exercised</u>	3.67	3.04	2.69
<u>Weighted average exercise price, Outstanding, ending balance</u>	12.66	3.80	3.29
<u>Weighted average exercise price, Exercisable, ending balance</u>	4.38	\$ 3.55	\$ 3.08
<u>Weighted average exercise price, Exercisable at December 31, 2021</u>	\$ 4.38		
<u>Weighted average Remaining Contractual term (years), Outstanding</u>	3 years 8 months 27 days		
<u>Weighted average Remaining Contractual term (years), Exercisable</u>	2 years 8 months 23 days		
<u>Aggregate intrinsic Value, Outstanding</u>	\$ 738	\$ 1,628	\$ 2,343
<u>Aggregate intrinsic Value, Exercisable</u>	\$ 683	\$ 1,161	\$ 1,746

Shareholders' Equity
(Schedule of information
about share options)
(Details)

12 Months Ended
Dec. 31, 2021
\$ / shares
shares

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Number of outstanding options 22,102

Number exercisable 16,398

Exercise price 4.38 [Member]

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price, minimum | \$ / shares \$ 4.38

Number of outstanding options 16,398

Number exercisable 16,398

Weighted average remaining Contractual of outstanding options 2 years 8 months 23 days

Exercise price 36.45 [Member]

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price, minimum | \$ / shares \$ 36.45

Number of outstanding options 5,704

Number exercisable 0

Weighted average remaining Contractual of outstanding options 6 years 8 months 26 days

Shareholders' Equity
(Schedule of information
about non vested options)
(Details) - \$ / shares

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Options

<u>Beginning balance</u>	26,672		
<u>Granted</u>	5,704	0	0
<u>Vested</u>	(26,672)		
<u>Forfeited</u>	0		
<u>Ending balance</u>	5,704	26,672	

Weighted average grant- date fair value

<u>Beginning balance</u>	\$ 2.93		
<u>Granted</u>	17.52		
<u>Vested</u>	2.93		
<u>Forfeited</u>	0		
<u>Ending balance</u>	\$ 17.52	\$ 2.93	

Shareholders' Equity
(Schedule of restricted share
unit activity) (Details) - \$ /
shares

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Options

<u>Outstanding, beginning balance</u>	89,925	309,792	519,785
<u>Granted</u>	5,704	0	0
<u>Vested</u>	(26,672)		
<u>Forfeited</u>	(106)	(12,876)	(10,750)
<u>Outstanding, ending balance</u>	22,102	89,925	309,792

Weighted average grant- date fair value

<u>Weighted average exercise price, Outstanding, beginning balance</u>	\$ 3.80	\$ 3.29	\$ 3.16
<u>Granted</u>	17.52		
<u>Vested</u>	2.93		
<u>Forfeited</u>	0		
<u>Weighted average exercise price, Outstanding, ending balance</u>	\$ 12.66	\$ 3.80	\$ 3.29

Restricted Stock Units (RSUs) [Member]

Options

<u>Outstanding, beginning balance</u>	1,337,684		
<u>Granted</u>	248,342		
<u>Vested</u>	(500,244)		
<u>Forfeited</u>	(26,601)		
<u>Outstanding, ending balance</u>	1,059,181	1,337,684	

Weighted average grant- date fair value

<u>Weighted average exercise price, Outstanding, beginning balance</u>	\$ 9.52		
<u>Granted</u>	34.33		
<u>Vested</u>	9.01		
<u>Forfeited</u>	10.88		
<u>Weighted average exercise price, Outstanding, ending balance</u>	\$ 15.55	\$ 9.52	

Earnings Per Share
(Schedule of computation of
basic and diluted earnings
per share) (Details) - USD (\$)
\$ / shares in Units, \$ in
Thousands

12 Months Ended

	Dec. 31,	Dec. 31,	Dec. 31,
	2021	2020	2019
<u>Basic EPS:</u>			
<u>Net income attributable to Shares</u>	\$ 60,277	\$ 21,778	\$ 21,986
<u>Weighted average number of Shares outstanding used in basic earnings per Share calculation</u>	43,644	39,383	37,626
<u>Diluted EPS:</u>			
<u>Net income attributable to Shares</u>	\$ 60,277	\$ 21,778	\$ 21,986
<u>Add amortization of notes issuance costs</u>	105	0	0
<u>Net income used in diluted earnings per Share calculation</u>	\$ 60,382	\$ 21,778	\$ 21,986
<u>Weighted average number of Shares outstanding used in basic earnings per Share calculation</u>	43,644	39,383	37,626
<u>Effect of stock-based awards</u>	988	989	806
<u>Effect of conversion of Notes</u>	\$ 403	\$ 0	\$ 0
<u>Weighted average number of Shares outstanding used in diluted earnings per Share calculation</u>	45,035	40,372	38,432
<u>Basic income from continuing operations per Share</u>	\$ 1.38	\$ 0.55	\$ 0.55
<u>Basic income from discontinued operations per Share</u>	0	0	0.03
<u>Basic net income per Share</u>	1.38	0.55	0.58
<u>Diluted income from continuing operations per Share</u>	1.34	0.54	0.54
<u>Diluted income from discontinued operations per Share</u>	0	0	0.03
<u>Diluted net income per Share</u>	\$ 1.34	\$ 0.54	\$ 0.57
<u>Number of options excluded from the diluted earnings per share calculation due to their anti-dilutive effect</u>	0	0	0

Entity-Wide Information
(Schedule of revenues by
geographic area) (Details) -
USD (\$)
\$ in Thousands

12 Months Ended

Dec. 31,	Dec. 31,	Dec. 31,
2021	2020	2019

Revenues from External Customers and Long-Lived Assets [Line Items]

<u>Revenues</u>	\$ 269,659	\$ 155,859	\$ 134,019
<u>Asia Pacific [Member]</u>			

Revenues from External Customers and Long-Lived Assets [Line Items]

<u>Revenues</u>	224,931	137,555	115,925
<u>United States [Member]</u>			

Revenues from External Customers and Long-Lived Assets [Line Items]

<u>Revenues</u>	28,641	9,847	10,388
<u>Europe [Member]</u>			

Revenues from External Customers and Long-Lived Assets [Line Items]

<u>Revenues</u>	\$ 16,087	\$ 8,457	\$ 7,706
-----------------	-----------	----------	----------

**Selected Income Statement
Data (Narrative) (Details) -
USD (\$)
\$ in Thousands**

12 Months Ended

	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Selected Income Statement Data [Line Items]			
Foreign currency income (expense)	\$ 58	\$ (351)	\$ (352)
Revenue Benchmark [Member] Customer Concentration Risk [Member] Customer One [Member]			
Selected Income Statement Data [Line Items]			
Percentage of Concentration Risk		11.00%	

**Selected Income Statement
Data (Schedule of selected
revenues) (Details) - USD (\$)
\$ in Thousands**

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

[Selected Income Statement Data \[Line Items\]](#)

Total revenues \$ 269,659 \$ 155,859 \$ 134,019

Sales of products [Member]

[Selected Income Statement Data \[Line Items\]](#)

Total revenues 259,332 148,257 127,396

Service fees [Member]

[Selected Income Statement Data \[Line Items\]](#)

Total revenues \$ 10,327 \$ 7,602 \$ 6,623

**Selected Income Statement
Data (Schedule of selected
selling, general and
administrative expenses
data) (Details) - USD (\$)
\$ in Thousands**

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Selected Income Statement Data [Abstract]

<u>Selling</u>	[1] \$ 33,614	\$ 22,969	\$ 19,294
<u>General and administrative</u>	9,359	8,063	7,187
<u>Total selling, general and administrative expenses</u>	42,973	31,032	26,481
<u>Including shipping and handling costs</u>	\$ 1,867	\$ 2,356	\$ 1,063

[1] Including shipping and handling costs

Selected Income Statement Data (Schedule of selected financial income (expenses) data) (Details) - USD (\$) \$ in Thousands	12 Months Ended		Dec. 31, 2019
	Dec. 31, 2021	Dec. 31, 2020	
<u>Selected Income Statement Data [Abstract]</u>			
<u>Interest income</u>	\$ 1,408	\$ 1,281	\$ 1,412
<u>Other, net</u>	[1] (378)	(506)	(611)
<u>Financial income (expenses), net</u>	\$ 1,030	\$ 775	\$ 801

[1] Other, net includes foreign currency income (expense) resulting from transactions not denominated in U.S. Dollars amounting to \$58, \$(351), and \$(352) in 2021, 2020 and 2019, respectively

Income Taxes (Narrative) (Details) - USD (\$) \$ in Thousands	1 Months Ended		12 Months Ended	
	Dec. 22, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Operating Loss Carryforwards [Line Items]</u>				
<u>Effective income tax rate</u>		23.00%	23.00%	23.00%
<u>Corporate statutory tax rate on 2018 and thereafter</u>	7.50%			7.50%
<u>Income tax on earning</u>		\$ 5,315		
<u>Major foreign subsidiaries NOL</u>		620		
<u>Tax credit carryforwards</u>		\$ 211		

**Income Taxes (Schedule of
composition of income (loss)
from continuing operations
before income taxes and
income tax expense (benefit))
(Details) - USD (\$)
\$ in Thousands**

12 Months Ended

	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Income Taxes [Abstract]</u>			
<u>Income from continuing operations before income taxes: Israel</u>	\$ 67,643	\$ 20,430	\$ 20,783
<u>Income from continuing operations before income taxes: Non-Israeli</u>	4,285	2,969	1,990
<u>Income from continuing operations before incomes taxes</u>	71,928	23,399	22,773
<u>Income tax expense from continuing operations, Current: Israel</u>	[1]9,930	0	0
<u>Income tax expense from continuing operations, Current: Non-Israeli</u>	1,603	670	424
<u>Current Income tax expense from continuing operations, Total</u>	11,533	670	424
<u>Deferred benefit: Israel</u>	714	943	1,351
<u>Deferred benefit: Non-Israeli</u>	(596)	8	175
<u>Deferred benefit</u>	118	951	1,526
<u>Actual income tax expense (benefit)</u>	\$ 11,651	\$ 1,621	\$ 1,950

[1] see Note 18B(b)

**Income Taxes (Schedule of
reconciliation of the
theoretical income tax
expense) (Details) - USD (\$)
\$ in Thousands**

12 Months Ended

	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
<u>Income Taxes [Abstract]</u>			
<u>Income from continuing operations before income taxes</u>	\$ 71,928	\$ 23,399	\$ 22,773
<u>Statutory tax rate</u>	23.00%	23.00%	23.00%
<u>Theoretical income tax expense</u>	\$ 16,543	\$ 5,382	\$ 5,238
<u>Income tax on earning of previous years</u>	5,306	0	0
<u>Non-deductible expenses</u>	[1] 285	239	337
<u>Differences between Israeli shekel and dollar-adjusted financial statements, net</u>	[2] 0	(739)	(479)
<u>Tax rate differential</u>	(10,715)	(3,251)	(3,340)
<u>Other</u>	232	(10)	194
<u>Actual income tax expense (benefit)</u>	\$ 11,651	\$ 1,621	\$ 1,950

[1] Including non-deductible share-based compensation.

[2] The Company has elected, as from the 2021 tax year, to measure its results for tax purposes on the basis of the changes in the exchange rate of the Dollar. The Company must continue to be taxed on this basis for at least three years.

**Income Taxes (Schedule of
deferred tax assets and
liabilities) (Details) - USD (\$)
\$ in Thousands**

Dec. 31, 2021 Dec. 31, 2020

Deferred tax assets:

<u>Allowance for doubtful accounts</u>	\$ 1	\$ 3
<u>Deferred revenue</u>	838	340
<u>Accrued expenses</u>	535	469
<u>Net operating loss and tax credit carryforwards</u>	211	644
<u>Lease liability</u>	278	170
<u>Other temporary differences</u>	217	344
<u>Deferred tax asset</u>	2,080	1,970

Deferred tax liabilities:

<u>Property, plant and equipment</u>	(700)	(618)
<u>Right of use assets</u>	(278)	(170)
<u>Undistributed earnings</u>	(875)	(700)
<u>Total deferred tax liabilities</u>	(1,853)	(1,488)
<u>Net deferred tax assets</u>	\$ 227	\$ 482

**Balances and Transactions
with Related Parties
(Narrative) (Details)**

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

[Affiliated Entity \[Member\]](#)

[Related Party Transaction \[Line Items\]](#)

Interest rate, related party	5.50%	5.50%	5.50%
--	-------	-------	-------

**Balances and Transactions
with Related Parties**

**(Schedule of related party
balances and transactions)**

Dec. 31, 2021 Dec. 31, 2020

(Details) - USD (\$)

\$ in Thousands

[Affiliated Entity \[Member\]](#)

[Related Party Transaction \[Line Items\]](#)

[Due from related parties](#)

\$ 15

\$ 3

**Balances and Transactions
with Related Parties
(Schedule of transactions
with related parties)
(Details) - Affiliated Entity
[Member] - USD (\$)
\$ in Thousands**

12 Months Ended

Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019

Related Party Transaction [Line Items]

<u>Purchases from related parties</u>	\$ 0	\$ 0	\$ 0
<u>Reimbursement of expenses</u>	0	0	100
<u>Interest income (expense) from Priortech</u>	\$ 0	\$ 0	\$ 0

**Subsequent Events
(Narrative) (Details)
\$ in Thousands**

**12 Months Ended
Dec. 31, 2021
USD (\$)**

Subsequent Event [Line Items]

One time tax expense \$ 5,315

1. Introduction
2. Background
3. Methodology
4. Results
5. Discussion
6. Conclusion
7. References
8. Appendix
9. Glossary
10. Index

1. Introduction
2. Literature Review
3. Methodology
4. Results
5. Discussion
6. Conclusion
7. References
8. Appendix
9. Glossary
10. Index

1. Introduction
2. Literature Review
3. Methodology
4. Results
5. Discussion
6. Conclusion
7. References
8. Appendix
9. Glossary
10. Index

1	Introduction
2	Chapter 1: The History of the Book
3	Chapter 2: The Structure of the Book
4	Chapter 3: The Language of the Book
5	Chapter 4: The Style of the Book
6	Chapter 5: The Content of the Book
7	Chapter 6: The Reception of the Book
8	Chapter 7: The Legacy of the Book
9	Chapter 8: The Future of the Book
10	Conclusion
11	Appendix A: Bibliography
12	Appendix B: Index
13	Appendix C: Glossary
14	Appendix D: Notes
15	Appendix E: References
16	Appendix F: Acknowledgments
17	Appendix G: Author's Note
18	Appendix H: About the Author
19	Appendix I: Contact Information
20	Appendix J: Copyright Notice
21	Appendix K: Disclaimer
22	Appendix L: Terms and Conditions
23	Appendix M: Privacy Policy
24	Appendix N: License Agreement
25	Appendix O: End User License Agreement
26	Appendix P: Software License Agreement
27	Appendix Q: Service Level Agreement
28	Appendix R: Non-Disclosure Agreement
29	Appendix S: Confidentiality Agreement
30	Appendix T: Intellectual Property Agreement
31	Appendix U: Trademark Agreement
32	Appendix V: Patent Agreement
33	Appendix W: Royalty Agreement
34	Appendix X: Distribution Agreement
35	Appendix Y: Marketing Agreement
36	Appendix Z: Sales Agreement
37	Appendix AA: Purchase Order
38	Appendix AB: Invoice
39	Appendix AC: Receipt
40	Appendix AD: Bill of Materials
41	Appendix AE: Certificate of Origin
42	Appendix AF: Inspection Report
43	Appendix AG: Test Report
44	Appendix AH: Quality Control Report
45	Appendix AI: Safety Report
46	Appendix AJ: Environmental Report
47	Appendix AK: Social Responsibility Report
48	Appendix AL: Sustainability Report
49	Appendix AM: Governance Report
50	Appendix AN: Risk Management Report
51	Appendix AO: Compliance Report
52	Appendix AP: Audit Report
53	Appendix AQ: Internal Control Report
54	Appendix AR: Information Security Report
55	Appendix AS: Data Protection Report
56	Appendix AT: Privacy Impact Assessment
57	Appendix AU: Data Breach Report
58	Appendix AV: Incident Response Report
59	Appendix AW: Business Continuity Report
60	Appendix AX: Disaster Recovery Report
61	Appendix AY: Crisis Management Report
62	Appendix AZ: Business Impact Analysis
63	Appendix BA: Risk Assessment
64	Appendix BB: Risk Register
65	Appendix BC: Risk Mitigation Plan
66	Appendix BD: Risk Monitoring and Reporting
67	Appendix BE: Risk Review
68	Appendix BF: Risk Communication
69	Appendix BG: Risk Culture
70	Appendix BH: Risk Governance
71	Appendix BI: Risk Appetite
72	Appendix BJ: Risk Tolerance
73	Appendix BK: Risk Capacity
74	Appendix BL: Risk Resilience
75	Appendix BM: Risk Adaptability
76	Appendix BN: Risk Agility
77	Appendix BO: Risk Innovation
78	Appendix BP: Risk Transformation
79	Appendix BQ: Risk Leadership
80	Appendix BR: Risk Excellence
81	Appendix BS: Risk Performance
82	Appendix BT: Risk Results
83	Appendix BU: Risk Impact
84	Appendix BV: Risk Contribution
85	Appendix BW: Risk Value
86	Appendix BX: Risk Benefit
87	Appendix BY: Risk Cost
88	Appendix BZ: Risk Loss
89	Appendix CA: Risk Damage
90	Appendix CB: Risk Harm
91	Appendix CC: Risk Injury
92	Appendix CD: Risk Illness
93	Appendix CE: Risk Disability
94	Appendix CF: Risk Death
95	Appendix CG: Risk Property Damage
96	Appendix CH: Risk Financial Loss
97	Appendix CI: Risk Reputational Damage
98	Appendix CJ: Risk Operational Disruption
99	Appendix CK: Risk Environmental Impact
100	Appendix CL: Risk Social Impact
101	Appendix CM: Risk Cultural Impact
102	Appendix CN: Risk Ethical Impact
103	Appendix CO: Risk Legal Impact
104	Appendix CP: Risk Regulatory Impact
105	Appendix CQ: Risk Tax Impact
106	Appendix CR: Risk Accounting Impact
107	Appendix CS: Risk Financial Reporting Impact
108	Appendix CT: Risk Stakeholder Impact
109	Appendix CU: Risk Market Impact
110	Appendix CV: Risk Industry Impact
111	Appendix CW: Risk Global Impact
112	Appendix CX: Risk Future Impact
113	Appendix CY: Risk Legacy Impact
114	Appendix CZ: Risk Enduring Impact
115	Appendix DA: Risk Lasting Impact
116	Appendix DB: Risk Permanent Impact
117	Appendix DC: Risk Irreversible Impact
118	Appendix DD: Risk Catastrophic Impact
119	Appendix DE: Risk Devastating Impact
120	Appendix DF: Risk Cataclysmic Impact
121	Appendix DG: Risk Apocalyptic Impact
122	Appendix DH: Risk Doomsday Impact
123	Appendix DI: Risk Armageddon Impact
124	Appendix DJ: Risk Ragnarok Impact
125	Appendix DK: Risk End of the World Impact
126	Appendix DL: Risk Final Impact
127	Appendix DM: Risk Ultimate Impact
128	Appendix DN: Risk Absolute Impact
129	Appendix DO: Risk Infinite Impact
130	Appendix DP: Risk Eternal Impact
131	Appendix DQ: Risk Everlasting Impact
132	Appendix DR: Risk Immortal Impact
133	Appendix DS: Risk Undying Impact
134	Appendix DT: Risk Ageless Impact
135	Appendix DU: Risk Timeless Impact
136	Appendix DV: Risk Boundless Impact
137	Appendix DW: Risk Limitless Impact
138	Appendix DX: Risk Unfathomable Impact
139	Appendix DY: Risk Incomprehensible Impact
140	Appendix DZ: Risk Unimaginable Impact
141	Appendix EA: Risk Beyond Comprehension Impact
142	Appendix EB: Risk Beyond Imagination Impact
143	Appendix EC: Risk Beyond Understanding Impact
144	Appendix ED: Risk Beyond Knowledge Impact
145	Appendix EE: Risk Beyond Experience Impact
146	Appendix EF: Risk Beyond Perception Impact
147	Appendix EG: Risk Beyond Sensation Impact
148	Appendix EH: Risk Beyond Thought Impact
149	Appendix EI: Risk Beyond Reason Impact
150	Appendix EJ: Risk Beyond Logic Impact
151	Appendix EK: Risk Beyond Intellect Impact
152	Appendix EL: Risk Beyond Mind Impact
153	Appendix EM: Risk Beyond Soul Impact
154	Appendix EN: Risk Beyond Spirit Impact
155	Appendix EO: Risk Beyond Heart Impact
156	Appendix EP: Risk Beyond Emotion Impact
157	Appendix EQ: Risk Beyond Passion Impact
158	Appendix ER: Risk Beyond Desire Impact
159	Appendix ES: Risk Beyond Will Impact
160	Appendix ET: Risk Beyond Power Impact
161	Appendix EU: Risk Beyond Authority Impact
162	Appendix EV: Risk Beyond Influence Impact
163	Appendix EW: Risk Beyond Control Impact
164	Appendix EX: Risk Beyond Mastery Impact
165	Appendix EY: Risk Beyond Expertise Impact
166	Appendix EZ: Risk Beyond Skill Impact
167	Appendix FA: Risk Beyond Talent Impact
168	Appendix FB: Risk Beyond Ability Impact
169	Appendix FC: Risk Beyond Capacity Impact
170	Appendix FD: Risk Beyond Potential Impact
171	Appendix FE: Risk Beyond Power Impact
172	Appendix FF: Risk Beyond Strength Impact
173	Appendix FG: Risk Beyond Force Impact
174	Appendix FH: Risk Beyond Energy Impact
175	Appendix FI: Risk Beyond Power Impact
176	Appendix FJ: Risk Beyond Influence Impact
177	Appendix FK: Risk Beyond Control Impact
178	Appendix FL: Risk Beyond Mastery Impact
179	Appendix FM: Risk Beyond Expertise Impact
180	Appendix FN: Risk Beyond Skill Impact
181	Appendix FO: Risk Beyond Talent Impact
182	Appendix FP: Risk Beyond Ability Impact
183	Appendix FQ: Risk Beyond Capacity Impact
184	Appendix FR: Risk Beyond Potential Impact
185	Appendix FS: Risk Beyond Power Impact
186	Appendix FT: Risk Beyond Strength Impact
187	Appendix FU: Risk Beyond Force Impact
188	Appendix FV: Risk Beyond Energy Impact
189	Appendix FW: Risk Beyond Power Impact
190	Appendix FX: Risk Beyond Influence Impact
191	Appendix FY: Risk Beyond Control Impact
192	Appendix FZ: Risk Beyond Mastery Impact
193	Appendix GA: Risk Beyond Expertise Impact
194	Appendix GB: Risk Beyond Skill Impact
195	Appendix GC: Risk Beyond Talent Impact
196	Appendix GD: Risk Beyond Ability Impact
197	Appendix GE: Risk Beyond Capacity Impact
198	Appendix GF: Risk Beyond Potential Impact
199	Appendix GF: Risk Beyond Power Impact
200	Appendix GF: Risk Beyond Strength Impact

1	Introduction
2	Chapter 1: The History of the Book
3	Chapter 2: The Structure of the Book
4	Chapter 3: The Language of the Book
5	Chapter 4: The Style of the Book
6	Chapter 5: The Content of the Book
7	Chapter 6: The Reception of the Book
8	Chapter 7: The Future of the Book
9	Conclusion
10	Appendix A: Bibliography
11	Appendix B: Index
12	Appendix C: Glossary
13	Appendix D: Notes
14	Appendix E: References
15	Appendix F: Acknowledgments
16	Appendix G: Author's Note
17	Appendix H: About the Author
18	Appendix I: Contact Information
19	Appendix J: Copyright Notice
20	Appendix K: Disclaimer
21	Appendix L: Privacy Policy
22	Appendix M: Terms of Service
23	Appendix N: License Agreement
24	Appendix O: End User License Agreement
25	Appendix P: Privacy Policy
26	Appendix Q: Terms of Service
27	Appendix R: License Agreement
28	Appendix S: End User License Agreement
29	Appendix T: Privacy Policy
30	Appendix U: Terms of Service
31	Appendix V: License Agreement
32	Appendix W: End User License Agreement
33	Appendix X: Privacy Policy
34	Appendix Y: Terms of Service
35	Appendix Z: License Agreement
36	Appendix AA: End User License Agreement
37	Appendix AB: Privacy Policy
38	Appendix AC: Terms of Service
39	Appendix AD: License Agreement
40	Appendix AE: End User License Agreement
41	Appendix AF: Privacy Policy
42	Appendix AG: Terms of Service
43	Appendix AH: License Agreement
44	Appendix AI: End User License Agreement
45	Appendix AJ: Privacy Policy
46	Appendix AK: Terms of Service
47	Appendix AL: License Agreement
48	Appendix AM: End User License Agreement
49	Appendix AN: Privacy Policy
50	Appendix AO: Terms of Service
51	Appendix AP: License Agreement
52	Appendix AQ: End User License Agreement
53	Appendix AR: Privacy Policy
54	Appendix AS: Terms of Service
55	Appendix AT: License Agreement
56	Appendix AU: End User License Agreement
57	Appendix AV: Privacy Policy
58	Appendix AW: Terms of Service
59	Appendix AX: License Agreement
60	Appendix AY: End User License Agreement
61	Appendix AZ: Privacy Policy
62	Appendix BA: Terms of Service
63	Appendix BB: License Agreement
64	Appendix BC: End User License Agreement
65	Appendix BD: Privacy Policy
66	Appendix BE: Terms of Service
67	Appendix BF: License Agreement
68	Appendix BG: End User License Agreement
69	Appendix BH: Privacy Policy
70	Appendix BI: Terms of Service
71	Appendix BJ: License Agreement
72	Appendix BK: End User License Agreement
73	Appendix BL: Privacy Policy
74	Appendix BM: Terms of Service
75	Appendix BN: License Agreement
76	Appendix BO: End User License Agreement
77	Appendix BP: Privacy Policy
78	Appendix BQ: Terms of Service
79	Appendix BR: License Agreement
80	Appendix BS: End User License Agreement
81	Appendix BT: Privacy Policy
82	Appendix BU: Terms of Service
83	Appendix BV: License Agreement
84	Appendix BU: End User License Agreement
85	Appendix BV: Privacy Policy
86	Appendix BV: Terms of Service
87	Appendix BV: License Agreement
88	Appendix BV: End User License Agreement
89	Appendix BV: Privacy Policy
90	Appendix BV: Terms of Service
91	Appendix BV: License Agreement
92	Appendix BV: End User License Agreement
93	Appendix BV: Privacy Policy
94	Appendix BV: Terms of Service
95	Appendix BV: License Agreement
96	Appendix BV: End User License Agreement
97	Appendix BV: Privacy Policy
98	Appendix BV: Terms of Service
99	Appendix BV: License Agreement
100	Appendix BV: End User License Agreement

Table-Of-Contents

1. Introduction

2. Literature Review

3. Methodology

4. Results

5. Discussion

6. Conclusion

7. References

8. Appendix

9. Glossary

10. Index

11. Bibliography

12. List of Figures

13. List of Tables

14. List of Equations

15. List of Symbols

16. List of Abbreviations

17. List of Acronyms

18. List of Initials

19. List of Footnotes

20. List of Endnotes

21. List of Citations

22. List of References

23. List of Bibliography

24. List of References

25. List of References

26. List of References

27. List of References

28. List of References

29. List of References

30. List of References

31. List of References

32. List of References

33. List of References

34. List of References

35. List of References

36. List of References

37. List of References

38. List of References

39. List of References

40. List of References

41. List of References

42. List of References

43. List of References

44. List of References

45. List of References

46. List of References

47. List of References

48. List of References

49. List of References

50. List of References

51. List of References

52. List of References

53. List of References

54. List of References

55. List of References

56. List of References

57. List of References

58. List of References

59. List of References

60. List of References

61. List of References

62. List of References

63. List of References

64. List of References

65. List of References

66. List of References

67. List of References

68. List of References

69. List of References

70. List of References

71. List of References

72. List of References

73. List of References

74. List of References

75. List of References

76. List of References

77. List of References

78. List of References

79. List of References

80. List of References

81. List of References

82. List of References

83. List of References

84. List of References

85. List of References

86. List of References

87. List of References

88. List of References

89. List of References

90. List of References

91. List of References

92. List of References

93. List of References

94. List of References

95. List of References

96. List of References

97. List of References

98. List of References

99. List of References

100. List of References

1	Introduction
2	Chapter 1: The History of the United States
3	Chapter 2: The American Revolution
4	Chapter 3: The Early Republic
5	Chapter 4: The Industrial Revolution
6	Chapter 5: The Civil War
7	Chapter 6: Reconstruction
8	Chapter 7: The Gilded Age
9	Chapter 8: The Progressive Era
10	Chapter 9: World War I
11	Chapter 10: The Roaring Twenties
12	Chapter 11: The Great Depression
13	Chapter 12: World War II
14	Chapter 13: The Cold War
15	Chapter 14: The Vietnam War
16	Chapter 15: The 1960s
17	Chapter 16: The 1970s
18	Chapter 17: The 1980s
19	Chapter 18: The 1990s
20	Chapter 19: The 2000s
21	Chapter 20: The 2010s
22	Chapter 21: The 2020s

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection process and offers suggestions for improving the accuracy and reliability of the results.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the importance of the study and the need for continued research in this area.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources used in the study, including academic journals, books, and industry reports.

7. The seventh part of the document contains a list of appendices and a glossary. It provides additional information and definitions for the terms used in the document.

8. The eighth part of the document includes a list of figures and tables. It provides a visual representation of the data and the results of the analysis.

9. The ninth part of the document contains a list of footnotes and a list of errata. It provides additional information and corrections for the document.

10. The tenth part of the document includes a list of acknowledgments and a list of contributors. It expresses gratitude to the individuals and organizations that supported the study.

1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection and analysis process and offers suggestions for how these challenges can be addressed in future studies.

5. The fifth part of the document provides a conclusion and a summary of the main points discussed throughout the document. It reiterates the importance of accurate record-keeping and the need for ongoing research in this field.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods and techniques used to collect and analyze data. It includes a detailed description of the experimental procedures and the tools used for data collection.

3. The third part of the document presents the results of the study. It includes a series of tables and graphs that illustrate the findings of the research. The data shows a clear trend in the relationship between the variables being studied.

4. The fourth part of the document discusses the implications of the findings. It highlights the potential applications of the research in various fields and the need for further investigation in this area.

5. The fifth part of the document concludes the study and provides a summary of the key findings. It also includes a list of references and a bibliography of the sources used in the research.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection process and offers suggestions for improving the accuracy and reliability of the results.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the significance of the findings and the need for continued research in this area.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources used in the study, including academic journals, books, and industry reports.

7. The seventh part of the document contains a list of appendices and supplementary materials. These include detailed data tables, charts, and graphs that provide further insight into the study's findings.

8. The eighth part of the document includes a list of figures and tables. These visual aids are used to present complex data in a more accessible and understandable format.

9. The ninth part of the document contains a list of footnotes and endnotes. These provide additional information and clarification on specific points raised in the main text.

10. The tenth part of the document includes a list of acknowledgments and a thank you note. It expresses appreciation to the individuals and organizations that provided support and assistance during the course of the study.

Small text block at the top left of the page, possibly containing a header or introductory text.

Main body of small text, appearing as a list or series of entries, possibly a table of contents or index.

1. The first part of the document discusses the importance of maintaining accurate records in a laboratory setting. It emphasizes the need for clear labeling and organization of samples and reagents to ensure the reliability of experimental results.

2. The second section details the various methods used for data collection and analysis. It covers both traditional manual techniques and modern digital tools, highlighting the advantages of automation in reducing human error and increasing efficiency.

3. The third part of the document focuses on the ethical considerations and safety protocols that must be followed in a laboratory environment. It stresses the importance of proper handling of hazardous materials and the need for thorough documentation of all procedures.

4. The fourth section discusses the role of collaboration and communication in scientific research. It encourages researchers to share their findings and work together to solve complex problems, as well as to provide regular updates on their progress.

5. The final part of the document provides a summary of the key points discussed and offers some concluding thoughts on the future of laboratory research. It suggests that continued investment in technology and training will be essential for advancing our understanding of the natural world.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and suggests areas for future research. It acknowledges the potential biases and limitations of the data and the methods used, and offers suggestions for how these issues can be addressed in future studies.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the importance of accurate record-keeping and the need for ongoing research in this field.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources of information used in the study, including academic journals, books, and other relevant literature.

7. The seventh part of the document contains a list of appendices and supplementary materials. These materials provide additional data and information that support the findings of the study.

8. The eighth part of the document includes a list of figures and tables. These visual aids help to illustrate the data and make it easier to understand the results of the study.

9. The ninth part of the document contains a list of footnotes and endnotes. These notes provide additional information and clarification on specific points raised in the text.

10. The tenth part of the document includes a list of acknowledgments and a thank-you note. It expresses appreciation to the individuals and organizations that provided support and assistance during the course of the study.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and suggests areas for future research. It acknowledges the potential biases and limitations of the data and the methods used, and offers suggestions for how these issues can be addressed in future studies.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the importance of accurate record-keeping and the need for ongoing research in this field.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources of information used in the study, including academic journals, books, and other relevant literature.

7. The seventh part of the document contains a list of appendices and a glossary. It provides additional information and definitions for the terms used in the document, as well as any other relevant data or materials.

8. The eighth part of the document includes a list of figures and tables. It provides a visual representation of the data and the results of the study, making it easier to understand and interpret the findings.

9. The ninth part of the document contains a list of footnotes and a list of corrections. It provides additional information and clarifications for the text, as well as any errors or corrections that have been identified.

10. The tenth part of the document includes a list of acknowledgments and a list of contributors. It expresses gratitude to the individuals and organizations that have supported the study and provided valuable input and feedback.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and suggests areas for future research. It acknowledges the potential biases and limitations of the data and the methods used, and offers suggestions for how these issues can be addressed in future studies.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the importance of accurate record-keeping and the need for ongoing research in this field.

6. The sixth part of the document includes a list of references and a list of figures. The references cite the various sources of information used in the study, and the figures provide a visual representation of the data and the results of the analysis.

7. The seventh part of the document is a list of appendices. These appendices provide additional information and data that are not included in the main body of the document. They include a list of abbreviations, a list of symbols, and a list of tables.

8. The eighth part of the document is a list of footnotes. These footnotes provide additional information and details about the study, including information about the authors and the funding sources.

9. The ninth part of the document is a list of acknowledgments. These acknowledgments thank the individuals and organizations that provided support and assistance during the course of the study.

10. The tenth part of the document is a list of contact information. This information includes the names and addresses of the authors and the organizations they represent, as well as the names and addresses of the publishers and distributors.

Table with multiple columns and rows, containing various data points and headers. The table is mostly empty with some faint text visible in the left margin.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and offers suggestions for further research. It highlights the need for continued monitoring and evaluation of the system to ensure its effectiveness and efficiency.

5. The fifth part of the document provides a summary of the key points and conclusions. It reiterates the importance of accurate record-keeping and the need for ongoing research and improvement in the field.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and offers suggestions for further research. It highlights the need for continued monitoring and evaluation of the system to ensure its effectiveness and efficiency.

5. The fifth part of the document provides a summary of the key points and conclusions. It reiterates the importance of the findings and the need for continued attention to the issues discussed in the document.

6. The sixth part of the document includes a list of references and a list of figures and tables. It provides a comprehensive overview of the sources used in the study and the data presented in the document.

7. The seventh part of the document is a list of appendices. It includes detailed information about the data collection process, the statistical analysis, and the results of the study.

8. The eighth part of the document is a list of footnotes. It provides additional information about the study and the authors, and includes references to other relevant work in the field.

9. The ninth part of the document is a list of acknowledgments. It expresses gratitude to the individuals and organizations that provided support and assistance during the course of the study.

10. The tenth part of the document is a list of references. It includes a comprehensive list of the sources used in the study, including books, articles, and other relevant work in the field.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods and techniques used to collect and analyze data. It includes a detailed description of the experimental procedures and the statistical tools employed.

3. The third part of the document presents the results of the study, including a comparison of the different methods and a discussion of the implications of the findings.

4. The fourth part of the document provides a conclusion and a summary of the key points. It also includes a list of references and a bibliography.

5. The fifth part of the document contains a glossary of terms and a list of abbreviations. It also includes a list of figures and tables.

6. The sixth part of the document contains a list of appendices and a list of references. It also includes a list of figures and tables.

7. The seventh part of the document contains a list of appendices and a list of references. It also includes a list of figures and tables.

8. The eighth part of the document contains a list of appendices and a list of references. It also includes a list of figures and tables.

9. The ninth part of the document contains a list of appendices and a list of references. It also includes a list of figures and tables.

10. The tenth part of the document contains a list of appendices and a list of references. It also includes a list of figures and tables.

1. Name: _____
2. Address: _____
3. City: _____
4. State: _____
5. Zip: _____
6. Phone: _____
7. Email: _____
8. Date of Birth: _____
9. Social Security Number: _____
10. Driver's License Number: _____
11. Vehicle Identification Number: _____
12. Insurance Policy Number: _____
13. Name of Insurance Company: _____
14. Name of Driver: _____
15. Name of Passenger: _____
16. Name of Rental Company: _____
17. Name of Location: _____
18. Name of Branch: _____
19. Name of Agent: _____
20. Name of Supervisor: _____
21. Name of Manager: _____
22. Name of Director: _____
23. Name of President: _____
24. Name of CEO: _____
25. Name of CFO: _____
26. Name of COO: _____
27. Name of CTO: _____
28. Name of CMO: _____
29. Name of CRO: _____
30. Name of CHRO: _____
31. Name of CHRO: _____
32. Name of CHRO: _____
33. Name of CHRO: _____
34. Name of CHRO: _____
35. Name of CHRO: _____
36. Name of CHRO: _____
37. Name of CHRO: _____
38. Name of CHRO: _____
39. Name of CHRO: _____
40. Name of CHRO: _____
41. Name of CHRO: _____
42. Name of CHRO: _____
43. Name of CHRO: _____
44. Name of CHRO: _____
45. Name of CHRO: _____
46. Name of CHRO: _____
47. Name of CHRO: _____
48. Name of CHRO: _____
49. Name of CHRO: _____
50. Name of CHRO: _____
51. Name of CHRO: _____
52. Name of CHRO: _____
53. Name of CHRO: _____
54. Name of CHRO: _____
55. Name of CHRO: _____
56. Name of CHRO: _____
57. Name of CHRO: _____
58. Name of CHRO: _____
59. Name of CHRO: _____
60. Name of CHRO: _____
61. Name of CHRO: _____
62. Name of CHRO: _____
63. Name of CHRO: _____
64. Name of CHRO: _____
65. Name of CHRO: _____
66. Name of CHRO: _____
67. Name of CHRO: _____
68. Name of CHRO: _____
69. Name of CHRO: _____
70. Name of CHRO: _____
71. Name of CHRO: _____
72. Name of CHRO: _____
73. Name of CHRO: _____
74. Name of CHRO: _____
75. Name of CHRO: _____
76. Name of CHRO: _____
77. Name of CHRO: _____
78. Name of CHRO: _____
79. Name of CHRO: _____
80. Name of CHRO: _____
81. Name of CHRO: _____
82. Name of CHRO: _____
83. Name of CHRO: _____
84. Name of CHRO: _____
85. Name of CHRO: _____
86. Name of CHRO: _____
87. Name of CHRO: _____
88. Name of CHRO: _____
89. Name of CHRO: _____
90. Name of CHRO: _____
91. Name of CHRO: _____
92. Name of CHRO: _____
93. Name of CHRO: _____
94. Name of CHRO: _____
95. Name of CHRO: _____
96. Name of CHRO: _____
97. Name of CHRO: _____
98. Name of CHRO: _____
99. Name of CHRO: _____
100. Name of CHRO: _____

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, which supports the hypothesis of the research.

4. The fourth part of the document discusses the implications of the findings for practice and policy. It suggests that the results can be used to inform decision-making and to develop more effective strategies.

5. The fifth part of the document concludes the study and provides a summary of the key points. It also identifies the limitations of the study and suggests areas for future research.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and offers suggestions for further research. It highlights the need for continued monitoring and evaluation of the system to ensure its effectiveness and efficiency.

5. The fifth part of the document provides a summary of the key points and conclusions. It reiterates the importance of the findings and the need for continued attention to the issues discussed.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources used in the study and provides information on how to access them.

7. The seventh part of the document contains a list of appendices and a table of contents. It provides a clear overview of the structure of the document and the location of each section.

8. The eighth part of the document includes a list of figures and tables. It provides a visual representation of the data and the results of the analysis.

9. The ninth part of the document contains a list of footnotes and a glossary. It provides additional information on the terms and concepts used in the document and clarifies any potential ambiguities.

10. The tenth part of the document includes a list of acknowledgments and a list of authors. It expresses gratitude to the individuals and organizations that supported the study and identifies the authors of the document.

Item	Description	Quantity	Unit	Price	Total
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Page 1 of 100

Section 1

Section 2

Section 3

Section 4

Section 5

Section 6

Section 7

Section 8

Section 9

Section 10

Section 11

Section 12

Section 13

Section 14

Section 15

Section 16

Section 17

Section 18

Section 19

Section 20

Section 21

Section 22

Section 23

Section 24

Section 25

Section 26

Section 27

Section 28

Section 29

Section 30

Section 31

Section 32

Section 33

Section 34

Section 35

Section 36

Section 37

Section 38

Section 39

Section 40

Section 41

Section 42

Section 43

Section 44

Section 45

Section 46

Section 47

Section 48

Section 49

Section 50

Section 51

Section 52

Section 53

Section 54

Section 55

Section 56

Section 57

Section 58

Section 59

Section 60

Section 61

Section 62

Section 63

Section 64

Section 65

Section 66

Section 67

Section 68

Section 69

Section 70

Section 71

Section 72

Section 73

Section 74

Section 75

Section 76

Section 77

Section 78

Section 79

Section 80

Section 81

Section 82

Section 83

Section 84

Section 85

Section 86

Section 87

Section 88

Section 89

Section 90

Section 91

Section 92

Section 93

Section 94

Section 95

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection process and offers suggestions for improving the quality of the data in subsequent studies.

5. The fifth part of the document provides a conclusion and a summary of the main points discussed throughout the report. It reiterates the significance of the findings and the need for continued research in this area.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources of information used in the study, including academic journals, books, and industry reports.

7. The seventh part of the document contains a list of appendices and supplementary materials. These include detailed data tables, charts, and graphs that provide further insight into the study's findings.

8. The eighth part of the document is a glossary of terms and definitions. It clarifies the meaning of key terms and concepts used throughout the report, ensuring that the reader has a clear understanding of the terminology.

9. The ninth part of the document is a list of acknowledgments. It expresses gratitude to the individuals and organizations that provided support and assistance during the course of the study.

10. The tenth part of the document is a list of footnotes and endnotes. It provides additional information and references that are not included in the main text of the report.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document details the various methods and techniques used to collect and analyze data. It covers both qualitative and quantitative research approaches, highlighting their strengths and limitations.

3. The third part of the document focuses on the interpretation and presentation of results. It provides guidelines for how to effectively communicate findings to different audiences, ensuring clarity and impact.

4. The fourth part of the document discusses the ethical considerations and potential biases that can influence research outcomes. It offers strategies to minimize these risks and ensure the integrity of the research process.

5. The fifth part of the document concludes with a summary of key findings and recommendations for future research. It identifies areas where further investigation is needed and suggests practical applications of the research results.

1. The first part of the document discusses the importance of maintaining accurate records of all business transactions. This includes not only sales and purchases but also expenses and income. Proper record-keeping is essential for determining the true financial health of the business and for preparing accurate tax returns.

2. The second part of the document focuses on the importance of staying up-to-date on changes in tax laws and regulations. Tax laws are constantly in flux, and failing to stay current can result in costly penalties and interest. It is recommended that businesses consult with a qualified tax professional to ensure they are always in compliance with the latest tax requirements.

3. The third part of the document discusses the importance of having a clear understanding of the business's financial position. This involves regularly reviewing financial statements, such as the balance sheet and income statement, to identify areas of strength and weakness. Understanding the financial position is crucial for making informed decisions about the future of the business.

4. The fourth part of the document addresses the importance of having a solid plan for the future. This includes setting clear goals and objectives, as well as developing strategies to achieve them. A well-defined plan can help a business stay focused and motivated, even in the face of challenges and uncertainty.

5. The fifth and final part of the document emphasizes the importance of seeking professional advice. Whether it's a tax professional, an accountant, or a business consultant, having access to expert advice can be invaluable. These professionals can provide personalized guidance and help businesses navigate complex financial and legal issues.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods and techniques used to collect and analyze data. It includes a detailed description of the experimental procedures and the tools used for data collection.

3. The third part of the document presents the results of the study, including a comparison of the different methods and techniques used. It discusses the strengths and weaknesses of each method and provides a summary of the findings.

4. The fourth part of the document discusses the implications of the study and provides recommendations for future research. It highlights the need for further investigation into the effectiveness of the different methods and techniques used.

5. The fifth part of the document provides a conclusion and a summary of the key findings. It emphasizes the importance of maintaining accurate records and the need for transparency and accountability in financial reporting.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the survey process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for future research and practice.

4. The fourth part of the document discusses the limitations of the study and the potential for bias. It also provides recommendations for how these limitations can be addressed in future research.

5. The fifth part of the document concludes the study and summarizes the main findings. It reiterates the importance of accurate record-keeping and the value of the data collected.

6. The sixth part of the document provides a list of references and sources used in the study. It includes a variety of academic journals, books, and online resources.

7. The seventh part of the document contains a list of appendices and supplementary materials. These include raw data, detailed survey questions, and additional statistical analyses.

8. The eighth part of the document provides a list of contact information for the authors and the research team. It includes email addresses and phone numbers for those interested in further information.

9. The ninth part of the document contains a list of acknowledgments and thanks. It expresses gratitude to the funding agencies, the research assistants, and the participants who made the study possible.

10. The tenth part of the document is a list of footnotes and endnotes. It provides additional details and clarifications for the main text.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. This section outlines the various methods and tools used to collect and analyze data, ensuring that all relevant information is captured and stored securely.

2. The second part of the document focuses on the implementation of these practices across different departments and projects. It provides detailed instructions on how to set up systems for data collection and analysis, including the selection of appropriate software and the training of staff. This section also addresses the challenges of data integration and the need for consistent data entry protocols.

3. The third part of the document discusses the importance of data security and privacy. It outlines the measures that should be taken to protect sensitive information from unauthorized access and disclosure. This includes the use of encryption, access controls, and regular security audits. The document also highlights the need for clear policies and procedures regarding data handling and retention.

4. The fourth part of the document addresses the issue of data quality and accuracy. It discusses the various factors that can affect data quality, such as human error, system limitations, and incomplete data. It provides strategies for identifying and correcting data quality issues, including the use of data validation rules and regular data audits.

5. The fifth part of the document discusses the importance of data analysis and reporting. It outlines the various techniques and tools used to analyze data and generate reports. This section emphasizes the need for clear and concise reporting, as well as the importance of providing context and interpretation for the data. It also discusses the role of data analysis in decision-making and the need for ongoing monitoring and evaluation.

6. The sixth part of the document discusses the importance of data governance and compliance. It outlines the various laws and regulations that apply to data handling and the need for a robust governance framework. This section discusses the role of data governance in ensuring that data is used in a responsible and ethical manner, and that all activities are in compliance with applicable laws and regulations.

7. The seventh part of the document discusses the importance of data sharing and collaboration. It outlines the various challenges of data sharing and the need for clear policies and procedures. This section discusses the benefits of data sharing and the need for secure and reliable data exchange mechanisms. It also discusses the importance of data sharing in promoting innovation and the development of new products and services.

8. The eighth part of the document discusses the importance of data literacy and training. It outlines the various skills and knowledge that are needed for effective data analysis and reporting. This section discusses the need for ongoing training and development, as well as the importance of fostering a data-driven culture within the organization. It also discusses the role of data literacy in promoting transparency and accountability.

9. The ninth part of the document discusses the importance of data ethics and privacy. It outlines the various ethical considerations that must be taken into account when handling data, including the need for transparency, consent, and the protection of individual rights. This section discusses the role of data ethics in building trust and the importance of ongoing monitoring and evaluation.

10. The tenth part of the document discusses the importance of data innovation and the future of data. It outlines the various emerging technologies and trends that are shaping the future of data, including artificial intelligence, machine learning, and the Internet of Things. This section discusses the need for ongoing innovation and the importance of staying up-to-date on the latest developments in the field.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It provides a comprehensive overview of the data collected and discusses the implications of the results for the field of research.

4. The fourth part of the document discusses the limitations of the study and suggests areas for future research. It highlights the need for further investigation into the issues identified during the study.

5. The fifth part of the document provides a conclusion and summarizes the key findings of the study. It reiterates the importance of accurate record-keeping and the value of the research conducted.

6. The sixth part of the document includes a list of references and a bibliography. It provides a comprehensive list of the sources used in the study and is organized alphabetically by author.

7. The seventh part of the document includes a list of appendices and a table of contents. It provides a detailed overview of the structure of the document and the location of each section.

8. The eighth part of the document includes a list of figures and a list of tables. It provides a detailed overview of the visual elements used in the study and is organized by figure or table number.

9. The ninth part of the document includes a list of abbreviations and a list of symbols. It provides a detailed overview of the shorthand used in the study and is organized alphabetically by abbreviation or symbol.

10. The tenth part of the document includes a list of footnotes and a list of endnotes. It provides a detailed overview of the supplementary information provided in the study and is organized by footnote or endnote number.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Page 1 of 1
Date: 10/10/2019
Time: 10:10:10
User: admin
IP: 192.168.1.1
Browser: Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/78.0.3930.162 Safari/537.36
URL: http://localhost:8080/